# Birkinshaw_2023_Antidepressants for pain management in adults with chronic pain a network meta-analysis.

Cochrane
Library

Cochrane Database of Systematic Reviews

Antidepressants for pain management in adults with chronic pain: a
network meta-analysis (Review)

Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA,
Phillippo D, Pincus T

Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. 
Antidepressants for pain management in adults with chronic pain: a network meta-analysis. 
Cochrane Database of Systematic Reviews 2023, Issue 5. Art. No.: CD014682. 
DOI: 10.1002/14651858.CD014682.pub2.

www.cochranelibrary.com

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
Figure 7..................................................................................................................................................................................................
Figure 8..................................................................................................................................................................................................
Figure 9..................................................................................................................................................................................................
Figure 10................................................................................................................................................................................................
Figure 11................................................................................................................................................................................................
Figure 12................................................................................................................................................................................................
Figure 13................................................................................................................................................................................................
Figure 14................................................................................................................................................................................................
Figure 15................................................................................................................................................................................................
Figure 16................................................................................................................................................................................................
Figure 17................................................................................................................................................................................................
Figure 18................................................................................................................................................................................................
Figure 19................................................................................................................................................................................................
Figure 20................................................................................................................................................................................................
Figure 21................................................................................................................................................................................................
Figure 22................................................................................................................................................................................................
Figure 23................................................................................................................................................................................................
Figure 24................................................................................................................................................................................................
Figure 25................................................................................................................................................................................................
Figure 26................................................................................................................................................................................................
Figure 27................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
5
13
15
15
21
22
24
25
32
33
35
36
37
38
39
40
42
43
44
45
46
47
48
49
50
51
52
53
54
55
57
58
59
62
63
64
88
428
473
484
484
484
484
485
485

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Antidepressants for pain management in adults with chronic pain: a
network meta-analysis

Hollie Birkinshaw1, Claire M Friedrich1, Peter Cole2, Christopher Eccleston3, Marc Serfaty4, Gavin Stewart5, Simon White6, R Andrew
Moore7, David Phillippo8, Tamar Pincus1

1Department of Psychology, University of Southampton, Southampton, UK. 2Oxford Pain Relief Unit, Churchill Hospital, Oxford
University Hospitals NHS Trust, Oxford, UK. 3Centre for Pain Research, University of Bath, Bath, UK. 4University College London, London,
UK. 5Newcastle University, Newcastle upon Tyne, UK. 6School of Pharmacy and Bioengineering, Keele University, Keele, UK. 7Newton
Ferrers, Plymouth, UK. 8Bristol Medical School, University of Bristol, Bristol, UK

Contact: Tamar Pincus, t.pincus@soton.ac.uk.

Editorial group: Cochrane Pain, Palliative and Supportive Care Group.
Publication status and date: New, published in Issue 5, 2023.

Citation: Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. Antidepressants
for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database of Systematic Reviews 2023, Issue 5. Art.
No.: CD014682. DOI: 10.1002/14651858.CD014682.pub2.

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Chronic pain is common in adults, and often has a detrimental impact upon physical ability, well-being, and quality of life. Previous reviews
have shown that certain antidepressants may be effective in reducing pain with some benefit in improving patients’ global impression of
change for certain chronic pain conditions. However, there has not been a network meta-analysis (NMA) examining all antidepressants
across all chronic pain conditions.

Objectives

To assess the comparative efficacy and safety of antidepressants for adults with chronic pain (except headache).

Search methods

We searched CENTRAL, MEDLINE, Embase, CINAHL, LILACS, AMED and PsycINFO databases, and clinical trials registries, for randomised
controlled trials (RCTs) of antidepressants for chronic pain conditions in January 2022.

Selection criteria

We  included  RCTs  that  examined  antidepressants  for  chronic  pain  against  any  comparator.  If  the  comparator  was  placebo,  another
medication, another antidepressant, or the same antidepressant at different doses, then we required the study to be double-blind. We
included RCTs with active comparators that were unable to be double-blinded (e.g. psychotherapy) but rated them as high risk of bias. We
excluded RCTs where the follow-up was less than two weeks and those with fewer than 10 participants in each arm.

Data collection and analysis

Two review authors separately screened, data extracted, and judged risk of bias. We synthesised the data using Bayesian NMA and pairwise
meta-analyses for each outcome and ranked the antidepressants in terms of their effectiveness using the surface under the cumulative
ranking curve (SUCRA). We primarily used Confidence in Meta-Analysis (CINeMA) and Risk of Bias due to Missing Evidence in Network meta-
analysis (ROB-MEN) to assess the certainty of the evidence. Where it was not possible to use CINeMA and ROB-MEN due to the complexity
of the networks, we used GRADE to assess the certainty of the evidence.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Our  primary  outcomes  were  substantial  (50%)  pain  relief,  pain  intensity,  mood,  and  adverse  events.  Our  secondary  outcomes  were
moderate pain relief (30%), physical function, sleep, quality of life, Patient Global Impression of Change (PGIC), serious adverse events,
and withdrawal.

Main results

This review and NMA included 176 studies with a total of 28,664 participants. The majority of studies were placebo-controlled (83), and
parallel−armed  (141).  The  most  common  pain  conditions  examined  were  fibromyalgia  (59  studies);  neuropathic  pain  (49  studies)  and
musculoskeletal pain (40 studies). The average length of RCTs was 10 weeks. Seven studies provided no useable data and were omitted
from the NMA. The majority of studies measured short-term outcomes only and excluded people with low mood and other mental health
conditions.

Across efficacy outcomes, duloxetine was consistently the highest-ranked antidepressant with moderate- to high-certainty evidence. In
duloxetine studies, standard dose was equally efficacious as high dose for the majority of outcomes. Milnacipran was often ranked as the
next most efficacious antidepressant, although the certainty of evidence was lower than that of duloxetine. There was insufficient evidence
to draw robust conclusions for the efficacy and safety of any other antidepressant for chronic pain.

Primary efficacy outcomes

Duloxetine standard dose (60 mg) showed a small to moderate effect for substantial pain relief (odds ratio (OR) 1.91, 95% confidence
interval (CI) 1.69 to 2.17; 16 studies, 4490 participants; moderate-certainty evidence) and continuous pain intensity (standardised mean
difference (SMD) −0.31, 95% CI −0.39 to −0.24; 18 studies, 4959 participants; moderate-certainty evidence). For pain intensity, milnacipran
standard dose (100 mg) also showed a small effect (SMD −0.22, 95% CI −0.39 to 0.06; 4 studies, 1866 participants; moderate-certainty
evidence). Mirtazapine (30 mg) had a moderate effect on mood (SMD −0.5, 95% CI −0.78 to −0.22; 1 study, 406 participants; low-certainty
evidence), while duloxetine showed a small effect (SMD −0.16, 95% CI −0.22 to −0.1; 26 studies, 7952 participants; moderate-certainty
evidence); however it is important to note that most studies excluded participants with mental health conditions, and so average anxiety
and depression scores tended to be in the 'normal' or 'subclinical' ranges at baseline already.

Secondary efficacy outcomes

Across all secondary efficacy outcomes (moderate pain relief, physical function, sleep, quality of life, and PGIC), duloxetine and milnacipran
were  the  highest-ranked  antidepressants  with  moderate-certainty  evidence,  although  effects  were  small.  For  both  duloxetine  and
milnacipran, standard doses were as efficacious as high doses.

Safety

There  was  very  low-certainty  evidence  for  all  safety  outcomes  (adverse  events,  serious  adverse  events,  and  withdrawal)  across  all
antidepressants. We cannot draw any reliable conclusions from the NMAs for these outcomes.

Authors' conclusions

Our review and NMAs show that despite studies investigating 25 different antidepressants, the only antidepressant we are certain about
for  the  treatment  of  chronic  pain  is  duloxetine.  Duloxetine  was  moderately  efficacious  across  all  outcomes  at  standard  dose.  There  is
also promising evidence for milnacipran, although further high-quality research is needed to be confident in these conclusions. Evidence
for  all  other  antidepressants  was  low  certainty.  As  RCTs  excluded  people  with  low  mood,  we  were  unable  to  establish  the  effects  of
antidepressants for people with chronic pain and depression. There is currently no reliable evidence for the long-term efficacy of any
antidepressant, and no reliable evidence for the safety of antidepressants for chronic pain at any time point.

P L A I N   L A N G U A G E   S U M M A R Y

How effective are antidepressants used to treat chronic pain and do they cause unwanted effects?

Key messages

• We are only confident in the effectiveness of one antidepressant: duloxetine. We found that a standard dose (60 mg) was effective, and
that there is no benefit to using a higher dose.

• We are uncertain about unwanted effects for any antidepressant as the data for this were very poor. Future research should address this.

• In clinical practice for chronic pain, a standard dose of duloxetine may be considered before trying other antidepressants.

•  Adopting  a  person-centred  approach  is  critical.  Pain  is  a  very  individual  experience  and  certain  medications  may  work  for  people
even  while  the  research  evidence  is  inconclusive  or  unavailable.  Future  studies  should  last  longer  and  focus  on  unwanted  effects  of
antidepressants.

What is chronic pain?

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chronic pain is pain of any kind that lasts for more than three months. Over one-third of people across the world experience chronic pain.
This often affects people's mood and well-being, and their ability to work and carry out daily tasks.

How do antidepressants treat chronic pain?

Antidepressants  are  medications  originally  developed  to  treat  depression.  Different  types  of  antidepressants  work  in  different  ways.
Antidepressants that work in the same way are grouped into classes. The most common classes are selective serotonin reuptake inhibitors
(SSRIs), tricyclic antidepressants (TCAs), and serotonin-noradrenalin reuptake inhibitors (SNRIs). Research suggests that antidepressants
may be effective for pain because the same chemicals that affect mood might also affect pain.

What did we want to find out?

We wanted to find out if antidepressants were effective for managing chronic pain and whether they cause unwanted effects.

What did we do?

We searched for studies that compared any antidepressant with any other treatment for any type of chronic pain (except headache). We
compared all the treatments against each other using a statistical method called network meta-analysis. This method allows us to rank
the effectiveness of the different antidepressants from best to worst.

What did we find?

We  found  176  studies  including  28,664  people  with  chronic  pain.  These  studies  investigated  89  different  types  or  combinations  of
treatment.  Studies  mainly  investigated  the  effect  of  antidepressants  on  three  different  types  of  pain:  fibromyalgia  (59  studies),  nerve
pain (49 studies), and musculoskeletal pain (e.g. osteoarthritis or low back pain; 40 studies). The most common antidepressant classes
investigated were SNRIs (74 studies), TCAs (72 studies), and SSRIs (34 studies). The most common antidepressants investigated were:
amitriptyline (a TCA; 43 studies); duloxetine (an SNRI; 43 studies), and milnacipran (an SNRI; 18 studies). Of the 146 studies that reported
where their funding came from, pharmaceutical companies funded 72 studies. The average study lasted 10 weeks.

Most of the studies compared an antidepressant with a placebo (which looks like the real medicine but doesn’t have any medicine in it), but
some studies compared an antidepressant against a different type of medicine, a different antidepressant, a different type of treatment
(like physiotherapy), or different doses of the same antidepressant.

Most of the studies in this review reported information on pain relief and unwanted effects. Fewer studies reported on quality of life, sleep,
and physical function.

Main results

• Duloxetine probably has a moderate effect on reducing pain and improving physical function. It was the antidepressant that we have the
most confidence in. Higher doses of duloxetine probably provided no extra benefits than standard doses. For every 1000 people taking
standard-dose duloxetine, 435 will experience 50% pain relief compared with 287 who will experience 50% pain relief taking placebo.

• Milnacipran may reduce pain, but we are not as confident in this result as duloxetine because there were fewer studies with fewer people
involved.

• Most studies excluded people with mental health conditions, meaning that participants were already in the 'normal' ranges for anxiety
and depression at the beginning of studies. This limited our analysis for mood. Mirtazapine and duloxetine may improve mood, but we
are very uncertain about the results.

• We do not know about unwanted effects of using antidepressants for chronic pain; there are not enough data to be certain about the
results.

What are the limitations of the evidence?

There are still a number of questions that we were unable to answer:

• Aside from duloxetine and milnacipran, we do not have confidence in the results from any other antidepressant included in this review
because there are not enough studies.

• We do not know whether antidepressants are effective at treating pain in the long term. The average length of studies was 10 weeks.

• There was no reliable evidence on the safety of taking antidepressants for chronic pain, both short- and long-term.

•  We  do  not  know  how  effective  antidepressants  are  for  people  with  both  chronic  pain  and  depression  as  the  most  studies  excluded
participants with depression and anxiety.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

How up to date is this evidence?

This review is up to date to January 2022.

Cochrane Database of Systematic Reviews

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

4

 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Substantial pain relief summary of findings

Estimates of effects, credible intervals, and certainty of the evidence for substantial pain relief in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); esreboxetine standard dose (4-8 mg)
and high dose (≥ 8 mg); milnacipran standard dose (100 mg) and high dose (> 100 mg); mirtazapine standard dose (30 mg)

Comparator (reference): placebo

Outcome: substantial pain relief (≥ 50% reduction in pain intensity from baseline) as measured on various scales including 0-10 VAS, 0-100 VAS, and the Brief Pain Inventory

Direction: higher is better (i.e. more people reporting substantial pain relief)

Total studies: 42

Total participants: 14,626

Relative ef-
fect

(OR and 95%
CI)

Anticipated absolute effect (event rate)*

With placebo With interven-

Difference

tion

Certainty of
the evidence
(CINeMA)

Ranking**

(2.5% to
97.5% credi-
ble interval)

Interpretation of
findings

Duloxetine standard dose

1.91

592/2061

1058/2429

RCTs: 16

Participants: 4490

(1.69 to 2.17)

287 per 1000

435 per 1000

Duloxetine high dose

1.91

431/1855

674/1837

RCTs: 14

Participants: 3692

(1.66 to 2.21)

232 per 1000

366 per 1000

Milnacipran high dose

1.64

38/145

88/239

RCTs: 1

Participants: 384

(1.04 to 2.58)

262 per 1000

368 per 1000

Esreboxetine standard dose

1.72

33/275

105/553

RCTs: 1

5

(1.13 to 2.62)

120 per 1000

190 per 1000

148 more per
1000

Moderatea

8

(5 to 12)

Equivalent to NNTB
of 7.1

134 more per
1000

Moderatea

8

(5 to 12)

Equivalent to NNTB
of 7.4

106 more per
1000

Very lowa,b

11

(4 to 19)

Equivalent to NNTB
of 9.4

70 more per
1000

Lowa

11

(4 to 19)

Equivalent to NNTB
of 14

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Participants: 828

Milnacipran standard dose

1.65

130/654

187/644

RCTs: 2

Participants: 1298

(1.28 to 2.13)

199 per 1000

290 per 1000

Mirtazapine standard dose

1.30

33/211

41/211

RCTs: 1

Participants: 422

(0.79 to 2.15)

156 per 1000

194 per 1000

Duloxetine low dose

1.71

150/523

242/593

RCTs: 6

Participants: 1116

(1.36 to 2.20)

287 per 1000

407 per 1000

Esreboxetine high dose

1.29

33/275

42/280

RCTs: 1

Participants: 555

(0.79 to 2.11)

120 per 1000

150 per 1000

Desvenlafaxine high dose

1.19

51/215

177/655

RCTs: 2

Participants: 870

(0.83 to 1.70)

237 per 1000

270 per 1000

Network meta-analysis-summary of findings table definitions

91 more per
1000

Lowa,c

12

(6 to 18)

Equivalent to NNTB
of 11

39 more per
1000

Lowe

15

(6 to 21)

Not significantly dif-
ferent from placebo

120 more per
1000

Moderatea,b,c

16

(11 to 20)

Equivalent to NNTB
of 8.3

30 more per
1000

Very lowa,b

16

(7 to 22)

Not significantly dif-
ferent from placebo

33 more per
1000

Very lowa,b

17

(11 to 21)

Not significantly dif-
ferent from placebo

*Anticipated absolute effect. Anticipated absolute effect compares 2 risks by calculating the difference between the risk of the intervention group with the risk of the con-
trol group.

** Mean rank and credible intervals are presented.

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; NNTB: number needed to treat for an additional beneficial outcome; OR: odds ratio; RCT: ran-
domised controlled trial; VAS: visual analogue scale

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

Summary of findings 2.   Pain intensity summary of findings

Estimates of effects, credible intervals, and certainty of the evidence for pain intensity in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran standard dose (100 mg) and high dose (> 100 mg)

Comparator (reference): placebo

Outcome: change in pain intensity, as measured on multiple scales including 0-10 VAS, 0-100 VAS, Brief Pain Inventory, and the Short-form McGill Pain Questionnaire

Direction: lower is better (i.e. a greater reduction in pain intensity)

Total studies: 50

Total participants: 14,926

Relative ef-
fect

Anticipated absolute effect (event rate)

With placebo With inter-

Difference

vention

Certainty of
the evidence
(CINeMA)

Ranking*

(2.5% to
97.5% credi-
ble interval)

Interpretation of
findings**

Duloxetine high dose

RCTs: 14

Participants: 3683

Duloxetine standard dose

RCTs: 18

Participants: 4959

-

-

-

-

-

-

SMD −0.37

Lowa,b

9

(−0.45 to −0.28)

(8 to 13)

Small to moderate
effect

SMD −0.31

Moderateb

11

(−0.39 to −0.24)

(10 to 15)

Small to moderate
effect

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Milnacipran high dose

RCTs: 2

Participants: 1670

Milnacipran standard dose

RCTs: 4

Participants: 1866

Duloxetine low dose

RCTs: 6

Participants: 1104

-

-

-

-

-

-

-

-

-

SMD −0.22

Lowa,c

14

Small effect

(−0.40 to −0.05)

(12 to 19)

SMD −0.22

Moderatea,b

14

Small effect

(−0.39 to −0.06)

(12 to 20)

SMD −0.11

Moderatea,c

17

(−0.25 to 0.03)

(12 to 21)

Not significant-
ly different from
placebo

Network meta-analysis-summary of findings table definitions

*Mean rank and credible intervals are presented.

**SMD interpretation based on clinical judgement and in line with Cohen 1988 and the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2022) as
small (0.2), moderate (0.5) and large (0.8).

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; RCT: randomised controlled trial; SMD: standardised mean difference; VAS: visual analogue scale

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

Summary of findings 3.   Mood summary of findings

Estimates of effects, credible intervals, and certainty of the evidence of antidepressants on mood in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses combined)

Comparator (reference): placebo

Outcome: change in mood (depression, anxiety, distress) scores as measured on various scales including the Beck Anxiety Inventory, Beck Depression Inventory, SF-36
Mental Component Score, and the SF-36 Mental Health Subscale

Direction: lower is better (i.e. a greater reduction of distress, depression, or anxiety)

Total studies: 38

Total participants: 12,985

Relative ef-
fect

Anticipated absolute effect (event rate)

With placebo With inter-

Difference

vention

Certainty of
the evidence
(CINeMA)

Ranking*

(2.5% to 97.5%
credible inter-
val)

Interpretation of
findings**

Mirtazapine

RCTs: 1

Participants: 406

Duloxetine

RCTs: 26

Participants: 7952

Milnacipran

RCTs: 5

Participants: 3109

-

-

-

-

-

-

-

-

-

SMD −0.5

Lowe

4 (2 to 7)

Moderate effect

(−0.78 to −0.22)

SMD −0.16

Moderatea

8 (5 to 11)

Small effect

(−0.22 to −0.1)

SMD −0.13

Moderatea,c

9 (5 to 13)

(−0.26 to 0.01)

Not significant-
ly different from
placebo

Network meta-analysis-summary of findings table definitions

*Mean rank and credible intervals are presented.

**SMD interpretation based on clinical judgement and in line with Cohen 1988 and the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2022) as
small (0.2), moderate (0.5) and large (0.8).

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; RCT: randomised controlled trial; SMD: standardised mean difference

9

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

Summary of findings 4.   Adverse events summary of findings

Estimates of effects, credible intervals, and certainty of the evidence for adverse events with antidepressants in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: amitriptyline standard dose (25-75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg);
milnacipran standard dose (100 mg) and high dose (> 100 mg); mirtazapine standard dose (30 mg)

Comparator (reference): placebo

Outcome: adverse events (as reported per study)

Direction: lower is better (i.e. fewer people reporting adverse events)

Total studies: 93

Total participants: 22,558

Relative ef-
fect

(OR and 95%
CI)

Anticipated absolute effect (event rate)*

With placebo With interven-

Difference

tion

Certainty of
the evidence
(GRADE)

Ranking**

(2.5% to
97.5% credi-
ble interval)

Interpretation of
findings

Desvenlafaxine high dose

1.67

174/220

590/685

RCTs: 2

1
0

(0.92 to 2.41)

791 per 1000

863 per 1000

72 more per
1000

Very lowa,b,c

30 (16 to 48)

Not significant-
ly different from
placebo

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

Participants: 905

Mirtazapine standard dose

1.70

135/228

162/229

RCTs: 2

Participants: 457

(0.48 to 2.91)

592 per 1000

712 per 1000

Duloxetine standard dose

1.88

1259/2164

1883/2834

RCTs: 20

Participants: 4998

(1.58 to 2.17)

582 per 1000

723 per 1000

Milnacipran standard dose

1.92

930/1235

1039/1256

RCTs: 8

Participants: 2491

(1.37 to 2.46)

753 per 1000

854 per 1000

Duloxetine high dose

1.93

1199/1912

1587/2088

RCTs: 10

Participants: 4000

(1.64 to 2.23)

627 per 1000

764 per 1000

Duloxetine low dose

2.03

271/437

325/594

RCTs: 6

Participants: 1031

(1.45 to 2.62)

620 per 1000

768 per 1000

Milnacipran high dose

2.44

930/1264

1294/1573

RCTs: 7

Participants: 2837

(1.89 to 2.98)

736 per 1000

872 per 1000

Amitriptyline standard dose

2.66

250/479

351/518

RCTs: 10

Participants: 997

(2.14 to 3.19)

522 per 1000

744 per 1000

120 more per
1000

Very lowb,c

31 (11 to 52)

Not significant-
ly different from
placebo

142 more per
1000

Very lowa,b

33 (24 to 42)

Equivalent NNTH is
7.0

101 more per
1000

Very lowa,b,c

33 (20 to 45)

Equivalent NNTH is
10

137 more per
1000

Very lowa,b

34 (24 to 43)

Equivalent NNTH is
7.03

148 more per
1000

Very lowa,b

35 (21 to 47)

Equivalent NNTH is
7.0

136 more per
1000

Very lowa,b

39 (25 to 50)

Equivalent NNTH is
6.8

222 more per
1000

Very lowa,b,e

41 (28 to 51)

Equivalent NNTH is
4.5

Esreboxetine standard dose

2.92

85/227

315/556

RCTs: 1

(1.90 to 3.93)

374 per 1000

636 per 1000

262 more per
1000

Very lowa,b,c,e

42 (21 to 56)

Equivalent NNTH is
3.8

Participants: 783

1
1

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Network meta-analysis-summary of findings table definitions

* Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the
control group.

** Mean ranks and credible intervals are presented.

CI: confidence interval; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; RCT: randomised controlled trial

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

1
2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Chronic  pain  is  common  in  adults  internationally,  and  is  defined
as pain lasting or recurring for three months or longer (IASP 2019).
Chronic pain can be a primary condition or can occur in the context
of a disease (Treede 2019).

Chronic pain and its impact on an individual is generally assessed
via  self-report.  It  is  estimated  that  about  one  in  five  adults
worldwide  experience  pain  that  is  moderate  or  severe  in  its
intensity  and  lasts  three  months  or  more  (Moore  2014),  however
estimates vary and may be higher. For example, reviews of chronic
pain  in  the  UK  suggest  that  between  a  third  and  a  half  of  the
population experience chronic pain (Fayaz 2016); and a review of
chronic low back pain in Africa reported the annual prevalence as
57% (Morris 2018). Some populations are more likely to experience
chronic pain: older adults, women, people not in employment due
to  ill  health  and  disability,  and  people  with  comorbidities  (Mills
2019).  Social  circumstances  are  particularly  influential;  people  in
low  socio-economic  circumstances  are  not  only  more  likely  to
experience  chronic  pain,  but  also  report  higher  levels  of  severity
and disability (Mills 2019).

The impact of chronic pain is similar across conditions, despite the
different aetiologies. Globally, chronic pain accounts for the highest
number of years lived with disability, and affects individuals’ daily
lives,  society  and  healthcare  services  (Breivik  2006;  Rice  2016).
Chronic  pain  accounts  for  up  to  one  in  five  general  practice
consultations each year in Europe, Africa and Asia (European Pain
Federation 2016; Jordan 2010; Morris 2018). Chronic pain is also one
of the global leading causes for sickness absence and people being
unable to work (Bevan 2012; Office for National Statistics 2019).

On an individual level, chronic pain can severely impair a person's
quality  of  life,  including  physical  functioning,  mood,  sleep,  and
ability  to  work  outside  the  home  (Breivik  2006).  It  has  also
been  long-established  that  chronic  pain  influences  a  person's
mood;  depression  is  estimated  to  be  three  to  four  times  more
prevalent in people with chronic pain than those without (Gureje
1998;  Sullivan  1992;  Tunks  2008).  Depression  is  characterised  by
persistent  feelings  of  sadness  or  low  mood,  loss  of  pleasure  in
activities,  fatigue,  loss  of  motivation,  changes  in  appetite  and
having  thoughts  of  suicide  or  self-harm  (American  Psychiatric
Association 2013). People have reported that experiencing only a
few  depressive  symptoms  can  be  both  distressing  and  disabling;
therefore,  it  is  important  to  address  these  as  effectively  as
possible  (NICE  2009a).  Depression  and  chronic  pain  are  complex
to  address  in  both  research  and  clinical  practice,  as  many  of  the
symptoms  of  chronic  pain  can  overlap  with  those  of  depression
(for  example,  fatigue  and  loss  of  motivation  or  pleasure  in
activities).  Furthermore,  the  content  of  depressive  thoughts  and
the  antecedents  of  feelings  of  sadness  experienced  by  people
in  chronic  pain  may  differ  to  those  experienced  in  people
with  depression  but  without  pain.  It  is  important  to  identify
differences  in  pain-related  distress  (i.e.  individuals  with  chronic
pain  experiencing  low  mood  because  of  their  pain)  and  clinical
depression, which may reflect on the prevalence statistics reported
above.

Successful  treatment  of  chronic  pain  can  result  in  significant
improvements in quality of life, including anxiety and depression

Cochrane Database of Systematic Reviews

(Goesling  2013;  Moore  2010a;  Moore  2014).  A  systematic  review
identified  that  for  people  with  fibromyalgia,  reductions  in  pain
intensity  of  50%  or  more  is  associated  with  self-reports  of  sleep,
fatigue  and  depression  reverting  to  normative  values  (Moore
2014).  Therefore,  efficacious  treatment  of  the  pain  condition  is
essential  for  improvement  of  both  pain  and  mood,  in  addition
to potential improvements in sleep, physical function and quality
of  life.  There  are  many  different  treatments  aimed  at  reducing
and  managing  chronic  pain,  including  analgesic  medication,
physiotherapy, self-management guidance, exercise, psychological
therapy,  antidepressants,  pain  management  clinics  and  surgery.
The  use  of  these  depends  upon  the  pain  condition,  severity  of
pain, individual characteristics, availability of services and national
policy and guidelines.

Description of the intervention

Antidepressants  are  medicines  developed  and  used  primarily  for
the  treatment  of  clinical  depression.  A  network  meta-analysis
(NMA)  of  the  21  most  common  antidepressants  has  shown  that
they  are  efficacious  in  the  treatment  of  acute  major  depression,
particularly severe depression (Cipriani 2018).

 Antidepressants are grouped into different classes based on their
chemical structure and presumed mechanism of action. The most
common classes are:

• tricyclic  antidepressants  (TCAs):  amitriptyline,  desipramine,

imipramine, nortriptyline, and others;

• selective  serotonin  reuptake  inhibitors  (SSRIs):  citalopram,

sertraline, fluoxetine, and others;

• serotonin  norepinephrine 

(SNRIs):
duloxetine,  levomilnacipran,  milnacipran,  venlafaxine,  and
others;

inhibitors 

reuptake 

• monoamine oxidase inhibitors (MAOIs):

◦ irreversible: phenelzine, tranylcipromine, izocarboxazid, and

others;

◦ reversible: brofaramine, moclobemide, tyrima, and others.

Antidepressants  are  recommended  for  first-line  treatment  of
depression,  but  can  also  be  used  'off-label'  in  clinical  practice
to treat other conditions, including chronic pain (British National
Formulary  2022a).  Prescriptions  of  antidepressants  are  relatively
common in patients with chronic pain internationally; for example,
12.3%  of  people  with  chronic  low  back  pain  in  Portugal  report
taking  antidepressants  for  pain  relief  (Gouveia  2017;  Kurita
2012).  Recent  guidance  from  the  National  Institute  for  Health
and  Care  Excellence  (NICE)  recommends  the  use  of  duloxetine,
amitriptyline,  fluoxetine,  paroxetine,  citalopram  and  sertraline  in
the management of chronic primary pain (NICE 2020). Amitriptyline
and  duloxetine  are  also  recommended  as  first-line  treatments
for  neuropathic  pain  in  primary  care  (NICE  2019).  Both  of  these
guidelines  recommend  these  antidepressants  regardless  of  a
person's  mood.  However,  other  guidelines  contradict  this,  for
example  antidepressants  can  be  prescribed  for  people  with  a
chronic physical health condition only if they are also experiencing
moderate  to  severe  depression  (NICE  2009b),  but  they  are  not
recommended  at  all  for  the  treatment  of  chronic  low  back
pain  (without  sciatica;  NICE  2017).  The  NICE  guidelines  for
chronic  primary  pain  recommend  antidepressants  as  the  only
pharmacological  intervention  to  manage  chronic  primary  pain
(NICE 2021).

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

These  guidelines  only  reviewed  the  evidence  from  head-to-head
trials,  and  subsequently  recommend  six  antidepressants  with
no  hierarchy:  amitriptyline,  citalopram,  duloxetine,  fluoxetine,
paroxetine, or sertraline. Therefore, guidance for clinicians is mixed
and  unclear.  Furthermore,  as  antidepressants  can  be  prescribed
for  treating  mood  or  pain,  the  proportions  of  antidepressants
prescribed  to  people  with  chronic  pain  for  the  primary  aim  to
reduce pain or improve mood is unknown.

There are also risks in the prescription of antidepressants. Adverse
events such as dizziness, headache, nausea, ejaculation disorder,
weight  loss,  tremor,  sweating  and  insomnia,  have  been  found
by  randomised  controlled  trials  (RCTs)  to  be  more  common  in
people taking antidepressants compared with those taking placebo
(Riediger 2017; Sinyor 2020). Use of antidepressants is associated
with  an  increased  risk  of  falls,  fractures,  all-cause  mortality,  and
stroke  in  older  adults  (aged  65  and  over),  and  self-harm  and
suicide  in  both  younger  adults  (aged  20  to  64)  and  older  adults
(Coupland  2011;  Coupland  2015).  Antidepressants  also  increase
the  risk  of  onset  of  seizures  (Hill  2015);  and  the  potential  for
gastrointestinal  bleeding  with  SSRIs  is  widely  recognised  (Jiang
2015). Therefore, long-term use of antidepressants for people with
chronic pain is expected to be associated with potential for harms
at the population level.

How the intervention might work

by 

antidepressants  work 

Antidepressants  were  originally  developed  to  treat  depression.
targeting  monoamine
Most 
neurotransmitters  associated  with  mood  and  emotion  and
their  receptors  in  the  nervous  system.  These  receptors,  such
as  5-hydroxytryptamine  receptors,  are  activated  by  many
neurotransmitters 
including  serotonin,  dopamine,  adrenaline
and  noradrenaline  (Harmer  2017).  Antidepressants  prevent  the
neurotransmitters  from  being  absorbed  into  neurons,  which
prolongs  their  activity  in  synapses.  The  process  by  which  this
relieves depression is not fully understood, but research currently
focuses on theories of neurochemical changes and neuroplasticity
(Harmer  2017).  Additionally,  depending  upon  the  class,  the
effect  of  antidepressants  may  be  delayed,  with  reported  clinical
improvement  often  taking  weeks  to  occur  (Harmer  2017;  Tylee
2007).

Antidepressants  are  also  often  used  to  manage  chronic  pain.
Antidepressants  are  reported  to  offer  an  analgesic  response  in
people with pain without depression, particularly for neuropathic
pain,  but  also  for  some  people  with  fibromyalgia,  osteoarthritis,
and back pain. It is theorised that the body's pain response systems
travelling    to  and  from  the  brainstem  involve  the  noradrenergic
neurotransmitters  (Taylor  2017).  Therefore,  by  increasing  the
amount  of  serotonin  and  noradrenaline  in  the  nervous  system,
this may subsequently block pain signals at the peripheral, spinal,
and  supraspinal  levels,  reducing  perceived  pain;  particularly  in
neuropathic pain (Finnerup 2021; Kremer 2018).

Additionally,  a  part  of  the  brain  called  the  locus  coeruleus  may
have an analgesic effect on pain in the body (Llorca-Torralba 2016).
Signals from this part of the brain are sent when the body reacts
to a stimulus, such as pain, and noradrenaline is released into the
dorsal  horn  in  the  spine  to  block  receptors.  Animal  studies  have
shown that when pain signals are continuously received, as is the
case  in  chronic  pain,  this  analgesic  response  lessens  over  time,
and noradrenaline is then not released (Llorca-Torralba 2016; Obata

Cochrane Database of Systematic Reviews

2017).  However,  when  antidepressants  are  given,  the  analgesic
response from the locus coeruleus is restored (Alba-Delgado 2012;
Llorca-Torralba 2016).

Why it is important to do this review

To date, there have been no NMAs investigating all antidepressants
for  all  chronic  pain  conditions.  There  is  no  evidence  comparing
classes  of  antidepressants  to  each  other  in  the  management  of
chronic  pain,  as  identified  by  the  recent  NICE  guidelines  (NICE
2020).  Therefore,  in  the  absence  of  any  one  RCT  comparing  the
efficacy and safety of all antidepressants for chronic pain, a NMA is
required to assess their relative effectiveness.

Previous  Cochrane  Reviews  have  investigated  the  efficacy  of
individual  antidepressants  in  improving  individual  chronic  pain
conditions,  and  where  possible  by  dose.  There  is  no  high-
quality  evidence  to  support  or  refute  the  use  of  amitriptyline,
milnacipran, nortriptyline, venlafaxine, desipramine or imipramine
for  management  of  neuropathic  pain  (Derry  2015a;  Derry  2015b;
Gallagher 2015; Hearn 2014a; Hearn 2014b; Moore 2015), principally
because of limited numbers of small studies with some high risks of
bias. This is despite amitriptyline being recommended as a first-line
treatment for neuropathic pain in primary care in guidelines for the
UK, Canada and the International Association for the Study of Pain
(Bates  2019;  Finnerup  2015;  Moulin  2014;  NICE  2019).  However,
there is moderate-quality evidence that duloxetine is efficacious for
diabetic peripheral neuropathy at doses of 60 mg and 120 mg (Lunn
2014).

For fibromyalgia, Cochrane Reviews of antidepressants show that
there  is  no  unbiased  evidence  that  amitriptyline,  desvenlafaxine,
venlafaxine  or  SSRIs  are  superior  to  placebo  (Walitt  2015;
Welsch  2018).  There  is  low-quality  evidence  that  duloxetine  and
milnacipran  have  some  benefit  in  improving  patients’  global
impression  of  change  (PGIC)  and  providing  an  improvement  in
pain relief of 30% or more, but no clinical benefit over placebo for
improvement in pain relief of 50% or more, health-related quality
of  life  or  fatigue  (Welsch  2018).  Similarly,  for  mirtazapine,  there
is  evidence  for  improvement  in  pain  relief  of  30%  or  more,  and
reduction  of  mean  pain  intensity  and  sleep  problems,  but  this
evidence  is  of  low  to  medium  quality,  and  there  is  no  benefit  for
improvement in pain relief of 50% or more, PGIC, 20% improvement
of health-related quality of life, reduction of fatigue or reduction in
negative mood (Welsch 2015).

Only  one  Cochrane  Review  has 
investigated  the  use  of
antidepressants for low back pain, and it found no clear evidence
to  support  the  use  of  any  antidepressants  (Urquhart  2008).
A more recent systematic review supports these conclusions (Koes
2018).  However,  when  analysed  using  the  baseline  observation
carried  forward  imputation  method  for  missing  data,  pooled
individual  patient  data  analyses  of  RCTs  have  shown  duloxetine
and etoricoxib to be effective in reducing pain for pain conditions
including chronic low back pain (Moore 2010b; Moore 2014). These
distributions were bimodal; participants generally responded very
well or very poorly, with few in between (Moore 2014).

These  previous  reviews  have  shown  that  there  is  no  evidence
comparing the data across all antidepressants and pain conditions.
Through  our  review  and  network  meta-analysis,  we  intend  to
compare  all  these  antidepressants  across  pain  conditions,  and
identify  whether  certain  classes  or  doses  of  antidepressants  are

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

useful in the management of pain and mood for people with chronic
pain,  and  for  certain  chronic  pain  conditions.  As  antidepressants
are also associated with a number of side effects, we will compare
the proportion of adverse events occurring with the use of different
antidepressants  (including  different  classes  of  antidepressants,
different  types  of  antidepressants,  and  different  dose  regimes)
within populations living with chronic pain.

There 
is  evidence  that  people  with  chronic  pain  may  be
experiencing pain-related distress rather than clinical depression,
although  both  conditions  can  present  with  similar  symptoms
(Rusu  2016).  The  distinction  between  pain-related  distress  and
depression is particularly important as primary care practitioners
are  often  given  contradictory  guidance:  they  are  encouraged
to  better  detect  depression  (Mitchell  2009;  Nuyen  2005),  whilst
avoiding  over-medicalisation  of  distress  and  thus  over-treatment
(Dowrick 2013; Mulder 2008). This is important as antidepressants
can be prescribed for both the management of pain and mood (e.g.
clinical depression) in people with chronic pain. This review aimed
to clarify this guidance as, unlike previous reviews in this area, we
intended to investigate whether there were differences dependent
upon  whether  the  antidepressants  were  prescribed  to  primarily
treat mood or pain.

O B J E C T I V E S

To assess the comparative efficacy and safety of antidepressants for
adults with chronic pain (except headache) by:

• assessing the efficacy of antidepressants by type, class and dose
in improving pain, mood, physical function, sleep, quality of life
and PGIC;

• assessing  the  number  of  adverse  events  and  serious  adverse

events for antidepressants by type, class and dose;

• ranking antidepressants for efficacy of treating pain, mood and

adverse events.

M E T H O D S

Criteria for considering studies for this review

Types of studies

We  included  RCTs  that  compared  any  antidepressant  with  any
comparator.  RCTs  are  the  best  design  to  minimise  bias  when
evaluating  the  effectiveness  of  an  intervention.  We  followed  the
guidance  in  the  Cochrane  Handbook  for  Systematic  Reviews  of
Interventions  for  the  inclusion  of  cross-over  RCTs,  which  requires
inclusion  of  this  type  of  study  unless  there  is  a  justifiable  reason
not  to  (McKenzie  2020).  The  risk  in  this  review  was  that  washout
periods between the periods of the study would not be long enough
for carry-over effects from the antidepressants or comparators to
be sufficiently minimised. Therefore, we only included cross-over
trials with washout periods of at least five times the length of the
antidepressant  half-life  (this  was  calculated  individually  for  each
antidepressant).

The  most  common  comparators  we  anticipated  finding  in  the
literature  were:  the  same  antidepressant  at  a  different  dose;  a
different  antidepressant;  placebo  (both  active  and  inert);  other
medications  for  pain  management  purposes  (e.g.  pregabalin,
gabapentin);  analgesics;  psychological  therapy  (e.g.  cognitive
behavioural  therapy,  acceptance  and  commitment  therapy);

Cochrane Database of Systematic Reviews

exercise;  physiotherapy;  multidisciplinary  pain  programmes;
herbal  medicines  and  nutraceuticals  (e.g.  St  John’s  Wort);
and  acupuncture.  Where  the  comparator  was  a  placebo,
antidepressant,  analgesic  or  other  medication 
for  pain
management  purposes,  these  studies  were  required  to  be
double-blind.  We  included  studies  that  examined  any  dose  of
antidepressants, with a study duration of at least two weeks and
minimum of 10 participants per arm. We excluded non-randomised
studies,  case  reports,  experimental  studies,  clinical  observations
and prevention studies.

Types of participants

We included adults (aged 18 years or older) reporting primary or
secondary pain in any part of their body (except headache) as their
primary  complaint,  that  matched  the  International  Association
for  the  Study  of  Pain  (IASP)  definition  of  chronic  pain  (i.e.  at
least three months' duration; IASP 2019). We included all studies
regardless  of  the  severity  of  participants'  chronic  pain,  although
we extracted whether severity was part of the inclusion criteria of
the individual studies. We excluded studies where the participants'
primary  complaint  was  headache  or  migraine,  as  this  had  been
covered  in  previous  Cochrane  Reviews  (Williams  2020).  Although
this  condition  does  fit  within  the  IASP  criteria,  the  diagnosis,
classification  and  treatment  of  primary  and  secondary  headache
are often different from that of other pain conditions; and clinical
trials  are  primarily  aimed  at  prevention  of  further  headaches
or  migraines  rather  than  symptomatic  treatment.  We  included
participants with multiple health conditions as long as the chronic
pain condition was the focus of the trial.

Types of interventions

Decision set

We  included  any  antidepressant  at  any  dose,  for  any  indication,
but  used  primarily  for  treatment  of  people  with  chronic  pain
and  compared  to  placebo  or  active  intervention.  We  included
antidepressants grouped into the following classes.

• Tricyclic  antidepressants  (TCAs):  amitriptyline,  clomipramine,
imipramine, trimipramine, doxepin, desipramine, protriptyline,
nortriptyline, dothiepin, lofepramine, and others

• Selective  serotonin  reuptake  inhibitors  (SSRIs):  fluvoxamine,
fluoxetine,  paroxetine,  sertraline,  citalopram,  escitalopram,
zimelidine and others
• Serotonin-noradrenaline 

inhibitors 

reuptake 

(SNRIs):

venlafaxine, milnacipran, duloxetine, and others

• Monoamine oxidase inhibitors (MAOIs):

◦ irreversible: phenelzine, tranylcipromine, izocarboxazid, and

others;

◦ reversible: brofaramine, moclobemide, tyrima, and others

• Other antidepressants

◦ Noradrenaline  reuptake 
atomoxetine, and others

inhibitors 

(NARIs):  reboxetine,

◦ Noradrenaline  and  dopamine  reuptake  inhibitors  (NDRIs):

amineptine, bupropion, and others

◦ Noradrenergic  and  specific  serotonergic  antidepressants
(NaSSAs)  including  tetracyclic  antidepressants  (TeCA)  such
as: mirtazapine, mianserin, maprotiline, and others

◦ Serotonin  antagonist  and  reuptake 

inhibitors  (SARIs):

trazodone, and others

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

◦ Unclassified: agomelatine, vilazodone, and others

Primary outcomes

We  categorised  doses  of  included  antidepressants  into  low,
standard,  and  high  doses.  These  are  displayed  in  Table  1.  As  the
majority  of  antidepressants  are  not  licensed  for  pain,  we  based
our judgements on the recommendations of daily doses for clinical
depression  in  the  British  National  Formulary  (British  National
Formulary 2022a). The judgements were made by clinical authors
of the review; initially by the clinical pharmacist and then approved
by discussion with a psychiatrist and anaesthetist.

Standard  doses  were  the  recommended  doses  for  depression  in
adults.  Low  doses  were  those  listed  as  initial  doses  (where  a
standard range is specified), the dose for elderly patients, or any
dose  below  the  standard  dose  (where  no  range  was  specified).
High doses were those listed at the upper range of standard dose
ranges,  or  above  the  standard  dose  where  no  range  is  specified.
Where studies included flexible dosing across multiple categories
and did not report mean dose, we labelled them as ‘unable to be
categorised’.

Supplementary sets

We  included  studies  with  any  active  comparator.  We  included
studies  where  the  antidepressant  is  combined  with  another
intervention,  as  long  as  there  was  an  arm  solely  for  the  other
intervention,  so  we  were  able  to  isolate  the  effects  of  the
antidepressant (e.g. antidepressant + drug versus drug). We did not
include combination studies where there was no way to isolate the
effects  of  an  antidepressant  (e.g.  antidepressant  A  +  drug  versus
antidepressant B). For this review we assumed that any participant
who  met  the  inclusion  criteria  was,  in  principle,  equally  likely  to
be  randomised  to  any  of  the  eligible  antidepressants;  however,
we  acknowledge  there  may  have  been  differences  in  patients’
expectations  of  treatment  and  outcomes  depending  upon  which
antidepressant was studied.

Types of outcome measures

We anticipated that there would be a variety of outcome measures
used  throughout  the  literature.  Due  to  the  distinction  between
distress and depression discussed above, this review used the term
'mood'  as  an  outcome,  to  include  depression  that  is  diagnosed,
mood that is measured via self-report, and distress.

For  pain  and  mood,  where  applicable  we  also  dichotomised
outcomes  into  pain  relief  or  improvement  of  50%  or  greater,
in  line  with  the  Initiative  on  Methods,  Measurement,  and  Pain
Assessment  in  Clinical  Trials  (IMMPACT)  guidance,  to  indicate
substantial  improvement  (Dworkin  2008).  Where  possible,  we
planned  separate  NMAs  to  compare  antidepressants  to  the
comparators immediately post-intervention, at short-term follow-
up (12 weeks or less post-treatment) and long-term follow up (over
12 weeks post-treatment). Where studies included multiple follow-
up  time  points,  we  took  the  most  recent  time  point  within  each
period. If multiple measures were used for the same outcome (e.g.
for continuous pain intensity both a 0 to 10 numerical rating scale
and the McGill Pain Questionnaire (Melzack 1975) were reported),
then  we  extracted  from  the  most  valid,  reliable,  and  widely  used
measure in the field.

• Substantial  pain  relief:  proportion  of  participants  (number
and  percentage  of  total  and  per  arm)  reporting  at  least  50%
reduction  in  pain  intensity  from  baseline,  irrespective  of  pain
measurement  method  (e.g.  visual  analogue  scale,  numerical
rating scale)

• Pain  intensity:  continuous  data  from  any  measures  of  pain
intensity  or  severity  (e.g.  visual  analogue  scale  or  validated
measures such as Brief Pain Inventory)

• Mood: continuous data from any measures of mood (e.g. visual

analogue scale, Hospital Anxiety and Depression Scale)

• Adverse  events:  the  proportion  of  participants  (number  of

percentage of total and per arm) reporting adverse events

Secondary outcomes

• Moderate  pain  relief:  the  proportion  of  participants  (number
and  percentage  of  total  and  per  arm)  reporting  at  least  30%
reduction  in  pain  intensity  from  baseline,  irrespective  of  pain
measurement  method  (e.g.  visual  analogue  scale,  numerical
rating scale).

• Physical  function:  continuous  data  from  any  measures  of
physical  movement  and  disability,  e.g.  numerical  rating  scale,
SF-36 Physical Component Score)

• Sleep: continuous data from any measures of quality of sleep,
including  insomnia,  restfulness,  etc.  (e.g.  Brief  Pain  Inventory,
Jenkins Sleep Scale)

• Quality of life: continuous data from any measure of quality of

life (e.g. numerical rating scale, EQ-5D)

• Patient  Global  Impression  of  Change  (PGIC):  the  proportion
of  participants  (number  and  percentage  of  total  and  per  arm)
reporting "much" and "very much" improved on the PGIC scale,
and continuous data from the PGIC scale.

• Serious adverse events: the proportion of participants (number
of  percentage  of  total  and  per  arm)  reporting  serious  adverse
events).

• Withdrawal:  the  proportion  of  participants  (number  and
percentage of total and per arm) withdrawing for any reason.

Search methods for identification of studies

This search was last run on 4 January 2022.

Electronic searches

We  searched 
restrictions.

the 

following  databases,  without 

language

• The  Cochrane  Central  Register  of  Controlled  Trials  (CENTRAL;
2021,  Issue  12)  via  the  Cochrane  Library  (searched  4  January
2022)

• MEDLINE and MEDLINE In-Process (via OVID) - 1946 to 4 January

2022

• Embase (via OVID) - 1974 to 4 January 2022
• CINAHL (via EBSCO) - 1981 to December 2021
• LILACS (via Birme - 1982 to Dec 2021)
• PsycINFO (via EBSCO)) - 1872 to 4 January 2022
• AMED (via OVID) - 1985 to December 2021

We tailored searches to individual databases. The search strategies
used  can  be  found  in  Appendix  1.  The  search  strategy  was

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

developed  by  the  Cochrane  Pain,  Palliative  and  Supportive
Care  (PaPaS)  Review  Group’s  Information  Specialist  and  was
independently  peer-reviewed.  The  PaPaS  Information  Specialist
performed the searches.

Searching other resources

We searched ClinicalTrials.govand the WHO International Clinical
Trials  Registry  Platform  (ICTRP)  for  unpublished  and  ongoing
studies. In addition, we searched grey literature, checked reference
lists  of  reviews  and  retrieved  articles  for  additional  studies,  and
performed  citation  searches  on  key  articles.  We  contacted  study
authors for additional information where necessary.

Data collection and analysis

Selection of studies

Two  review  authors  (HB  and  CF)  independently  determined
eligibility  of  each  study  identified  by  the  search.  Review  authors
independently  eliminated  studies  that  clearly  did  not  satisfy
inclusion criteria, and obtained full copies of the remaining studies.
HB  and  CF  read  these  studies  independently  to  select  relevant
studies,  and  in  the  event  of  a  disagreement,  third  and  fourth
authors adjudicated (TP and CE). We did not anonymise the studies
in  any  way  before  assessment.  We  have  included  a  PRISMA  flow
chart that shows the status of identified studies (Moher 2009), as
recommended  in  Cochrane  Handbook  for  Systematic  Reviews  of
Interventions  (Lefebvre  2022).  We  included  studies  in  the  review
irrespective of whether measured outcome data were reported in a
'useable' way. We recorded reasons for exclusion of any ineligible
studies at the full-text stage.

Data extraction and management

Two  review  authors  (HB  and  CF)  independently  extracted  data
using a standard piloted form and checked for agreement before
entry into Review Manager Web (RevMan Web 2023). In the event
of disagreement, third and fourth authors (TP and CE) adjudicated.
We collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
collected characteristics of the included studies in sufficient detail
to  populate  the  table  of  'Characteristics  of  included  studies'.  We
extracted the following information.

• Study  design:  authors,  publication  year  and  journal,  duration,
sponsorship,  conflicts  of  interest,  aim  (pain  or  emotional
functioning),  design,  number  of  treatment  arms,  setting,
missing  data  methods,  power  calculation  used,  definition  of
chronic  pain,  minimum  level  of  pain  for  entry,  inclusion  and
exclusion criteria

• Setting
• Participant characteristics: overall number, number in each arm,
withdrawal  (total,  per  arm  and  by  sex),  type  of  participant,
chronic pain conditions, sex, age, baseline differences

• Intervention: type of antidepressant, class, dose (freeform and

dichotomised), route of administration, duration

• Comparator(s):  type  (e.g.  placebo,  psychological  therapy),
description (if placebo medication: active or inert, appearance,
taste,  smell,  titration,  number  of  tablets),  type  and  class  (if
other  antidepressant),  doses,  route  of  administration,  length,
intensity (if physical or psychological comparator)

Cochrane Database of Systematic Reviews

• Outcomes  (data  from  all  time  points  reported  in  the  study):
domain  (e.g.  pain,  physical  functioning),  measure,  measure
validation, baseline data, results for each time point, effect sizes
• Adverse  events  and  withdrawals  (proportion  overall  and  per
arm): any, serious, withdrawal due to adverse event, withdrawal
due to lack of efficacy

Assessment of risk of bias in included studies

Two  review  authors  (HB  and  CF)  independently  assessed  risk  of
bias  for  each  study,  using  the  criteria  outlined  in  the  Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  (Higgins  2011),
with  any  disagreements  resolved  by  discussion.  We  completed  a
risk of bias table for each included study using the Cochrane risk of
bias tool (RoB 1) in Review Manager 5 (Review Manager 2020).

We assessed the following for each study.

• Random sequence generation (checking for possible selection
bias). We assessed the method used to generate the allocation
sequence as being at:
◦ low  risk  of  bias  (any  truly  random  process,  e.g.  random
number table; computer random number generator); or
◦ unclear risk of bias (method used to generate sequence not

clearly stated).

◦ We excluded studies using a non-random process (e.g. odd or

even date of birth; hospital or clinic record number).
• Allocation  concealment  (checking  for  possible  selection  bias).
The method used to conceal allocation to interventions prior to
assignment  determines  whether  intervention  allocation  could
have  been  foreseen  in  advance  of  or  during  recruitment,  or
changed after assignment. We assessed the methods as being at:
◦ low  risk  of  bias  (e.g.  telephone  or  central  randomisation;
consecutively numbered, sealed, opaque envelopes); or

◦ unclear risk of bias (method not clearly stated).
◦ We will exclude studies that do not conceal allocation (e.g.

open list).

• Blinding  of  participants  and  personnel  (checking  for  possible
performance  bias).  Due  to  the  inclusion  of  studies  using  any
comparator, our review will contain both double-blinded RCTs
and those studies in which double-blinding is not possible (i.e.
RCTs of psychological therapy or acupuncture). In the RCTs that
are  double-blinded,  we  assessed  the  methods  used  to  blind
study  participants  and  personnel  from  knowledge  of  which
intervention a participant received in the double-blind trials. We
assessed methods as being at:
◦ low  risk  of  bias  (the  study  states  that  it  was  blinded  and
describes  the  method  used  to  achieve  blinding,  such  as
identical  tablets  matched  in  appearance  or  smell,  or  a
double-dummy technique); or

◦ unclear risk of bias (the study states that it was blinded but
does  not  provide  an  adequate  description  of  how  this  was
achieved).

◦ Studies in which double-blinding was not possible due to the
comparator will be considered to have high risk of bias.
• Blinding  of  outcome  assessment  (checking  for  possible
detection bias). We assessed the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed the methods as
being at:

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

◦ low risk of bias (the study has a clear statement that outcome
assessors were unaware of treatment allocation, and ideally
describes how this was achieved);

◦ unclear risk of bias (the study states that outcome assessors
were  blind  to  treatment  allocation  but  it  lacks  a  clear
statement on how this was achieved); or

◦ high risk of bias (the outcome assessment was not blinded).
• Selective  reporting  (checking  for  reporting  bias).  We  assessed
whether  primary  and  secondary  outcome  measures  were
pre-specified  and  whether  these  were  consistent  with  those
reported. We assessed the methods as being at:
◦ low risk of bias (study protocol is available with pre-specified

measures);

◦ unclear  risk  of  bias  (insufficient  information  available  to

permit a judgement of high or low risk of bias); or

◦ high  risk  of  bias  (not  all  of  the  study’s  prespecified
primary outcomes have been reported; one or more primary
outcomes have been reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not
prespecified; one or more reported primary outcomes were
not pre-specified (unless clear justification for their reporting
is  provided,  such  as  an  unexpected  adverse  effect);  one  or
more outcomes of interest in the review have been reported
incompletely  so  that  they  cannot  be  entered  in  a  meta-
analysis; the study report failed to include results for a key
outcome that would be expected to have been reported for
such a study).

• Incomplete  outcome  data  (checking  for  possible  attrition  bias
due to the amount, nature and handling of incomplete outcome
data). We assessed the methods used to deal with incomplete
data as being at:
◦ low  risk  of  bias  (no  missing  outcome  data;  reasons  for
missing outcome data are unlikely to be related to the true
outcome;  missing  outcome  data  are  balanced  in  numbers
across intervention groups, with similar reasons for missing
data across groups; missing data have been imputed using
'baseline observation carried forward’ (BOCF) analysis);
◦ unclear  risk  of  bias  (insufficient  reporting  of  attrition/
exclusions  to  permit  a  judgement  of  low  or  high  risk  of
bias  (e.g.  number  randomised  not  stated;  no  reasons  for
missing  data  provided;  or  the  study  did  not  address  this
outcome)); or

◦ high  risk  of  bias  (the  reason  for  missing  outcome  data  is
likely  to  be  related  to  true  outcome,  with  either  imbalance
in numbers or reasons for missing data across intervention
groups;  ‘as-treated’  analysis  was  done  with  substantial
departure  of  the  intervention  received  from  that  assigned
at  randomisation;  potentially 
inappropriate  application
of  simple  imputation;  use  of  'last  observation  carried
forward’ (LOCF) without the addition of any other low risk of
bias methods).

• Other bias. We assessed any other potential sources of bias that

were not included in the other domains.

We considered studies to be at high risk of bias overall if they met
the criteria for high risk of bias in any of the above domains.

Measures of treatment effect

For  the  outcomes  measuring  continuous  data  (pain  intensity,
life,  and  PGIC
function,  sleep,  quality  of 
mood,  physical 

Cochrane Database of Systematic Reviews

continuous),  studies  reported  data  as  either  post-intervention
scores (the mean scores at the end of the intervention period) or
change scores (mean change from baseline score). We conducted
separate  analyses  for  these.  As  is  common  in  pain  management
studies,  for  all  outcomes  (apart  from  PGIC)  studies  used  a
broad  range  of  scales  to  measure  the  outcomes.  Therefore,
once  data  were  extracted,  we  converted  them  into  standardised
mean  difference  (SMD)  with  95%  confidence  intervals  (CIs).
We  interpreted  SMD  as  small  (0.2),  moderate  (0.5)  and  large
(0.8),  in  line  with  Cohen  1988  and  the  Cochrane  Handbook  for
Systematic Reviews of Interventions (Higgins 2022a). For outcomes
with  dichotomous  data  (substantial  pain  relief,  adverse  events,
moderate  pain  relief,  PGIC  much/very  much  improved,  serious
adverse  events,  and  withdrawal),  we  used  odds  ratios  (OR)  with
95% CIs.

Unit of analysis issues

For  most  RCTs,  we  did  not  encounter  any  unit  of  analysis
complexities  as  participants  were  randomised  to  different  study
arms, allowing direct analysis. For cross-over RCTs, if the results for
the  first  period  (prior  to  cross-over)  were  reported,  we  extracted
these  in  an  attempt  to  avoid  cross-over  effects.  If  the  results
from  the  first  period  were  not  reported  then  we  extracted  the
final study results, provided there was a sufficient washout period
of  at  least  five  times  the  length  of  the  antidepressant  half-
life  (minimum  washout  period  length  calculated  separately  for
each  antidepressant).  The  majority  of  cross-over  trials  reported
the  combined  effects  of  both  periods  (only  one  study  reported
first  period  and  second  period  effects  separately),  therefore  we
analysed cross-over trials using these combined effects. Our search
did not return any cluster-RCTs that met our inclusion criteria.

Dealing with missing data

For all missing study-level statistical data relevant to our outcomes
we first tried to contact the authors of the study. If we could not get
the data from the authors, then we followed the guidance from the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2022). If standard deviations were missing then we used the Review
Manager  calculator  (RevMan  Web  2023)  to  calculate  these  from
other data reported in the study. We did not impute any data, but
assessed each study’s risk of bias due to missing data.

Assessment of heterogeneity

We  assessed  heterogeneity  within  the  network  meta-analyses
using  the  Tau  statistic,  in  line  with  the  guidance  in  the  Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  (Deeks  2022).
We  assessed  heterogeneity  using  Confidence  in  Meta-Analysis
(CINeMA) software, which calculated the Chi2 test and the I2 statistic
for  each  pairwise  comparison  on  each  outcome  (Nikolakopoulou
2020). As outlined in the Cochrane Handbook for Systematic Reviews
of  Interventions,  we  interpreted  the  I2  statistic  as  follows  (Deeks
2022).

• 0% to 40%: might not be important
• 30% to 50%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity

We took into account the magnitude and strength of effects when
assessing heterogeneity.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Assessment of the transitivity assumption

We  carefully  scrutinised  transitivity,  which  is  the  key  underlying
assumption  of  NMA.  Transitivity  requires  studies  to  be  similar
on  average  across  all  factors  that  might  alter  treatment  effects
other  than  the  intervention  comparison  being  made  (Chaimani
2022).  To  address  this,  we  only  included  studies  with  similar
clinical  populations  (i.e.  participants  reporting  pain  lasting  at
least three months; Furukawa 2016). Previous research, combined
with review authors' clinical experience and knowledge, identified
variables that could potentially influence our primary outcome:

• pain condition;
• age;
• pain intensity at baseline;
• depressive severity at baseline;
• treatment duration; and
• dosing schedule.

We  explored  the  impact  of  these  factors  by  assessing  the
indirectness of the network.

The  inclusion  of  placebo  and  concerns  about  its  potential  to
violate  the  transitivity  assumption  have  been  highlighted  in
general  (Cipriani  2013),  and  particularly  in  depression  studies
(Rutherford  2009).  Therefore,  we  explicitly  compared  placebo-
controlled studies with those that provide head-to-head evidence
as a form of validation of the network.

Assessment of reporting biases

We assessed reporting biases using the Cochrane risk of bias tool
(RoB 1) in Review Manager 5 (Review Manager 2020), by checking
for  study  protocols  and  pre-specified  outcomes  (as  detailed  in
the  Assessment  of  risk  of  bias  in  included  studies  section).  We
also  used  funnel  plots  for  pairwise  analyses  for  antidepressants
where  more  than  10  studies  were  available,  as  advised  in  the
Cochrane Handbook for Systematic Reviews of Interventions  (Page
2022).  Funnel  plots  were  drawn  using  ROB-MEN,  which  is  part  of
CINeMA, and used to assess the significant small study effects via
funnel plot asymmetry.

Data synthesis

We  undertook  separate  NMAs 
for  each  outcome.  NMAs
combine information (evidence) from both direct comparisons of
interventions within RCTs, and indirect comparisons across studies
based on a common placebo comparator (Caldwell 2005; Jansen
2011).  Direct  comparisons  (direct  evidence)  occur  when  two  or
more  interventions  are  compared  head  to  head  in  a  study;  in
the  absence  of  head-to-head  comparisons,  interventions  can  be
indirectly compared (indirect evidence).

We  analysed  the  data  for  all  primary  and  secondary  outcomes
using Bayesian random-effects NMAs implemented using the R (r-
project.org)  package  multinma  (Phillippo  2022).  Where  dose  was
included  in  the  network,  we  categorised  them  (low,  standard,
high)  and  incorporated  them  as  separate  nodes.  Where  a  study
had  multiple  arms  investigating  different  doses  of  the  same
antidepressant that fall into in the same category (e.g. two different
low  doses),  we  did  not  combine  them;  by  using  the  multinma
package  we  were  able  to  keep  these  as  separate  arms  in  the
analysis.

Cochrane Database of Systematic Reviews

We  fitted  random-effects  models  using  broad  normal  prior
distributions 
for  the  treatment  effects,  and  study-specific
intercepts and a half-normal prior for the heterogeneity standard
deviation. We used four chains, each with 2000 iterations and 1000
post-warm up draws per chain.

We  explored  network  connectivity  via  network  plots.  In  the
network  plot,  for  treatment-only  models,  the  nodes  represent
each  intervention.  In  treatment-dose  models,  the  antidepressant
nodes  represent  the  antidepressant  and  dose  (low,  standard,
high).  The  colour  of  the  node  represents  the  antidepressant
class,  and  the  "nonad"  label  refers  to  all  interventions  that  were
not  an  antidepressant.  The  size  of  each  node  represents  the
combined sample size of participants from all studies investigating
that  intervention,  and  the  thickness  of  the  lines  represents  the
number  of  studies  for  that  comparison.  The  forest  plots  present
the  estimates  and  credible  intervals  for  each  intervention  in  the
network, with reference to placebo.

We assessed convergence using the potential scale reduction factor
for  each  parameter,  ensured  that  effective  sample  sizes  were
sufficiently  large  (Vehtari  2021),  and  verified  that  there  were  no
divergent transitions (Betancourt 2015). We explored heterogeneity
by fitting connected networks for treatment, treatment-dose, class,
risk  of  bias,  and  condition  where  network  geometry  allowed
sufficient connectivity (Dias 2013).

We  assessed  model  fit  using  mean  residual  deviance,  and
explored  inconsistency  through  unrelated  mean-effect  models
(UME) and node-splitting where network geometry allowed (Dias
2013a). We used dev-dev plots, which compare residual deviance
contributions from each model, to explore inconsistency. The data
points are plotted against a line of equality; points on the line fit
equally well under either model, whereas points above or below the
line indicate better fits for one of the two models (Phillippo 2022).
Node-splitting  plots  present  the  evidence  of  direct,  indirect,  and
combined evidence on the same plot to allow comparisons.

  We  reported  effect  estimates  and  cumulative  posterior  ranks  of
effect  alongside  strength  of  evidence  assessment  using  GRADE
(Schünemann 2013).

To  rank  the  treatments  for  each  outcome  by  probability  of  best
treatment, we used the surface under the cumulative ranking curve
(SUCRA) and the mean ranks. We reported relative effects and mean
rank  of  treatments  and  plotted  cumulative  rankograms  showing
the range of rankings of different treatments for each outcome.

We used the deviance information criterion (DIC) to compare the
different  models  for  reporting  (treatment  only,  treatment-dose,
class and, change score and post-intervention studies for contrast-
based models) to assess their parsimony. Substantive differences
in DIC (> 5) or models with marginally lower DIC but lower Tau and
fewer studies with residual deviance greater than 3 in combination
were deemed superior. We selected models to report on the basis
of  parsimony,  minimisation  of  inconsistency  (identified  via  UME
and  node-splitting  models),  residual  deviance  and  heterogeneity
(measured as Tau). This approach balanced clinical exploration of
results and the risk of overfitting (Dias 2013).

NMA,  UME  and  node-splitting  models  were  implemented  in
multinma  in  R  (version  4·1.3).  Further  details  of  the  modelling
framework are described by Phillippo 2018; Phillippo 2022.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Subgroup analysis and investigation of heterogeneity

Where  data  allowed,  we  performed  subgroup  analyses  for  the
following factors.

• Class of antidepressant (SSRI, SNRI, TCA, MAOI, etc.)
• Type of pain condition

We used a Bayesian random-effects NMA to account for expected
heterogeneity  and  variation  in  the  data.  These  methods  allowed
the uncertainty inherent in the between-study variance component
to  be  reflected  in  effect  estimate  precision.  We  performed  these
subgroup analyses by building separate models, however this was
dependent on the geometry and connectedness of the networks.

Due  to  sparsity  of  data,  we  were  unable  to  perform  subgroup
analyses for the following factors for any outcome.

• Aim of the study (i.e. whether the intervention is aimed at pain

or mood)
◦ Only one study had a main aim of addressing mood (Richards

2015)

• Baseline level of depression (none, mild, moderate, severe, as

defined by the individual measure criteria)
◦ Upon  examination,  the  average  scores  for  the  five  most
commonly used scales (Beck Depression Inventory, Brief Pain
Inventory Mood Item, SF-36 Mental Component Score, SF-36
Mental  Health  Subscale,  and  Hamilton  Depression  Rating
Scale) were all in the none/minimal ranges.

Sensitivity analysis

We could only undertake analysis by risk of bias judgement (high
and not high) for substantial pain relief. We were unable to perform
sensitivity analyses for any outcome that compared active placebo
to  inert  placebo,  as  in  total  only  nine  studies  used  an  active
placebo.

Summary of findings and assessment of the certainty of the
evidence

To assess the certainty of the NMA, we primarily used the CINeMA
framework  (Nikolakopoulou  2020).  In  contrast  to  the  NMAs  in
this review, which were conducted within a Bayesian framework,
CINeMA operates within a frequentist framework using the netmeta
package  in  R  (Rücker  2017).  The  CINeMA  framework  considers
the  impact  of  certain  issues  within  NMAs  on  clinical  decision
making  made  from  the  results.  This  framework  is  based  on
GRADE,  and  considers  the  following  six  domains  specific  to  NMA
(Nikolakopoulou 2020).

• Within-study bias (impact of risk of bias in the included studies)
◦ CINeMA assesses the impact of risk of bias by combining the
study's risk of bias (as judged by the review authors using a
risk of bias tool) with its contribution to the network meta-
analysis.

• Reporting bias (publication and other reporting biases)

◦ Reporting bias in CINeMA is categorised as either 'suspected'
or 'undetected'. Suspected reporting bias is when the review
methods  do  not  take  into  account  unpublished  data,  the
meta-analysis is based on a small number of positive early
findings,  or  treatments  are  exclusively  studied  in  industry-
funded studies. Undetected reporting bias is when data from
unpublished studies has been identified and findings agree,

Cochrane Database of Systematic Reviews

when prospective trial registration has been completed and
there are no deviations from protocols, and comparisons of
estimates between small and large studies agree.

• Indirectness  (relevance  to  the  research  question,  addressing

transitivity)
◦ Each  study  in  the  NMA  is  evaluated  according  to  its
relevance to the research question. Study-level judgements
are combined with the percentage contribution of the study
to the network. This approach assesses potential transitivity
issues in the NMA.

• Imprecision (the precision of the NMA, by combining direct with

indirect evidence)
◦ Relevant treatment effects that represent a minimal clinically
important  difference  (MCID)  are  defined  and  the  range  of
clinical equivalence is produced (the value of the MCID either
side  of  the  line  of  no  effect).  CINeMA  then  compares  the
treatment  effects  included  in  the  95%  CI  to  the  range  of
clinical  equivalence.  If  the  95%  CI  of  a  treatment  effect
crosses the range of clinical equivalence, then it is considered
to  have  major  concerns  of  imprecision.  If  the  95%  CI  of
a  treatment  effect  only  crosses  one  side  of  the  range  of
equivalence then there are no concerns of imprecision.

• Heterogeneity (variability in the results of studies)

◦ CINeMA  accounts  for  both  heterogeneity  between  studies
by  comparing  the  confidence  and  prediction  intervals  of  a
treatment effect. When confidence and prediction intervals
indicate  the  same  effect,  then  there  is  no  evidence  of
heterogeneity; conversely if a prediction interval leads to a
different  conclusion  than  the  CIs  then  there  is  evidence  of
heterogeneity.

• Incoherence  (agreement  between  the  results  of  direct  and

indirect evidence)
◦  This is the variation between direct and indirect evidence in
the network and also an assessment of transitivity. CINeMA
compares  the  95%  CIs  of  the  estimates  of  the  direct  and
indirect estimates. If both of these estimates lie on the same
side  of  the  range  of  clinical  equivalence,  then  there  are  no
concerns about incoherence.

The CINeMA framework results in the review authors summarising
the  judgements  across  the  domains  into  the  four  domains  of
GRADE (high certainty, moderate certainty, low certainty, very low
certainty).

For  outcomes  where  we  were  unable  to  use  CINeMA  due  to  the
complexity of the network (adverse events, serious adverse events,
and withdrawal), we used GRADE. The GRADE system considers the
following five considerations to assess the certainty of the body of
evidence for each outcome.

• Serious or very serious study limitations (risk of bias)
• Important or serious inconsistency of results
• Some or major indirectness of evidence
• Serious or very serious imprecision
• Probability of publication bias

The GRADE system results in the assignment of one of the following
grades to the evidence.

• High  certainty:  we  are  very  confident  that  the  true  effect  lies

close to that of the estimate of the effect.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• Moderate  certainty:  we  are  moderately  confident  in  the  effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different.
• Low certainty: our confidence in the effect estimate is limited;
the true effect may be substantially different from the estimate
of the effect.

tables. This decision was made to ensure quality and certainty of
the final results and conclusions. We based this decision through
reference of the tiers of evidence for pain research; Tier 2 uses data
from at least 200 participants (Wiffen 2016).

R E S U L T S

• Very low certainty: we have very little confidence in the effect
estimate;  the  true  effect  is  likely  to  be  substantially  different
from the estimate of effect.

Description of studies

Results of the search

Two authors (HB and GS) independently interpreted the findings,
and collaboratively made the final judgements across all outcomes.
To  present  our  findings,  we  have  produced  separate  summary
of  findings  tables  for  all  outcomes.  We  have  used  the  template
summary  of  findings  tables  designed  for  NMAs  (Yepes-Nuñez
2019).  Due  to  the  scale  of  the  analyses,  we  only  included
antidepressants that had 200 or more participants in total receiving
the  antidepressant  in  the  write-ups  and  summary  of  findings

We ran the original search on 6 May 2020, and the top-up search
on  4  January  2022.  Both  searches  searched  six  databases  and
clinicaltrials.gov. The original search returned 21,569 records, and
the top-up search returned 1814 records for a total of 23,383. After
removing duplicates, we screened the titles and abstracts of 16,569
records. From this, we excluded 15,738 records, leaving 831 full-text
records. After full-text screening, we included 176 studies. The study
flow diagram is presented in Figure 1.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 1.   PRISMA flow diagram of studies found, screened, and included

23,383 records 
identified through 
database 
searching and trial 
registries

16,569 records 
after duplicates 
removed

16,569 records 
screened

15,738 records 
excluded

831 full-text 
articles assessed 
for eligibility

655 full-text 
articles excluded, 
with reasons

176 studies 
included in 
qualitative 
synthesis

169 studies 
included in 
quantitative 
synthesis (network 
meta-analysis)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Included studies

• Five  studies  were  partially 

funded  by  pharmaceutical

In total, we included 176 studies in the review, with a total of 28,664
adult participants with a mean age of 50.6 years.

companies.

• 67  studies  were  funded  through  non-pharmaceutical  means,

mainly government, charity, or institutional funding.

There were a variety of study designs across studies.

• 32 studies did not report the source of funding.

• Antidepressant versus placebo (83 studies, e.g. Hudson 2021)
• Antidepressant  versus  active  comparator 

(22 

studies,

e.g. Enomoto 2018)

• Antidepressant  versus  the  same  antidepressant  at  different

doses versus placebo (17 studies, e.g. Arnold 2012b)

• Antidepressant  versus  active  comparator  versus  combined
antidepressant + active comparator (13 studies, e.g. Ang 2013)
• Antidepressant  versus  active  comparator  versus  placebo  (9

studies, e.g. Rowbotham 2012)

• Antidepressant  versus  different  antidepressant  (9  studies,

e.g. Kaur 2011)

• Antidepressant  versus  active  comparator  versus  combined
antidepressant + active comparator versus placebo (8 studies,
e.g. Gilron 2016)

• Antidepressant versus different antidepressant versus placebo

(7 studies, e.g. Heymann 2001)

• Antidepressant  versus  different  antidepressant  versus  active

comparator (4 studies, e.g. Boyle 2012)

• Antidepressant  versus  the  same  antidepressant  at  different

doses (2 studies, e.g. Chappell 2009a)

• Antidepressant versus same antidepressants at different doses
versus different antidepressant versus different antidepressant
at different doses versus placebo (1 study, Atkinson 2007)

• Antidepressant 

versus
combined antidepressants versus placebo (1 study, Goldenberg
1996)

versus  different  antidepressant 

Most  studies  were  parallel-arm  design  (141  studies)  compared  to
cross-over design (35 studies).

Studies mainly included participants with only one type of chronic
pain.

• 59 studies included fibromyalgia
• 49 studies included neuropathic pain
• 40 studies included musculoskeletal pain
• Nine  studies  included  primary  pain  syndromes  (not  including
fibromyalgia)  that  is,  described  only  as  'somatoform'  or
'idiopathic' pain

• Six studies included gastrointestinal pain
• Four studies included non-cardiac chest pain
• Two studies included burning mouth syndrome
• Two studies included visceral pain
• One study included atypical facial pain
• One study included phantom limb pain
• One study included pelvic pain

Two studies included participants with any type of chronic pain.

Most studies were funded by pharmaceutical companies.

• 72 studies were fully funded by pharmaceutical companies.

Most studies had a primary aim of reducing pain.

• 144 studies had a primary aim of reducing pain.
• Two studies had a primary aim of treating mood.
• Eight studies had a primary aim of treating both pain and mood.
• 22 studies had other primary aims (e.g. sleep, other symptoms).

Studies ranged in length from two weeks to nine months, with an
average length of 10 weeks.

Only  six  studies  followed  up  with  participants  after  participants
finished  taking  the  study  treatment  (Creed  2003;  Kayiran  2010;
NCT00066937; Sencan 2004; Tanum 1996; Zitman 1990). The follow-
up time points ranged from four weeks post-treatment to one year
post-treatment.

Seven studies with a total of 156 participants provided no useable
data  and  were  therefore  omitted  from  the  NMAs  (Atkinson  2007;
Engel 1998; Kalso 1996; Ozerbil 2006; Sarzi Puttini 1988; Tasmuth
2002; Ward 1986).

Of  the  176  studies  and  28,664  participants,  the  number
of  participants  receiving  each  antidepressant  (not  including
combined interventions) are as follows.

• Amitriptyline: 1843 (43 studies)
• Bupropion: 54 (1 study)
• Citalopram: 97 (5 studies)
• Clomipramine: 124 (2 studies)
• Desipramine: 336 (7 studies)
• Desvenlafaxine: 884 (2 studies)
• Dothiepin: 55 (3 studies)
• Doxepin: 30 (2 studies)
• Duloxetine: 6362 (43 studies)
• Escitalopram: 93 (3 studies)
• Esreboxetine: 978 (2 studies)
• Fluoxetine: 277 (11 studies)
• Imipramine: 300 (7 studies)
• Maprotiline: 135 (4 studies)
• Mianserin: 107 (2 studies)
• Milnacipran: 3110 (18 studies)
• Mirtazapine: 255 (2 studies)
• Moclobemide: 42 (1 study)
• Nortriptyline: 374 (7 studies)
• Paroxetine: 422 (9 studies)
• Pirlindole: 50 (1 study)
• Reboxetine: 18 (1 study)
• Sertraline: 91 (3 studies)
• Trazodone: 63 (3 studies)
• Trimipramine: 18 (1 study)
• Venlafaxine: 489 (8 studies)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• Zimeldine: 10 (1 study)

• Washout  period  not  more  than  five  lengths  of  antidepressant

In total, 9854 participants received a placebo across 130 studies.

half-life: 11

Excluded studies

We  excluded  a  total  of  655  references  with  reasons  throughout
the course of this review. The main reasons for exclusion were as
follows.

• Duplicate records (including trial registrations): 144 records
• Not chronic pain condition: 71 records
• Not accessible (primarily conference abstracts): 92 records
• Pooled analysis: 50 records
• Open-label: 42 records
• Fewer than 10 participants per arm: 22 records
• Single-blind: 15 records

Figure 2.   Risk of bias of included studies by domain

Reasons 
the Characteristics of excluded studies section.

for  exclusion  other  than  these  are  reported 

in

We  categorised  15  studies  as  'awaiting  classification'  due  to
uncertainties  regarding  blinding  or  pain  duration  (Characteristics
of  studies  awaiting  classification),  and  26  studies  are  ongoing
(Characteristics of ongoing studies).

Risk of bias in included studies

Risk of bias findings from the included studies are shown in Figure 2
and Figure 3. Overall, we rated 116 of 176 studies as 'high risk', and
60 as 'not high risk'. However, of the 60 studies not rated as high risk,
29 had three or more domains rated as 'unclear'.

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias

Low risk of bias

Unclear risk of bias

High risk of bias

0%

25%

50%

75% 100%

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   Risk of bias of included studies by study

Cochrane Database of Systematic Reviews

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

e
c
n
a
m
r
o
f
r
e
p
(

l
e
n
n
o
s
r
e
p

d
n
a

s
t
n
a
p
i
c
i
t
r
a
p
f
o

g
n
i
d
n
i
l

B

?

+

+

+

+

?

?

?

−

?

+

+

?

+

+

+

+

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

n
o
i
t
c
e
t
e
d
(

t
n
e
m
s
s
e
s
s
a

e
m
o
c
t
u
o

f
o
g
n
i
d
n
i
l

B

?

+

+

+

+

?

?

?

−

?

+

+

?

+

+

+

+

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

n
o
i
t
i
r
t
t
a
(

a
t
a
d

e
m
o
c
t
u
o

e
t
e
l
p
m
o
c
n
I

−

?

?

−

−

−

−

−

?

−

−

−

−

+

+

+

+

)
s
a
i
b

n
o
i
t
c
e
l
e
s
(

n
o
i
t
a
r
e
n
e
g

e
c
n
e
u
q
e
s
m
o
d
n
a
R

?

+

+

+

?

+

?

?

?

+

?

+

?

+

+

+

+

)
s
a
i
b

n
o
i
t
c
e
l
e
s
(

t
n
e
m
l
a
e
c
n
o
c

n
o
i
t
a
c
o
l
l

A

?

+

+

+

?

+

?

+

?

?

?

+

?

+

+

+

+

)
s
a
i
b

g
n
i
t
r
o
p
e
r
(

g
n
i
t
r
o
p
e
r

e
v
i
t
c
e
l
e
S

−

?

−

+

?

?

+

+

−

?

?

?

?

?

+

+

+

s
a
i
b

r
e
h
t
O

−

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

29060/433

Abou-Raya 2012

Agger 2017

Ahmed 2016

Alcoff 1982

Allen 2014

Allen 2017

Anderberg 2000

Ang 2013

Aragona 2005

Arnold 2002

Arnold 2004

Arnold 2005

Arnold 2010a

Arnold 2010b

Arnold 2010c

Arnold 2012a

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Arnold 2012a

Arnold 2012b

Ash 1999

Atkinson 1998

Atkinson 1999

Atkinson 2007

Bansal 2009

Bateman 2013

Bird 2000

Boyle 2012

Branco 2010

Braz 2013

Calderon 2011

Cannon 1994

Cardenas 2002

Carette 1986

Carette 1994

Caruso 1987

Chappell 2008

Chappell 2009a

Chappell 2009b

Chappell 2011

Clauw 2008

Creed 2003

de Zanette 2014

Dickens 2000

Drossman 2003

Eberhard 1988

Engel 1998

Enomoto 2018

Enteshari-Moghaddam 2019

Forssell 2004

Foster 2010a

Foster 2010b

Frakes 2011

Gao 2010

+

+

?

+

+

+

+

?

?

?

?

?

+

?

?

?

+

?

+

?

+

+

+

+

?

+

+

?

?

+

+

+

+

?

?

?

+

+

?

+

+

+

+

?

?

?

?

?

?

?

+

?

?

?

?

+

+

+

+

?

+

+

?

?

?

+

+

+

+

?

?

?

+

+

+

+

+

+

+

?

+

?

?

+

−

+

+

−

?

+

+

?

+

?

+

−

+

+

−

+

?

+

?

+

+

?

?

+

+

+

+

+

+

+

+

?

+

?

?

+

−

+

+

−

?

+

+

?

+

?

+

−

+

+

−

+

?

+

?

+

+

?

?

+

+

−

−

−

−

−

?

−

?

?

−

−

−

?

?

−

−

−

−

−

+

−

−

?

?

+

?

−

+

?

+

−

−

?

+

−

+

−

?

?

?

?

?

+

?

+

?

?

?

?

?

?

?

?

+

?

+

−

?

?

+

?

?

?

?

+

−

?

+

−

+

+

+

+

+

+

+

+

+

−

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Frakes 2011

Gao 2010

Gao 2015

Gillving 2021

Gilron 2009

Gilron 2015

Gilron 2016

Ginsberg 1996

Ginsberg 1998

Goldenberg 1986

Goldenberg 1996

Goldman 2010

Goldstein 2005

González-Viejo 2005

Goodkin 1990

Gould 2020

Grace 1985

Graff-Radford 2000

Hadianfard 2012

Hameroff 1984

Hammody 2015

Hannonen 1998

Heymann 2001

Holbech 2015

Hudson 2021

Hussain 2011

Isomeri 1993

Iwaki 2020

Johansson 1979

Joharchi 2019

Jose 2007

Kalso 1996

Katz 2005

Kaur 2011

Kayiran 2010

Keefe 2011

Khoromi 2007

?

?

?

+

+

+

+

?

?

?

+

+

+

?

?

+

?

?

+

?

?

?

+

+

+

?

?

?

+

?

+

?

+

+

?

+

+

?

?

?

+

+

+

+

?

?

?

+

+

+

?

+

?

?

?

?

?

?

+

?

+

+

?

?

?

?

?

?

?

?

+

?

?

?

?

+

?

+

+

+

+

?

?

?

+

+

?

−

+

−

+

+

−

?

?

+

+

+

+

?

−

?

+

?

+

?

?

?

−

−

+

?

+

?

+

+

+

+

+

?

?

+

+

?

−

+

−

+

+

−

?

?

+

+

+

+

?

−

?

+

?

+

?

?

?

−

−

+

+

−

−

−

−

−

?

?

−

+

−

+

?

+

−

−

−

+

?

−

−

?

−

−

+

?

−

−

−

−

−

−

−

?

+

−

+

+

+

+

?

+

+

?

?

−

?

?

?

?

?

?

?

?

?

?

?

?

?

+

+

?

?

+

?

+

?

?

−

?

?

?

+

+

+

+

+

+

+

−

+

+

+

+

+

+

+

+

+

+

+

+

+

−

+

+

+

+

+

+

+

+

+

+

+

?

+

+

+

+

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Keefe 2011

Khoromi 2007

Kim 2013

Konno 2016

Lee 2010

Lee 2016

Leijon 1989

Lipone 2020

Loldrup 1989

Luo 2009

Maarrawi 2018

Macfarlane 1986

Mahmoud 2021

Majdinasab 2019

Masand 2009

Matthey 2013

Max 1988

Max 1992

Mease 2009

Miki 2016

Morello 1999

Muller 2008

Murakami 2015

Nabi 2021

Natelson 2015

NCT00066937

NCT01225068

NCT01510457

Nørregaard 1995

Otto 2008

Ozerbil 2006

Pakfetrat 2019

Patkar 2007

Petzke 2013

Pickering 2018

Pilowsky 1990

+

+

?

+

+

+

?

+

+

?

+

?

+

+

?

+

?

?

?

+

?

+

+

+

?

?

?

?

?

+

+

?

+

?

+

+

?

?

?

+

+

?

+

?

?

?

+

?

+

+

+

+

?

?

?

+

?

?

?

?

+

?

?

?

?

+

?

?

+

?

+

?

−

+

?

+

+

+

+

+

+

+

+

+

+

?

+

?

?

?

+

+

+

+

+

−

+

?

+

?

+

+

+

?

+

+

+

−

−

+

?

+

+

+

+

+

+

+

+

+

+

?

+

?

?

?

+

+

+

+

+

−

+

?

+

?

+

+

+

?

+

+

+

−

−

−

?

+

+

−

+

−

−

−

−

?

−

?

−

−

?

−

−

?

−

+

+

−

−

−

−

−

?

−

?

+

−

−

−

−

?

+

?

+

?

−

+

?

?

?

+

?

?

?

−

?

?

?

?

?

?

?

+

+

?

−

−

?

?

−

?

?

−

−

+

−

+

+

?

+

+

+

+

+

+

+

?

?

?

?

+

+

+

?

+

−

−

+

+

+

+

−

−

−

+

+

+

+

+

+

+

+

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Pilowsky 1990

Pirbudak 2003

Rani 1996

Raskin 2005

Razazian 2014

RBR-5dsrhv

Richards 2015

Rintala 2007

Robinson 2004

Rowbotham 2004

Rowbotham 2005

Rowbotham 2012

Russell 2008

Sarzi Puttini 1988

Schukro 2016

Scudds 1989

Sencan 2004

Shakiba 2018

Sindrup 2003

Skljarevski 2009

Skljarevski 2010a

Skljarevski 2010b

Smith 2013

Sofat 2017

Spinhoven 2010

Srinivasan 2021

Staud 2015

Suttiruksa 2016

Talley 2008

Tammiala-Salonen 1999

Tanum 1996

Tasmuth 2002

Tesfaye 2013

Tétreault 2016

Trugman 2014

Uchio 2018

+

?

?

+

+

+

+

+

?

?

?

+

+

?

+

?

?

+

+

+

?

?

+

?

+

+

+

+

+

?

?

+

+

?

?

+

?

?

?

+

+

+

+

?

+

?

?

+

?

?

+

?

?

+

+

+

?

?

+

+

?

+

?

+

+

?

?

?

+

?

?

+

−

?

+

+

−

−

+

+

+

+

+

?

?

?

+

+

−

+

+

+

?

?

+

+

−

+

+

+

+

+

+

?

+

+

?

+

−

?

+

+

−

−

+

+

+

+

+

?

?

?

+

+

−

+

+

+

?

?

+

+

−

+

+

+

+

+

+

?

+

+

?

+

−

?

?

−

−

−

?

−

+

−

−

?

−

−

−

+

+

−

−

−

−

+

−

−

−

+

−

?

−

−

+

?

−

−

?

+

−

?

?

?

−

?

+

?

?

?

?

+

−

?

−

?

?

+

?

+

+

+

+

−

?

?

−

?

?

?

?

?

+

+

+

+

+

+

+

+

−

?

+

+

+

+

+

+

+

+

+

+

+

+

+

?

+

?

+

?

−

+

−

+

+

+

+

+

+

+

−

+

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Trugman 2014

Uchio 2018

Urquhart 2018

Vahedi 2005

Van Ophoven 2004

Ventafridda 1987

Vitton 2004

Vollmer 2014

Vranken 2011

Vrethem 1997

Wang 2017

Ward 1986

Ware 2010

Watson 1992

Watson 1998

Wernicke 2006

Wolfe 1994

Yasuda 2011

Yeephu 2013

Yucel 2005

Zabihiyeganeh 2021

Zitman 1990

?

+

+

+

?

?

+

?

+

?

+

?

+

?

+

+

+

+

+

?

?

?

?

+

+

?

?

?

+

?

+

?

+

?

+

?

+

+

?

?

+

?

?

?

?

+

+

+

?

+

+

?

+

+

+

?

+

+

+

?

?

?

+

?

−

?

?

+

+

+

?

+

+

?

+

+

+

?

+

+

+

?

?

?

+

?

−

?

?

+

+

+

+

−

−

+

+

?

+

−

?

+

+

−

−

+

?

+

−

−

+

+

+

?

?

?

?

+

+

?

+

−

+

?

?

?

?

?

+

?

?

?

−

+

+

+

+

?

?

+

+

+

+

?

+

+

+

+

+

+

+

+

−

−

Allocation

We  did  not  assess  any  studies  as  high  risk  of  bias  for  sequence
generation or allocation concealment. For sequence generation, we
judged 95 studies to be at low risk, and 81 studies as unclear. For
allocation concealment, we judged 75 studies to have satisfactory
procedures and rated them as low risk and the other 101 studies we
rated as unclear. We rated only 64 studies as low risk of bias for both
sequence generation and allocation concealment.

Blinding

For  this  review,  we  required  studies  comparing  antidepressants
with  other  antidepressants,  different  doses  of  the  same
antidepressant,  or  other  pharmacological  interventions  to  be
double-blind.  We  accepted  that  some  interventions  could  not  be
blinded by their nature (e.g. psychological therapy, physiotherapy).
These studies were included but judged to be high risk of bias for
both blinding of participants, and blinding of outcomes assessors.
Seventeen studies were of non-pharmacological interventions and
therefore rated high risk of bias for both domains. As this review is
focused on pain, all outcomes were self-reported by participants,
and therefore judgements were often the same for both domains.
In total, we rated 106 studies as low risk for both domains, and 49

studies as unclear for both domains. Low risk of bias was achieved
in studies by study drugs appearing identical, having matched or
sham dosing schedules across all arms, and using active placebos
that mimic the side effects of antidepressants.

Incomplete outcome data

We rated the majority of studies as high risk of bias for incomplete
outcome  data;  102  studies  were  high  risk.  Studies  were  high  risk
primarily  due  to  only  using  the  last-observation-carried-forward
imputation  method,  reporting  data  only  on  participants  who
completed  the  study,  or  having  significantly  unequal  attrition
across arms. We rated 37 studies as low risk of bias; these studies
either had no or very little attrition, or used appropriate imputation
methods such as baseline-observation-carried-forward or multiple
imputation.  We  rated  37  studies  as  unclear,  due  to  not  clearly
specifying missing data methods.

Selective reporting

We  could  not  find  protocols  or  trial  registrations  for  the  majority
of  studies.  We  rated  108  studies  as  unclear  risk  of  bias,  due  to
missing  protocols  or  trial  registrations  published  retrospectively,
after  the  study  had  begun.  We  rated  44  studies  as  low  risk  of
bias;  outcomes  and  analyses  in  the  published  papers  matched

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

prospective protocols or registrations. We rated 24 studies as high
risk of bias. Four of these studies were never published in journal
articles, and data were extracted from trials registries (29060/433;
NCT00066937; NCT01225068; NCT01510457). For the other studies
rated  as  high  risk  of  bias,  there  were  discrepancies  between  the
protocols and published papers that we judged to be of significant
risk of bias (e.g. protocol states that outcomes would be collected
that were not reported).

Other potential sources of bias

We  did  not  identify  any  other  sources  of  bias  for  145  studies.  We
rated 17 studies as unclear risk of bias; primarily due to data not
being presented in numerical form, or being reported in a different
method to the protocol (e.g. percentage change rather than post-
intervention).  We  rated  14  studies  as  high  risk  of  bias  for  the
following reasons:

• No published, peer-reviewed articles (29060/433; NCT00066937;

NCT01225068; NCT01510457)

• Washout  periods  and  tapering  issues  (Bateman  2013;  Gilron

2016)

• Poor reporting with mistakes in article (Hammody 2015)
• Insufficient power (Morello 1999)
• Significant differences at baseline (Razazian 2014)
• Selection bias prior to participation (Spinhoven 2010)
• Significant  differences  between  published  article  and  trial

registry (Trugman 2014; Zabihiyeganeh 2021)

• Using a potential intervention as a placebo (Zitman 1990)

We  found  some  evidence  of  publication  bias  in  one  analysis
(duloxetine versus placebo for substantial pain relief), as identified
from funnel plots (used to assess small study effects as a proxy for
publication bias).

Effects of interventions

See:  Summary  of  findings  1  Substantial  pain  relief  summary
of  findings;  Summary  of  findings  2  Pain  intensity  summary  of
findings;  Summary  of  findings  3  Mood  summary  of  findings;
Summary of findings 4 Adverse events summary of findings

Overview

The  following  sections  detail  the  results  of  the  NMAs  for  all
outcomes  included  in  the  review.  Due  to  the  scale  of  the
analysis,  we  only  include  antidepressants  with  more  than  200
participants  in  the  write-ups  and  summary  of  findings  tables.
Each outcome has a table listing all the interventions included in
the  NMA.  Antidepressants  with  fewer  than  200  participants,  and
non-antidepressant  interventions  are  also  included  in  figures  for
completeness and context.

For all outcomes, we made decisions on which networks to report
in this results section. For all outcomes, we considered treatment

Cochrane Database of Systematic Reviews

and  treatment-dose  networks.  For  continuous  outcomes,  we
considered  both  change  scores  and  post-intervention  scores
networks.  For  each  outcome  we  have  reported  the  most  robust
and reliable network. The details of these decisions are reported
in  Appendix  2.  The  networks  that  we  have  not  reported  in  this
manuscript are available in the supplemental file.

The  sections  are  reported  in  order  of  primary  and  secondary
outcomes.

Primary outcomes:

• Substantial pain relief
• Pain intensity
• Mood
• Adverse events

Secondary outcomes:

• Moderate pain relief
• Physical function
• Sleep
• Quality of life
• Patient  Global  Impression  of  Change  (PGIC):  proportion  of
participants reporting "much" and "very much" improved, and
continuous scores
• Serious adverse events
• Withdrawal

Primary outcomes

Summary of findings tables are provided for substantial pain relief
(Summary  of  findings  1);  pain  intensity  (Summary  of  findings  2);
mood (Summary of findings 3); and adverse events (Summary of
findings 4).

Substantial pain relief (50% reduction)

We report the treatment-dose network for substantial pain relief, as
it was the model with the least heterogeneity and had no evidence
of inconsistency.

We  included  42  RCTs  with  a  total  of  14,626  participants  (range
in  study  from  47  to  1108).  There  were  25  different  interventions,
and  some  comparisons  were  informed  only  by  direct  evidence
from  one  study.  Table  2  shows  the  number  of  RCTs  and  total
number  of  participants  for  each  antidepressant  dose  included  in
the  analysis.  We  could  not  include  data  from  two  studies  due  to
disconnected networks. There were no concerns regarding model
fit  based  on  residual  deviance  and  convergence  diagnostics.  The
network  diagram  is  presented  in  Figure  4,  and  the  forest  plot
in Figure 5.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Substantial pain relief network plot. NASSA: noradrenergic and specific serotonergic antidepressants;
SNRI: serotonin noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic
antidepressants; nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Substantial pain relief forest plot (log odds ratio with credible intervals). NASSA: noradrenergic and
specific serotonergic antidepressants; SNRI: serotonin noradrenalin reuptake inhibitors; SSRI: selective serotonin
reuptake inhibitors; TCA: tricyclic antidepressants; nonad: non-antidepressants

The  top-ranked  antidepressants  for  substantial  pain  relief  are
shown  in  Table  3.  Duloxetine  standard  dose  and  duloxetine  high
dose were the highest-ranked antidepressants for substantial pain
relief, and equally efficacious in comparison to placebo (OR 1.91,
95% CI 1.69 to 2.17 and OR 1.91, 95% CI 1.66 to 2.21, respectively).
Milnacipran  high  dose  (OR  1.64,  95%  CI  1.04  to  2.58)  and
esreboxetine standard dose (OR 1.72, 95% CI 1.13 to 2.62) were also
equally  ranked,  but  less  effective  than  duloxetine  standard  dose
and duloxetine high dose. Mirtazapine standard dose, esreboxetine
high  dose,  and  desvenlafaxine  high  dose  showed  no  significant
difference in comparison to placebo.

A  visual  representation  of  the  cumulative  rankings  for  every
treatment  included  in  the  analysis  and  did  not  substantially
alter  interpretation  of  relative  effects  or  mean  rank  credible
intervals.  The  unrelated  mean-effect  model  had  similar  deviance
information criteria to the dose-treatment model, with no evidence
of  inconsistency.  We  confirmed  this  with  node-splitting  models
for  all  nine  comparisons  where  it  was  possible  to  compare
direct and indirect evidence.  The comparison of pregabalin with
placebo  had  the  smallest  Bayesian  P  value  (P  =  0.3)  indicative  of
inconsistency where direct evidence suggests underestimation of
the effect of pregabalin based on a single study. These figures are
available in the supplemental file. The availability of a consistent
evidence-network precluded the need for exploration of transitivity
violations.

Exploration of heterogeneity

Despite the risk of over-fitting, we summarise results for multiple
models  because  of  the  importance  of  substantial  pain  as  an
outcome for patients, clinicians, and overall quality of life.  The full
results of all models are reported in the supplemental file.

Class

We generated a network by aggregating treatment into classes. The
analysis included four antidepressant classes: SNRI, TCA, TeCA, and
NaSSA, however we could not draw any reliable conclusions about
class  differences  due  to  inconsistency  and  overlapping  credible
intervals.

Condition

reported 

substantial  pain 

Studies 
included  neuropathic,
fibromyalgia,  musculoskeletal,  primary,  and  gastrointestinal  pain
conditions.  However,  only  neuropathic  and  fibromyalgia  pain
conditions had connected networks. We could not derive reliable
treatment rankings for neuropathic pain, as the unrelated mean-
effect  models  and  node-splitting  indicated  inconsistency.  For
fibromyalgia, although the network geometry precluded analysis
of  inconsistency,  esreboxetine,  milnacipran,  and  duloxetine  were
relatively  equally  ranked:  esreboxetine  (mean  rank  =  2.02,  97.5%
credible interval = 1 to 4); milnacipran (mean = 2.30, 97.5% credible
interval = 1 to 4); duloxetine (2.48, 97.5% credible interval = 1 to 4).

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias

We  conducted  a  sensitivity  analysis  to  explore  the  effect  of
removing  studies  at  high  risk  of  bias.  We  rated  15  studies  as  low
risk of bias. The model of the resulting network was unstable with
divergent transitions indicating problems with model convergence.
Unrelated  mean-effects  models  and  the  dev-dev  plot  did  not
identify  inconsistency,  but  we  could  not  confirm  this  by  node
splitting due to network geometry. Results were consistent with the
treatment-dose model. The two best-ranked antidepressants were
esreboxetine (mean rank = 3.73. 97.5% credible interval = 2 to 7),
and duloxetine (mean = 4.64, 97.5% credible interval = 3 to 6).

statistic  values  (73.6%  and  65.8%)  indicating  heterogeneity.  We
rated  duloxetine  low,  standard,  and  high  doses  as  moderate
certainty. We rated all other antidepressant doses as low, or very
low certainty, primarily due to major concerns regarding studies at
high risk of bias, imprecision (estimates crossing zero), and a small
number of RCTs and participants contributing to the estimates.

Pain intensity

For  pain  intensity,  we  report  the  change-score  treatment-dose
network, as it was more robust than the other networks, with low
heterogeneity and no indications of inconsistency.

CINeMA

Results

In  addition  to  fitting  multiple  models  to  explore  heterogeneity
and utilising unrelated mean-effects and node-splitting models to
explore  inconsistency,  we  undertook  further  analysis  of  pairwise
direct evidence and network evidence (excluding multi-arm studies
of dose) to facilitate strength of evidence assessment using CINeMA.

The  design-by-treatment  test  showed  no  inconsistency  between
direct  and  indirect  evidence  (Chi2  =  14.069,  P  =  0.296),  although
duloxetine  low  dose  and  desvenlafaxine  high  dose  had  high  I2

We  included  49  RCTs  with  a  total  of  14,504  participants  (range
from  26  to  1191).  We  removed  one  study  from  this  analysis
due  to  implausible  results  (Miki  2016).  Twenty-eight  studies
compared against placebo, nine were studies with a head-to-head
comparison  with  another  active  comparator,  and  12  were  dose-
comparison  studies.  There  were  21  different  interventions,  and
some  comparisons  were  informed  only  by  direct  evidence  from
one study. Table 4 shows the number of RCTs and total number of
participants for each intervention included in the analysis. There
were  no  concerns  regarding  model  fit.  The  network  diagram  is
presented in Figure 6 and the forest plot in Figure 7.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 6.   Pain intensity network diagram. SNRI: serotonin noradrenalin reuptake inhibitors; SSRI: selective
serotonin reuptake inhibitors; TCA: tricyclic antidepressants; nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 7.   Pain intensity forest plot (standardised mean difference with credible intervals). SNRI: serotonin
noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants;
nonad: non-antidepressants

Ranking of antidepressants

CINeMA

The  top-ranked  antidepressants  for  pain  intensity  change  scores
are  shown  in  Table  5.  Duloxetine  high  and  standard  dose  were
the  highest-ranked  antidepressants  for  pain  intensity,  with  small
to  moderate  effects  (SMD  −0.37,  95%  CI  −0.45  to  −0.28  and  SMD
−0.31,  95%  CI  −0.39  to  −0.24,  respectively).  Milnacipran  high  and
standard  doses  had  a  small  effect  (SMD  −0.22,  95%  CI  −0.40  to
−0.05).  Duloxetine  low  dose  showed  no  significant  difference  in
comparison to placebo.

A  visual  representation  of  the  cumulative  rankings  for  every
intervention  included  in  the  analysis  did  not  alter  interpretation.
The unrelated mean-effect model had similar deviance information
criteria  to  the  dose-treatment  model,  with  no  evidence  of
inconsistency.  We  confirmed  this  with  node-splitting  models  for
all  nine  comparisons  where  it  was  possible  to  compare  direct
and  indirect  evidence.  The  lowest  Bayesian  P  value  was  for  the
comparison of duloxetine standard dose compared to duloxetine
high  dose  (0.08).  These  figures  are  available  in  the  supplemental
files (link provided in Appendix 3).

Condition and risk of bias

We  were  unable  to  undertake  further  NMAs  of  condition  or  risk
of bias due to small sample sizes, network geometry and the risk
of over-fitting, but these were examined in pairwise analyses and
network analysis (excluding multi-dose arms) in CINeMA to inform
strength of evidence assessment.

The  design-by-treatment  test  showed  no  inconsistency  between
direct  and  indirect  evidence  (Chi2  =  8.34;  P  =  0.82),  although
duloxetine  standard  dose  and  milnacipran  standard  dose  had
high I2 statistic values (65.3% and 67.7%) indicating heterogeneity.
We  had  moderate  certainty  in  the  estimates  for  duloxetine  low,
standard,  and  milnacipran  standard  doses.  We  rated  all  other
antidepressant  doses  as  low  certainty  due  to  major  concerns
regarding  studies  at  high  risk  of  bias  and  imprecision  (estimates
crossing zero).

Mood

For mood, we report the change-score treatment network as this
was the most robust and reliable network, with low heterogeneity
and no indications of inconsistency.

Results

We included 38 RCTs with a total of 12,985 participants (range from
42 to 1191). Twenty-two studies compared against placebo only, six
were multi-arm studies with another active comparator, nine were
comparing  the  same  antidepressant  in  different  doses,  and  one
compared  two  antidepressants  together.  There  were  16  different
interventions, and some comparisons were informed only by direct
evidence from one study. We rated 23 studies as high risk of bias.
At  baseline,  the  average  scores  for  the  five  most  commonly  used
scales (Beck Depression Inventory, Brief Pain Inventory Mood Item,

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

SF-36  Mental  Component  Score,  SF-36  Mental  Health  Subscale,
and  Hamilton  Depression  Rating  Scale)  were  all  in  the  none  or
minimal ranges. We could not include data from one study due to
disconnected networks. There were no concerns regarding model

fit. An overview of the interventions in the analysis is given in Table
6. The network diagram is presented in Figure 8 and the forest plot
is presented in Figure 9.

Figure 8.   Mood network diagram. NASSA: noradrenergic and specific serotonergic antidepressants; SNRI: serotonin
noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants;
nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 9.   Mood forest plot (standardised mean difference with credible intervals). NASSA: noradrenergic and
specific serotonergic antidepressants; SNRI: serotonin noradrenalin reuptake inhibitors; SSRI: selective serotonin
reuptake inhibitors; TCA: tricyclic antidepressants; nonad: non-antidepressants

Ranking of antidepressants

The top-ranked antidepressants for mood change scores are shown
in Table 7. Mirtazapine was the highest-ranked antidepressant for
mood  with  a  moderate  effect  (SMD  −0.5,  95%  CI  −0.78  to  −0.22),
based on one RCT. Duloxetine and milnacipran were equally ranked.
Duloxetine  showed  very  small  effects  (SMD  −0.16,  95%  CI  −0.22
to −0.1), and milnacipran showed no difference in comparison to
placebo.

A  visual  representation  of  the  cumulative  rankings  for  every
intervention  included  in  the  analysis  did  not  alter  interpretation
of  the  results.  This  figure  is  available  the  supplemental  files  (link
provided  in  Appendix  3).  The  unrelated  mean  effect  model  had
similar deviance information criteria to the dose treatment model,
with no evidence of inconsistency.

Class, condition, and risk of bias

We  did  not  undertake  further  analyses  because  of  small  sample
sizes,  network  geometry  and  the  risk  of  over-fitting  but  pairwise
and NMA (excluding multi-dose study) were performed in CINeMA
to inform strength of evidence assessment.

CINeMA

The design-by-treatment test showed no evidence of inconsistency
(Chi2  =  1.83,  P  =  0.4),  and  all  I2  statistic  values  were  below  40%,
despite the analysis being unable to run node-splitting. We rated

both duloxetine and milnacipran as moderate certainty; there were
no  domains  indicating  major  concern.  We  rated  mirtazapine  as
having low-certainty evidence, as the estimates were formed from
only one study.

Adverse events

For adverse events we report the treatment-dose network. There
were  similar  levels  of  heterogeneity  and  inconsistency  across
networks  but  we  were  able  to  run  node-splitting  models  for
treatment dose.

Results

We  included  93  RCTs  with  a  total  of  22,558  participants.  Of  all
the studies in the network, 47 studies compared antidepressants
only  against  placebo,  27  were  multi-arm  studies    with  another
active  comparator,  15  were  dose-comparison  studies,  and  four
compared two antidepressants to each other. We rated 62 studies
 as high risk of bias. There were 60 different interventions, and some
comparisons were informed only by direct evidence from one study.
We  could  not  include  data  from  one  study  due  to  disconnected
networks. There were no concerns regarding model fit. Of the 60
interventions  included  in  the  network,  only  nine  met  the  criteria
of  200  or  more  participants  to  be  included  in  the  summary.  An
overview of all the interventions included in the network is given
in Table 8. The network diagram is presented in Figure 10, and the
forest plot is presented in Figure 11.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 10.   Adverse events network diagram. MAOI_rev: monoamine oxidase inhibitors (reversible); NASSA:
noradrenergic and specific serotonergic antidepressants; SNRI: serotonin noradrenalin reuptake inhibitors; SSRI:
selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants; TECA: tetracyclic antidepressants; nonad:
non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 11.   Adverse events forest plot (log odds ratio with credible intervals). MAOI_rev: monoamine oxidase
inhibitors (reversible); NASSA: noradrenergic and specific serotonergic antidepressants; SNRI: serotonin
noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants; TECA:
tetracyclic antidepressants; nonad: non-antidepressants

Ranking of antidepressants

The  ranking  of  the  nine  antidepressants  with  200  or  more
participants  is  given  in  Table  9.  Data  for  adverse  events  were
sparse, and studies were underpowered. All antidepressants with
over  200  participants  in  the  antidepressant  arm  were  closely
ranked.  Desvenlafaxine  and  mirtazapine  were  the  highest-ranked
antidepressants,  with  no  significant  difference  compared  to
placebo (OR 1.67, 95% CI 0.92 to 2.41 and OR 1.70, 95% CI 0.48 to
2.91, respectively). The evidence for both of these antidepressant
doses  was  based  on  only  two  studies  each.  Duloxetine  standard
dose, milnacipran standard dose, and duloxetine high dose were

equally  ranked.  Duloxetine  low  dose,  milnacipran  high  dose,
amitriptyline standard dose, and esreboxetine standard dose were
the  lowest-ranked  antidepressants,  with  all  odds  ratios  greater
than 2.

A  visual  representation  of  the  cumulative  rankings  for  every
intervention  included  in  the  analysis  did  not  alter  interpretation.
We  further  investigated  inconsistency  through  unrelated  mean-
effect  models  and  node-splitting  models  for  all  30  comparisons
where  it  was  possible  to  compare  direct  and  indirect  evidence.
There  was  evidence  of  inconsistency  in  unrelated  mean-effects

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

models  but  not  node-splitting.  These  figures  are  available  in
the  supplemental  files  (link  provided  in  Appendix  3).  However,
multiple  divergent  transition  warnings  indicate  the  potential  for
inconsistency to be poorly estimated in the latter models.

Class, condition, and risk of bias

Our  overall  model  of  adverse  events  is  problematic  due  to
divergent transitions, low effective sample sizes and inconsistency
in  unrelated  mean-effects  model.  We  were  unable  to  undertake
further exploration of class, condition and risk of bias given the high
uncertainty in overall effects.

CINeMA

We were unable to use CINeMA for this outcome due to complexity
of the network. Therefore, two review authors (HB and GS) made
the  judgements  based  on  GRADE  and  CINeMA  domains  and  the
available results. We judged all antidepressants and doses as very
low certainty primarily due to concerns with within-study bias, and
imprecision in the network.

Secondary outcomes

Moderate pain relief (30% reduction)

For moderate pain relief we report the treatment network as this
model had low heterogeneity and no evidence of inconsistency. We
present the summary of findings for moderate pain relief in Table
10.

Results

We included 40 RCTs with a total of 14,208 participants (range from
37 to 1025). Twenty studies compared against placebo, eight were
multi-arm studies with another active comparator, 11 were dose-
comparison studies, and one study compared two antidepressants
head  to  head.  There  were  17  different  interventions,  and  some
comparisons were informed only by direct evidence from one study.
We  rated  25  studies  as  high  risk  of  bias.  There  were  no  concerns
regarding model fit. The network diagram is presented in Figure 12,
and  the  forest  plot  is  presented  in  Figure  13.  An  overview  of  the
interventions included in the analysis is given in Table 11.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 12.   Moderate pain relief network diagram. NASSA: noradrenergic and specific serotonergic antidepressants;
SNRI: serotonin noradrenalin reuptake inhibitors; TCA: tricyclic antidepressants; nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 13.   Moderate pain relief forest plot. NASSA: noradrenergic and specific serotonergic antidepressants; SNRI:
serotonin noradrenalin reuptake inhibitors; TCA: tricyclic antidepressants; nonad: non-antidepressants

Ranking of antidepressants

Condition and risk of bias

The top-ranked antidepressants for moderate pain relief are shown
in  Table  12.  All  antidepressants  with  more  than  200  participants
in  the  antidepressant  arm  showed  an  effect  for  moderate  pain
relief, and were very closely ranked. Mirtazapine was the highest-
ranked antidepressant (OR 1.92, 95% CI 1.45 to 2.39), followed by
duloxetine (OR 1.79, 95% CI 1.67 to 1.91), milnacipran (OR 1.70, 95%
CI 1.48 to 1.92) and esreboxetine (OR 1.65, 95% CI 1.32 to 1.98).

A  visual  representation  of  the  cumulative  rankings  for  every
intervention  included  in  the  analysis  did  not  alter  interpretation.
The  unrelated  mean-effect  model  showed  no  evidence  of
inconsistency.  We  confirmed  this  with  node-splitting  models  for
all nine comparisons where it was possible to compare direct and
indirect evidence. The comparison of duloxetine and placebo had
the lowest Bayesian P value (0.18) with indirect evidence indicative
of a larger effect than direct evidence. These figures are available in
the supplemental files (link provided in Appendix 3).

Exploration of heterogeneity

We  also  explored  the  impact  of  including  dose  in  the  model.
There  was  low  heterogeneity  (Tau  =  0.11),  and  whilst  there
was  no  evidence  of  inconsistency  in  unrelated  mean-effects  and
node-splitting  models,  there  were  several  divergent  transitions.
The  analysis  showed  similar  rankings  of  antidepressants  to
the  treatment-only  model,  with  mirtazapine,  duloxetine,  and
milnacipran  remaining  the  highest-ranked  across  doses.  The  full
results  of  all  the  analyses  are  reported  in  the  supplemental  files
(link provided in Appendix 3).

Class

Three classes were included in the treatment -only analysis: NaSSA,
SNRI,  and  TCA.  Only  the  NaSSA  and  SNRI  classes  had  over  200
participants  in  the  analyses.  SNRI  was  the  highest-ranked  class
(logOR: 0.56; CrI: 0.45 to 0.60) followed by NaSSA (logOR: 0.67; CrI:
0.11 to 1.23).

We  were  unable  to  undertake  further  NMAs  due  to  small  sample
size,  network  geometry  and  risk  of  over-fitting;  but  pairwise  and
NMA  excluding  multi-dose  studies  were  undertaken  to  inform
strength of evidence assessment using CINeMA.

CINeMA

The design-by-treatment test showed no evidence of inconsistency
between the direct and indirect evidence in the network (Chi2 = 2.65,
P = 0.62), and only esreboxetine had an I2 statistic value of above
40%  (44.6%).  We  rated  duloxetine  and  milnacipran  as  moderate
certainty, while we downgraded mirtazapine and esreboxetine due
to low numbers of studies and participants.

Physical function

For physical function, we report the change-score treatment-dose
network as it had lower heterogeneity than other models and no
inconsistency.  We  present  the  summary  of  findings  for  physical
function in Table 13.

Results

We  included  32  RCTs  with  a  total  of  11,760  participants  (range
from 42 to 1025). Twenty studies compared against placebo, four
were head-to-head studies with another active comparator, seven
were dose-comparison studies, and one was a direct head-to-head
comparison  between  two  different  antidepressants.  There  were
18 different interventions, and some comparisons were informed
only  by  direct  evidence  from  one  study.  We  rated  21  studies  as
high  risk  of  bias.  We  did  not  need  to  remove  any  studies  due  to
disconnected networks. There were no concerns regarding model
fit. The network diagram is presented in Figure 14, the forest plot of
placebo comparisons in Figure 15, and Table 14 shows the number
of  RCTs  and  total  number  of  participants  for  each  intervention
included in the analysis.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 14.   Physical function network diagram. NASSA: noradrenergic and specific serotonergic antidepressants;
SNRI: serotonin noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic
antidepressants; nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 15.   Physical function forest plot (standardised mean difference with credible intervals). NASSA:
noradrenergic and specific serotonergic antidepressants; SNRI: serotonin noradrenalin reuptake inhibitors; SSRI:
selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants; nonad: non-antidepressants

Ranking of antidepressants

Condition and risk of bias

The  top-ranked  antidepressants  for  physical  function  change
scores are shown in Table 15. Duloxetine standard dose (SMD −0.24,
95% CI −0.32 to −0.18), duloxetine high dose (SMD −0.23, 95% CI 0.30
to 0.16), and milnacipran standard dose (SMD −0.18, 95% CI −0.30 to
−0.07) were the highest-ranked antidepressants with small effects.
Duloxetine standard dose and duloxetine high doses were equally
effective.  Milnacipran  high  dose  showed  no  significant  difference
compared to placebo (SMD −0.10, 95% CI −0.22 to 0.07). Mirtazapine
standard  dose  was  the  lowest-ranked  antidepressant  (SMD  0.62,
95% CI 0.11 to 0.69).

A  visual  representation  of  the  cumulative  rankings  for  every
intervention  included  in  the  analysis  did  not  alter  interpretation.
We  performed  node-splitting  models  for  all  four  comparisons
where it was possible to compare direct and indirect evidence. The
lowest Bayesian P value was for the comparison of duloxetine high
dose compared to placebo, where direct evidence showed a larger
effect than indirect evidence (P = 0.07). These figures are available
in the supplemental files (link provided in Appendix 3).

Class

We included four classes of antidepressants in the analysis: SNRI,
SSRI,  TCA,  and  NaSSA,  however  due  to  interventions  including
combinations  of  drugs,  we  could  not  analyse  models  including
class.

We  were  unable  to  undertake  further  NMAs  due  to  small  sample
sizes, network geometry and the risk of over-fitting.

CINeMA

The design-by-treatment test showed no evidence of inconsistency
between  the  direct  and  indirect  evidence  (Chi2  =  6.45,  P  =  0.69),
and  no  antidepressants  had  an  I2  statistic  value  of  over  40%,
although values could not be generated for mirtazapine. We rated
duloxetine  and  milnacipran  as  moderate  certainty,  downgraded
only due to some concerns with within-study bias. We downgraded
esreboxetine  and  mirtazapine  further  to  low  due  to  the  small
number of studies and participants included in the analyses.

Sleep

For sleep, we report the change-score treatment-dose network as
this was the most robust and reliable model. We present summary
of findings for sleep in presented Table 16.

Results

We included 18 RCTs with a total of 6301 participants (range from
42 to 1195). Twelve studies compared against placebo and six were
dose-comparison studies. There were eight different interventions,
and  some  comparisons  were  informed  only  by  direct  evidence
from one study. We rated nine studies as high risk of bias overall.
There were no concerns regarding model fit. The network diagram
is  presented  in  Figure  16,  the  forest  plot  for  placebo  comparison
is  presented  in  Figure  17,  and  an  overview  of  all  interventions
included in the analysis is given in Table 17.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 16.   Sleep network diagram. SNRI: serotonin noradrenalin reuptake inhibitors; SSRI: selective serotonin
reuptake inhibitors

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 17.   Sleep forest plot (standardised mean difference with credible intervals). SNRI: serotonin noradrenalin
reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors

Ranking of antidepressants

The  top-ranked  antidepressants  for  sleep  are  displayed  in  Table
18.  Duloxetine  standard  and  high  doses  were  the  highest-ranked
antidepressants, and the only antidepressants to show a significant
effect when compared to placebo, although the effects were small
(standard dose: SMD −0.21, 95% CI −0.30 to −0.12; high dose: SMD
−0.14,  95%  CI  −0.27  to  −0.01).  Milnacipran  standard  dose  (SMD
−0.06, 95% CI −0.30 to 0.17) and high dose (SMD −0.03, 95% CI −0.29
to 0.20) showed no significant difference in comparison to placebo.

A  visual  representation  of  the  cumulative  rankings  for  every
intervention included in the analysis did not alter interpretations.
Node-splitting  models  had  divergent  transitions  and  indicated
inconsistency  for  the  comparison  of  high  and  standard  dose
duloxetine  (P  0.02).  We  therefore  downgraded  the  strength  of
evidence for the duloxetine high dose estimate. These figures are
available in the supplemental files (link provided in Appendix 3).

Exploration of heterogeneity

Class, condition and risk of bias

Although there were two different classes in the network (SNRI and
SSRI),  SSRI  was  only  represented  by  one  study  using  citalopram
with  21  participants;  therefore  only  SNRI  crossed  the  threshold
of 200 participants. We did not explore condition and risk of bias
further using NMA because of concerns about sample size, network
geometry and the risk of over-fitting.

CINeMA

The design-by-treatment test showed no evidence of inconsistency
between  the  direct  and  indirect  evidence  in  the  network  (Chi2=
7.39,  P  =  0.4)  despite  the  concerns  identified  in  node-splitting

models.  No  antidepressants  had  I2  statistic  values  of  above  40%,
although  we  could  not  calculate  values  for  milnacipran  high  or
standard  doses.  We  rated  only  duloxetine  as  moderate  certainty,
downgraded from high due to some concerns about within-study
bias  and  inconsistency  from  the  NMA.  We  rated  duloxetine  high
dose,  milnacipran  high  dose,  and  milnacipran  standard  dose  as
very  low  certainty.  We  downgraded  duloxetine  high  dose  due
to  major  concerns  regarding  within-study  bias  and  incoherence.
We  downgraded  milnacipran  standard  and  high  doses  due  to
major  concerns  regarding  within-study  bias,  and  some  concerns
regarding imprecision, heterogeneity, and inconsistency. Of note,
both milnacipran doses analyses were informed by the same study.

Quality of life

For  quality  of  life  we  report  the  post-intervention  treatment
network, as this was the network with the lowest heterogeneity. We
present summary of findings for quality of life in Table 19.

Results

We included 19 RCTs with a total of 3103 participants (range from
30 to 998). Five studies compared against placebo, 11 were multi-
arm studies with another active comparator, two were direct head-
to-head  comparisons  of  different  antidepressants,  and  one  was
a  dose-comparison  study.  There  were  23  different  interventions,
and  some  comparisons  were  informed  only  by  direct  evidence
from one study. We could not include data from one study due to
disconnected  networks.  We  rated  13  studies  as  high  risk  of  bias
overall. There were no concerns regarding model fit. The network
diagram is presented in Figure 18 and the forest plot is presented
in  Figure  19.  An  overview  of  the  interventions  included  in  the
analysis is presented in Table 20.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 18.   Quality of life network diagram. SNRI: serotonin noradrenalin reuptake inhibitors; SSRI: selective
serotonin reuptake inhibitors; TCA: tricyclic antidepressants; nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 19.   Quality of life forest plot (standardised mean difference with credible intervals). SNRI: serotonin
noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants;
nonad: non-antidepressants

Ranking of antidepressants

CINeMA

The  top-ranked  antidepressants  for  quality  of  life  are  displayed
in  Table  21.  Neither  esreboxetine  nor  duloxetine  showed  a
significant difference compared to placebo for quality of life (SMD
−0.30,  95%  CI  −1.24  to  0.64  and  SMD  0.02,  95%  CI  −0.56  to  0.58,
respectively).

A  visual  representation  of  the  cumulative  rankings  for  every
intervention included in the analysis did not alter interpretations.
Node-splitting  models  were  undertaken  for  all  13  comparisons
where  it  was  possible  to  compare  direct  and  indirect  evidence.
The  comparison  with  the  lowest  Bayesian  P  value  (0.16)  was
fluoxetine  compared  to  amitriptyline.  These  figures  are  available
in the supplemental files (link provided in Appendix 3). Unrelated
mean-effects models also failed to identify inconsistency.

Exploration of heterogeneity

We explored models including both treatment and dose; this model
had higher heterogeneity (Tau = 0.67) and similar residual deviance
to that of the treatment-only model.

Class, condition and risk of bias

We were unable to generate meaningful networks including class,
condition, and risk of bias. Only one class had antidepressants with
over 200 participants (SNRI). Small sample sizes, network geometry
and the risk of over-fitting precluded analyses of condition and risk
of bias.

The  design-by-treatment  test  showed  evidence  of  significant
inconsistency  between  the  direct  and  indirect  evidence  in  the
network  (Chi2  =  80.27,  P  =  0.00)  despite  node-splitting  and
unrelated mean-effect models indicating no concern. The I2 statistic
value for duloxetine showed evidence of heterogeneity (I2= 67.2%)
and  could  not  be  calculated  for  esreboxetine.  Therefore,  we
rated  duloxetine  as  having  low-certainty  evidence  (downgraded
due  to  within-study  bias,  heterogeneity,  and  inconsistency)  and
esreboxetine  as  very  low-certainty  evidence  (downgraded  due  to
within-study bias, inconsistency, and low numbers of studies).

Patient Global Impression of Change (PGIC)

PGIC was reported in two ways: as a continuous score, and as the
proportion of participants scoring one (very much improved) and
two (much improved). We include both of these results.

PGIC much and very much improved

For PGIC much and very much improved we report the treatment-
dose network as this had low heterogeneity with no inconsistency.
We  present  summary  of  findings  for  PGIC  much  or  very  much
improved in Table 22.

Results

We included 12 RCTs with a total of 6995 participants (range from
43 to 1025). Eight studies compared against placebo and four were

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

dose-comparison studies. There were nine different interventions,
and some comparisons were informed only by direct evidence from
one study. We judged seven studies to be high risk of bias. There
were  no  concerns  regarding  model  fit.  The  network  diagram  is

presented  in Figure  20,  and  the  forest  plot  is  presented  in  Figure
21. An overview of all interventions included in the analysis is given
in Table 23.

Figure 20.   Patient Global Impression of Change much/very much improved network diagram. SNRI: serotonin
noradrenalin reuptake inhibitors

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 21.   Patient Global Impression of Change much/very much improved forest plot. SNRI: serotonin
noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants;
nonad: non-antidepressants

Ranking of antidepressants

The  top-ranked  antidepressants  for  PGIC  much  and  very  much
improved  are  presented  in  Table  24.  Duloxetine  standard  dose
was  the  highest-ranked  antidepressant  for  PGIC  much  and  very
much improved, with a large effect (OR 2.29, 95% CI 1.98 to 2.60).
Duloxetine  high  dose  (OR  2.03,  95%  CI  1.62  to  2.44),  milnacipran
high dose (OR 1.99, 95% CI 1.77 to 2.21), and milnacipran standard
dose (OR 1.95, 95% CI 1.73 to 2.17) were the next highest-ranked
antidepressants. Both esreboxetine doses showed a smaller effect
(standard:  OR  1.79,  95%  CI  1.44  to  2.14;  high:  OR  1.63,  95%  CI
1.24 to 2.02), but were among the lowest-ranked antidepressants.
Desvenlafaxine  high  dose  showed  no  significant  effects  when
compared to placebo (OR 1.01, 95% CI 0.58 to 1.44).

A  visual  representation  of  the  SUCRA  rankings 
for  every
intervention  included  in  the  analysis  did  not  alter  interpretation.
The unrelated mean-effect model had no evidence of inconsistency.
We  were  only  able  to  compare  direct  and  indirect  evidence  for
milnacipran standard versus milnacipran high dose with a Bayesian
P  value  of  0.66,  indicative  of  no  inconsistency.  These  figures  are
available the supplemental files (link provided in Appendix 3)..

Exploration of heterogeneity

• Class,  condition  and  risk  of  bias:  we  were  unable  to  include
class,  condition,  and  risk  of  bias  in  the  models.  For  class,
all  the  antidepressants  included  in  the  model  were  SNRI.  For
condition and risk of bias, the sparse network geometry created

disconnected networks with small sample sizes and high risk of
over-fitting.

• CINeMA:  the  design-by-treatment  test  showed  no  evidence  of
inconsistency  (Chi2  =  0.35,  P  =  0.84),  and  no  antidepressants
had  I2  statistic  values  of  over  40%.  We  rated  the  majority  of
the evidence to be very low certainty, due to within-study bias
and low study and participant numbers. We rated milnacipran
high dose as low certainty, downgraded due to major concerns
of  within-study  bias.  We  rated  milnacipran  and  duloxetine
standard dose as moderate certainty, only downgraded due to
concerns about within-study bias.

PGIC continuous

For  PGIC  continuous  we  report  the  treatment-dose  network  as  it
had low heterogeneity and the most clinical utility.  We present the
summary of findings in Table 25.

Results

We  included  24  RCTs  with  a  total  of  8415  participants  (range
from 194 to 804). Twelve studies compared against only placebo,
three were multi-arm studies with another active comparator, and
nine  were  dose-comparison  studies.  There  were  seven  different
interventions, and some comparisons were informed only by direct
evidence from one study. We judged 15 studies as high risk of bias
overall. There were no concerns regarding model fit. The network
diagram  is  presented  in  Figure  22,  and  the  forest  plot  of  placebo
comparisons  is  presented  in  Figure  23.  An  overview  of  all  the
interventions included in the analysis is given in Table 26.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 22.   Patient Global Impression of Change continuous network diagram. SNRI: serotonin noradrenalin
reuptake inhibitors; nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 23.   Patient Global Impression of Change continuous forest plot (standardised mean difference with credible
intervals). SNRI: serotonin noradrenalin reuptake inhibitors; nonad: non-antidepressants

Ranking of antidepressants

The top-ranked antidepressants for PGIC continuous are presented
in Table 27. Duloxetine standard and high doses were the highest-
ranked  antidepressants,  with  a  small  to  moderate  effect  (SMD
−0.36,  95%  CI  −0.44  to  −0.29  and  SMD  −0.33,  95%  CI  −0.40  to
−0.26,  respectively).  Duloxetine  low  dose  was  the  lowest-ranked
antidepressant  with  a  small  effect  (SMD  −0.23,  95%  CI  −0.35  to
−0.11).

A  visual  representation  of  the  cumulative  rankings  for  every
intervention included in the analysis did not alter interpretations.
Both  unrelated  mean-effect  models  and  node-splitting  models
showed  evidence  of 
inconsistency.  The  highest  Bayesian  P
value  (0.03)  suggested  that  direct  evidence  overestimated  the
effectiveness of high-dose duloxetine versus placebo compared to
indirect evidence, resulting in strength of evidence downgrading.
These figures are available in the supplemental files (link provided
in Appendix 3).

Exploration of heterogeneity

• Class,  condition,  and  risk  of  bias:  we  were  unable  to  run
models  including  class,  condition,  and  risk  of  bias.  We  were
unable to analyse class as there was only one class present in
the network (SNRI). We were unable to analyses condition and
risk of bias due to the high risk of over-fitting.

• CINeMA:  the  design-by-treatment  test  showed  no  evidence  of
inconsistency  between  the  direct  and  indirect  evidence  in  the

network (Chi2 = 14.98, P = 0.13), and no antidepressants had an
I2 statistic value higher than 40%. We rated duloxetine standard
and high doses as moderate certainty as a result of incoherence.
We downgraded duloxetine low dose to moderate certainty due
to  some  concerns  regarding  within-study  bias  in  addition  to
network inconsistency.

Serious adverse events

For  serious  adverse  events  we  report  the  treatment-dose  model.
Both treatment and treatment-dose models had studies with high
levels  of  imprecision;  treatment-dose  was  selected  for  reporting
due  to  its  clinical  utility.  We  present  the  summary  of  findings
in Table 28.

Results

We  included  71  RCTs  with  a  total  of  19,304  participants  (range
from  26  to  1025).  Thirty-nine  studies  compared  against  placebo,
12  compared  against  another  active  comparator,  15  were  dose-
comparison  studies,  and  four  studies  compared  two  different
antidepressants  against  each  other.  There  were  31  different
interventions, and some comparisons were informed only by direct
evidence  from  one  study.  We  judged  45  studies  as  high  risk
of  bias.  We  could  not  include  data  from  three  studies  due  to
disconnected networks. There were no concerns regarding model
fit. The network diagram is presented in Figure 24, and the forest
plot of placebo comparisons is presented in Figure 25. An overview
of all interventions included in the analysis is given in Table 29.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 24.   Serious adverse events network diagram. NARI: noradrenaline reuptake inhibitors; NDRI: Noradrenaline
and dopamine reuptake inhibitors; NASSA: noradrenergic and specific serotonergic antidepressants; SNRI: serotonin
noradrenaline reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants;
nonad: non-antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 25.   Serious adverse events forest plot (log odds ratio with credible intervals). NARI: noradrenaline reuptake
inhibitors; NDRI: Noradrenaline and dopamine reuptake inhibitors; NASSA: noradrenergic and specific serotonergic
antidepressants; SNRI: serotonin noradrenaline reuptake inhibitors; SSRI: selective serotonin reuptake inhibitors;
TCA: tricyclic antidepressants; nonad: non-antidepressants

Ranking of antidepressants

The  top-ranked  antidepressants  for  serious  adverse  events  are
displayed  in  Table  30.  Data  for  serious  adverse  events  were  very
sparse,  and  studies  were  generally  underpowered  to  detect  rare
events. No antidepressants showed any significant difference when
compared  with  placebo,  and  the  confidence  intervals  were  very
wide.

We undertook a visual representation of the cumulative rankings
for  every  intervention  included  in  the  analysis.  The  unrelated
mean-effect model had no evidence of inconsistency. We confirmed

this  with  node-splitting  models  for  all  16  comparisons  where  it
was possible to compare direct and indirect evidence. The lowest
Bayesian  P  value  (0.07)  was  for  the  comparison  of  pregabalin
and  low-dose  duloxetine.  These  figures  are  available  in  the
supplemental files (link provided in Appendix 3).

• Class, condition, and risk of bias: we were unable to undertake
further  analysis  of  class,  condition,  or  risk  of  bias  in  networks
due  to  small  sample  sizes,  network  geometry  and  the  risk  of
over-fitting.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• CINeMA:  we  were  unable  to  use  CINeMA  for  this  outcome
due  to  complexity  of  the  network.  Therefore,  two  review
authors  (HB  and  GS)  made  the  judgements  based  on  GRADE
and  CINeMA  domains  and  the  available  results.  We  judged
all  antidepressants  and  doses  as  very  low  certainty,  primarily
due  to  concerns  with  within-study  bias,  heterogeneity,  and
imprecision in the network.

Withdrawal

For  withdrawal,  we  report  the  treatment  network.  Although  this
model has high heterogeneity, we determined that including dose
would increase the network complexity to a point where analysis
would be infeasible. We present the summary of findings in Table
31.

Results

We  included  152  RCTs  with  a  total  of  28,120  participants  (range
from 24 to 1025). Seventy-three studies compared against placebo,
47  were  multi-arm  studies  with  another  active  comparator,  18
were dose-comparison studies, and 14 were head-to-head studies
comparing two different antidepressants. There were 77 different
interventions, and some comparisons were informed only by direct
evidence from one study. We rated 106 studies as high risk of bias.
We could not include data from two studies due to disconnected
networks. There were no concerns regarding model fit. We present
the  network  diagram  in  Figure  26,  and  the  forest  plot  of  placebo
comparisons in Figure 27. We give an overview of all interventions
included in the analysis in Table 32.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 26.   Withdrawal network diagram. MAOI_rev: monoamine oxidase inhibitors (reversible); NARI:
noradrenaline reuptake inhibitors; NDRI: noradrenaline and dopamine reuptake inhibitors; NASSA: noradrenergic
and specific serotonergic antidepressants; SNRI: serotonin noradrenaline reuptake inhibitors; SSRI: selective
serotonin reuptake inhibitors; TCA: tricyclic antidepressants; TECA: tetracyclic antidepressants; nonad: non-
antidepressants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 27.   Withdrawal forest plot (log odds ratio with credible intervals). MAOI_rev: monoamine oxidase inhibitors
(reversible); NARI: noradrenaline reuptake inhibitors; NDRI: Noradrenaline and dopamine reuptake inhibitors;
NASSA: noradrenergic and specific serotonergic antidepressants; SNRI: serotonin noradrenaline reuptake inhibitors;
SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants; TECA: tetracyclic antidepressants;
nonad: non-antidepressants

Ranking of antidepressants

The  ranking  of  antidepressants  with  over  200  participants  in
order of highest-ranked to lowest-ranked is presented in Table 33.
Nortriptyline was the highest-ranked antidepressant. Nortriptyline,
mirtazapine,  amitriptyline,  desvenlafaxine,  and  venlafaxine  all
showed  no  significant  difference  compared  to  placebo  for
withdrawal.  Duloxetine,  milnacipran,  esreboxetine,  desipramine,
and paroxetine all showed significant effects, ranging from small to
moderate.

A  visual  representation  of  the  cumulative  rankings  for  every
intervention included in the analysis is given in the supplemental
files  (link  provided  in  Appendix  3).  We  were  unable  to  draw  any
very  reliable  conclusions  due  to  all  antidepressants  having  wide,
overlapping credible intervals.

Exploration of heterogeneity

Due  to  the  complexity  and  geometry  of  the  network,  we  were
only able to examine models including class, and were unable to
examine condition or risk of bias.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Class

We  included  10  classes  of  antidepressant  in  the  analysis:  SNRI,
SSRI, TCA, MAOI reversible, NARI, NaSSA, NDRI, SARI, TCA+SSRI, and
TeCA. There was slightly higher heterogeneity than the treatment-
only  model  (Tau  =  0.33),  but  no  evidence  of  inconsistency  in  the
unrelated mean effects models. Half of the classes had fewer than
200  participants,  leaving  SNRI,  SSRI,  TCA,  NaSSA,  and  TeCA  with
reliable sample sizes. The rankings of these classes are presented
in Table 34.

CINeMA

We were unable to use CINeMA for this outcome due to complexity
of the network. Therefore, two review authors (HB and GS) made
the  judgements  based  on  GRADE  and  CINeMA  domains  and  the
available results. We judged all antidepressants except duloxetine
as very low certainty, primarily due to concerns with within-study
bias,  heterogeneity,  and  imprecision  in  the  network.  We  rated
duloxetine  as  low  certainty,  as  the  only  antidepressant  without
major concerns due to imprecision.

D I S C U S S I O N

Summary of main results

Overall

We  report  an  NMA  of  176  double-blind  RCTs  that  investigated
antidepressants  for  chronic  pain.  Studies  included  28,664  adult
participants with a mean age of 50.6 years. The majority of studies
investigated antidepressants from three classes: SNRI (74 studies);
TCA (72 studies); and SSRI (34 studies). There was a variety of study
designs, however the majority of studies were placebo-controlled
(83  studies).  The  remainder  compared  an  antidepressant  against
an  active  comparator  with  no  placebo  (22  studies)  or  compared
two  or  more  different  doses  of  the  same  antidepressant  with  a
placebo  arm  (17  studies).  Most  studies  were  parallel-arm  design
(141 studies) compared to cross-over design (35 studies). Studies
mainly  included  participants  with  only  one  type  of  chronic  pain:
59 studies included participants with fibromyalgia; 49 neuropathic
pain;  40  musculoskeletal  pain;  and  26  included  participants  with
other  conditions  (e.g.  gastrointestinal,  primary  pain  conditions,
non-cardiac chest pain etc.). Finally, 72 studies were fully funded by
pharmaceutical companies. Thirty-two studies did not report the
source of funding.

Seven studies, with a total of 156 participants, provided no useable
data  and  were  therefore  omitted  from  the  NMAs.  At  the  time
of  writing  the  review,  the  majority  of  antidepressants  are  not
licenced for use in chronic pain. Only amitriptyline and duloxetine
are  indicated  for  types  of  chronic  pain  in  the  British  National
Formulary; amitriptyline for neuropathic pain, and duloxetine for
diabetic  neuropathy  (British  National  Formulary  2022b;  British
National Formulary 2022c).

The  following  results  are  based  on  NMA.  One  study  (Vrethem
1997), reported the results separately according to the type of pain
condition. This study was stratified into two to include the results
for both conditions.

Cochrane Database of Systematic Reviews

ranked  antidepressant  that  had  data  from  over  200  participants
in  total  across  studies,  and  the  only  antidepressant  with  robust
evidence that showed an effect with moderate-certainty evidence.
For substantial pain and pain intensity, standard-dose duloxetine
was  as  efficacious  as  high-dose  duloxetine.  For  pain  intensity
and  mood,  milnacipran  also  showed  reliable  effectiveness,  with
moderate-certainty evidence. At a class level, SNRIs were the only
class to have an effect with reliable evidence. For pain intensity, we
removed one study that showed improbable effects from the data
extracted  from  the  published  article  (Miki  2016).  We  emailed  the
study authors for clarification but received no response.

Secondary efficacy outcomes

Across all the secondary efficacy outcomes (moderate pain relief,
physical  function,  sleep,  quality  of  life,  and  PGIC)  duloxetine
and  milnacipran  were  the  highest-ranked  and  most  trustworthy
antidepressants  respectively.  Very  few  other  antidepressants
included over 200 participants, and those that did were ranked as
very low certainty. For both duloxetine and milnacipran, standard
doses were as effective as high doses, although effects for both were
small.

Safety

We extracted adverse event, serious adverse event, and withdrawal
data  from  the  studies  included  in  the  review.  The  data  for  these
outcomes  were  poor.  Although  we  have  reported  the  ranking  of
antidepressants  in  the  summary  of  findings  tables,  the  quality
and certainty of this evidence for all antidepressants and doses is
very  low,  and  we  cannot  draw  any  reliable  conclusions  from  the
analyses.

Overall completeness and applicability of evidence

We  were  able  to  draw  some  conclusions  about  the  effectiveness
and  rankings  of  antidepressants  in  the  efficacy  and  safety  of
treating chronic pain. The evidence is particularly lacking for long-
term outcomes and safety data.

Participants

The  sample  of  participants  in  the  included  studies  was  mostly
female  (68.3%)  and  had  a  mean  age  of  50.6  years.  Most  studies
had  a  minimum  pain  intensity  inclusion  criterion,  with  92
studies  requiring  participants  to  score  4  or  higher  on  a  0  to  10
scale  or  equivalent  at  baseline,  and  most  participants  reported
experiencing pain for over one year.

Our  inclusion  criteria  for  participants  was  strict,  we  required  the
study population to have had pain for three months or longer. If this
timeframe was not explicitly reported by the study or required for
a diagnosis of the pain condition, then we excluded it. Therefore,
we  excluded  six  studies  from  our  full-text  screening  with  a  study
population described as having a ‘chronic’ pain condition without
information regarding duration. This may mean that we excluded
other relevant studies, but we believe the number of studies to be
affected by this to be minimal.

Interventions

Primary efficacy outcomes

For  the  primary  efficacy  outcomes  (substantial  pain  relief,  pain
intensity,  and  mood)  duloxetine  was  consistently  the  highest-

There  were  89  different  interventions  included  in  the  review,  26
of which were antidepressants. We included all interventions that
matched  the  inclusion  criteria  regardless  of  dose,  formulation,
and  route  of  administration.  Only  four  antidepressants  were

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

investigated in over 10 studies. The only antidepressant that had
robust  studies  and  evidence  is  duloxetine,  with  43  studies  and  a
total of 11,608 participants randomised. Participants in duloxetine
studies accounted for over a third of all the participants included
in  this  review.  Milnacipran  also  showed  some  reliable  evidence
across outcomes, with 11 studies and a total of 5083 participants.
Forty-three studies, with a total of 3372 participants, investigated
amitriptyline,  although  the  certainty  of  this  evidence  was  very
low,  and  only  three  studies  randomised  over  200  participants.
Fluoxetine  was  the  fourth  antidepressant  to  be  included  in  more
than 10 studies, but the quality and certainty of the evidence was
very low, with 11 studies including 630 participants in total. All other
antidepressants were included in fewer than 10 studies.

Study designs and comparisons

A  variety  of  study  designs  were  used  by  studies  included
in  the  review.  Half  the  studies  included  in  the  review  were
two-arm,  parallel-designed  studies  comparing  antidepressant
to  placebo  (89  out  of  176  studies).  There  were  also  dose-
comparison  studies,  comparisons  against  active  comparators,
combined  antidepressant  interventions  (e.g.  antidepressant  +
psychological therapy), and a number of studies included multiple
types of these comparisons. Some of the combined antidepressant
comparisons precluded full analysis in the NMA as we were unable
to  isolate  the  effects  of  the  antidepressant  alone.  There  were
few  head-to-head  studies  comparing  two  antidepressants  with  a
placebo arm for reference.

The  majority  of  studies  provided  useable  data  for  the  primary
efficacy  outcomes;  131  studies  measured  pain  intensity,  and  87
measured  mood.  Although  these  figures  represent  the  majority
of  studies,  it  is  evident  that  a  large  number  of  studies  in  chronic
pain  do  not  report  these  key  outcomes.  In  the  review,  over  half
of  studies  did  not  measure  mood,  and  almost  a  third  did  not
measure or report pain intensity. Despite the 2005 publication of
the IMMPACT guidelines for core outcomes of chronic pain studies
(Dworkin  2008),  only  44  and  43  studies  reported  the  proportion
of  participants  achieving  50%  and  30%  pain  relief,  respectively.
For  the  secondary  outcomes,  around  a  third  of  studies  reported
physical  function,  less  than  a  quarter  reported  sleep,  and  only  a
quarter reported quality of life.

All outcomes aside from withdrawal used self-reported measures.
There  was  considerable  heterogeneity  in  the  outcome  measures
used  across  all  outcomes  such  that  SMD  was  required  for
the  continuous  outcomes.  Additionally,  studies  reported  a  mix
of  change  scores  (change  in  outcome  from  baseline  to  post-
intervention)  and  post-intervention  scores.  As  we  had  to  use
SMD,  this  meant  that  we  could  not  build  one  NMA  that
included  all  data  for  each  outcome;  rather  we  were  required  to
build both change-score and post-intervention-score models and
subsequently  decide  which  model  to  report  for  each  outcome.
Typically,  larger  studies,  funded  by  pharmaceutical  companies,
reported  change  scores,  whilst  smaller  studies  reported  post-
intervention  scores.  Future  reviews  would  benefit  from  studies
reporting both types of scores, so that results can be combined for
a holistic evidence synthesis. We found that the data for the safety
outcomes were particularly poor; adverse events were reported in
various different ways across studies, and studies were often not
powered adequately or lasted long enough to detect events.

Cochrane Database of Systematic Reviews

Mood

As  antidepressants  are  primarily  designed  and  used  to  manage
depression, and low mood is a common comorbidity with chronic
pain, we planned to explore their impact upon mood in this analysis
in several ways.

First,  we  planned  to  undertake  a  subgroup  analysis  exploring
whether there were any differences in outcomes between studies
reporting a main aim of targeting pain compared to those reporting
a main aim of targeting mood. We were unable to undertake this
analysis as only two studies had a main aim of targeting mood. In
contrast, 144 studies had a main aim of targeting pain.

Second, we planned to undertake analyses examining differences
in outcomes for studies stratified by levels of depression at baseline
(none,  mild,  moderate,  and  severe  as  defined  by  the  diagnostic
tools  used).  The  majority  of  studies  excluded  participants  with
diagnoses  of  major  depressive  disorder  and  other  mental  health
conditions.  Because  of  this,  baseline  measures  of  depression  or
anxiety, or both, failed to exceed average scores of mild depression
at baseline.

As we were unable to undertake these analyses, we are unable to
assess the effect of depression and mood on the outcomes of the
NMA, and unable to draw any meaningful conclusions regarding the
mood outcome.

Timing

Most of the studies included in this review were of short duration:
the average length of the study from baseline to post-intervention
was 10 weeks. We planned to undertake analyses at several time
points:

• post-intervention  (immediately  at  the  end  of  the  treatment

period);

• short-term  follow-up  (<  12  weeks  after  the  treatment  had

finished);

• long-term  follow-up  (≥  12  weeks  after  the  treatment  had

finished).

We were only able to undertake analyses at the post-intervention
time  point  as  only  a  small  number  of  studies  had  follow-
up  periods  of  any  length  after  the  intervention  had  been
completed (6/176 studies). Therefore, we are unable to draw any
conclusions  regarding  the  long-term  efficacy  and  safety  of  using
antidepressants for chronic pain.

Ongoing studies

We categorised 26 studies as 'ongoing', which are investigating the
following antidepressants.

• Duloxetine (12 studies)
• Amitriptyline (4 studies)
• Citalopram (2 studies)
• Venlafaxine (2 studies)
• Agomelatine (1 study)
• Bupropion (1 study)
• Clomipramine (1 study)
• Fluoxetine (1 study)
• Mianserin (1 study)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

• Nortriptyline (1 study)

The ongoing studies are investigating the following pain conditions.

• Neuropathic pain (9 studies)
• Osteoarthritis (6 studies)
• Low back pain (4 studies)
• Chest pain (2 studies)
• Facial pain (2 studies)
• Irritable bowel syndrome (1 study)
• Mastalgia (1 study)
• Phantom limb pain (1 study)

Considering their context, we do not anticipate that the evidence
from  these  studies  will  have  a  significant  impact  on  the  findings
of this review. We consider our results for duloxetine, neuropathic
pain, and musculoskeletal pain to be robust - the addition of these
results are unlikely to change this. These studies may contribute to
conclusions for amitriptyline if the sample sizes are large enough;
we  were  unable  to  include  amitriptyline  in  the  write-up  of  the
review as often there were not more than 200 participants from the
studies.

Quality of the evidence

Overall quality

followed  by  milnacipran.  We 

We  assessed  the  quality  of  the  evidence  using  CINeMA
(Nikolakopoulou 2020) (and ROB-MEN (Chiocchia 2021), and GRADE
(Schünemann  2013),  where  appropriate).  Across  the  outcomes,
the  only  antidepressant  with  consistently  robust  evidence  is
duloxetine, 
judged  all  other
antidepressants as having low- or very low-certainty evidence. The
most common reasons for downgrading comparisons were within-
study  bias,  imprecision  in  the  NMA  (wide  credible  intervals),  and
small numbers of studies and participants. Additionally, we graded
all evidence for safety as very low certainty due to heterogeneity,
imprecision, and sparsity of data.

Risk of bias

Overall,  the  risk  of  bias  for  included  studies  was  relatively  high.
Using  RoB  1  resulted  in  116  studies  being  defined  as  high  risk  of
bias  overall.  We  often  downgraded  evidence  due  to  within-study
bias across antidepressants and outcomes. There are several points
relating  to  risk  of  bias  to  be  discussed.  The  common  method  of
deciding the overall rating of a study’s risk of bias stipulates that if
any one domain is high risk, then the whole study is rated as high
risk of bias. As we included studies that compared antidepressants
to  other  active  comparators,  this  included  interventions  whose
designs  inherently  require  participants  and  study  staff  to  be
unblinded  (e.g.  psychological  therapies).  To  be  consistent  with
other studies in the review, we rated these as high risk of bias for
the blinding domains, but it has been recognised previously that
these  domains  are  not  appropriate  for  these  interventions,  and
in  previous  reviews  these  domains  have  been  omitted  (Williams
2020).

Additionally,  we  found  that  a  number  of  studies  simply  do  not
report  the  information  needed  to  make  a  judgement.  Of  the  60
studies rated as ‘not high’ risk of bias, over half had three or more
domains judged as ‘unclear’. Therefore, this raises concerns as to
the reporting quality of these studies, an ongoing problem in health

Cochrane Database of Systematic Reviews

research (Pirosca 2022). There is a number of clinical trial reporting
guidelines available which these studies have not abided by, which
suggests that some of the studies may have been rated as high risk
of bias if the correct information had been provided.

Heterogeneity 

We  found  substantial  heterogeneity  in  direct  comparisons  and
entire networks across outcomes when including all doses of each
treatment together in the NMAs. Where this was evident, splitting
treatments  by  dose  categories  removed  heterogeneity  for  most
outcomes. Therefore, most of the outcomes were analysed using a
split-dose model. Further exploration of heterogeneity by including
antidepressant class and pain condition had to be balanced against
the  risk  of  over-fitting  multiple  models  (Dias  2013).  The  decision
process for this is discussed within each outcome results section.

Imprecision

Imprecision  was  a  problem  across  most  of  our  NMAs.  Of  the  26
different  antidepressants  included  in  our  review,  only  four  were
used in more than 10 studies. Although we included all treatments
in  each  analysis,  for  each  outcome  we  graded  any  study  with
fewer  than  200  participants  in  the  antidepressant  arms  as  very
low  by  default  and  excluded  these  from  the  written  summaries
and  summary  of  findings  tables.  The  remaining  networks  were
generally  robust  at  a  network  level,  but  problems  remained  with
network connectivity relying on single studies. Imprecision was a
major  problem  for  safety  data,  particularly  adverse  events,  and
serious adverse events, meaning that we cannot be sure of the true
effect for these outcomes.

Inconsistency

inconsistency 

For  each  outcome,  we  used  unrelated  mean-effect  and  node-
splitting  models  to  assess 
in  treatment  and
split  treatment-dose  networks.  Network  geometry  was  generally
adequate to allow both unrelated mean-effect models and node-
splitting models to be used to assess discrepancy between direct
and  indirect  evidence.  Where  discrepancies  were  identified,  we
considered  the  potential  for  transitivity  assumption  violations  in
strength-of-evidence  assessments  and  model  choice.  On  some
occasions  the  distributions  of  estimates  from  direct  and  indirect
evidence  were  wide  due  to  low  power,  or  we  were  unable  to
make important comparisons due to an absence of head-to-head
studies. In these circumstances, transitivity assumption violations
cannot be discounted. In general, there was sufficient evidence to
identify  discrepancy  between  direct  and  indirect  evidence  -  and
such  discrepancies  were  rare  -  especially  considering  the  size  of
the networks and the potential diversity of participants across pain
conditions.

Publication bias

We  used  ROB-MEN  to  assess  publication  bias  in  the  review
(Chiocchia  2021).  For  the  primary  outcomes,  we  were  only  able
to produce funnel plots for the duloxetine-placebo comparison as
it  was  the  only  comparison  with  over  10  studies.  These  funnel
plots  showed  some  evidence  of  publication  bias,  and  therefore
the  comparisons  were  rated  as  ‘some  concerns’.  As  all  other
antidepressants tended to report small effects with small numbers
of  studies  and  participants,  we  judged  all  comparisons  to  have
‘some concerns’.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Potential biases in the review process

We  minimised  the  potential  for  bias  in  the  review  process  as
much as possible. We published our protocol through the Cochrane
Library and followed this for the review process (Birkinshaw 2021).
We had an extensive search strategy that included six databases,
and  also  searched  clinical  trials  registries  for  unpublished  and
ongoing  studies.  The  chance  of  a  missed  study  is  minimal,  and
even  more  minimal  is  the  chance  of  any  missed  study  having  a
substantial effect on the overall results.

Two  review  authors  completed  screening,  data  extraction,  and
risk  of  bias  assessments  in  duplicate  and  independently,  with
all  disagreements  resolved  by  discussion.  Where  possible,  we
contacted study authors to request missing data, but their response
rate  was  low.  Where  the  study  was  registered  in  a  clinical  trials
registry, we collected data that were not reported in the published
paper from the results section of the registry.

We used CINeMA (Nikolakopoulou 2020) and ROB-MEN (Chiocchia
2021) to assess our confidence in the results. Two review authors
made the final interpretation and judgements in discussion.

Agreements and disagreements with other studies or
reviews

To  our  knowledge,  this  is  the  only  NMA  that  has  examined  all
antidepressants  for  all  types  of  chronic  pain;  previous  reviews  in
this topic area have focused solely on one pain condition, or one
antidepressant, or have examined efficacy by drug, dose, and pain
condition.  There  have  been  a  number  of  systematic  reviews  and
meta-analyses  over  the  past  decade  examining  antidepressants
for different types of pain conditions, the majority of which were
Cochrane Reviews.

For  neuropathic  pain,  multiple  reviews  have  shown  there  is
no  high-quality  or  high-certainty  evidence  for  the  efficacy  of
amitriptyline, desipramine, imipramine, milnacipran, nortriptyline,
or  venlafaxine  (Derry  2015a;  Derry  2015b;  Gallagher  2015;  Hearn
2014a; Hearn 2014b; Moore 2015). However, there was moderate-
certainty  evidence  that  duloxetine  is  efficacious  for  diabetic
peripheral  neuropathy  (Lunn  2014).  For  fibromyalgia,  reviews
show  that  there  was  no  unbiased  evidence  that  amitriptyline,
desvenlafaxine,  venlafaxine,  or  SSRIs  were  better  than  placebo,
but  there  is  low-certainty  evidence  that  duloxetine,  milnacipran,
and mirtazapine are efficacious (Walitt 2015; Welsch 2018). Finally,
for  musculoskeletal  pain,  two  reviews  found  no  clear  evidence
to  support  the  use  of  antidepressants  for  low  back  pain  (Koes
2018; Urquhart 2008), though a recent systematic review and meta-
analysis  showed  moderate-certainty  evidence  for  SNRIs  for  low
back  pain  (Ferreira  2021).  The  majority  of  studies  in  Ferreira  and
colleagues' review and meta-analysis investigated chronic low back
pain, although acute low back pain studies were also included.

Although  we  were  unable  to  examine  the  outcomes  by
condition,  our  results  are  broadly  in  line  with  previous  reviews.
We  found  no  high-quality  or  high-certainty  evidence  for  the
efficacy of amitriptyline, desipramine, desvenlafaxine, imipramine,
mirtazapine, nortriptyline, or venlafaxine in any of our outcomes.
Our review and NMA found that duloxetine had robust evidence and
was the highest rated antidepressant for the majority of outcomes.
For most outcomes, milnacipran was the second most efficacious
antidepressant, although the certainty of evidence ranged between

Cochrane Database of Systematic Reviews

very  low  and  moderate.  For  outcomes  where  a  treatment-dose
model was used, standard and high doses of both duloxetine and
milnacipran were equally effective.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

For people with chronic pain

from  randomised  controlled  trials  suggests  that
Research 
duloxetine is more effective than other antidepressants (including
amitriptyline)  for  management  of  chronic  pain.  For  people  with
chronic pain considering trying an antidepressant for pain relief, it
may be worth trying duloxetine first before other antidepressants.
However, it is important to acknowledge that there is no 'one size
fits  all'  with  both  antidepressants  and  pain.  Adopting  a  person-
centred approach is critical.

For clinicians

Amitriptyline  was  not  among  the  highest-ranked  antidepressants
in  terms  of  efficacy  for  either  substantial  pain  relief  or  reduction
in  pain  intensity.  The  evidence  suggests  that  generic  duloxetine
could be the first option when considering the use antidepressants
for chronic pain management. Additionally, for duloxetine there is
often  no  benefit  to  using  a  high  dose;  using  a  standard  dose  (60
mg) is often as effective as using a high dose (> 60 mg). We were
unable to be certain about the adverse events and harms for any
antidepressant, so this is important to consider when prescribing
antidepressants for chronic pain.

For policy makers

A  full  analysis  of  international  guidelines  is  out  of  scope,  but
the  National  Institute  for  Health  and  Care  Excellence  (NICE)
guidelines for the treatment of chronic primary pain recommends
antidepressants  as  the  only  pharmacological  treatment  option
(NICE  2021).  In  these  guidelines,  NICE  specifically  recommend
amitriptyline,  citalopram,  duloxetine,  fluoxetine,  paroxetine,  or
sertraline,  with  no  recommendations  regarding  dose.  Our  review
and  analyses  found  only  moderate-  to  high-certainty  evidence
for  duloxetine  in  the  management  of  chronic  pain,  evidence  for
amitriptyline, citalopram, fluoxetine, paroxetine or sertraline was
low quality and of very low certainty.

For funders of the intervention

Currently,  amitriptyline 
is  the  most  common  and  first-line
antidepressant  prescribed  for  the  management  of  chronic  pain;
however,  there  are  no  large,  high-quality  studies  to  support  this
position.  There  is  also  a  lack  of  head-to-head  studies  where
multiple  antidepressants  are  compared  in  the  same  study.  It  is
important  to  recognise  that  there  are  no  long-term  safety  data
available for any antidepressant used for chronic pain treatment,
and  that  collection  and  reporting  of  these  data  during  trials  is
essential.

Implications for research

General implications

• For  all  antidepressants  aside  from  duloxetine,  there  is  a
lack  of  high-quality,  robust  studies  to  establish  effectiveness
and  safety.  Amitriptyline  and  milnacipran  particularly  require
further research; amitriptyline because it is the most common

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

antidepressant  prescribed  for  chronic  pain  management,  and
milnacipran  because  it  has  consistently  ranked  equivalent  or
very close to duloxetine.

• Adverse  events  should  be  reported  following  the  CONSORT
guidelines,  as  highlighted  many  times  previously  (Edwards
1999; Phillips 2019).

inhibitors 

• Serotonin-noradrenalin  reuptake 

(SNRIs)  as  a
class  require  further  research.  Duloxetine  and  milnacipran
were  consistently  the  highest-ranked  antidepressants  across
outcomes.  Research  to  identify  and  explore  the  mechanisms
underpinning  the  effectiveness  of  these  antidepressants  is
required.

• The relationship between chronic pain and depression deserves
further  attention.  It  is  common  in  studies  of  analgesics  to
exclude  participants  with  comorbid  mental  health  disorders
such  as  clinical  depression,  anxiety,  or  psychosis.  As  a
consequence, we know nothing of the effects of antidepressants
on  pain  in  these  populations.  Further,  depression  and  anxiety
are common consequences of chronic pain, and often co-exist.
Although the dosing schedules of anti-depressant medicines are
different when prescribed for analgesia rather than depression
(typically smaller) there is a possibility of dual effect, but this is
not possible to study in these trials.

Design implications

• Longer  trials  are  required:  there  is  no  evidence  regarding  the
long-term  efficacy  or  safety  of  using  antidepressants  for  the
treatment  of  chronic  pain.  This  is  critical  as  it  is  likely  that
patients will be prescribed antidepressants for long periods of
time, and currently we do not know if there are likely to be any
harms related to this.

• Head-to-head  trials  between  antidepressants  are  required  to
accurately  measure  the  effects  of  antidepressants  for  chronic
pain.

• Larger sample sizes: there is no need for small trials; sufficient

sizes are required to establish effect.

• There is a need for pragmatic trials with more complex designs
to address changes in medication. Pragmatic trial designs that
account for individual difference have been recommended for
over a decade (Moore 2010c), yet the majority of studies are still
designed as two-arm placebo-controlled trials.

Measurement implications

• There 

is  now  guidance  on  the  optimal  conduct  and
reporting  of  clinical  trials,  and  specific  guidance  on  the
reporting  of  pain  trials,  the  Consolidated  Standards  of
Reporting  Trials  (CONSORT;  Schulz  2010),  and  Initiative  on
Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT; Dworkin  2008).  These  recommendations  should  be
adhered  to  in  order  to  reduce  research  waste  and  efficiently
inform clinical decision making.

• Where  applicable,  both  post-intervention  and  change  scores
should  be  reported  to  enable  comprehensive  evidence
synthesis.

• If trials are reporting responder analyses (e.g. 50% pain relief),
then  they  should  also  report  the  continuous  data,  to  reduce
the  chance  of  Type  1  errors.  Some  studies  in  our  review  only
reported responder analyses and could not be included in the
counterpart continuous measures.

A C K N O W L E D G E M E N T S

Cochrane  Review  Group  funding  acknowledgement:  this  project
was  funded  by  the  National  Institute  for  Health  Research  (NIHR)
via  Cochrane  Infrastructure  funding  to  Cochrane  Pain,  Palliative
and Supportive Care (PaPaS). The views expressed are those of the
author(s) and not necessarily those of the NIHR or the Department
of Health and Social Care.

We  acknowledge  and  thank  the  NIHR  Health  Technology
Assessment programme (HTA) for funding this review.

We  thank  Joanne  Abbott  (Information  Specialist  for  Cochrane
PaPaS  Review  Group)  for  developing  and  running  the  search
strategy, and Iris Gordon (Information Specialist for Cochrane Eyes
and Vision Review Group) for peer reviewing the search strategy.

We thank the peer reviewers of the protocol Dr Sarah Nevitt, Kevin
Pacheco-Barrios MD, Dr Christina Abdel Shaheed, and Prof Amanda
C  de  C  Williams,  and  consumer  reviewers  Harrison  Nelson  and
Stella O’Brien.

Editorial and peer-reviewer contributions

Cochrane Pain, Palliative and Supportive Care (PaPaS) supported
the authors in the development of this review.

The  following  people  conducted  the  editorial  process  for  this
article.

• Sign-off Editor (final editorial decision): Dr Neil O'Connell, PaPaS
Co-ordinating Editor, and Reader at Brunel University London
• Contact Editor: Bethan Copsey, Leeds Institute of Clinical Trials

Research, University of Leeds, UK

• Managing  Editor  (selected  peer  reviewers,  collated  peer-
reviewer  comments,  provided  editorial  guidance  to  authors,
edited  the  article):  Anna  Erskine  and  Jessica  Thomas  (Oxford
University Hospitals (OUH) NHS Foundation Trust, Oxford, UK)
• Assistant  Managing  Editor  (conducted  editorial  checks  and
supported  editorial  team):  Kerry  Harding  (Oxford  University
Hospitals (OUH) NHS Foundation Trust, Oxford, UK)

• Information  Specialist  (searching  support):  Joanne  Abbott
(Oxford  University  Hospitals  (OUH)  NHS  Foundation  Trust,
Oxford, UK)

• Peer reviewers: Brian Duncan (consumer reviewer, Psychology);
Dr Ye Jin, Mental Health centre, Yingkou, Liaoning, China (clinical
reviewer); Giovanni Ferreira, Institute for Musculoskeletal Health
&  Sydney  Musculoskeletal  Health,  The  University  of  Sydney
(clinical  reviewer);  José  A  López-López,  Department  of  Basic
Psychology  and  Methodology,  Faculty  of  Psychology  and
Speech  Therapy,  University  of  Murcia,  Murcia  (Spain)  (clinical
reviewer);  Rachel  Richardson  (Cochrane  Evidence  Production
and  Methods  Directorate),  Sofia  Tsokani  (Cochrane  Evidence
Production and Methods Directorate).

• Copy-editing  (initial  copy-edit  and  final  proofread):  Denise
(Cochrane  Evidence  Production  and  Methods

Mitchell 
Directorate)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

References to studies included in this review

Aragona 2005 {published data only}

R E F E R E N C E S

29060/433 {published data only}

29060/433. Treatment of fibromyalgia: a randomized,
double-blind, placebo-controlled study of paroxetine, a
selective serotonin re-uptake inhibitor. https://www.gsk-
studyregister.com/en/trial-details/?id=29060/433 (first received
1 December 2005).

Abou-Raya 2012 {published data only}

Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the
management of pain in older adults with knee osteoarthritis:
randomised placebo-controlled trial. Age and Ageing
2012;41(5):646-52. [DOI: 10.1093/ageing/afs072]

Agger 2017 {published data only}

Agger JL, Schröder A, Gormsen LK, Jensen JS, Jensen TS,
Fink PK. Imipramine versus placebo for multiple functional
somatic syndromes (STreSS-3): a double-blind, randomised
study. Lancet Psychiatry 2017;4(5):378-88. [DOI: 10.1016/
S2215-0366(17)30126-8]

Ahmed 2016 {published data only}

Ahmed M, Aamir R, Jishi Z, Scharf MB. The effects of milnacipran
on sleep disturbance in fibromyalgia: a randomized, double-
blind, placebo-controlled, two-way crossover study. Journal
of Clinical Sleep Medicine 2016;12(1):79-86. [DOI: 10.5664/
jcsm.5400]

Alcoff 1982 {published data only}

Alcoff J, Jones E, Rust P, Newman R. Controlled trial of
imipramine for chronic low back pain. Family Practice
1982;14(5):841-6.

Allen 2014 {published data only}

Allen R, Sharma U, Barlas S. Clinical experience with
desvenlafaxine in treatment of pain associated with diabetic
peripheral neuropathy. Journal of Pain Research 2014;7:339-51.
[DOI: 10.2147/JPR.S55682]

Allen 2017 {published data only}

Allen R, Sharma U, Barlas S. Clinical experience with
desvenlafaxine in treatment of patients with fibromyalgia
syndrome. Clinical Pharmacology in Drug Development
2017;6(3):224-33. [DOI: 10.1002/cpdd.271]

Anderberg 2000 {published data only}

Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram
in patients with fibromyalgia—a randomized, double-
blind, placebo-controlled study. European Journal of Pain
2000;4(1):27-35. [DOI: 10.1053/eujp.1999.0148]

Ang 2013 {published data only}

Ang DC, Jensen MP, Steiner JL, Hilligoss J, Gracely RH, Saha C.
Combining cognitive-behavioral therapy and milnacipran
for fibromyalgia: a feasibility randomized-controlled trial.
Clinical Journal of Pain 2013;29(9):747-54. [DOI: 10.1097/
AJP.0b013e31827a784e]

Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A,
Conte A, et al. Randomized double-blind comparison of
serotonergic (Citalopram) versus noradrenergic (Reboxetine)
reuptake inhibitors in outpatients with somatoform, DSM-IV-
TR pain disorder. European Journal of Pain 2005;9(1):33-8. [DOI:
10.1016/j.ejpain.2004.03.003]

Arnold 2002 {published data only}

Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE
Jr. A randomized, placebo-controlled, double-blind, flexible-
dose study of fluoxetine in the treatment of women with
fibromyalgia. American Journal of Medicine 2002;112(3):191-7.
[DOI: 10.1016/s0002-9343(01)01089-0]

Arnold 2004 {published data only}

Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S,
et al. A double-blind, multicenter trial comparing duloxetine
with placebo in the treatment of fibromyalgia patients with or
without major depressive disorder. Arthritis & Rheumatology
2004;50(9):2974-84. [DOI: 10.1002/art.20485]

Arnold 2005 {published data only}

Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ,
Iyengar S, et al. A randomized, double-blind, placebo-
controlled trial of duloxetine in the treatment of women with
fibromyalgia with or without major depressive disorder. Pain
2005;119(1-3):5-15. [DOI: 10.1016/j.pain.2005.06.031]

Arnold 2010a {published data only}

Arnold LM, Chatamra K, Hirsch I, Stoker M. Safety and efficacy
of esreboxetine in patients with fibromyalgia: an 8-week,
multicenter, randomized, double-blind, placebo-controlled
study. Clinical Therapeutics 2010;32(9):1618-32. [DOI: 10.1016/
j.clinthera.2010.08.003]

Arnold 2010b {published data only}

Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y.
Efficacy and safety of milnacipran 100 mg/day in patients with
fibromyalgia: results of a randomized, double-blind, placebo-
controlled trial. Arthritis & Rheumatology 2010;62(9):2745-56.
[DOI: 10.1002/art.27559]

Arnold 2010c {published data only}

Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM.
Flexible dosed duloxetine in the treatment of fibromyalgia:
a randomized, double-blind, placebo-controlled trial.
Journal of Rheumatology 2010;37(12):2578-86. [DOI: 10.3899/
jrheum.100365]

Arnold 2012a {published data only}

Arnold LM, Zhang S, Pangallo BA. Efficacy and safety
of duloxetine 30 mg/d in patients with fibromyalgia: a
randomized, double-blind, placebo-controlled study.
Clinical Journal of Pain 2012;28(9):775-81. [DOI: 10.1097/
AJP.0b013e3182510295]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2012b {published data only}

Branco 2010 {published data only}

Arnold LM, Hirsch I, Sanders P, Ellis A, Hughes B. Safety
and efficacy of esreboxetine in patients with fibromyalgia:
a fourteen-week, randomized, double-blind, placebo-
controlled, multicenter clinical trial. Arthritis & Rheumatology
2012;64(7):2387-97. [DOI: 10.1002/art.34390]

Branco JC, Zachrisson O, Perrot S, Mainguy Y, Multinational
Coordinator Study Group. A European multicenter randomized
double-blind placebo-controlled monotherapy clinical
trial of milnacipran in treatment of fibromyalgia. Journal of
Rheumatology 2010;37(4):851-9. [DOI: 10.3899/jrheum.090884]

Ash 1999 {published data only}

Braz 2013 {published data only}

Ash G, Dickens CM, Creed FH, Jayson MI, Tomenson B. The
effects of dothiepin on subjects with rheumatoid arthritis and
depression. Rheumatology 1999;38(10):959-67. [DOI: 10.1093/
rheumatology/38.10.959]

Atkinson 1998 {published data only}

Atkinson JH, Slater MA, Williams RA, Zisook S, Patterson TL,
Grant I, et al. A placebo-controlled randomized clinical trial of
nortriptyline for chronic low back pain. Pain 1998;76(3):287-96.
[DOI: 10.1016/S0304-3959(98)00064-5]

Atkinson 1999 {published data only}

Atkinson JH, Slater MA, Wahlgren DR, Williams RA, Zisook S,
Pruitt SD, et al. Effects of noradrenergic and serotonergic
antidepressants on chronic low back pain intensity. Pain
1999;83(2):137-45. [DOI: 10.1016/s0304-3959(99)00082-2]

Atkinson 2007 {published data only}

Atkinson JH, Slater MA, Capparelli EV, Wallace MS,
Zisook S, Abramson I, et al. Efficacy of noradrenergic
and serotonergic antidepressants in chronic back pain: a
preliminary concentration-controlled trial. Journal of Clinical
Psychopharmacology 2007;27(2):135-42. [DOI: 10.1097/
jcp.0b013e3180333ed5]

Bansal 2009 {published data only}

Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P.
Amitriptyline vs. pregabalin in painful diabetic neuropathy:
a randomized double blind clinical trial. Diabetic Medicine
2009;26(10):1019-26. [DOI: 10.1111/j.1464-5491.2009.02806.x]

Bateman 2013 {published data only}

Bateman L, Palmer RH, Trugman JM, Lin Y. Results of switching
to milnacipran in fibromyalgia patients with an inadequate
response to duloxetine: a phase IV pilot study. Journal of Pain
Research 2013;6:311-18. [DOI: 10.2147/JPR.S43395]

Bird 2000 {published data only}

Bird H, Broggini M. Paroxetine versus amitriptyline for
treatment of depression associated with rheumatoid arthritis:
a randomized, double blind, parallel group study. Journal of
Rheumatology 2000;27(12):2791-7.

Boyle 2012 {published data only}

Boyle J, Eriksson MEV, Gribble L, Gouni R, Johnsen S,
Coppini DV, et al. Randomized, placebo-controlled comparison
of amitriptyline, duloxetine, and pregabalin in patients with
chronic diabetic peripheral neuropathic pain: impact on pain,
polysomnographic sleep, daytime functioning, and quality of
life. Diabetes Care 2012;35(12):2451-8. [DOI: 10.2337/dc12-0656]

Braz AS, Morais LC, Paula AP, Diniz MF, Almeida RN. Effects
of Panax ginseng extract in patients with fibromyalgia: a 12-
week, randomized, double-blind, placebo-controlled trial.
Revista Brasileira de Psiquiatria [Brazilian Journal of Psychiatry]
2013;35(1):21-8. [DOI: 10.1016/j.rbp.2013.01.004]

Calderon 2011 {published data only}

Calderon PS, Tabaquim ML, de Oliveira LC, Camargo AP,
Netto TC, Conti PC. Effectiveness of cognitive-behavioral
therapy and amitriptyline in patients with chronic
temporomandibular disorders: a pilot study. Brazilian
Dental Journal 2011;22(5):415-21. [DOI: 10.1590/
s0103-64402011000500012]

Cannon 1994 {published data only}

Cannon RO 3rd, Quyyumi AA, Mincemoyer R, Stine AM,
Gracely RH, Smith WB, et al. Imipramine in patients with chest
pain despite normal coronary angiograms. New England
Journal of Medicine 1994;330(20):1411-7. [DOI: 10.1056/
NEJM199405193302003]

Cardenas 2002 {published data only}

Cardenas DD, Warms CA, Turner JA, Marshall H, Brooke MM,
Loeser JD. Efficacy of amitriptyline for relief of pain in spinal
cord injury: results of a randomized controlled trial. Pain
2002;96(3):365-73. [DOI: 10.1016/S0304-3959(01)00483-3]

Carette 1986 {published data only}

Carette S, McCain GA, Bell DA, Fam AG. Evaluation of
amitriptyline in primary fibrositis. A double-blind, placebo-
controlled study. Arthritis & Rheumatology 1986;29(5):655-9.
[DOI: 10.1002/art.1780290510]

Carette 1994 {published data only}

Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA,
Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine,
and placebo in the treatment of fibromyalgia: a randomized,
double-blind clinical trial. Arthritis & Rheumatology
1994;37(1):32-40. [DOI: 10.1002/art.1780370106]

Caruso 1987 {published data only}

Caruso I, Sarzi Puttini PC, Boccassini L, Santandrea S, Locati M,
Volpato R, et al. Double-blind study of dothiepin versus placebo
in the treatment of primary fibromyalgia syndrome. Journal
of International Medical Research 1987;15(3):154-9. [DOI:
10.1177/030006058701500305]

Chappell 2008 {published data only}

Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN,
Spaeth M. A six-month double-blind, placebo-controlled,
randomized clinical trial of duloxetine for the treatment
of fibromyalgia. International Journal of General Medicine
2008;1:91-102. [DOI: 10.2147/ijgm.s3979]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chappell 2009a {published data only}

Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M,
D'Souza DN, Moldofsky H. A 1-year safety and efficacy study of
duloxetine in patients with fibromyalgia. Clinical Journal of Pain
2009;25(5):365-75. [DOI: 10.1097/AJP.0b013e31819be587]

Chappell 2009b {published data only}

Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V,
Li LC, et al. Duloxetine, a centrally acting analgesic, in the
treatment of patients with osteoarthritis knee pain: a 13-week,
randomized, placebo-controlled trial. Pain 2009;146(3):253-60.
[DOI: 10.1016/j.pain.2009.06.024]

Chappell 2011 {published data only}

Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V,
Belenkov Y, et al. A double-blind, randomized, placebo-
controlled study of the efficacy and safety of duloxetine
for the treatment of chronic pain due to osteoarthritis of
the knee. Pain Practice 2011;11(1):33-41. [DOI: 10.1111/
j.1533-2500.2010.00401.x]

Clauw 2008 {published data only}

Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.
Milnacipran for the treatment of fibromyalgia in adults: a
15-week, multicenter, randomized, double-blind, placebo-
controlled, multiple-dose clinical trial. Clinical Therapeutics
2008;30(11):1988-2004. [DOI: 10.1016/j.clinthera.2008.11.009]

pain syndromes. Neuropsychobiology 1988;19(1):25-34. [DOI:
10.1159/000118429]

Engel 1998 {published data only}

Engel CC Jr, Walker EA, Engel AL, Bullis J, Armstrong A. A
randomized, double-blind crossover trial of sertraline in women
with chronic pelvic pain. Journal of Psychosomatic Research
1998;44(2):203-7. [DOI: 10.1016/s0022-3999(97)00215-8]

Enomoto 2018 {published data only}

Enomoto H, Yasuda H, Nishiyori A, Fujikoshi S, Furukawa M,
Ishida M, et al. Duloxetine in patients with diabetic peripheral
neuropathic pain in Japan: a randomized, doubleblind,
noninferiority comparative study with pregabalin. Journal of
Pain Research 2018;11:1857-68. [DOI: 10.2147/JPR.S170646]

Enteshari-Moghaddam 2019 {published data only}

Enteshari-Moghaddam A, Azami A, Isazadehfar K, Mohebbi H,
Habibzadeh A, Jahanpanah P. Efficacy of duloxetine
and gabapentin in pain reduction in patients with knee
osteoarthritis. Clinical Rheumatology 2019;38(10):2873-80. [DOI:
10.1007/s10067-019-04573-7]

Forssell 2004 {published data only}

Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine
in the treatment of atypical facial pain: a randomized controlled
trial. Journal of Orofacial Pain 2004;18(2):131-7.

Creed 2003 {published data only}

Foster 2010a {published data only}

Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et
al, North of England IBS Research Group. The cost-effectiveness
of psychotherapy and paroxetine for severe irritable bowel
syndrome. Gastroenterology 2003;124(2):303-17. [DOI: 10.1053/
gast.2003.50055]

de Zanette 2014 {published data only}

de Zanette SA, Vercelino R, Laste G, Rozisky JR, Schwertner A,
Machado CB, et al. Melatonin analgesia is associated with
improvement of the descending endogenous pain-modulating
system in fibromyalgia: a phase II, randomized, double-dummy,
controlled trial. BMC Pharmacology and Toxicology 2014;15:40.
[DOI: 10.1186/2050-6511-15-40]

Dickens 2000 {published data only}

Dickens C, Jayson M, Sutton C, Creed F. The relationship
between pain and depression in a trial using paroxetine
in sufferers of chronic low back pain. Psychosomatics
2000;41(6):490-9. [DOI: 10.1176/appi.psy.41.6.490]

Foster DC, Kotok MB, Huang L-S, Watts A, Oakes D, Howard FM,
et al. Oral desipramine and topical lidocaine for vulvodynia:
a randomized controlled trial. Obstetrics & Gynecology
2010;116(3):583-93. [DOI: 10.1097/AOG.0b013e3181e9e0ab]

Foster 2010b {published data only}

Foster HE Jr, Hanno PM, Nickel JC, Payne CK, Mayer RD,
Burks DA, et al. Effect of amitriptyline on symptoms in
treatment naïve patients with interstitial cystitis/painful
bladder syndrome. Journal of Urology 2010;183(5):1853-58.
[DOI: 10.1016/j.juro.2009.12.106]

Frakes 2011 {published data only}

Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM.
Duloxetine added to oral nonsteroidal anti-inflammatory drugs
for treatment of knee pain due to osteoarthritis: results of a
randomized, double-blind, placebo-controlled trial. Current
Medical Research and Opinion 2011;27(12):2361-72. [DOI:
10.1185/03007995.2011.633502]

Drossman 2003 {published data only}

Gao 2010 {published data only}

Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB,
Duncan S, et al. Cognitive-behavioral therapy versus education
and desipramine versus placebo for moderate to severe
functional bowel disorders. Gastroenterology 2003;125(1):19-31.
[DOI: 10.1016/s0016-5085(03)00669-3]

Eberhard 1988 {published data only}

Eberhard G, von Knorring L, Nilsson HL, Sundequist U,
Björling G, Linder H, et al. A double-blind randomized study of
clomipramine versus maprotiline in patients with idiopathic

Gao Y, Ning G, Jia W-P, Zhou Z-G, Xu Z-R, Liu Z-M, et al.
Duloxetine versus placebo in the treatment of patients with
diabetic neuropathic pain in China. Chinese Medical Journal
2010;123(22):3184-92.

Gao 2015 {published data only}

Gao Y, Guo X, Han P, Li Q, Yang G, Qu S, et al. Treatment of
patients with diabetic peripheral neuropathic pain in China:
a double-blind randomised trial of duloxetine vs. placebo.
International Journal of Clinical Practice 2015;69(9):957-66. [DOI:
10.1111/ijcp.12641]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gillving 2021 {published data only}

Goldstein 2005 {published data only}

Gillving M, Demant D, Holbech JV, Gylfadottir SS, Bach FW,
Jensen TS, et al. A randomized, controlled trial of a β2-agonist
in painful polyneuropathy. Pain 2021;162(5):1364-73. [DOI:
10.1097/j.pain.0000000000002140]

Gilron 2009 {published data only}

Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL.
Nortriptyline and gabapentin, alone and in combination for
neuropathic pain: a double-blind, randomised controlled
crossover trial. Lancet 2009;374(9697):1252-61. [DOI: 10.1016/
S0140-6736(09)61081-3]

Gilron 2015 {published data only}

Gilron I, Tu D, Holden RR, Jackson AC, DuMerton-
Shore D. Combination of morphine with nortriptyline for
neuropathic pain. Pain 2015;156(8):1440-8. [DOI: 10.1097/
j.pain.0000000000000149]

Gilron 2016 {published data only}

Gilron I, Chaparro LE, Tu D, Holden RR, Milev R, Towheed T, et
al. Combination of pregabalin with duloxetine for fibromyalgia:
a randomized controlled trial. Pain 2016;157(7):1532-40. [DOI:
10.1097/j.pain.0000000000000558]

Ginsberg 1996 {published data only}

Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey J-
P. A randomized placebo-controlled trial of sustained-
release amitriptyline in primary fibromyalgia. Journal
of Musculoskeletal Pain 1996;4(3):37-47. [DOI: 10.1300/
J094v04n03_05]

Ginsberg 1998 {published data only}

Ginsberg F, Joos E, Géczy J, Brahwyler J, Vandekerckhove K,
Famaey J-P. A pilot randomized placebo-controlled study
of pirlindole in the treatment of primary fibromyalgia.
Journal of Musculoskeletal Pain 1998;6(2):5-17. [DOI: 10.1300/
J094v06n02_02]

Goldenberg 1986 {published data only}

Goldenberg DL, Felson DT, Dinerman H. A randomized,
controlled trial of amitriptyline and naproxen in the treatment
of patients with fibromyalgia. Arthritis & Rheumatology
1986;29(11):1371-7. [DOI: 10.1002/art.1780291110]

Goldenberg 1996 {published data only}

Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C.
A randomized, double-blind crossover trial of fluoxetine
and amitriptyline in the treatment of fibromyalgia. Arthritis
& Rheumatology 1996;39(11):1852-9. [DOI: 10.1002/
art.1780391111]

Goldstein DJ, Lu Y, Detke M J, Lee TC, Iyengar S. Duloxetine
vs. placebo in patients with painful diabetic neuropathy. Pain
2005;116(1-2):109-18. [DOI: 10.1016/j.pain.2005.03.029]

González-Viejo 2005 {published data only}

González-Viejo MA, Avellanet M, Hernández-Morcuende MI. A
comparative study of fibromyalgia treatment: ultrasonography
and physiotherapy versus sertraline treatment [Étude
comparative dans traitement de la fibromyalgie: ultrasons
et kinésithérapie versus sertraline]. Annales de Réadaptation
et de Médecine Physique 2005;48(8):610-5. [DOI: 10.1016/
j.annrmp.2005.03.012]

Goodkin 1990 {published data only}

Goodkin K, Gullion CM, Agras WS. A randomized, double-
blind, placebo-controlled trial of trazodone hydrochloride
in chronic low back pain syndrome. Journal of Clinical
Psychopharmacology 1990;10(4):269-78.

Gould 2020 {published data only}

Gould HM, Atkinson JH, Chircop-Rollick T, D'Andrea J, Garfin S,
Patel SM, et al. A randomized placebo-controlled trial of
desipramine, cognitive behavioral therapy, and active placebo
therapy for low back pain. Pain 2020;12:1341-9. [DOI: 10.1097/
j.pain.0000000000001834]

Grace 1985 {published data only}

Grace EM, Bellamy N, Kassam Y, Buchanan WW. Controlled,
double-blind, randomized trial of amitriptyline in relieving
articular pain and tenderness in patients with rheumatoid
arthritis. Current Medical Research and Opinion 1985;9(6):426-9.
[DOI: 10.1185/03007998509109614]

Graff-Radford 2000 {published data only}

Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline
and fluphenazine in the treatment of postherpetic
neuralgia. Clinical Journal of Pain 2000;16(3):188-92. [DOI:
10.1097/00002508-200009000-00002]

Hadianfard 2012 {published data only}

Hadianfard MJ, Hosseinzadeh Parizi M. A randomized
clinical trial of fibromyalgia treatment with acupuncture
compared with fluoxetine. Iranian Red Crescent Medical Journal
2012;14(10):631.

Hameroff 1984 {published data only}

Hameroff SR, Weiss JL, Lerman JC, Cork RC, Watts KS, Crago BR,
et al. Doxepin's effects on chronic pain and depression: a
controlled study. Journal of Clinical Psychiatry 1984;45(3 Pt
2):47-53.

Goldman 2010 {published data only}

Hammody 2015 {published data only}

Goldman RH, Stason WB, Park SK, Kim R, Mudgal S, Davis RB, et
al. Low-dose amitriptyline for treatment of persistent arm pain
due to repetitive use. Pain 2010;149(1):117-23. [DOI: 10.1016/
j.pain.2010.01.016]

Hammody EL, Matloub SY, Shihab SS. Pregabalin versus
amitriptyline in the treatment of fibromyalgia patients (a
double blind comparative study). Iraqi Postgraduate Medical
Journal 2015;14(1):39-45.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

Hannonen 1998 {published data only}

Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R,
Roponen P. A randomized, double-blind, placebo-controlled

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

study of moclobemide and amitriptyline in the treatment of
fibromyalgia in females without psychiatric disorder. British
Journal of Rheumatology 1998;37(12):1279-86. [DOI: 10.1093/
rheumatology/37.12.1279]

Kalso 1996 {published data only}

Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively
relieves neuropathic pain following treatment of breast cancer.
Pain 1996;64(2):293-302. [DOI: 10.1016/0304-3959(95)00138-7]

Heymann 2001 {published data only}

Katz 2005 {published data only}

Heymann RE, Helfenstein M, Feldman D. A double-blind,
randomized, controlled study of amitriptyline, nortriptyline
and placebo in patients with fibromyalgia. An analysis of
outcome measures. Clinical and Experimental Rheumatology
2001;19(6):697-702.

Holbech 2015 {published data only}

Holbech JV, Bach FW, Finnerup NB, Brosen K, Jensen TS,
Sindrup SH. Imipramine and pregabalin combination for
painful polyneuropathy: a randomized controlled trial. Pain
2015;156(5):958-66. [DOI: 10.1097/j.pain.0000000000000143]

Katz J, Pennella-Vaughan J, Hetzel RD, Kanazi GE, Dworkin RH.
A randomized, placebo-controlled trial of bupropion
sustained release in chronic low back pain. Journal of Pain
2005;6(10):656-61. [DOI: 10.1016/j.jpain.2005.05.002]

Kaur 2011 {published data only}

Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A.
A comparative evaluation of amitriptyline and duloxetine in
painful diabetic neuropathy: a randomized, double-blind,
cross-over clinical trial. Diabetes Care 2011;34(4):818-22. [DOI:
10.2337/dc10-1793]

Hudson 2021 {published and unpublished data}

Kayiran 2010 {published data only}

Hudson B, Williman JA, Stamp LK, Alchin JS, Hooper GJ,
Mangin D, et al. Nortriptyline for pain in knee osteoarthritis:
a double-blind randomised controlled trial in New Zealand
general practice. British Journal of General Practice
2021;71(708):e538-46. [DOI: 10.3399/BJGP.2020.0797]

Kayiran S, Dursun E, Dursun N, Ermutlu N, Karamursel S.
Neurofeedback intervention in fibromyalgia syndrome; a
randomized, controlled, rater blind clinical trial. Applied
Psychophysiology and Biofeedback 2010;35(4):293-302. [DOI:
10.1007/s10484-010-9135-9]

Hussain 2011 {published data only}

Hussain SA, Al Khalifa II, Jasim NA, Gorial FI. Adjuvant
use of melatonin for treatment of fibromyalgia. Journal
of Pineal Research 2011;50(3):267-71. [DOI: 10.1111/
j.1600-079X.2010.00836.x]

Keefe 2011 {published data only}

Keefe FJ, Shelby RA, Somers TJ, Varia I, Blazing M, Waters SJ, et
al. Effects of coping skills training and sertraline in patients with
non-cardiac chest pain: a randomized controlled study. Pain
2011;152(4):730-41. [DOI: 10.1016/j.pain.2010.08.040]

Isomeri 1993 {published data only}

Isomeri R, Mikkelsson M, Latikka P, Kammonen K. Effects of
amitriptyline and cardiovascular fitness training on pain in
patients with primary fibromyalgia. Journal of Musculoskeletal
Pain 1993;1(3-4):253-60.

Khoromi 2007 {published data only}

Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline
and their combination vs. placebo in patients with chronic
lumbar root pain. Pain 2007;130(1-2):66-75. [DOI: 10.1016/
j.pain.2006.10.029]

Iwaki 2020 {published data only}

Kim 2013 {published data only}

Iwaki H, Ando R, Tada S, Nishikawa N, Tsujii T, Yamanishi Y, et
al. A double-blind, randomized controlled trial of duloxetine for
pain in Parkinson's disease. Journal of the Neurological Sciences
2020;414:116833.

Johansson 1979 {published data only}

Johansson F, von Knorring L. A double-blind controlled study
of seratonin uptake inhibitor (zimelidine) versus placebo in
chronic pain patients. Pain 1979;7(1):69-78.

Joharchi 2019 {published data only}

Joharchi K, Memari M, Azargashb E, Saadat N. Efficacy and
safety of duloxetine and pregabalin in Iranian patients
with diabetic peripheral neuropathic pain: a double-blind,
randomized clinical trial. Journal of Diabetes and Metabolic
Disorders 2019;18(2):575-82.

Jose 2007 {published data only}

Jose VM, Bhansali A, Hota D, Pandhi P. Randomized
double-blind study comparing the efficacy and safety of
lamotrigine and amitriptyline in painful diabetic neuropathy.
Diabetic Medicine 2007;24(4):377-83. [DOI: 10.1111/
j.1464-5491.2007.02093.x]

Kim JL, Rele S, Marks DM, Masand PS, Yerramsetty P, Millet RA,
et al. Effects of milnacipran on neurocognition, pain, and fatigue
in fibromyalgia: a 13-week, randomized, placebo-controlled,
crossover trial. Primary Care Companion  for CNS Disorders
2013;15(6):PCC.13m01555. [DOI: 10.4088/PCC.13m01555]

Konno 2016 {published data only}

Konno S, Oda N, Ochiai T, Alev L. Randomized, double-blind,
placebo-controlled phase iii trial of duloxetine monotherapy
in Japanese patients with chronic low back pain. Spine
2016;41(22):1709-17. [DOI: 10.1097/BRS.0000000000001707]

Lee 2010 {published data only}

Lee H, Kim JH, Min B-H, Lee JH, Son HJ, Kim JJ, et al. Efficacy of
venlafaxine for symptomatic relief in young adult patients with
functional chest pain: a randomized, double-blind, placebo-
controlled, crossover trial. American Journal of Gastroenterology
2010;105(7):1504-12. [DOI: 10.1038/ajg.2010.82]

Lee 2016 {published data only}

Lee YC, Massarotti E, Edwards RR, Lu B, Liu C, Lo Y, et al. Effect
of milnacipran on pain in patients with rheumatoid arthritis
with widespread pain: a randomized blinded crossover trial.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Journal of Rheumatology 2016;43(1):38-45. [DOI: 10.3899/
jrheum.150550]

Leijon 1989 {published data only}

Leijon G, Boivie J. Central post-stroke pain—a controlled trial of
amitriptyline and carbamazepine. Pain 1989;36(1):27-36. [DOI:
10.1016/0304-3959(89)90108-5]

Lipone 2020 {published data only}

Lipone P, Ehler E, Nastaj M, Palka-Kisielowska I, Cruccu G,
Truini A, et al. Efficacy and safety of low doses of trazodone in
patients affected by painful diabetic neuropathy and treated
with gabapentin: a randomized controlled pilot study. CNS
Drugs 2020;34(11):1177-89. [DOI: 10.1007/s40263-020-00760-2]

Loldrup 1989 {published data only}

Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P.
Clomipramine and mianserin in chronic idiopathic pain
syndrome. A placebo controlled study. Psychopharmacology
1989;99(1):1-7. [DOI: 10.1007/BF00634443]

Luo 2009 {published data only}

Luo Y-L, Zhang M-Y, Wu W-Y, Li C-B, Lu Z, Li Q-W. A randomized
double-blind clinical trial on analgesic efficacy of fluoxetine
for persistent somatoform pain disorder. Progress in
Neuro-Psychopharmacology and Biological Psychiatry
2009;33(8):1522-5. [DOI: 10.1016/j.pnpbp.2009.08.013]

Maarrawi 2018 {published data only}

Maarrawi J, Abdel Hay J, Kobaiter-Maarrawi S, Tabet P,
Peyron R, Garcia-Larrea L. Randomized double-blind controlled
study of bedtime low-dose amitriptyline in chronic neck pain.
European Journal of Pain 2018;22(6):1180-87. [DOI: 10.1002/
ejp.1206]

Macfarlane 1986 {published data only}

Macfarlane JG, Jalali S, Grace EM. Trimipramine in rheumatoid
arthritis: a randomized double-blind trial in relieving pain
and joint tenderness. Current Medical Research and Opinion
1986;10(2):89-93. [DOI: 10.1185/03007998609110424]

Mahmoud 2021 {published data only}

Mahmoud AM, Ragab SG, Boules ML, Botros JM. Comparison
between two low doses of amitriptyline in the management of
chronic neck pain: a randomized, double-blind, comparative
study. Pain Research & Management 2021;2021:8810178. [DOI:
10.1155/2021/8810178]

Majdinasab 2019 {published data only}

Majdinasab N, Kaveyani H, Azizi M. A comparative double-
blind randomized study on the effectiveness of duloxetine and
gabapentin on painful diabetic peripheral polyneuropathy.
Drug Design, Development and Therapy 2019;13:1985-92. [DOI:
10.2147/DDDT.S185995]

Masand 2009 {published data only}

Masand PS, Pae C-U, Krulewicz S, Peindl K, Mannelli P, Varia IM,
et al. A double-blind, randomized, placebo-controlled
trial of paroxetine controlled-release in irritable bowel
syndrome. Psychosomatics 2009;50(1):78-86. [DOI: 10.1176/
appi.psy.50.1.78]

Cochrane Database of Systematic Reviews

Matthey 2013 {published data only}

Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y,
et al. Dual reuptake inhibitor milnacipran and spinal pain
pathways in fibromyalgia patients: a randomized, double-blind,
placebo-controlled trial. Pain Physician 2013;16(5):E553-62.

Max 1988 {published data only}

Max MB, Schafer SC, Culnane M, Smoller B, Dubner R,
Gracely RH. Amitriptyline, but not lorazepam, relieves
postherpetic neuralgia. Neurology 1988;38(9):1427-32. [DOI:
10.1212/wnl.38.9.1427]

Max 1992 {published data only}

Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R.
Effects of desipramine, amitriptyline, and fluoxetine on pain
in diabetic neuropathy. New England Journal of Medicine
1992;326(19):1250-6. [DOI: 10.1056/NEJM199205073261904]

Mease 2009 {published data only}

Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W.
The efficacy and safety or milnacipran for treatment of
fibromyalgia. A randomized, double-blind, placebo-controlled
trial. Journal of Rheumatology 2009;36(2):398-409. [DOI:
10.3899/jrheum.080734]

Miki 2016 {published data only}

Miki K, Murakami M, Oka H, Onozawa K, Yoshida S, Osada K.
Efficacy of mirtazapine for the treatment of fibromyalgia
without concomitant depression: a randomized, double-
blind, placebo-controlled phase IIa study in Japan. Pain
2016;157(9):2089-96. [DOI: 10.1097/j.pain.0000000000000622]

Morello 1999 {published data only}

Morello CM, Leckband SG, Stoner CP, Moorhouse DF,
Sahagian GA. Randomized double-blind study comparing the
efficacy of gabapentin with amitriptyline on diabetic peripheral
neuropathy pain. Arch Intern Med 1999;159(16):1931-7. [DOI:
10.1001/archinte.159.16.1931]

Muller 2008 {published data only}

Muller JE, Wentzel I, Koen L, Niehaus DJ, Seedat S, Stein DJ.
Escitalopram in the treatment of multisomatoform disorder:
a double-blind, placebo-controlled trial. International
Clinical Psychopharmacology 2008;23(1):43-8. [DOI: 10.1097/
YIC.0b013e32825ea301]

Murakami 2015 {published data only}

Murakami M, Osada K, Mizuno H, Ochiai T, Alev L, Nishioka K. A
randomized, double-blind, placebo-controlled phase III trial of
duloxetine in Japanese fibromyalgia patients. Arthritis Research
and Therapy 2015;17:224. [DOI: 10.1186/s13075-015-0718-y]

Nabi 2021 {published data only}

Nabi BN, Saberi A, Eghbali BB, Hosseininezhad M, Biazar G,
Malekabadi AA, et al. Efficacy and safety of TENS and duloxetine
in patients with painful diabetic neuropathy: a single blind
randomized clinical trial. Journal of Advances in Medical and
Biomedical Research 2021;29(136):286-92.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Natelson 2015 {published data only}

Petzke 2013 {published data only}

Natelson BH, Vu D, Mao X, Weiduschat N, Togo F, Lange G, et
al. Effect of milnacipran treatment on ventricular lactate in
fibromyalgia: a randomized, double-blind, placebo-controlled
trial. Journal of Pain 2015;16(11):1211-9. [DOI: 10.1016/
j.jpain.2015.08.004]

Petzke F, Jensen KB, Kosek E, Choy E, Carville S, Fransson P,
et al. Using fMRI to evaluate the effects of milnacipran
on central pain processing in patients with fibromyalgia.
Scandinavian Journal of Pain 2013;4(2):65-74. [DOI: 10.1016/
j.sjpain.2012.10.002]

NCT00066937 {published data only}

Pickering 2018 {published data only}

NCT00066937. Comparison of psychological
and pharmacological treatments for pain due to
temporomandibular joint disorder (TMD) [Pain management in
temporomandibular joint disorders]. https://clinicaltrials.gov/
show/NCT00066937 (first received 8 August 2003).

Pickering G, Macian N, Delage N, Picard P, Cardot J-M, Sickout-
Arondo S, et al. Milnacipran poorly modulates pain in patients
suffering from fibromyalgia: a randomized double-blind
controlled study. Drug Design, Development and Therapy
2018;12:2485-96. [DOI: 10.2147/DDDT.S162810]

NCT01225068 {published data only}

Pilowsky 1990 {published data only}

NCT01225068. Effect of milnacipran in chronic neuropathic
low back pain [An exploratory randomized placebo controlled
trial of milnacipran in patients with chronic neuropathic low
back pain]. https://clinicaltrials.gov/show/NCT01225068 (first
received 20 October 2010).

NCT01510457 {published data only}

NCT01510457. Milnacipran for chronic pain in knee
osteoarthritis [Milnacipran for the pain, sensory sensitization
and mood changes in knee osteoarthritis]. https://
clinicaltrials.gov/show/NCT01510457 (first received 16 January
2012).

Nørregaard 1995 {published data only}

Nørregaard J, Volkmann H, Danneskiold-Samstøe B.
A randomized controlled trial of citalopram in the
treatment of fibromyalgia. Pain 1995;61(3):445-9. [DOI:
10.1016/0304-3959(94)00218-4]

Otto 2008 {published data only}

Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH.
Escitalopram in painful polyneuropathy: a randomized,
placebo-controlled, cross-over trial. Pain 2008;139(2):275-83.
[DOI: 10.1016/j.pain.2008.04.012]

Pilowsky I, Barrow CG. A controlled study of psychotherapy
and amitriptyline used individually and in combination in
the treatment of chronic intractable, 'psychogenic' pain. Pain
1990;40(1):3-19. [DOI: 10.1016/0304-3959(90)91045-K]

Pirbudak 2003 {published data only}

Pirbudak L, Karakurum G, Oner U, Gulec A, Karadasli H. Epidural
corticosteroid injection and amitriptyline for the treatment of
chronic low back pain associated with radiculopathy. Pain Clinic
2003;15(3):247-53. [DOI: 10.1163/156856903767650763]

Rani 1996 {published data only}

Rani PU, Naidu MU, Prasad VB, Rao TR, Shobha JC.
An evaluation of antidepressants in rheumatic pain
conditions. Anesthia & Analgesia 1996;83(2):371-5. [DOI:
10.1097/00000539-199608000-00029]

Raskin 2005 {published data only}

Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL,
Iyengar S, et al. A double-blind, randomized multicenter
trial comparing duloxetine with placebo in the management
of diabetic peripheral neuropathic pain. Pain Medicine
2005;6(5):346-56. [DOI: 10.1111/j.1526-4637.2005.00061.x]

Razazian 2014 {published data only}

Ozerbil 2006 {published data only}

Ozerbil O, Okudan N, Gökbel H, Levendoğlu F. Comparison of
the effects of two antidepressants on exercise performance of
the female patients with fibromyalgia. Clinical Rheumatology
2006;25(4):495-7. [DOI: 10.1007/s10067-005-0076-2]

Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A,
Mahmoodi M. Evaluation of the efficacy and safety of
pregabalin, venlafaxine, and carbamazepine in patients with
painful diabetic peripheral neuropathy. A randomized, double-
blind trial. Neurosciences 2014;19(3):192-8.

Pakfetrat 2019 {published data only}

RBR-5dsrhv {published data only}

Pakfetrat A, Talebi M, Dalirsani Z, Mohajery SA, Zamani R,
Ghazi A. Evaluation of the effectiveness of crocin isolated
from saffron in treatment of burning mouth syndrome: a
randomized controlled trial. Avicenna Journal of Phytomedicine
2019;9(6):505-16. [DOI: 10.22038/AJP.2019.12764]

RBR-5dsrhv. Comparation of treatments of temporomandibular
joint problems [Comparative study of temporomandibular
disfunction therapies: randomized blind controled
clinical trials]. https://trialsearch.who.int/Trial2.aspx?
TrialID=RBR-5dsrhv (first received 28 May 2018).

Patkar 2007 {published data only}

Richards 2015 {published data only}

Patkar AA, Masand PS, Krulewicz S, Mannelli P, Peindl K,
Beebe KL, et al. A randomized, controlled, trial of controlled
release paroxetine in fibromyalgia. American Journal of Medicine
2007;120(5):448-54. [DOI: 10.1016/j.amjmed.2006.06.006]

Richards JS, Bombardier CH, Wilson CS, Chiodo AE, Brooks L,
Tate DG, et al. Efficacy of venlafaxine XR for the treatment
of pain in patients with spinal cord injury and major
depression: a randomized, controlled trial. Archives of Physical
Medicine and Rehabilitation 2015;96(4):680-9. [DOI: 10.1016/
j.apmr.2014.11.024]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rintala 2007 {published data only}

Rintala DH, Holmes SA, Courtade D, Fiess RN, Tastard LV,
Loubser PG. Comparison of the effectiveness of amitriptyline
and gabapentin on chronic neuropathic pain in persons
with spinal cord injury. Archives of Physical Medicine
and Rehabilitation 2007;88(12):1547-60. [DOI: 10.1016/
j.apmr.2007.07.038]

Robinson 2004 {published data only}

Robinson LR, Czerniecki JM, Ehde DM, Edwards WT, Judish DA,
Goldberg ML, et al. Trial of amitriptyline for relief of pain in
amputees: results of a randomized controlled study. Archives
of Physical Medicine and Rehabilitation 2004;85(1):1-6. [DOI:
10.1016/s0003-9993(03)00476-3]

Rowbotham 2004 {published data only}

Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine
extended release in the treatment of painful diabetic
neuropathy: a double-blind, placebo-controlled study. Pain
2004;110(3):697-706. [DOI: 10.1016/j.pain.2004.05.010]

Rowbotham 2005 {published data only}

Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment
response in antidepressant-naïve postherpetic neuralgia
patients: double-blind, randomized trial. Journal of Pain
2005;6(11):741-6. [DOI: 10.1016/j.jpain.2005.07.001]

Rowbotham 2012 {published data only}

Rowbotham MC, Arslanian A, Nothaft W, Duan WR, Best AE,
Pritchett Y, et al. Efficacy and safety of the alpha4β2 neuronal
nicotinic receptor agonist ABT-894 in patients with diabetic
peripheral neuropathic pain. Pain 2012;153(4):862-8. [DOI:
10.1016/j.pain.2012.01.009]

Russell 2008 {published data only}

Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM,
Detke MJ, et al. Efficacy and safety of duloxetine for treatment
of fibromyalgia in patients with or without major depressive
disorder: results from a 6-month, randomized, double-blind,
placebo-controlled, fixed-dose trial. Pain 2008;136(3):432-44.
[DOI: 10.1016/j.pain.2008.02.024]

treatment with amitriptyline. Journal of Rheumatology
Supplement 1989;19:98-103.

Sencan 2004 {published data only}

Sencan S, Ak S, Karan A, Muslumanoglu L, Ozcan E, Berker E. A
study to compare the therapeutic efficacy of aerobic exercise
and paroxetine in fibromyalgia syndrome. Journal of Back and
Musculoskeletal Rehabilitation 2004;17(2):57-61. [DOI: 10.3233/
BMR-2004-17204]

Shakiba 2018 {published data only}

Shakiba M, Moazen-Zadeh E, Noorbala AA, Jafarinia M,
Divsalar P, Kashani L, et al. Saffron (Crocus sativus) versus
duloxetine for treatment of patients with fibromyalgia: a
randomized double-blind clinical trial. Avicenna Journal of
Phytomedicine 2018;8(6):513-23.

Sindrup 2003 {published data only}

Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS.
Venlafaxine versus imipramine in painful polyneuropathy: a
randomized, controlled trial. Neurology 2003;60(8):1284-9.

Skljarevski 2009 {published data only}

Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A,
Iyengar S, et al. A double-blind, randomized trial of duloxetine
versus placebo in the management of chronic low back pain.
European Journal of Neurology 2009;16(9):1041-8. [DOI:
10.1111/j.1468-1331.2009.02648.x]

Skljarevski 2010a {published data only}

Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS,
Detke MJ, et al. Efficacy and safety of duloxetine in patients
with chronic low back pain. Spine 2010;35(13):E578-85. [DOI:
10.1097/BRS.0b013e3181d3cef6]

Skljarevski 2010b {published data only}

Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S,
Miazgowski T, et al. Duloxetine versus placebo in patients with
chronic low back pain: a 12-week, fixed-dose, randomized,
double-blind trial. Journal of Pain 2010;11(12):1282-90. [DOI:
10.1016/j.jpain.2010.03.002]

Sarzi Puttini 1988 {published data only}

Smith 2013 {published data only}

Sarzi Puttini P, Cazzola M, Boccassini L, Ciniselli G,
Santandrea S, Caruso I, et al. A comparison of dothiepin
versus placebo in the treatment of pain in rheumatoid
arthritis and the association of pain with depression. Journal
of International Medical Research 1988;16(5):331-7. [DOI:
10.1177/030006058801600502]

Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED,
Ahles T, et al. Effect of duloxetine on pain, function, and quality
of life among patients with chemotherapy-induced painful
peripheral neuropathy: a randomized clinical trial. Journal of
the American Medical Association 2013;309(13):1359-67. [DOI:
10.1001/jama.2013.2813]

Schukro 2016 {published data only}

Sofat 2017 {published data only}

Schukro RP, Oehmke MJ, Geroldinger A, Heinze G, Kress H-
G, Pramhas S. Efficacy of duloxetine in chronic low back
pain with a neuropathic component: a randomized, double-
blind, placebo-controlled crossover trial. Anesthesiology
2016;124(1):150-8. [DOI: 10.1097/ALN.0000000000000902]

Sofat N, Harrison A, Russell MD, Ayis S, Kiely PD, Baker EH, et al.
The effect of pregabalin or duloxetine on arthritis pain: a clinical
and mechanistic study in people with hand osteoarthritis.
Journal of Pain Research 2017;10:2437-49. [DOI: 10.2147/
JPR.S147640]

Scudds 1989 {published data only}

Spinhoven 2010 {published data only}

Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in
pain responsiveness in patients with fibrositis after successful

Spinhoven P, Van der Does AJ, Van Dijk E, Van Rood YR.
Heart-focused anxiety as a mediating variable in the
treatment of noncardiac chest pain by cognitive-behavioral

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

therapy and paroxetine. Journal of Psychosomatic Research
2010;69(3):227-35. [DOI: 10.1016/j.jpsychores.2010.02.005]

Srinivasan 2021 {published data only}

Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK,
Hota D. Efficacy and safety of low-dose naltrexone in
painful diabetic neuropathy: a randomized, double-blind,
active-control, crossover clinical trial. Journal of Diabetes
2021;13(10):770-8. [DOI: 10.1111/1753-0407.13202]

Staud 2015 {published data only}

Staud R, Lucas YE, Price DD, Robinson ME. Effects of milnacipran
on clinical pain and hyperalgesia of patients with fibromyalgia:
results of a 6-week randomized controlled trial. Journal of Pain
2015;16(8):750-9. [DOI: 10.1016/j.jpain.2015.04.010]

Suttiruksa 2016 {published data only}

Suttiruksa S, Yeephu S, Prateepavanich P, Suthisisang C.
Effects of mirtazapine on quality of life of Thai patients with
fibromyalgia syndrome: a double-blind, randomized, placebo-
controlled trial. Asian Biomedicine 2016;10(5):435-45. [DOI:
10.5372/1905-7415.1005.506]

Talley 2008 {published data only}

Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M.
Antidepressant therapy (imipramine and citalopram) for
irritable bowel syndrome: a double-blind, randomized,
placebo-controlled trial. Digestive Diseases and Sciences
2008;53(1):108-15. [DOI: 10.1007/s10620-007-9830-4]

Tammiala-Salonen 1999 {published data only}

Tammiala-Salonen T, Forssell H. Trazodone in burning mouth
pain: a placebo-controlled, double-blind study. Journal of
Orofacial Pain 1999;13(2):83-8.

Trugman 2014 {published data only}

Trugman JM, Palmer RH, Ma Y. Milnacipran effects on 24-hour
ambulatory blood pressure and heart rate in fibromyalgia
patients: a randomized, placebo-controlled, dose-escalation
study. Current Medical Research and Opinion 2014;30(4):589-97.
[DOI: 10.1185/03007995.2013.861812]

Uchio 2018 {published data only}

Uchio Y, Enomoto H, Alev L, Kato Y, Ishihara H, Tsuji T, et al.
A randomized, double-blind, placebo-controlled phase III
trial of duloxetine in Japanese patients with knee pain due to
osteoarthritis. Journal of Pain Research 2018;11:809-21. [DOI:
10.2147/JPR.S164128]

Urquhart 2018 {published data only}

Urquhart DM, Wluka AE, Van Tulder M, Heritier S, Forbes A,
Fong C, et al. Efficacy of low-dose amitriptyline for chronic low
back pain: a randomized clinical trial. JAMA Internal Medicine
2018;178(11):1474-81. [DOI: 10.1001/jamainternmed.2018.4222]

Vahedi 2005 {published data only}

Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R.
The effect of fluoxetine in patients with pain and constipation-
predominant irritable bowel syndrome: a double-blind
randomized-controlled study. Alimentary Pharmacology
and Therapeutics 2005;22(5):381-5. [DOI: 10.1111/
j.1365-2036.2005.02566.x]

Van Ophoven 2004 {published data only}

Van Ophoven A, Pokupic S, Heinecke A, Hertle L. A
prospective, randomized, placebo controlled, double-
blind study of amitriptyline for the treatment of interstitial
cystitis. Journal of Urology 2004;172(2):533-6. [DOI:
10.1097/01.ju.0000132388.54703.4d]

Tanum 1996 {published data only}

Ventafridda 1987 {published data only}

Tanum L, Malt UF. A new pharmacologic treatment of functional
gastrointestinal disorder. A double-blind placebo-controlled
study with mianserin. Scandinavian Journal of Gastroenterology
1996;31(4):318-25. [DOI: 10.3109/00365529609006404]

Tasmuth 2002 {published data only}

Tasmuth T, Härtel B, Kalso E. Venlafaxine in neuropathic pain
following treatment of breast cancer. European Journal of Pain
2002;6(1):17-24. [DOI: 10.1053/eujp.2001.0266]

Tesfaye 2013 {published data only}

Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tölle T, Bouhassira D,
et al. Duloxetine and pregabalin: high-dose monotherapy or
their combination? the "COMBO-DN study"— a multinational,
randomized, double-blind, parallel-group study in
patients with diabetic peripheral neuropathic pain. Pain
2013;154(12):2616-25. [DOI: 10.1016/j.pain.2013.05.043]

Tétreault 2016 {published and unpublished data}

Tétreault P, Mansour A, Vachon-Presseau E, Schnitzer TJ,
Apkarian AV, Baliki MN. Brain connectivity predicts placebo
response across chronic pain clinical trials. PLOS Biology
2016;14(10):e1002570. [DOI: 10.1371/journal.pbio.1002570]

Ventafridda V, Bonezzi C, Caraceni A, De Conno F, Guarise G,
Ramella G, et al. Antidepressants for cancer pain and
other painful syndromes with deafferentation component:
comparison of amitriptyline and trazodone. Italian Journal
of Neurological Sciences 1987;8(6):579-87. [DOI: 10.1007/
BF02333665]

Vitton 2004 {published data only}

Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-
blind placebo-controlled trial of milnacipran in the treatment
of fibromyalgia. Human Psychopharmacology: Clinical and
Experimental 2004;19 Suppl 1:S27-35. [DOI: 10.1002/hup.622]

Vollmer 2014 {published data only}

Vollmer TL, Robinson MJ, Risser RC, Malcolm SK. A randomized,
double-blind, placebo-controlled trial of duloxetine for the
treatment of pain in patients with multiple sclerosis. Pain
Practice 2014;14(8):732-44. [DOI: 10.1111/papr.12127]

Vranken 2011 {published data only}

Vranken JH, Hollmann MW, Van der Vegt MH, Kruis MR,
Heesen M, Vos K, et al. Duloxetine in patients with central
neuropathic pain caused by spinal cord injury or stroke: a
randomized, double-blind, placebo-controlled trial. Pain
2011;152(2):267-73. [DOI: 10.1016/j.pain.2010.09.005]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Vrethem 1997 {published data only}

Yucel 2005 {published data only}

Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T,
Thorell LH. A comparison of amitriptyline and maprotiline
in the treatment of painful polyneuropathy in diabetics and
nondiabetics. Clinical Journal of Pain 1997;13(4):313-23. [DOI:
10.1097/00002508-199712000-00009]

Yucel A, Ozyalcin S, Koknel Talu G, Kiziltan E, Yucel B,
Andersen OK, et al. The effect of venlafaxine on ongoing and
experimentally induced pain in neuropathic pain patients: a
double blind, placebo controlled study. European Journal of
Pain 2005;9(4):407-16. [DOI: 10.1016/j.ejpain.2004.09.009]

Wang 2017 {published data only}

Zabihiyeganeh 2021 {published data only}

Wang G, Bi L, Li X, Li Z, Zhao D, Chen J, et al. Efficacy and safety
of duloxetine in Chinese patients with chronic pain due to
osteoarthritis: a randomized, double-blind, placebo-controlled
study. Osteoarthritis Cartilage 2017;25(6):832-8. [DOI: 10.1016/
j.joca.2016.12.025]

Ward 1986 {published data only}

Ward NG. Tricyclic antidepressants for chronic low-back
pain. Mechanisms of action and predictors of response. Spine
1986;11(7):661-5. [DOI: 10.1097/00007632-198609000-00003]

Ware 2010 {published data only}

Ware MA, Fitzcharles M-A, Joseph L, Shir Y. The effects of
nabilone on sleep in fibromyalgia: results of a randomized
controlled trial. Anesthesia & Analgesia 2010;110(2):604-10.
[DOI: 10.1213/ANE.0b013e3181c76f70]

Watson 1992 {published data only}

Watson PN, Chipman M, Reed K, Evans RJ, Birkett N.
Amitriptyline versus maprotiline in postherpetic neuralgia:
a randomized, double-blind, crossover trial. Pain
1992;48(1):29-36. [DOI: 10.1016/0304-3959(92)90128-X]

Watson 1998 {published data only}

Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus
amitriptyline in postherpetic neuralgia: a randomized trial.
Neurology 1998;51(4):1166-71. [DOI: 10.1212/wnl.51.4.1166]

Wernicke 2006 {published data only}

Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P,
Iyengar S, et al. A randomized controlled trial of duloxetine
in diabetic peripheral neuropathic pain. Neurology
2006;67(8):1411-20. [DOI: 10.1212/01.wnl.0000240225.04000.1a]

Wolfe 1994 {published data only}

Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo
controlled trial of fluoxetine in fibromyalgia. Scandinavian
Journal of Rheumatology 1994;23(5):255-9. [DOI:
10.3109/03009749409103725]

Yasuda 2011 {published data only}

Yasuda H, Hotta N, Nakao K, Kasuga M, Kashiwagi A,
Kawamori R. Superiority of duloxetine to placebo in improving
diabetic neuropathic pain: results of a randomized controlled
trial in Japan. Journal of Diabetes Investigation 2011;2(2):132-9.
[DOI: 10.1111/j.2040-1124.2010.00073.x]

Yeephu 2013 {published data only}

Yeephu S, Suthisisang C, Suttiruksa S, Prateepavanich P,
Limampai P, Russell IJ. Efficacy and safety of mirtazapine
in fibromyalgia syndrome patients: a randomized placebo-
controlled pilot study. Annals of Pharmacotherapy
2013;47(7-8):921-32. [DOI: 10.1345/aph.1R725]

Zabihiyeganeh M, Kadijani AA, Afshar SV, Janbozorgi M,
Akbari A, Mirzaei A. The effect of cognitive-behavioral therapy
versus duloxetine on the laboratory indices of inflammation in
fibromyalgia: a randomized controlled trial. Journal of Rational-
Emotive & Cognitive-Behavior Therapy 202s;40:512–26. [DOI:
10.1007/s10942-021-00426-y]

Zitman 1990 {published data only}

Zitman FG, Linssen AC, Edelbroek PM, Stijnen T. Low dose
amitriptyline in chronic pain: the gain is modest. Pain
1990;42(1):35-42. [DOI: 10.1016/0304-3959(90)91089-2]

References to studies excluded from this review

Amelin 1991 {published data only}

Amelin AV, Vasil'ev IN, Ignatov ID, Skoromets AA. The combined
use of acupuncture and antidepressants for managing the
spondylogenic lumbosacral pain syndrome. Farmakologiia i
Toksikologiia [Pharmacology and Toxicology] 1991;54(5):12-3.

Amr 2010 {published data only}

Amr YM, Yousef AA. Evaluation of efficacy of the perioperative
administration of venlafaxine or gabapentin on acute and
chronic postmastectomy pain. Clinical Journal of Pain
2010;26(5):381-5. [DOI: 10.1097/AJP.0b013e3181cb406e]

Arnold 2014 {published data only}

Arnold L, Sarzi-Puttini P, Arsenault P, Khan T, Bhadra
Brown P, Clair A, et al. Pregabalin is effective irrespective of
antidepressant class in fibromyalgia patients currently receiving
antidepressant medication for comorbid depression. Journal of
Pain 2014;15(4 Suppl 1):S75. [DOI: 10.1016/j.jpain.2014.01.307]

Avan 2018 {published data only}

Avan R, Janbabaei G, Hendouei N, Alipour A, Borhani S,
Tabrizi N, et al. The effect of pregabalin and duloxetine
treatment on quality of life of breast cancer patients with
taxane-induced sensory neuropathy: a randomized clinical trial.
Journal of Research in Medical Sciences 2018;23(1):52. [DOI:
10.4103/jrms.JRMS_1068_17]

Beaumont 1980 {published data only}

Beaumont G, Seldrup J. Comparative trial of clomipramine
and placebo in the treatment of terminal pain. Journal of
International Medical Research 1980;8 Suppl 3:67-9.

Braak 2011 {published data only}

Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM,
Boeckxstaens GE. Randomised clinical trial: the effects
of amitriptyline on drinking capacity and symptoms in
patients with functional dyspepsia, a double-blind placebo-

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

controlled study. Alimentary Pharmacology and Therapeutics
2011;34(6):638-48. [DOI: 10.1111/j.1365-2036.2011.04775.x]

Carette 1995 {published data only}

Carette S, Oakson G, Guimont C, Steriade M. Sleep
electroencephalography and the clinical response to
amitriptyline in patients with fibromyalgia. Arthritis
& Rheumatology 1995;38(9):1211-7. [DOI: 10.1002/
art.1780380906]

ChiCTR2000030195 {published data only}

ChiCTR2000030195. Duloxetine reduces postoperative pain
and improves quality of life after single-segment lumbar fusion
procedures in centrally sensitized patients: a prospective
randomized controlled study. https://trialsearch.who.int/
Trial2.aspx?TrialID=ChiCTR2000030195 (first received 25
February 2020).

ChiCTR-TRC-12001968 {published data only}

ChiCTR-TRC-12001968. Epidemiology survey and the effects
of low-dose amitriptyline on intractable functional dyspepsia:
a prospective, randomized, controlled study. https://
trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR-TRC-12001968
(first received 13 February 2012).

ChiCTR-TRC-12001969 {published data only}

ChiCTR-TRC-12001969. Incidence of refractory irritable bowel
syndrome and the effects of low dose amitriptyline in the
patients: a prospective, randomized-controlled trial. https://
trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR-TRC-12001969
(first received 29 February 2012).

Chitsaz 2009 {published data only}

Chitsaz A, Janghorbani M, Shaygannejad V, Ashtari F,
Heshmatipour M, Freeman J. Sensory complaints of the
upper extremities in multiple sclerosis: relative efficacy of
nortriptyline and transcutaneous electrical nerve stimulation.
Clinical Journal of Pain 2009;25(4):281-5. [DOI: 10.1097/
AJP.0b013e318190862b]

CTRI/2015/05/005791 {published data only}

CTRI/2015/05/005791. Treatment of irritable bowel syndrome
(IBS) by a plant based Ayurvedic formulation [Ayurvedic
formulation developed for the prevention and management
of irritable bowel syndrome (IBS)]. https://trialsearch.who.int/
Trial2.aspx?TrialID=CTRI/2015/05/005791 (first received 21 May
2015).

Daghaghzadeh 2015 {published data only}

Daghaghzadeh H, Naji F, Afshar H, Sharbafchi MR, Feizi A,
Maroufi M, et al. Efficacy of duloxetine add on in treatment
of inflammatory bowel disease patients: a double-blind
controlled study. Journal of Research in Medical Sciences
2015;20(6):595-601. [DOI: 10.4103/1735-1995.165969]

Dinat 2015 {published data only}

Dinat N, Marinda E, Moch S, Rice AS, Kamerman PR.
Randomized, double-blind, crossover trial of amitriptyline for
analgesia in painful HIV-associated sensory neuropathy. PLOS
One 2015;10(5):e0126297. [DOI: 10.1371/journal.pone.0126297]

Cochrane Database of Systematic Reviews

Ehrnrooth 2001 {published data only}

Ehrnrooth E, Grau C, Zachariae R, Andersen J. Randomized trial
of opioids versus tricyclic antidepressants for radiation-induced
mucositis pain in head and neck cancer. Acta Oncologica
2001;40(6):745-50. [DOI: 10.1080/02841860152619179]

EUCTR2005-005555-17-NL {published data only}

EUCTR2005-005555-17-NL. [S,S]-reboxetine add-on trial:
a randomized, double-blind, placebo-controlled, multi-
center trial of [S,S]-reboxetine in patients with postherpetic
neuralgia (PHN) concomitantly treated with pregabalin. https://
trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2005-005555-17-
NL (first received 5 October 2006).

EUCTR2006-003656-38-GB {published data only}

EUCTR2006-003656-38-GB. A double-blind, randomised,
parallel groups investigation into the effects of pregabalin,
duloxetine and amitriptyline on aspects of pain, sleep, and
next day performance in patients suffering from diabetic
peripheral neuropathy. https://trialsearch.who.int/Trial2.aspx?
TrialID=EUCTR2006-003656-38-GB (first received 18 September
2006).

EUCTR2006-005506-32-DK {published data only}

EUCTR2006-005506-32-DK. Pain, anxiety and depression in
neuropathic and non-neuropathic pain: effect of monoamine
modulation. https://trialsearch.who.int/Trial2.aspx?
TrialID=EUCTR2006-005506-32-DK (first received 12 January
2007).

EUCTR2009-013061-26-FI {published data only}

EUCTR2009-013061-26-FI. Efficacy, safety, tolerability and
pharmacokinetics of concomitant administration of tramadol
with duloxetine or pregabalin: a randomized controlled
flexible-dose study in patients with neuropathic pain. https://
trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2009-013061-26-
FI (first received 8 June 2009).

EUCTR2016-003146-89-GB {published data only}

EUCTR2016-003146-89-GB. Optimal pathway for treating
neuropathic pain in diabetes mellitus [A multicentre, double-
blind, centre-stratified multi-period crossover trial to
evaluate the efficacy of the optimal pathway for treatIng
neuropathic pain in diabetes mellitus (OPTION-DM)]. https://
trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2016-003146-89-
GB (first received 10 September 2018).

EUCTR2017-003307-21-NL {published data only}

EUCTR2017-003307-21-NL. Personalized treatment of functional
dyspepsia with nortriptyline [Tailored treatment of functional
dyspepsia with nortriptyline: a multi-center double-blind
placebo-controlled trial (TENDER)]. https://trialsearch.who.int/
Trial2.aspx?TrialID=EUCTR2017-003307-21-NL (first received 19
December 2017).

EUCTR2018-000133-12-GB {published data only}

EUCTR2018-000133-12-GB. Efficacy and safety of products
containing trazodone and gabapentin in patients affected
by painful diabetic neuropathy [Efficacy and safety of fixed-
dose combination (FDC) products containing trazodone and
gabapentin in patients affected by painful diabetic neuropathy:

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

randomized, controlled, dose finding study]. https://
trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2018-000133-12-
GB (first received 26 June 2018).

EUCTR2019-003437-42-DK {published data only}

EUCTR2019-003437-42-DK. The effect of duloxetine on pain
sensitivity in patients with osteoarthritis [A mechanism based
proof of concept study of the effects of duloxetine in the
treatment of patients with osteoarthritic knee pain]. https://
trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003437-42-
DK (first received 30 August 2019).

Farshchian 2018 {published data only}

Farshchian N, Alavi A, Heydarheydari S, Moradian N.
Comparative study of the effects of venlafaxine and duloxetine
on chemotherapy-induced peripheral neuropathy. Cancer
Chemotherapy and Pharmacology 2018;82(5):787-93. [DOI:
10.1007/s00280-018-3664-y]

Frank 1988 {published data only}

Frank RG, Kashani JH, Parker JC, Beck NC, Brownlee-Duffeck M,
Elliott TR, et al. Antidepressant analgesia in rheumatoid
arthritis. Journal of Rheumatology 1988;15(11):1632-8.

Gardela 1991 {published data only}

Gardela G. Value of adjuvant treatment with imipramine
for lumbosacral pain syndrome. Polski Tygodnik Lekarski
1991;46(30-31):544-6.

Gelijkens 2014 {published data only}

Gelijkens V, Van Zundert J, De Vooght P, Vander Laenen M,
Heylen R, Vanelderen P. The effectiveness of amitriptyline in the
treatment of subacute lumbar radicular pain. European Journal
of Anaesthesiology 2014;31:232.

Ghadir 2011 {published data only}

Ghadir MR, Habibinejad H, Heidari A, Vahedi H. Doxepin is more
effective than nortriptyline and placebo for the treatment of
diarrhea-predominant irritable bowel syndrome: a randomized
triple-blind placebo-controlled trial. Tehran University Medical
Journal 2011;69(6):352-8.

Goldenberg 2010 {published data only}

Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W,
Gendreau RM. Durability of therapeutic response to milnacipran
treatment for fibromyalgia. Results of a randomized, double-
blind, monotherapy 6-month extension study. Pain Medicine
2010;11(2):180-94. [DOI: 10.1111/j.1526-4637.2009.00755.x]

Gomez-Perez 1985 {published data only}

Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG,
Gonzalez-Barranco J, Lozano-Castañeda O. Nortriptyline
and fluphenazine in the symptomatic treatment of
diabetic neuropathy. A double-blind cross-over study. Pain
1985;23(4):395-400. [DOI: 10.1016/0304-3959(85)90010-7]

Greenbaum 1987 {published data only}

Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW,
Greenbaum RB, et al. Effects of desipramine on irritable bowel
syndrome compared with atropine and placebo. Digestive

Cochrane Database of Systematic Reviews

Diseases and Sciences 1987;32(3):257-66. [DOI: 10.1007/
BF01297051]

Henry 2018 {published data only}

Henry NL, Unger JM, Schott A, Hansen L, Lew D, Wade JL,
et al. A randomized placebo-controlled phase III study of
duloxetine for treatment of aromatase inhibitor (AI)-associated
musculoskeletal symptoms in women with early-stage breast
cancer: SWOG S1202. Journal of Clinical Oncology 2014;32(15
Suppl 1):1.

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ,
Prow D, et al. Randomized, placebo controlled trial
of duloxetine for aromatase inhibitor (AI)-associated
musculoskeletal symptoms (AIMSS) in early stage breast cancer
(SWOG S1202). Cancer Research 2017;77(4 Suppl):S5-6. [DOI:
10.1158/1538-7445.SABCS16-S5-06]

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ,
Prow DM, et al. Randomized, multicenter, placebo-controlled
clinical trial of duloxetine versus placebo for aromatase
inhibitor-associated arthralgias in early-stage breast cancer:
SWOG S1202. Journal of Clinical Oncology 2018;36(4):326-32.

Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL,
et al. Association between body mass index (BMI) and
response to duloxetine for aromatase inhibitor (AI)-associated
musculoskeletal symptoms (AIMSS). Cancer Research 2018;79(4
Suppl 1):1.

Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, et
al. Association between body mass index and response to
duloxetine for aromatase inhibitor-associated musculoskeletal
symptoms in SWOG S1202. Cancer 2019;125(12):2123-9.

IRCT201506171647N4 {published data only}

IRCT201506171647N4. The effect of mesalazine and
nortriptyline in patients with irritable bowel syndrome with
diarrhea: a randomized clinical trial [The effect of mesalazine
and nortriptyline on improvement of severity and frequency
of abdominal pain and stool frequency recorded daily
in patients with irritable bowel syndrome with diarrhea:
a randomized clinical trail]. https://trialsearch.who.int/
Trial2.aspx?TrialID=IRCT201506171647N4 (first received 13 July
2015).

IRCT20170829035966N1 {published data only}

IRCT20170829035966N1. Efficacy of laughter yoga and
anti-anxiety drugs on irritable bowel syndrome. https://
trialsearch.who.int/Trial2.aspx?TrialID=IRCT20170829035966N1
(first received 17 January 2018).

IRCT20191210045685N1 {published data only}

IRCT20191210045685N1. Effectiveness of duloxetine in chronic
low back pain [Effetiveness of duloxetine on severity of pain
and quality of life in chronic low back pain in patients who had
posterior spinal fixation (PSF)]. https://trialsearch.who.int/
Trial2.aspx?TrialID=IRCT20191210045685N1 (first received 4
July 2020).

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ISRCTN16086699 {published data only}

Kreiter 2021 {published data only}

ISRCTN16086699. MODULATE: a study to evaluate the
effectiveness of either amitriptyline, ondansetron, loperamide,
or dietary intervention (the low FODMAP diet) against standard
dietary advice for the treatment of diarrhoea in patients
with stable ulcerative colitis [Management of diarrhoea in
ulcerative colitis: multi-arm multi-stage trial of low FODMAP
diet, amitriptyline, ondansetron, or loperamide: MODULATE].
https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN16086699
(first received 13 February 2020).

ISRCTN63671932 {published data only}

ISRCTN63671932. Multicentre trial of combined cognitive
behavioural therapy and antidepressant treatment
in functional bowel disorders [Cognitive behavioural
therapy and antidepressant treatment in functional bowel
disorders: a multicentre randomised, parallel, three arm
trial studying behavioural and medication impact]. https://
trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN63671932 (first
received 30 January 2007).

Kaosombatwattana 2015 {published data only}

Kaosombatwattana U, Pongprasobchai S, Limsrivilai J,
Leelakusolvong S, Tanwandee T. Efficacy and safety of
nortriptyline in functional dyspepsia in Asians: a randomized
double-blind placebo-controlled trial. Gastroenterology
2015;148(4 Suppl 1):S822.

Kautio 2008 {published data only}

Kautio A-L, Haanpää M, Saarto T, Kalso E. Amitriptyline in the
treatment of chemotherapy-induced neuropathic symptoms.
Journal of Pain and Symptom Management 2008;35(1):31-9.
[DOI: 10.1016/j.jpainsymman.2007.02.043]

Kreiter D, Drukker M, Mujagic Z, Vork L, Rutten BP, van Os J, et
al. Symptom-network dynamics in irritable bowel syndrome
with comorbid panic disorder using electronic momentary
assessment: a randomized controlled trial of escitalopram vs.
placebo. Journal of Psychosomatic Research 2021;141:110351.
[DOI: 10.1016/j.jpsychores.2020.110351]

Kroenke 2006 {published data only}

Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J.
Venlafaxine extended release in the short-term treatment
of depressed and anxious primary care patients with
multisomatoform disorder. Journal of Clinical Psychiatry
2006;67(1):72-80. [DOI: 10.4088/jcp.v67n0111]

Kuiken 2003 {published data only}

Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin
reuptake inhibitor fluoxetine does not change rectal sensitivity
and symptoms in patients with irritable bowel syndrome: a
double blind, randomized, placebo-controlled study. Clinical
Gastroenterology and Hepatology 2003;1(3):219-28.

Kvinesdal 1984 {published data only}

Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment
for painful diabetic neuropathy. Journal of the American Medical
Association 1984;251(13):1727-30.

Ladabaum 2010 {published data only}

Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E,
Bacchetti P, et al. Citalopram provides little or no benefit in
nondepressed patients with irritable bowel syndrome. Clinical
Gastroenterology and Hepatology 2010;8(1):42-8. [DOI: 10.1016/
j.cgh.2009.09.008]

Khalilian 2021 {published data only}

Lara Muñoz 1986 {published data only}

Khalilian A, Ahmadimoghaddam D, Saki S, Mohammadi Y,
Mehrpooya M. A randomized, double-blind, placebo-
controlled study to assess efficacy of mirtazapine for
the treatment of diarrhea predominant irritable bowel
syndrome. BioPsychoSocial Medicine 2021;15:3. [DOI: 10.1186/
s13030-021-00205-2]

Lara Muñoz M, Navarro M, Guarneros A, Plancarte Sánchez R,
Bayón A, Fuente JR. Potentiating effect of amitriptyline over
analgesics in patients with cancer pain [Efecto potenciador
de la amitriptilina sobre los analgésicos en pacientes con
dolor oncológico]. Revista Mexicana de Anestesiología
1986;9(4):217-20.

Khosrawi 2018 {published data only}

Li 2019 {published data only}

Khosrawi S, Khosravi M, Haghighat S, Akbari M. Duloxetine in
the treatment of carpal tunnel syndrome: a pilot randomized
clinical trial study. Journal of isfahan Medical School
2018;36(479):517-23. [DOI: 10.22122/JIMS.V36I479.9795]

Kieburtz 1998 {published data only}

Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD,
Ellis RJ, et al. A randomized trial of amitriptyline and
mexiletine for painful neuropathy in HIV infection. Neurology
1998;51(6):1682-8. [DOI: 10.1212/wnl.51.6.1682]

Kishore-Kumar 1990 {published data only}

Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B,
Gracely RH, et al. Desipramine relieves postherpetic neuralgia.
Clinical Pharmacology & Therapeutics 1990;47(3):305-12. [DOI:
10.1038/clpt.1990.33]

Li W-D, Jia L, Jiang S-M, Ping L, Xu M. The therapeutic effect of
low-dose amitriptyline on patients with refractory diarrhea-
predominant irritable bowel syndrome and its 1-year follow-
up study. International Journal of Clinical and Experimental
Medicine 2019;12(1):891-8.

Matsuoka 2019a {published data only}

Matsuoka H, Ishiki H, Iwase S, Koyama A, Kawaguchi T,
Kizawa Y, et al. Study protocol for a multi-institutional,
randomised, double-blinded, placebo-controlled phase III trial
investigating additive efficacy of duloxetine for neuropathic
cancer pain refractory to opioids and gabapentinoids: the
DIRECT study. BMJ Open 2017;7(8):e017280. [DOI: 10.1136/
bmjopen-2017-017280]

Matsuoka H, Iwase S, Miyaji T, Kawaguchi T, Ariyoshi K,
Oyamada S, et al. Additive duloxetine for cancer-related
neuropathic pain nonresponsive or intolerant to opioid-

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

pregabalin therapy: a randomized controlled trial (JORTC-
PAL08). Journal of Pain and Symptom Management
2019;58(4):645-53. [DOI: 10.1016/j.jpainsymman.2019.06.020]

Matsuoka H, Iwase S, Miyaji T, Kawaguchi T, Ariyoshi K,
Oyamada S, et al. Predictors of duloxetine response in patients
with neuropathic cancer pain: a secondary analysis of a
randomized controlled trial-JORTC-PAL08 (DIRECT) study.
Supportive Care in Cancer 2020;28(6):2931-9. [DOI: 10.1007/
s00520-019-05138-9]

Max 1987 {published data only}

Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ,
Smoller B, et al. Amitriptyline relieves diabetic neuropathy
pain in patients with normal or depressed mood. Neurology
1987;37(4):589-96. [DOI: 10.1212/wnl.37.4.589]

Max 1991 {published data only}

Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH,
Smoller B, et al. Efficacy of desipramine in painful diabetic
neuropathy: a placebo-controlled trial. Pain 1991;45(1):3-9.
[DOI: 10.1016/0304-3959(91)90157-S]

McQuay 1992 {published data only}

McQuay HJ, Carroll D, Glynn CJ. Dose-response for
analgesic effect of amitriptyline in chronic pain. Anaesthesia
1993;48(4):281-5. [DOI: 10.1111/j.1365-2044.1993.tb06943.x]

McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the
treatment of chronic pain. Anaesthesia 1992;47(8):646-52. [DOI:
10.1111/j.1365-2044.1992.tb02383.x]

Mishra 2012 {published data only}

Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP.
A comparative efficacy of amitriptyline, gabapentin, and
pregabalin in neuropathic cancer pain: a prospective
randomized double-blind placebo-controlled study. American
Journal of Hospice and Palliative Medicine 2012;29(3):177-82.
[DOI: 10.1177/1049909111412539]

NCT00006157 {published data only}

NCT00006157. Treatment of functional bowel disorders
[Multicenter trial of functional bowel disorders]. https://
clinicaltrials.gov/ct2/show/NCT00006157 (first received 9
August 2000).

NCT00189059 {published data only}

NCT00189059. Effects of amitriptyline for the treatment of pain
on driving performance and cognition [Effects of pain and the
treatment of pain with amitriptyline on driving performance,
attentional capacity and psychomotor performance in chronic
neuropathic pain patients]. https://clinicaltrials.gov/show/
NCT00189059 (first received 16 September 2005).

NCT00191919 {published data only}

NCT00191919. A randomized double blind study evaluating
duloxetine in outpatients with MDD and pain [A ten-week,
randomized, double-blind study evaluating the efficacy of
duloxetine 60mg once daily versus placebo in outpatients with
major depressive disorder and pain]. https://clinicaltrials.gov/
show/NCT00191919 (first received 19 September 2005).

Cochrane Database of Systematic Reviews

NCT00283842 {published data only}

NCT00283842. Study evaluating desvenlafaxine succinate
sustained-release (DVS SR) in adult outpatients with pain
associated with diabetic peripheral neuropathy [A multicenter,
randomized, double-blind, placebo-controlled, parallel-group,
13-week, adaptive-design study of 4 fixed oral doses of DVS
SR in adult outpatients with pain associated with diabetic
peripheral neuropathy]. https://clinicaltrials.gov/show/
NCT00283842 (first received 30 January 2006).

NCT00592384 {published data only}

NCT00592384. Project to improve symptoms and mood in
people with spinal cord injury (PRISMS) [A controlled trial of
venlafaxine XR for major depression after spinal cord injury: a
multi-site study]. https://clinicaltrials.gov/show/NCT00592384
(first received 14 January 2008).

NCT00610909 {published data only}

NCT00610909. Paroxetine - controlled release in the treatment
of irritable bowel syndrome (IBS) [Single-site, double-blind,
flexible-dose, placebo-controlled study of the efficacy,
tolerability, & safety of paroxetine - controlled release in
the treatment of irritable bowel syndrome (IBS)]. https://
clinicaltrials.gov/show/NCT00610909 (first received 8 February
2008).

NCT00619983 {published data only}

NCT00619983. Three way interaction between gabapentin,
duloxetine, and donepezil in patients with diabetic neuropathy.
https://clinicaltrials.gov/show/NCT00619983 (first received 21
February 2008).

NCT00625833 {published data only}

NCT00625833. A trial of [S,S]-reboxetine In patients with chronic
painful diabetic peripheral neuropathy [A randomized, double-
blind placebo controlled trial of [S,S]-reboxetine in patients
with chronic painful diabetic peripheral neuropathy]. https://
clinicaltrials.gov/show/NCT00625833 (first received 28 February
2008).

NCT00696787 {published data only}

NCT00696787. A study evaluating desvenlafaxine sustained
release (DVS SR) in adult female outpatients with fibromyalgia
[A multicenter, randomized, double-blind, placebo-controlled,
pregabalin-referenced, parallel-group, adaptive design study
of DVS SR in adult female outpatients with fibromyalgia
syndrome]. https://clinicaltrials.gov/show/NCT00696787 (first
received 13 June 2008).

NCT00754793 {published data only}

NCT00754793. Sinusitis and facial pain disorders anti-
depression trial (SFPAT). https://clinicaltrials.gov/show/
NCT00754793 (first received 18 September 2008).

NCT00945945 {published data only}

NCT00945945. A study of duloxetine in patients with
osteoarthritis knee pain [A phase 3b study to assess the efficacy
of duloxetine 60 mg once daily compared with placebo on
the reduction of pain caused by osteoarthritis of the knee,
in a 13-week, double-blind, randomized study]. https://

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

clinicaltrials.gov/ct2/show/NCT00945945 (first received 24 July
2009).

NCT01116531 {published data only}

NCT01116531. Efficacy, safety, tolerability and
pharmacokinetics of concomitant administration of tramadol
with duloxetine or pregabalin [Efficacy, safety, tolerability and
pharmacokinetics of concomitant administration of tramadol
with duloxetine or pregabalin: a randomized controlled
flexible-dose study in patients with neuropathic pain]. https://
clinicaltrials.gov/show/NCT01116531 (first received 5 May 2010).

NCT01173055 {published data only}

NCT01173055. A study to evaluate the effects of milnacipran
on pain processing and functional MRI in patients with
fibromyalgia [A randomized, double-blind,placebo-controlled,
two-way crossover study to evaluate the effect of milnacipran
on pain processing and functional magnetic resonance imaging
activation patterns in patients with fibromyalgia]. https://
clinicaltrials.gov/show/NCT01173055 (first received 30 July
2010).

NCT01471379 {published data only}

NCT01471379. Milnacipran (Savella) in irritable bowel syndrome
(IBS) [A randomized, double-blind, placebo-controlled study to
assess the efficacy of milnacipran in the treatment of irritable
bowel syndrome]. https://clinicaltrials.gov/show/NCT01471379
(first received 16 November 2011).

NCT01579279 {published data only}

NCT01579279. A study comparing the efficacy and safety of
ABT-652 to placebo in subjects with diabetic neuropathic pain
[A multicenter, randomized, double-blind, placebo- and active-
controlled study comparing the analgesic efficacy and safety of
ABT-652 to placebo in subjects with diabetic neuropathic pain].
https://clinicaltrials.gov/show/NCT01579279 (first received 17
April 2012).

NCT01869907 {published data only}

NCT01869907. Effect of minocycline on pain caused by nerve
damage (EMON) [Effect of minocycline on neuropathic pain].
https://clinicaltrials.gov/show/NCT01869907 (first received 5
June 2013).

NCT01268709 {published data only}

NCT01910259 {published data only}

NCT01268709. Effect of doxepin and nortriptyline on irritable
bowel syndrome. https://clinicaltrials.gov/show/NCT01268709
(first received 31 December 2010).

NCT01288937 {published data only}

NCT01288937. A placebo controlled, randomized, double blind
trial of milnacipran for the treatment of idiopathic neuropathy
pain. https://clinicaltrials.gov/show/NCT01288937 (first
received 3 February 2011).

NCT01359514 {published data only}

NCT01359514. Mechanism-based choice of therapy for
neuropathic pain [Mechanism-based choice of therapy for
neuropathic pain: can treatments success in neuropathic post-
operative pain be coupled to psychophysical pain modulation
profile?]. https://clinicaltrials.gov/show/NCT01359514 (first
received 24 May 2011).

NCT01359826 {published data only}

NCT01359826. The effect of milnacipran on fatigue and quality
of life in lupus patients [The effect of milnacipran on fatigue and
quality of life in a lupus cohort]. https://clinicaltrials.gov/show/
NCT01359826 (first received 25 May 2011).

NCT01377038 {published data only}

NCT01377038. OASIS: osteoarthritis sensitivity integration
study (OASIS) [Central pain mechanisms in osteoarthritis:
a longitudinal cohort]. https://clinicaltrials.gov/show/
NCT01377038 (first received 20 June 2011).

NCT01451606 {published data only}

NCT01451606. Duloxetine for the treatment of chronic pelvic
pain [Evaluating duloxetine's analgesic effectiveness in chronic
pelvic pain]. https://clinicaltrials.gov/show/NCT01451606 (first
received 13 October 2011).

NCT01910259. MS-SMART: multiple sclerosis-secondary
progressive multi-arm randomisation trial (MS-SMART) [A multi-
arm phase IIB randomised, double blind placebo-controlled
clinical trial comparing the efficacy of three neuroprotective
drugs in secondary progressive multiple sclerosis]. https://
clinicaltrials.gov/show/NCT01910259 (first received 29 July
2013).

NCT02650544 {published data only}

NCT02650544. Efficacy and safety analyses of mirtazapine in
NSCLC patients with depression [Efficacy and safety analyses
of mirtazapine in the treatment of malignant tumor related
depression: a phase II, placebo-controlled, randomized, double-
blinded clinical trial in advanced non-small cell lung cancer
patients]. https://clinicaltrials.gov/show/NCT02650544 (first
received 8 January 2016).

NCT02970591 {published data only}

NCT02970591. A comparison of three different treatment
options for irritable bowel syndrome (CARIBS) [The role
of carbohydrates in irritable bowel syndrome (CARIBS):
protocol for a randomized controlled trial comparing three
different treatment options]. https://clinicaltrials.gov/show/
NCT02970591 (first received 22 November 2016).

NCT03364075 {published data only}

NCT03364075. Genetic variants associated with low back
pain and their response to treatment with duloxetine or
propranolol [Genetic variants associated with the occurrence of
localized low back pain or low back pain with widespread pain
symptoms, and their response to treatment with duloxetine or
propranolol]. https://clinicaltrials.gov/show/NCT03364075 (first
received 6 December 2017).

NCT03522207 {published data only}

NCT03522207. Accuracy and efficacy of trazodone (Desyrel)
on sleep quality and pain management of TMD patient
[Stabilisation de la qualité du sommeil chez le sujet en douleurs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

orofaciales chroniques - étude expérimentale en chassé
croisé: trazodone/ placebo]. https://clinicaltrials.gov/show/
NCT03522207 (first received 11 May 2018).

NCT04747314 {published data only}

NCT04747314. Treating negative affect in low back pain patients
(TNA-LBP) [Proof of concept study to treat negative affect
in chronic low back pain]. https://clinicaltrials.gov/show/
NCT04747314 (first received 10 February 2021).

Nickel 2005 {published data only}

Nickel MK, Nickel C, Lahmann C, Mitterlehner FO, Tritt K,
Leiberich PK, et al. Changes in instrumental activities of daily
living disability after treatment of depressive symptoms in
elderly women with chronic musculoskeletal pain: a double-
blind, placebo-controlled trial. Aging Clinical and Experimental
Research 2005;17(4):293-6. [DOI: 10.1007/BF03324613]

Panerai 1990 {published data only}

Panerai AE, Monza G, Movilia P, Bianchi M, Francucci BM,
Tiengo M. A randomized, within-patient, cross-over, placebo-
controlled trial on the efficacy and tolerability of the tricyclic
antidepressants chlorimipramine and nortriptyline in central
pain. Acta Neurologica Scandinavica 1990;82(1):34-8. [DOI:
10.1111/j.1600-0404.1990.tb01584.x]

Parker 2003 {published data only}

Parker JC, Smarr KL, Slaughter JR, Johnston SK, Priesmeyer ML,
Hanson KD, et al. Management of depression in rheumatoid
arthritis: a combined pharmacologic and cognitive-behavioral
approach. Arthritis Care & Research 2003;49(6):766-77. [DOI:
10.1002/art.11459]

Parkman 2013 {published data only}

Parkman HP, Van Natta ML, Abell TL, McCallum RW,
Sarosiek I, Nguyen L, et al. Effect of nortriptyline on
symptoms of idiopathic gastroparesis: the NORIG randomized
clinical trial. Journal of the American Medical Association
2013;310(24):2640-9. [DOI: 10.1001/jama.2013.282833]

Pilowsky 1982 {published data only}

Pilowsky I, Hallett EC, Bassett DL, Thomas PG,
Penhall RK. A controlled study of amitriptyline in the
treatment of chronic pain. Pain 1982;14(2):169-79. [DOI:
10.1016/0304-3959(82)90097-5]

Pilowsky 1995 {published data only}

Pilowsky I, Spence N, Rounsefell B, Forsten C, Soda J. Out-
patient cognitive-behavioural therapy with amitriptyline
for chronic non-malignant pain: a comparative study
with 6-month follow-up. Pain 1995;60(1):49-54. [DOI:
10.1016/0304-3959(94)00087-U]

Poulsen 1987 {published data only}

Poulsen DL, Hansen HJ, Langemark M, Olesen J, Bech P.
Discomfort or disability in patients with chronic pain syndrome.
Psychotherapy and Psychosomatics 1987;48(1-4):60-2. [DOI:
10.1159/000288032]

Raja 2002 {published data only}

Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR,
Travison TG, Sabeen S, et al. Opioids versus antidepressants in
postherpetic neuralgia: a randomized, placebo-controlled trial.
Neurology 2002;59(7):1015-21. [DOI: 10.1212/wnl.59.7.1015]

Rajagopalan 1998 {published data only}

Rajagopalan M, Kurian G, John J. Symptom relief with
amitriptyline in the irritable bowel syndrome. Journal of
Gastroenterology and Hepatology 1998;13(7):738-41. [DOI:
10.1111/j.1440-1746.1998.tb00723.x]

Saxe 2009 {published data only}

Saxe PA, Arnold LM, Gendreau RM, Spera A, Gendreau J, Wang Y.
A randomized, double-blind, placebo-controlled clinical trial of
milnacipran 100 mg/day for the management of fibromyalgia:
results from a 2-week discontinuation phase. Arthritis and
Rheumatism 2009;60:1421.

Seddighnia 2020 {published data only}

Seddighnia A, Tadayon Najafabadi B, Ghamari K, Noorbala AA,
Ebrahimi Daryani N, Kashani L, et al. Vortioxetine effects
on quality of life of irritable bowel syndrome patients: a
randomized, double-blind, placebo-controlled trial. Journal of
Clinical Pharmacy and Therapeutics 2020;45(1):97-104. [DOI:
10.1111/jcpt.13032]

Selvarajah 2018 {published data only}

Selvarajah D, Petrie J, White D, Julious S, Bortolami O,
Cooper C, et al. Multicentre, double-blind, crossover trial
to identify the optimal pathway for treating neuropathic
pain in diabetes mellitus (OPTION-DM): study protocol for
a randomised controlled trial. Trials 2018;19(1):578. [DOI:
10.1186/s13063-018-2959-y]

Semenchuk 2001 {published data only}

Semenchuk MR, Sherman S, Davis B. Double-blind, randomized
trial of bupropion SR for the treatment of neuropathic pain.
Neurology 2001;57(9):1583-8. [DOI: 10.1212/wnl.57.9.1583]

Strauss 2019 {published data only}

Strauss DH, Santhanam DR, McLean SA, Beaudoin FL. Study
protocol for a randomised, double-blind, placebo-controlled
clinical trial of duloxetine for the treatment and prevention
of musculoskeletal pain: altering the transition from acute to
chronic pain (ATTAC pain). BMJ Open 2019;9(3):e025002. [DOI:
10.1136/bmjopen-2018-025002]

Tadyon Najafabadi 2019 {published data only}

Tadyon Najafabadi B, Ghamari K, Kermany Ranjabari T,
Noorbala AA, Ebrahimi Daryani N, Vanaki E, et al. Therapeutic
effects of saffron (Crocus sativus) versus fluoxetine on irritable
bowel syndrome: a double-blind randomized clinical trial.
Advances in Integrative Medicine 2019;6(4):167-73. [DOI:
10.1016/j.aimed.2019.01.001]

Tondlova 2002 {published data only}

Tondlova H, Bastecky J. Citalopram and dosulepine in adjuvant
treatment of oncological pain. Bolest 2002;5(4):247-52.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

van Houdenhove 1992 {published data only}

Van Houdenhove B, Verstraeten D, Onghena P, De Cuyper H.
Chronic idiopathic pain, mianserin and 'masked' depression.
Psychotherapy and Psychosomatics 1992;58(1):46-53. [DOI:
10.1159/000288609]

Varia 2000 {published data only}

Varia I, Logue E, O'Connor C, Newby K, Wagner HR, Davenport C,
et al. Randomized trial of sertraline in patients with
unexplained chest pain of noncardiac origin. American Heart
Journal 2000;140(3):367-72. [DOI: 10.1067/mhj.2000.108514]

Vork 2018 {published data only}

Vork L, Mujagic Z, Drukker M, Keszthelyi D, Conchillo J,
Hesselink M, et al. Randomized controlled trial of escitalopram
vs placebo in irritable bowel syndrome (IBS) and comorbid
panic disorder: comparison of retrospective symptom
assessments and the real- time experience sampling
methodology. Neurogastroenterology and Motility 2018;30
Suppl 1:166-7. [DOI: 10.1111/nmo.13423]

Wang 2014 {published data only}

Wang Y-J. Clinical efficacy of sertraline combined with otilonium
bromide in irritable bowel syndrome patients. World Chinese
Journal of Digestology 2014;23:3517-20.

References to studies awaiting assessment

ACTRN12620000656932 {published data only}

ACTRN12620000656932. Duloxetine and pregabalin for
neuropathic cancer pain [A phase III, international, multi-
centre, double-blind, dose increment, parallel-arm, randomised
controlled trial of duloxetine versus pregabalin over 14 days for
opioid unresponsive cancer-related neuropathic pain]. https://
trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12620000656932
(first received 5 June 2020).

Brown 2015 {published data only}

Brown TR, Slee A. A randomized placebo-controlled
trial of duloxetine for central pain in multiple sclerosis.
International Journal of MS Care 2015;17(2):83-9. [DOI:
10.7224/1537-2073.2014-001]

Cánovas Martínez 2009 {published data only}

Cánovas Martínez L, Gómez Gutiérrez I, Castro Bande M, Peralta
Espinosa E, Prieto Gutiérrez JM, Segado Jiménez I. Analgesic
efficacy of the association of duloxetine plus pregabalin in
neuropathic pain: experience in 60 patients. Revista de la
Sociedad Española del Dolor 2009;16(7):381-5.

Chandra 2006 {published data only}

Chandra K, Shafig N, Pandhi P, Gupta S, Malhotra S. Gabapentin
versus nortriptyline in post-herpetic neuralgia patients: a
randomized, double-blind clinical trial—The GONIP Trial.
International Journal of Clinical Pharmacology and Therapeutics
2006;44(8):358-63. [DOI: 10.5414/cpp44358]

Di 2019 {published data only}

Di C, Xu D. Effect of concomitant administration of oxycontin
and amitriptyline on patients with severe cancer pain and

Cochrane Database of Systematic Reviews

depression. Tropical Journal of Pharmaceutical Research
2019;18(1):129-34. [DOI: 10.4314/tjpr.v18i1.19]

Hammack 2002 {published data only}

Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ,
Soori GS, et al. Phase III evaluation of nortriptyline for
alleviation of symptoms of cis-platinum-induced peripheral
neuropathy. Pain 2002;98(1-2):195-203. [DOI: 10.1016/
s0304-3959(02)00047-7]

Jia 2006 {published data only}

Jia H-Y, Li Q-F, Song D-P, Liu Y, Ran X. Effects of venlafaxine and
carbamazepine for painful peripheral diabetic neuropathy:
a randomized, double-blind and double-dummy, controlled
multi-center trial. Chinese Journal of Evidence-Based Medicine
2006;6(5).

Keskinbora 2006 {published data only}

Keskinbora K, Pekel AF, Aydinli I. Comparison of efficacy of
gabapentin and amitriptyline in the management of peripheral
neuropathic pain. A ̆grı (Algoloji) Derne ̆gi'nin Yayın Organıdır
[Journal of the Turkish Society of Algology] 2006;18(2):34-40.

Riesner 2008 {published data only}

Riesner H-J, Zeitler C, Schreiber H, Wild A. Additional treatment
in chronic pain syndrome due to hip and knee arthritis
with the selective serotonin reuptake inhibitor fluvoxamine
(Fevarin) [Eine additive Therapie chronischer Schmerzen
bei fortgeschrittener Gon-/Coxarthrose mit dem selektiven
Serotonin-Reuptake-Hemmer Fluvoxamin (Fevarin®)]. Zeitschrift
für Orthopädie und Unfallchirurgie 2008;146(6):742-6. [DOI:
10.1055/s-2008-1039038]

Salehifar 2020 {published data only}

Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N,
Avan R. Comparison of the efficacy and safety of pregabalin
and duloxetine in taxane-induced sensory neuropathy:
a randomized controlled trial. Clinical Drug Investigation
2020;40(3):249-57. [DOI: 10.1007/s40261-019-00882-6]

Shabbir 2011 {published data only}

Shabbir B, Shafi F, Mahboob F. Amitriptyline vs pregabalin in
painful diabetic neuropathy a randomised placebo-based study.
Pakistan Journal of Medical and Health Sciences 2011;5(4):745-7.

Shlay 1998 {published data only}

Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P,
Wentworth D, et al, for the Terry Beirn Community Programs for
Clinical Research on AIDS. Acupuncture and amitriptyline for
pain due to HIV-related peripheral neuropathy: a randomized
controlled trial. Journal of the American Medical Association
1998;280(18):1590-5. [DOI: 10.1001/jama.280.18.1590]

Taghizadeh 2020 {published data only}

Taghizadeh M, Elahabadi I, Kamiab Z, Zaydabadi Nejad N,
Mortazavi Lahijani M, Vazirinejad R, et al. A comparative
study on the effects of fluoxetine and tamoxifen on the
treatment of mastalgia: a randomized clinical trial. KOOMESH
2020;22(4):574-80.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Xu 2006 {published data only}

CTRI/2021/02/031068 {published data only}

Xu J, Cheng YQ, Lv SP, Li XZ, Feng R, Cui RM. A controlled
study of paroxetine and amitriptyline in the treatment of
primary fibromyalgia syndrome. Chinese Mental Health Journal
2006;20(8):542-4.

Zakerkish 2017 {published data only}

Zakerkish M, Amiri F, Nasab NM, Ghorbani A. Comparative
efficacy of duloxetine versus nortriptyline in patients
with diabetic peripheral neuropathic pain: a double blind
randomized controlled trial. Iranian Red Crescent Medical
Journal 2017;19(8):e59995. [DOI: 10.5812/ircmj.59995]

References to ongoing studies

ACTRN12619000878178 {published data only}

ACTRN12619000878178. Venlafaxine for pain reduction
in patients with knee osteoarthritis [A randomised
controlled trial of venlafaxine to treat patients with knee
osteoarthritis pain]. https://trialsearch.who.int/Trial2.aspx?
TrialID=ACTRN12619000878178 (first received 20 June 2019).

ACTRN12619001082190 {published data only}

ACTRN12619001082190. Serotonin noradrenaline reuptake
inhibitors (SNRI) medications for the treatment of osteoarthritis
pain (STOP) trial [Venlafaxine compared to duloxetine for the
treatment of osteoarthritis pain: a double-blind, randomised,
non-inferiority trial]. https://trialsearch.who.int/Trial2.aspx?
TrialID=ACTRN12619001082190 (first received 6 August 2019).

Ammitzboll 2021 {published data only}

Ammitzbøll N, Arendt-Nielsen L, Bertoli D, Brock C, Olesen AE,
Kappel A, et al. A mechanism-based proof of concept
study on the effects of duloxetine in patients with painful
knee osteoarthritis. Trials 2021;22(1):958. [DOI: 10.1186/
s13063-021-05941-y]

ChiCTR1900027038 {published data only}

ChiCTR1900027038. Synergistic analgesia of duloxetine in
phantom limb pain: a randomized controlled trial. https://
trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR1900027038 (first
received 29 October 2019).

CTRI/2018/10/015944 {published data only}

CTRI/2018/10/015944. A study of gabapentin and duloxetine
in painful diabetic neuropathy [A comparative evaluation of
duloxetine and gabapentin in painful diabetic neuropathy:
a randomised control trial]. https://trialsearch.who.int/
Trial2.aspx?TrialID=CTRI/2018/10/015944 (first received 8
October 2018).

CTRI/2018/10/015983 {published data only}

CTRI/2018/10/015983. Vitamin D as an add on therapy in the
treatment of diabetic peripheral neuropathy [Effectiveness of
vitamin d as a supplement with conventional therapy in the
treatment of diabetic peripheral neuropathy - a randomized
controlled clinical trial]. https://trialsearch.who.int/Trial2.aspx?
TrialID=CTRI/2018/10/015983 (first received 10 October 2018).

CTRI/2021/02/031068. Comparing the benefit of tablet
pregabalin with tablet duloxetine and only tablet pregabalin in
nerve pain in diabetes and relation with PPARG and Akt gene
[A randomized double-blind comparative study evaluating the
efficacy of a combination of pregabalin and duloxetine versus
pregabalin alone and the modulation of mRNA expression
of PPARG and Akt genes in patients of painful diabetic
peripheral neuropathy]. https://trialsearch.who.int/Trial2.aspx?
TrialID=CTRI/2021/02/031068 (first received 8 February 2021).

CTRI/2021/03/031875 {published data only}

CTRI/2021/03/031875. Effect of duloxetine in central post-
stroke pain [Efficacy of duloxetine in patients with central
post-stroke pain: a randomised double blind placebo
controlled study]. https://trialsearch.who.int/Trial2.aspx?
TrialID=CTRI/2021/03/031875 (first received 10 March 2021).

EUCTR2019-000243-27-DK {published data only}

EUCTR2019-000243-27-DK. Bupropion for the treatment
of nerve pain. A randomized, double-blind study [The
effect of bupropion in peripheral neuropathic pain. A
randomized, double-blind, placebo-controlled study]. https://
trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-000243-27-
DK (first received 10 May 2021).

EUCTR2019-000324-17-GB {published data only}

EUCTR2019-000324-17-GB. Amitriptyline at low-dose and
titrated for irritable bowel syndrome as second-line treatment
(the ATLANTIS study): a double-blind placebo-controlled
trial [Amitriptyline at low-dose and titrated for irritable
bowel syndrome as second-line treatment (the ATLANTIS
study): a double-blind placebo-controlled trial]. https://
trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN48075063 (first
received 7 June 2019).

EUCTR2019-001202-14-NL {published data only}

EUCTR2019-001202-14-NL. Effect of an antidepressant on chest
pain in patients with achalasia. https://trialsearch.who.int/
Trial2.aspx?TrialID=EUCTR2019-001202-14-NL (first received 18
April 2019).

EUCTR2021-002288-24-NL {published data only}

EUCTR2021-002288-24-NL. Effect of citalopram on chest
pain in patients with chest pain of unkown origin [Effect
of citalopram on chest pain in patients with functional
chest pain - Ci-FCP]. https://trialsearch.who.int/Trial2.aspx?
TrialID=EUCTR2021-002288-24-NL (first received 27 July 2021).

IRCT20110413006186N13 {published data only}

IRCT20110413006186N13. The effect of electric stimulation
through skin and duloxetine on diabetic neuropathic pain [A
comparison of the effectiveness of transcutaneous electrical
nerve stimulation and duloxetine on diabetic peripheral
neuropathic pain]. https://trialsearch.who.int/Trial2.aspx?
TrialID=IRCT20110413006186N13 (first received 27 May 2019).

IRCT20200205046381N1 {published data only}

IRCT20200205046381N1. Comparing the analgesic effect of
fluoxetine and vitamin E with vitamin E only in breast pain
due to fibrocystic breast disease. https://trialsearch.who.int/

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Trial2.aspx?TrialID=IRCT20200205046381N1 (first received 28
February 2020).

IRCT20200620047852N1 {published data only}

IRCT20200620047852N1. Agomelatin in chronic low back pain
[Comparing the analgesic effect of agomelatin versus placebo
in combination with pregabalin in patients with chronic low
back pain: a randomized, double-blinded study]. https://
trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200620047852N1
(first received 23 June 2020).

NCT00981149 {published data only}

NCT00981149. Duloxetine for treatment of painful
temporomandibular joint disorder. https://clinicaltrials.gov/
show/NCT00981149 (first received 22 September 2009).

NCT03249558 {published data only}

NCT03249558. Effect of combined morphine and duloxetine on
chronic pain. https://clinicaltrials.gov/show/NCT03249558 (first
received 15 August 2017).

NCT03324035 {published data only}

NCT03324035. Treatment of neuropathic pain in leprosy.
https://clinicaltrials.gov/show/NCT03324035 (first received 27
October 2017).

NCT04704453 {published data only}

NCT04704453. Study to evaluate the interest of qutenza in
patients with head and neck cancer in remission and with
sequelae neuropathic pain. https://clinicaltrials.gov/show/
NCT04704453 (first received 11 January 2021).

NCT04727502 {published data only}

NCT04727502. Comparison of duloxetine versus pregabalin
[Comparison of duloxetine versus pregabalin in post-
mastectomy pain syndrome: a randomized controlled trial].
https://clinicaltrials.gov/show/NCT04727502 (first received 27
January 2021).

PACTR202001764151121 {published data only}

PACTR202001764151121. Efficacy of clomipramine for chronic
lumbar radicular pain: a randomized clinical trial. https://
trialsearch.who.int/Trial2.aspx?TrialID=PACTR202001764151121
(first received 6 November 2019).

RBR-6pqx4n {published data only}

RBR-6pqx4n. Efficacy of duloxetine in chronic facial pain.
https://trialsearch.who.int/Trial2.aspx?TrialID=RBR-6pqx4n
(first received 3 September 2018).

Reckziegel 2017 {published data only}

Reckziegel D, Bailey H, Cottam WJ, Tench CR, Mahajan RP,
Walsh DA, et al. Imaging pain relief in osteoarthritis (IPRO):
protocol of a double-blind randomised controlled mechanistic
study assessing pain relief and prediction of duloxetine
treatment outcome. BMJ Open 2017;7(6):e014013. [DOI:
10.1136/bmjopen-2016-014013]

TCTR20190303001 {published data only}

TCTR20190303001. A comparison of analgesic efficacy
between amitriptyline and mianserin in chronic low back pain

Cochrane Database of Systematic Reviews

patients: a randomized double-blind controlled trial. https://
trialsearch.who.int/Trial2.aspx?TrialID=TCTR20190303001 (first
received 3 April 2023).

TCTR20210311009 {published data only}

TCTR20210311009. Comparison effectiveness of
nortriptyline and placebo in the treatment of chronic
osteoarthritis knee. https://trialsearch.who.int/Trial2.aspx?
TrialID=TCTR20210311009 (first received 11 March 2021).

Wluka 2021 {published data only}

Wluka AE, Urquhart DM, Teichtahl AJ, Hussain SM, Forbes A,
Arnold C, et al. Effect of low-dose amitriptyline on reducing pain
in clinical knee osteoarthritis compared to benztropine: study
protocol of a randomised, double blind, placebo-controlled
trial. BMC Musculoskeletal Disorders 2021;22(1):826. [DOI:
10.1186/s12891-021-04690-y]

Additional references

Alba-Delgado 2012

Alba-Delgado C, Mico JA, Sánchez-Blázquez P, Berrocoso E.
Analgesic antidepressants promote the responsiveness of locus
coeruleus neurons to noxious stimulation: implications for
neuropathic pain. Pain 2012;153(7):1438-49. [DOI: 10.1016/
j.pain.2012.03.034]

American Psychiatric Association 2013

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 5th edition. Washington (DC):
American Psychiatric Association, 2013.

Bates 2019

Bates D, Schultheis C, Hanes MC, Jolly SM, Chakravarthy KV,
Deer TR, et al. A comprehensive algorithm for the management
of neuropathic pain. Pain Medicine 2019;20 Suppl 1:S2-12. [DOI:
10.1093/pm/pnz075]

Betancourt 2015

Betancourt M, Girolami M. Hamiltonian Monte Carlo for
hierarchical models. In: Upadhyay SK, Singh U, Dey DK,
Loganathan A, editors(s). Current Trends in Bayesian
Methodology With Applications. 1st edition. Boca Raton (FL):
CRC Press, 2015:80-100.

Bevan 2012

Bevan S. The impact of back pain on sickness absence in
Europe. London (UK): Work Foundation; 2012 June.

Boulton 2005

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et
al. Diabetic neuropathies: a statement by the American Diabetes
Association. Diabetes Care 2005;28(4):956-62. [DOI: 10.2337/
diacare.28.4.956]

Breivik 2006

Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey
of chronic pain in Europe: prevalence, impact on daily life and
treatment. European Journal of Pain 2006;10(4):287-333. [DOI:
10.1016/j.ejpain.2005.06.009]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

British National Formulary 2022a

Coupland 2015

British National Formulary 79. bnf.nice.org.uk/ (accessed 29
June 2022).

British National Formulary 2022b

British National Formulary - Amitriptyline hydrochloride.
https://bnf.nice.org.uk/drugs/amitriptyline-hydrochloride/
(accessed 29 June 2022).

British National Formulary 2022c

British National Formulary - Duloxetine. https://bnf.nice.org.uk/
drugs/duloxetine/ (accessed 29 June 2022).

Caldwell 2005

Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of
multiple treatments: combining direct and indirect evidence.
BMJ 2005;331(7521):897-900. [DOI: 10.1136/bmj.331.7521.897]

Chaimani 2022

Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Chapter 11:
Undertaking network meta-analyses. In: Higgins JP, Thomas
J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).
Cochrane Handbook for Systematic Reviews of Interventions
Version 6.3 (updated February 2022). Cochrane, 2022. Available
from www.training.cochrane.org/handbook.

Chiocchia 2021

Chiocchia V, Nikolakopoulou A, Higgins JP, Page MJ,
Papakonstantinou T, Cipriani A, et al. ROB-MEN: a tool
to assess risk of bias due to missing evidence in network
meta-analysis. BMC Medicine 2021;19(1):304. [DOI: 10.1186/
s12916-021-02166-3]

Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J.
Antidepressant use and risk of suicide and attempted suicide or
self harm in people aged 20 to 64: cohort study using a primary
care database. BMJ 2015;350:h517. [DOI: 10.1136/bmj.h517]

Deeks 2022

Deeks JJ, Higgins JP, Altman DG, on behalf of the Cochrane
Statistical Methods Group. Chapter 10: Analysing data and
undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler
J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
6.3 (updated February 2022). Cochrane, 2022. Available from
www.training.cochrane.org/handbook.

Derry 2015a

Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran
for neuropathic pain in adults. Cochrane Database of
Systematic Reviews 2015, Issue 7. Art. No: CD011789. [DOI:
10.1002/14651858.CD011789]

Derry 2015b

Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline
for neuropathic pain in adults. Cochrane Database of
Systematic Reviews 2015, Issue 1. Art. No: CD011209. [DOI:
10.1002/14651858.CD011209.pub2]

Dias 2013

Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis
for decision making 3: heterogeneity—subgroups, meta-
regression, bias, and bias-adjustment. Medical Decision Making
2013;33(5):618-40. [DOI: 10.1177/0272989X13485157]

Cipriani 2013

Dias 2013a

Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual
and technical challenges in network meta-analysis.
Annals of Internal Medicine 2013;159(2):130-7. [DOI:
10.7326/0003-4819-159-2-201307160-00008]

Cipriani 2018

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ,
Ogawa Y, et al. Comparative efficacy and acceptability of 21
antidepressant drugs for the acute treatment of adults with
major depressive disorder: a systematic review and network
meta-analysis. Lancet 2018;391(10128):1357-66. [DOI: 10.1016/
S0140-6736(17)32802-7]

Cohen 1988

Cohen J. Statistical Power Analysis in the Behavioral Sciences.
2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc,
1988.

Coupland 2011

Coupland C, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, et
al. A study of the safety and harms of antidepressant drugs for
older people: a cohort study analysis using a large primary care
database. Health Technology Assessment 2011;15(28):1-202.
[DOI: 10.3310/hta15280]

Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE.
Evidence synthesis for decision making 4: Inconsistency
in networks of evidence based on randomized controlled
trials. Medical Decision Making 2013;33(5):641-56. [DOI:
10.1177/0272989X12455847]

Dowrick 2013

Dowrick C, Frances A. Medicalising unhappiness: new
classification of depression risks more patients being put
on drug treatment from which they will not benefit. BMJ
2013;347:f7140. [DOI: 10.1136/bmj.f7140]

Dworkin 2008

Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS,
Farrar JT, et al. Interpreting the clinical importance of
treatment outcomes in chronic pain clinical trials: IMMPACT
recommendations. Journal of Pain 2008;9(2):105-21. [DOI:
10.1016/j.jpain.2007.09.005]

Edwards 1999

Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting
of adverse effects in clinical trials should be improved:
lessons from acute postoperative pain. Journal of Pain and
Symptom Management 1999;18(6):427-37. [DOI: 10.1016/
s0885-3924(99)00093-7]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

European Pain Federation 2016

Gureje 1998

European Pain Federation. Pain proposal: improving
the current and future management of chronic pain.
europeanpainfederation.eu/wp-content/uploads/2016/06/
pain_proposal.pdf (accessed 1 July 2020).

Gureje O, von Korff M, Simon GE, Gater R. Persistent pain and
well-being: a World Health Organization study in primary care.
Journal of the American Medical Association 1998;280(2):147-51.
[DOI: 10.1001/jama.280.2.147]

Fayaz 2016

Harmer 2017

Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT.
Prevalence of chronic pain in the UK: a systematic review
and meta-analysis of population studies. BMJ Open
2016;6(6):e010364. [DOI: 10.1136/bmjopen-2015-010364]

Harmer CJ, Duman RS, Cowen PJ. How do antidepressants
work? New perspectives for refining future treatment
approaches. Lancet Psychiatry 2017;4(5):409-18. [DOI: 10.1016/
S2215-0366(17)30015-9]

Ferreira 2021

Hearn 2014a

Ferreira GE, McLachlan AJ, Lin C-W, Zadro JR, Abdel-Shaheed C,
O’Keeffe M, et al. Efficacy and safety of antidepressants for
the treatment of back pain and osteoarthritis: systematic
review and meta-analysis. BMJ 2021;372:m4825. [DOI: 10.1136/
bmj.m4825]

Finnerup 2015

Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R,
Dworkin RH, et al. Pharmacotherapy for neuropathic pain in
adults: a systematic review and meta-analysis. Lancet Neurology
2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]

Finnerup 2021

Finnerup NB, Kuner R, Jensen TS. Neuropathic pain:
from mechanisms to treatment. Physiological Reviews
2021;101(1):259-301. [DOI: 10.1152/physrev.00045.2019]

Free 2007

Free ML. Cognitive Therapy in Groups: Guidelines and Resources
for Practice. 2nd edition. Hoboken (NJ): John Wiley & Sons,
2007.

Furukawa 2016

Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG,
Turner EH, et al. Comparative efficacy and acceptability of
first-generation and second-generation antidepressants in the
acute treatment of major depression: protocol for a network
meta-analysis. BMJ Open 2016;6(7):e010919. [DOI: 10.1136/
bmjopen-2015-010919]

Gallagher 2015

Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC.
Venlafaxine for neuropathic pain in adults. Cochrane Database
of Systematic Reviews 2015, Issue 8. Art. No: CD011091. [DOI:
10.1002/14651858.CD011091.pub2]

Goesling 2013

Goesling J, Clauw DJ, Hassett AL. Pain and depression: an
integrative review of neurobiological and psychological factors.
Current Psychiatric Reports 2013;15(12):421. [DOI: 10.1007/
s11920-013-0421-0]

Gouveia 2017

Gouveia N, Rodrigues A, Ramiro S, Eusébio M, Machado PM,
Canhão H, et al. The use of analgesic and other pain-relief
drugs to manage chronic low back pain: results from a national
survey. Pain Practice 2017;17(3):353-65. [DOI: 10.1111/
papr.12455]

Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine
for neuropathic pain in adults. Cochrane Database of
Systematic Reviews 2014, Issue 9. Art. No: CD011003. [DOI:
10.1002/14651858.CD011003.pub2]

Hearn 2014b

Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine
for neuropathic pain in adults. Cochrane Database of
Systematic Reviews 2014, Issue 5. Art. No: CD010769. [DOI:
10.1002/14651858.CD010769.pub2]

Higgins 2011

Higgins JP, Altman DG, Sterne JA, editor(s), on behalf of the
Cochrane Statistical Methods Group and the Cochrane Bias
Methods Group. Chapter 8: Assessing risk of bias in included
studies. In: Higgins JP, Green S editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011. Available from
https://training.cochrane.org/handbook/archive/v5.1/.

Higgins 2022a

Higgins JP, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect
measures and computing estimates of effect. In: Higgins JP,
Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA
editor(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 6.3 (updated February 2022). Cochrane,
2022. Available from www.training.cochrane.org/handbook.

Hill 2015

Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J.
Antidepressant use and risk of epilepsy and seizures in people
aged 20 to 64 years: cohort study using a primary care database.
BMC Psychiatry 2015;15:315. [DOI: 10.1186/s12888-015-0701-9]

IASP 2019

Bark A. Chronic pain has arrived in the ICD-11.
www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?
ItemNumber=8340&navItemNumber=643 (accessed 1 July
2020).

Jansen 2011

Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N,
et al. Interpreting indirect treatment comparisons and network
meta-analysis for health-care decision making: report of the
ISPOR Task Force on Indirect Treatment Comparisons Good
Research Practices: part 1. Value in Health 2011;14(4):417-28.
[DOI: 10.1016/j.jval.2011.04.002]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jiang 2015

McKenzie 2020

Jiang H-Y, Chen H-Z, Hu X-J, Yu ZH-, Yang W, Deng M, et al.
Use of selective serotonin reuptake inhibitors and risk of
upper gastrointestinal bleeding: a systematic review and
meta-analysis. Clinical Gastroenterology and Hepatology
2015;13(1):42-50.e3. [DOI: 10.1016/j.cgh.2014.06.021]

Jordan 2010

Jordan KP, Kadam UT, Hayward R, Porcheret M, Young C,
Croft P. Annual consultation prevalence of regional
musculoskeletal problems in primary care: an observational
study. BMC Musculoskeletal Disorders 2010;11:144. [DOI:
10.1186/1471-2474-11-144]

Klit 2009

Klit H, Finnerup NB, Jensen TS. Central post-stroke pain:
clinical characteristics, pathophysiology, and management.
Lancet Neurology 2009;8(9):857-68. [DOI: 10.1016/
S1474-4422(09)70176-0]

Koes 2018

McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV,
Thomas J. Chapter 3: Defining the criteria for including studies
and how they will be grouped for the synthesis. In: Higgins
JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
VA, editor(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 6.1 (updated September 2020). Cochrane,
2020. Available from training.cochrane.org/handbook/archive/
v6.1/chapter-03.

Melzack 1975

Melzack R. The McGill Pain Questionnaire: major properties
and scoring methods. Pain 1975;1(3):277-99. [DOI:
10.1016/0304-3959(75)90044-5]

Mills 2019

Mills SE, Nicolson KP, Smith BH. Chronic pain: a review of its
epidemiology and associated factors in population-based
studies. British Journal of Anaesthesia 2019;123(2):273-83. [DOI:
10.1016/j.bja.2019.03.023]

Koes BW, Backes D, Bindels PJ. Pharmacotherapy for chronic
non-specific low back pain: current and future options.
Expert Opinion on Pharmacotherapy 2018;19(6):537-45. [DOI:
0.1080/14656566.2018.1454430]

Mitchell 2009

Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in
primary care: a meta-analysis. Lancet 2009;374(9690):609-19.
[DOI: 10.1016/S0140-6736(09)60879-5]

Kremer 2018

Moher 2009

Kremer M, Yalcin I, Goumon Y, Wurtz X, Nexon L, Daniel D,
et al. A dual noradrenergic mechanism for the relief of
neuropathic allodynia by the antidepressant drugs duloxetine
and amitriptyline. Journal of Neuroscience 2018;38(46):9934-54.
[DOI: 10.1523/JNEUROSCI.1004-18.2018]

Kurita 2012

Kurita GP, Sjøgren P, Juel K, Højsted J, Ekholm O. The burden
of chronic pain: a cross-sectional survey focussing on diseases,
immigration, and opioid use. Pain 2012;153(12):2332-8. [DOI:
10.1016/j.pain.2012.07.023]

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group.
Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement. PLOS Medicine
2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]

Moore 2010a

Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ.
Fibromyalgia: moderate and substantial pain intensity
reduction predicts improvement in other outcomes and
substantial quality of life gain. Pain 2010;149(2):360-4. [DOI:
10.1016/j.pain.2010.02.039]

Lefebvre 2022

Moore 2010b

Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A,
Marshall C, et al. Chapter 4: Searching for and selecting studies.
In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
Welch VA, editor(s). Cochrane Handbook for Systematic Reviews
of Interventions Version 6.3 (updated February 2022). Cochrane,
2022. Available from www.training.cochrane.org/handbook.

Llorca-Torralba 2016

Llorca-Torralba M, Borges G, Neto F, Mico JA, Berrocoso E.
Noradrenergic locus coeruleus pathways in pain
modulation. Neuroscience 2016;338:93-113. [DOI: 10.1016/
j.neuroscience.2016.05.057]

Lunn 2014

Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful
neuropathy, chronic pain or fibromyalgia. Cochrane Database
of Systematic Reviews 2014, Issue 1. Art. No: CD007115. [DOI:
10.1002/14651858.CD007115.pub3]

Moore AR, Smugar SS, Wang H, Peloso PM, Gammaitoni A.
Numbers-needed-to-treat analyses—do timing, dropouts, and
outcome matter? Pooled analysis of two randomized, placebo-
controlled chronic low back pain trials. Pain 2010;151(3):592-7.
[DOI: 10.1016/j.pain.2010.07.013]

Moore 2010c

Moore RA, Derry S, McQuay HJ, Straube S, Aldington D,
Wiffen P, et al, ACTINPAIN writing group of the IASP Special
Interest Group (SIG) on Systematic Reviews in Pain Relief.
Clinical effectiveness: an approach to clinical trial design more
relevant to clinical practice, acknowledging the importance of
individual differences. Pain 2010;149(2):173-6. [DOI: 10.1016/
j.pain.2009.08.007]

Moore 2014

Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in
chronic painful conditions–individual patient data responder
analysis. European Journal of Pain 2014;18(1):67-75. [DOI:
10.1002/j.1532-2149.2013.00341.x]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Moore 2015

Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline
for neuropathic pain in adults. Cochrane Database of
Systematic Reviews 2015, Issue 7. Art. No: CD008242. [DOI:
10.1002/14651858.CD008242.pub3]

Morris 2018

Morris LD, Daniels KJ, Ganguli B, Louw QA. An update on the
prevalence of low back pain in Africa: a systematic review and
meta-analyses. BMC Musculoskeletal Disorders 2018;19(1):196.
[DOI: 10.1186/s12891-018-2075-x]

Moulin 2014

Moulin DE, Boulanger A, Clark AJ, Clarke H, Dai T, et al.
Pharmacological management of chronic neuropathic pain:
revised consensus statement from the Canadian Pain Society.
Pain Research and Management 2014;19(6):328-35. [DOI:
10.1155/2014/754693]

Mulder 2008

Mulder RT. An epidemic of depression or the medicalization
of distress? Perspectives in Biology and Medicine
2008;51(2):238-50. [DOI: 10.1353/pbm.0.0009]

NICE 2009a

National Institute for Health Care Excellence. Depression
in adults: recognition and management. www.nice.org.uk/
guidance/cg90 (accessed 1 July 2020).

NICE 2009b

National Institute for Health Care Excellence. Depression in
adults with a chronic physical health problem: recognition and
management. www.nice.org.uk/guidance/cg91/chapter/1-
Guidance (accessed 1 July 2020).

NICE 2017

National Institute for Health Care Excellence. Low back pain and
sciatica in over 16s. https://www.nice.org.uk/guidance/qs155
(accessed 1 July 2020).

NICE 2019

National Institute for Health Care Excellence. Neuropathic
pain in adults: pharmacological management in non-specialist
settings. www.nice.org.uk/guidance/cg173 (accessed 1 July
2020).

NICE 2020

National Institute for Health Care Excellence. Chronic pain in
over 16s: assessment and management. www.nice.org.uk/
guidance/gid-ng10069/documents/draft-guideline (accessed 1
September 2020).

NICE 2021

National Institute for Health Care Excellence. Chronic pain
(primary and secondary) in over 16s: assessment of all chronic
pain and management of chronic primary pain. https://
www.nice.org.uk/guidance/ng193 (accessed 29 June 2022).

Nikolakopoulou 2020

Nikolakopoulou A, Higgins JP, Papakonstantinou T, Chaimani A,
Del Giovane C, Egger M, et al. CINeMA: an approach for

Cochrane Database of Systematic Reviews

assessing confidence in the results of a network meta-
analysis. PLOS Medicine 2020;17(4):e1003082. [DOI: 10.1371/
journal.pmed.1003082]

Nuyen 2005

Nuyen J, Volkers, AC, Verhaak PF, Schellevis FG,
Groenewegen PP, van den Bos GA. Accuracy of diagnosing
depression in primary care: the impact of chronic somatic
and psychiatric co-morbidity. Psychological Medicine
2005;35(8):1185-95. [DOI: 10.1017/s0033291705004812]

Obata 2017

Obata H. Analgesic mechanisms of antidepressants for
neuropathic pain. Internation Journal of Molecular Sciences
2017;18(11):2483. [DOI: 10.3390/ijms18112483]

Office for National Statistics 2019

Office for National Statistics. Sickness absence in the
UK. www.ons.gov.uk/employmentandlabourmarket/
peopleinwork/labourproductivity/articles/
sicknessabsenceinthelabourmarket/2018 (accessed 1 July
2020).

Page 2022

Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of
bias due to missing results in a synthesis. In: Higgins JP, Thomas
J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).
Cochrane Handbook for Systematic Reviews of Interventions
Version 6.3 (updated February 2022). Cochrane, 2022. Available
from www.training.cochrane.org/handbook.

Phillippo 2018

Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ.
Methods for population-adjusted indirect comparisons
in health technology appraisal. Medical Decision Making
2018;38(2):200-11. [DOI: 10.1177/0272989X17725740]

Phillippo 2022 [Computer program]

multinma: Bayesian Network Meta-Analysis of Individual and
Aggregate Data. Phillippo DM, Version R package version 0.4.2.
David Phillippo, 2022. https://dmphillippo.github.io/multinma/.
[DOI: 10.5281/zenodo.3904454]

Phillips 2019

Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting
of adverse events in randomised controlled trials: a review. BMJ
Open 2019;9(2):e024537. [DOI: 10.1136/bmjopen-2018-024537]

Pirosca 2022

Pirosca S, Shiely F, Clarke M, Treweek S. Tolerating bad health
research: the continuing scandal. Trials 2022;23(1):458. [DOI:
10.1186/s13063-022-06415-5]

Review Manager 2020 [Computer program]

Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The
Cochrane Collaboration, 2020.

RevMan Web 2023 [Computer program]

Review Manager Web (RevMan Web). Version 5.0.0.
The Cochrane Collaboration, 2023. Available at
revman.cochrane.org.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rice 2016

Sullivan 1992

Rice AS, Smith BH, Blyth FM. Pain and the global burden
of disease. Pain 2016;157(4):791-6. [DOI: 10.1097/
j.pain.0000000000000454]

Riediger 2017

Sullivan MJ, Reesor K, Mikail S, Fisher RT. The treatment
of depression in chronic low back pain: review
and recommendations. Pain 1992;50:5-13. [DOI:
10.1016/0304-3959(92)90107-M]

Riediger C, Schuster T, Barlinn K, Maier S, Weitz J, Siepmann T.
Adverse effects of antidepressants for chronic pain: a systematic
review and meta-analysis. Frontiers in Neurology 2017;8:307.
[DOI: 10.3389/fneur.2017.00307]

Taylor 2017

Taylor BK, Westlund KN.  The noradrenergic locus coeruleus
as a chronic pain generator. Journal of Neuroscience Research
2017;95(6):1336-46. [DOI: 10.1002/jnr.23956]

Rusu 2016

Treede 2019

Rusu AC, Santos R, Pincus T. Pain-related distress and clinical
depression in chronic pain: a comparison between two
measures. Scandinavian Journal of Pain 2016;12:62-7. [DOI:
10.1016/j.sjpain.2016.04.001]

Rutherford 2009

Rutherford BR, Sneed JR, Roose SP. Does study design
influence outcome? The effects of placebo control and
treatment duration in antidepressant trials. Psychotherapy and
Psychosomatics 2009;78:172-81. [DOI: 10.1159/000209348]

Rücker 2017 [Computer program]

netmeta: Network meta-analysis using frequentist methods.
Rücker G, Schwarzer G, Krahn U, König J, Version R package
version 0.9-5. Rücker, 2017. https://cran.r-project.org/
package=netmeta.

Schulz 2010

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement:
updated guidelines for reporting parallel group randomised
trials. Journal of Pharmacology and Pharmacotherapeutics
2010;1(2):100-7. [DOI: 10.4103/0976-500X.72352]

Schünemann 2013

Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s).
Handbook for grading the quality of evidence and the strength
of recommendations using the GRADE approach (updated
October 2013). GRADE Working Group, 2013. Available from
gdt.guidelinedevelopment.org/app/handbook/handbook.html
(accessed prior to 4 May 2023).

Schünemann 2022

Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ,
Glasziou P, et al. Chapter 15: Interpreting results and
drawing conclusions. In: Higgins JP, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
6.3 (updated February 2022). Cochrane, 2022. Available from
www.training.cochrane.org/handbook.

Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R,
et al. Chronic pain as a symptom or a disease: the IASP
Classification of Chronic Pain for the International Classification
of Diseases (ICD-11). Pain 2019;160(1):19-27. [DOI: 10.1097/
j.pain.0000000000001384]

Tunks 2008

Tunks ER, Crook J, Weir R. Epidemiology of chronic pain with
psychological comorbidity: prevalence, risk, course, and
prognosis. Canadian Journal of Psychiatry 2008;53(4):224-34.
[DOI: 10.1177/070674370805300403]

Tylee 2007

Tylee A, Walters P. Onset of action of antidepressants. BMJ
2007;334(7600):911-2. [DOI: 10.1136/bmj.39197.619190.80]

Urquhart 2008

Urquhart DM, Hoving JL, Assendelft WW, Roland M,
van Tulder MW. Antidepressants for non-specific low back pain.
Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No:
CD001703. [DOI: 10.1002/14651858.CD001703.pub3]

Vehtari 2021

Vehtari A, Gelman A, Simpson D, Carpenter B, and Bürkner PC.
Rank-normalization, folding, and localization: an improved
method for assessing convergence of MCMC. Bayesian Analysis
2021;16(2):667-718. [DOI: 10.1214/20-ba122135.]

Walitt 2015

Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W.
Selective serotonin reuptake inhibitors for fibromyalgia
syndrome. Cochrane Database of Systematic Reviews 2015, Issue
6. Art. No: CD011735. [DOI: 10.1002/14651858.CD011735]

Welsch 2015

Welsch P, Bernardy K, Derry S, Moore RA, Häuser W.
Mirtazapine for fibromyalgia in adults. Cochrane Database
of Systematic Reviews 2018, Issue 8. Art. No: CD012708. [DOI:
10.1002/14651858.CD012708.pub2]

Sinyor 2020

Welsch 2018

Sinyor M, Cheung CP, Abraha HY, Lanctôt KL, Saleem M, Liu CS,
et al. Antidepressant-placebo differences for specific adverse
events in major depressive disorder: a systematic review.
Journal of Affective Disorders 2020;267:185-90. [DOI: 10.1016/
j.jad.2020.02.013]

Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and
noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No:
CD010292. [DOI: 10.1002/14651858.CD010292.pub2]

Wiffen 2016

Wiffen P, Moore RA. Pain leads the way: the development of
evidence-based medicine for pain relief. International Journal

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

of Clinical Pharmacology and Therapeutics 2016;54(7):505-13.
[DOI: 10.5414/CP202546]

meta-analysis. Journal of Clinical Epidemiology 2019;115:1-13.
[DOI: 10.1016/j.jclinepi.2019.04.018]

Williams 2020

Yunus 1983

Yunus MB. Fibromyalgia syndrome: a need for uniform
classification. Journal of Rheumatology 1983;10:841-4.

Zung 1965

Zung WW. A self-rating depression scale. Archives
of General Psychiatry 1965;12:63-70. [DOI: 10.1001/
archpsyc.1965.01720310065008]

References to other published versions of this review

Birkinshaw 2021

Birkinshaw H, Friedrich C, Cole P, Eccleston C, Serfaty M,
Stewart G, et al. Antidepressants for pain management in adults
with chronic pain: a network meta-analysis. Cochrane Database
of Systematic Reviews 2021, Issue 4. Art. No: CD014682. [DOI:
10.1002/14651858.CD014682]

Williams AC, Fisher E, Hearn L, Eccleston C. Psychological
therapies for the management of chronic pain (excluding
headache) in adults. Cochrane Database of Systematic
Reviews 2020, Issue 8. Art. No: CD007407. [DOI:
10.1002/14651858.CD007407.pub4]

Wolfe 2010

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS,
Mease P, et al. The American College of Rheumatology
preliminary diagnostic criteria for fibromyalgia and
measurement of symptom severity. Arthritis Care & Research
2010;62(5):600-10.

Yepes-Nuñez 2019

Yepes-Nuñez JJ, Li S-A, Guyatt G, Jack SM, Brozek JL, Beyene J,
et al. Development of the summary of findings table for network

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

29060/433 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Belgium

Participants

Pain condition: fibromyalgia

Population: people with fibromyalgia and depressive symptoms

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Fibromyalgia meeting ACR criteria
• ≥ 4 on 0-10 pain intensity VAS
• Concomitant depressive symptoms

Exclusion criteria

• Physical health comorbidities
• Psychiatric disorders

Total participants randomised: 52

Age in years (mean): 45

Gender: 12/45 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

29060/433  (Continued)

• n = 26

Paroxetine 20 mg

• n = 26
• SSRI
• Fixed dose

AEs

SAEs

Withdrawal

Outcomes

Missing data methods

ITT but no method reported

Funding source

Pharamaceutical: GlaxoSmithKline

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

No information given regarding blinding procedures

Unclear risk

Self-reported outcomes from participants but unsure of blinding measures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Use ITT for primary outcome but don't report imputation method. Com-
pleter-only analysis for the secondary outcomes

Attrition

Total: 13/52 (25.0%)

Placebo: 5/26 (19.2%)

Paroxetine 20 mg: 8/26 (30.8%)

Selective reporting (re-
porting bias)

High risk

State a number of measures that they will collect but don't report findings for
(Abnormal Involuntary Movement Scale, fatigue VAS). No protocol, no publica-
tion

Other bias

High risk

Not published - just a scientific summary on GSK registry. Trial ran in 1995 but
only posted in 2005

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Abou-Raya 2012 

Study characteristics

Methods

Design: parallel

Duration: 16 weeks

Assessment: baseline and post-intervention

Country: Egypt

Participants

Pain condition: knee OA

Population: older adults (aged ≥ 65) with knee OA

Minimum pain duration: ≥ 40 on 0 -100 scale

Inclusion criteria

• ACR clinical and radiographic criteria of primary knee OA
• Mean knee pain intensity of at least ≥ 40 on 0-100 scale preceding week
• Knee pain > 14 days/month during 3 consecutive months preceding enrolment

Exclusion criteria

• Morbid obesity (BMI > 32 kg/m2), joint inflammatory diseases and or crystal-induced arthropathies,
or any other concomitant disease (such as neuropsychiatric disease including cognitive impairment,
Alzheimer’s disease, Parkinson’s disease, cerebrovascular disease, cardiovascular disease, liver and
renal disease)

• Taking any other antidepressants that could interfere with the evaluation of the intervention

Total participants randomised: 288

Age in years (mean, SD): 68.5 (SD NR)

Gender: 241/288 were female

Interventions

Duloxetine

• 144 participants
• 60 mg/day

Placebo

• 144 participants
• Matched to duloxetine

Outcomes

Pain intensity

Physical function

Mood

AE

SAE

Withdrawal

Missing data methods

ITT but method not specified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Abou-Raya 2012  (Continued)

Funding source

Non-pharmaceutical: sponsored by University of Alexandria, Egypt

Conflicts of interest

Author conflicts of interest NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised by a clinical pharmacist using a computerised
random number list.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Allocation was concealed in sealed envelopes.

Low risk

Double-blind, and placebo was identical to duloxetine.

Low risk

Self-reported outcomes by blinded participants

Unclear risk

States ITT but no imputation method reported

Attrition:

Total: 34/288 (11.8%)

Placebo: 13/144 (9.0%)

Duloxetine 60 mg: 21/144 (14.6%)

Selective reporting (re-
porting bias)

Unclear risk

Protocol registered retrospectively: https://clinicaltrials.gov/show/
NCT01425827 2011:

Pain is the only stated outcome in the trial registry

Other bias

Low risk

No other sources of bias were identified.

Agger 2017 

Study characteristics

Methods

Design: parallel

Duration: 15 weeks

Assessment: baseline and post-intervention (15 weeks)

Country: Denmark

Participants

Pain condition: multiorgan bodily distress syndrome (including fibromyalgia, IBS, and non-cardiac
chest pain)

Population: adults aged 20-50 with a diagnosis of chronic multi-organ bodily distress syndrome

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Agger 2017  (Continued)

Minimum pain duration: no

Inclusion criteria

Cochrane Database of Systematic Reviews

• A diagnosis of chronic (i.e. minimum 2 years) multi-organ bodily distress syndrome, which requires
functional somatic symptoms from at least 3 of 4 bodily systems, leading to moderate or severe im-
pairment in daily living

• The diagnosis was established by a medical doctor after a thorough physical and psychological assess-
ment including diagnostic interview (Schedules for Clinical Assessment in Neuropsychiatry), physical
examination, blood test, ECG, and a close review of all medical records

Exclusion criteria

• Lifetime diagnosis of psychosis, mania, or depression with psychotic symptoms
• Concurrent severe psychiatric disorder demanding treatment—e.g. current depressive episode
• Undergoing concomitant treatment with antidepressants, anticonvulsants, analgesics, or other med-
ication with pain-relieving properties were excluded, unless this medication could be discontinued
• Imipramine treatment in sufficient dosage within the past year; known hypersensitivity to or intol-
erance of imipramine; abuse of alcohol, narcotics, or illicit drugs; physical comorbidity that would
make imipramine inappropriate, including arrhythmias, epilepsy, hepatic insufficiency; absence of
use of contraception for female participants; pregnancy and breastfeeding; and use of medication
that would interact with imipramine

Total participants randomised: 139

Age in years (mean, SD): NR

Gender: 94/139 were female

Interventions

Imipramine

• 70 participants
• Flexible dose, 25-75 mg/day depending on tolerance

Placebo

• 68 participants
• Matched dosing schedule

Outcomes

AE

Withdrawal

Missing data methods

ITT but imputation method NR

Funding source

Non-pharmaceutical: The Research Clinic for Functional Disorders, Aarhus University Hospital, Den-
mark

Conflicts of interest

JLA, AS, LKG, JSJ, and PKF declare no competing interests. TSJ reports personal fees from Pfizer and
Mundipharma, outside the submitted work.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

The randomisation code was generated by a trained, but independent em-
ployee at the hospital pharmacy at Aarhus University Hospital through a web--
based system.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Agger 2017  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Coded (numbered) packs of study drug and matched placebo were produced
according to the randomisation schedule by the hospital pharmacy.

Double-blinded study, with medications over-encapsulated by the hospital
pharmacy to ensure identical appearance

Low risk

Self-reported outcomes by blinded participants

Unclear risk

ITT but no imputation method given

Attrition:

Total: 21/139 (15.1%)

Placebo: 15/68 (22.1%)

Imipramine 25-75 mg: 13/70 (18.6%)

Selective reporting (re-
porting bias)

High risk

Published article reports slightly different registered outcomes to those men-
tioned in the protocol: https://clinicaltrials.gov/ct2/show/NCT01518634

They registered they will measure VAS for pain and the FIC checklist but do not
report VAS and use a different checklist.

Other bias

Low risk

No other sources of bias were identified.

Ahmed 2016 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline and post-intervention (6 weeks)

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia and clinically significant sleep disturbance

Inclusion criteria

• Adults with fibromyalgia as defined by ACR 1990 criteria
• Clinically significant sleep disturbance, defined as subjective complaint of maintaining sleep at least

3 times per week for at least 1 month

Exclusion criteria

• Liver disease, blood disorder, autoimmune disease, endocrine, cardiovascular, hypertension, renal,
hepatic, gastrointestinal, or neurological disorder, active peptic ulcer or inflammatory bowel disease,
significant sleep apnoea, periodic leg movement disorder (PLMD) or restless legs syndrome (RLS), un-
controlled glaucoma

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ahmed 2016  (Continued)

Cochrane Database of Systematic Reviews

• Any form of severe psychiatric illness, moderate to severe depression, including significant risk of sui-

cide

Total participants randomised: 19

Age in years (mean, SD): 49.2

Gender: 17/19 were female

Interventions

Milnacipran

• 19 participants
• Fixed dose of 100 mg/day
• 50 mg taken twice daily (morning and evening)

Placebo

• 19 participants
• Matching dose schedule

Outcomes

Sleep

Quality of life

Pain intensity

AE

SAE

Withdrawal

Missing data methods

LOCF

Funding source

Pharmaceutical: Forest Research Institute, New Jersey, USA

Conflicts of interest

Authors indicated no other financial conflicts of interest

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Computer-generated random numbers were used for enrollment and alloca-
tion to sequence (1:1): milnacipran → placebo or placebo → milnacipran

Allocation concealment
(selection bias)

Low risk

The investigator, clinical staff, participants, and the study sponsor were blind-
ed to sequence allocation. A noninvolved staff member generated the random
allocation sequence and kept an electronic copy in a secure location.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Study drug was supplied as masked tablets of milnacipran and matching
placebos.

Low risk

Outcomes self-reported by blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ahmed 2016  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Only use LOCF and unbalanced dropout

Attrition:

Total: 4/19 (21.1%)

Placebo: 1/19 (5.5%)

Milnacipran 100 mg: 3/19 (16.7%)

Selective reporting (re-
porting bias)

Low risk

Trial registered prospectively: https://clinicaltrials.gov/show/NCT01234675

Study outcomes reported match those in the protocol

Other bias

Low risk

No other sources of bias were identified

Alcoff 1982 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention (8 weeks)

Country: USA

Participants

Pain condition: low back pain

Population: adults with chronic low back pain

Inclusion criteria

• Low back pain for at least 6 weeks if first episode, or ≥ 2 prior episodes lasting at least 2 weeks with a

current episode of a minimum of 2 weeks' duration

Exclusion criteria

NR, but the following potential participants were excluded:

• 1 person had a persistent diastolic blood pressure reading of > 90 mm Hg
• 1 person had ECG changes consistent with an old myocardial infarction

Total participants randomised: 50

Age in years (mean, SD): NR

Gender: 24/50 were female

Pain duration (categorical): < 2 years (n = 8), 2–4 years (n = 6), > 4 years (n = 14)

Interventions

Imipramine

• 28 participants
• Fixed dose of 150 mg/day

Placebo

• 22 participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Alcoff 1982  (Continued)

• Identical appearance and dosing to imipramine

Outcomes

Withdrawal

Missing data methods

NR

Funding source

Non-pharmaceutical: the Bureau of Medicine and Surgery, Department of the Navy, Clinical Investiga-
tion Program, USA

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Not enough information - just says 'randomly assigned'

Allocation concealment
(selection bias)

Unclear risk

Only the pharmacist knew the treatment allocation, but unclear how this was
allocated

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, placebo was identical in appearance

Low risk

Self-reported outcomes by blinded participants

High risk

Missing data methods NR and unequal attrition between arms

Attrition:

Total: 9/50 (18.0%)

Placebo attrition: 2/22 (9.1%)

Imipramine 150 mg: 7/28 (25.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Allen 2014 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention (13 weeks)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Allen 2014  (Continued)

Country: USA

Participants

Pain condition: diabetic peripheral neuropathy

Population: adults with diabetic peripheral neuropathy

Inclusion criteria

Cochrane Database of Systematic Reviews

• Male  and  female  outpatients  with  diabetes,  stable  and  optimised  glycaemic  control  for  at  least  3

months before the study

• Clinically  and/or  neurophysiologically  diagnosed  painful  diabetic  distal  symmetric  sensorimotor
polyneuropathy  affecting  primarily  the  lower  extremities,  and  symptoms  that  included  chronic
paraesthesias,  dysaesthesias,  hyperaesthesia,  hyperalgesia,  or  allodynia  or  some  combination  of
these symptoms in the lower extremities for > 6 months

• A score of ≥ 3 on the physical examination portion of the MNSI at screening and baseline
• An average pain score of at least 4 (where 0 = no pain and 10 = worst possible pain) on the NRS for
symmetrical neuropathic pain in the feet and legs, based on the last 7 daily scores recorded before
randomisation

Exclusion criteria

• Any previous treatment with desvenlafaxine or previous treatment with venlafaxine that could not be
tolerated, had a history of drug allergies that the investigator believed would put the patient at risk,
had significant asymmetrical neuropathic signs and symptoms or a neuropathy that was not due to
diabetes, had other pain or any condition that may have confounded interpretation of symptoms in
the lower leg and/or feet, or had suffered foot ulcers or amputation affecting all or part of a foot or toes
• Peripheral vascular disease manifested by ischaemic claudication; MDD; evidence of significant risk
of suicide or self-harm; uncontrolled hypertension; symptoms of orthostatic hypotension; raised in-
traocular pressure; elevated total cholesterol or triglycerides; unstable renal disease (creatinine clear-
ance, 50 mL/min); gastrointestinal disease or surgery known to interfere with the absorption or excre-
tion of drugs; current major illness or clinically important medical disease that might put the patient
at risk during the study; history of any of the following: seizure disorder; neoplastic disorder within 5
years; myocardial infarction within 6 months; stroke or transient ischaemic attack within 3 years; nar-
row angle glaucoma; or clinically important abnormalities on screening physical examination, ECG,
laboratory evaluation, or urine drug screen

Total participants randomised: 412

Age in years (mean, SD): 60.3 (SD NR)

Gender: 108/412 were female

Pain duration: NR

Interventions

Desvenlafaxine 50 mg

• 63 participants
• Fixed dose of 50 mg/day

Desvenlafaxine 100 mg

• 87 participants
• Fixed dose of 100 mg/day

Desvenlafaxine 200 mg

• 99 participants
• Fixed dose of 200 mg/day

Desvenlafaxine 400 mg

• 69 participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Allen 2014  (Continued)

• Fixed dose of 400 mg/day

Placebo

• 90 participants

Outcomes

Pain intensity

50% pain reduction

PGIC

AE

SAE

Withdrawal

Missing data methods

LOCF

Funding source

Pharmaceutical: sponsored by Wyeth, company now owned by Pfizer

Conflicts of interest

Rob Allen, is a former Pfizer employee currently working as an independent consultant. Suna Barlas, is
a Pfizer employee. Uma Sharma, is a former Pfizer employee and currently works at MMS Holdings Inc.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Blinding of all patients and site personnel to treatment allocation was ensured
by using a computerised randomisation/enrollment system to assign partici-
pant numbers and study drug package numbers

Allocation concealment
(selection bias)

Low risk

Study drug package numbers were produced by the computer-randomised
system

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Unclear as to whether placebo was identical to desvenlafaxine medication

Unclear risk

Self-reported outcomes by participants, but unclear blinding procedures re-
garding medication appearance

High risk

LOCF and unbalanced attrition across arms

Attrition:

Total: 107/412 (30.0%)

Placebo: 15/90 (16.7%)

Desvenlafaxine 50 mg: 12/63 (19.0%)

Desvenlafaxine 100 mg: 18/87 (20.7%)

Desvenlafaxine 200 mg: 31/99 (31.3%)

Desvenlafaxine 400 mg: 27/69 (39.1%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Allen 2014  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

The 2 stated in the protocol are reported in the paper, but the article also re-
ports other outcomes that were not included in the protocol.

Other bias

Low risk

No other sources of bias identified

Allen 2017 

Study characteristics

Methods

Design: parallel

Duration: 15 weeks (intended to be 27 weeks but terminated early)

Assessment: baseline, study termination (15 weeks)

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Inclusion criteria

• fibromyalgia diagnosis according to the ACR 1990 diagnostic criteria, including widespread pain for >
3 months with at least 11 of 18 defined tender points on examination at screening and baseline.

• Average pain score of ≥ 4 on the 0-10 NRS

Exclusion criteria

• Previous treatment with desvenlafaxine, a history of intolerance of venlafaxine, or a history of drug
allergies, pregnancy or breastfeeding, history of seizure disorder, neoplastic disorder within 5 years,
myocardial infarction within 6months, stroke or transient ischaemic attack within 3 years, narrow-an-
gle glaucoma, or clinically important abnormalities on screening

• The presence of a clinically important medical disease, presence or history of psychotic, bipolar, or
major depressive disorder, alcohol or drug abuse/dependence, or evidence of significant risk of sui-
cide or self -harm

Total participants randomised: 697

Age in years (mean, SD): NR

Gender: NR

Pain duration: NR

Interventions

Desvenlafaxine 50 mg

• 136 participants
• fixed dose of 50 mg/day

Desvenlafaxine 100 mg

• 139 participants
• fixed dose of 100 mg/day

Desvenlafaxine 200 mg

• 142 participants
• fixed dose of 200 mg/day

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Allen 2017  (Continued)

Desvenlafaxine 400 mg

• 149 participants
• fixed dose of 400 mg/day

Placebo

• 130 participants

Outcomes

Pain intensity

50% pain reduction

PGIC

AE

SAE

Withdrawal

Missing data methods

LOCF

Funding source

Pharmaceutical: Wyeth Research, now incorportated into Pfizer

Conflicts of interest

Rob Allen, MD, is a former Pfizer employee currently working as an independent consultant. Suna Bar-
las, PhD, is a Pfizer employee. Uma Sharma, PhD, is a former Pfizer employee and currently works at
MMS Holdings Inc.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Study terminated early (at 15 weeks instead of 27 weeks) due to interim efficacy analysis not meeting
the preplanned efficacy criteria

Authors' judgement

Support for judgement

Unclear risk

Not enough information - just says 'randomly assigned'

Unclear risk

No information given

Unclear risk

No information on matching appearance or dosing schedules of antidepres-
sants and placebo

Unclear risk

Self-reported outcomes by participants, but blinding information unclear

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Study terminated, so missing data from all time points past 15 weeks. LOCF.
Very high attrition across all arms before study termination.

Attrition:

Total: 445/697 (63.8%)

Placebo: 84/130 (67.7%)

Desvenlafaxine 50 mg: 87/136 (66.0%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Allen 2017  (Continued)

Cochrane Database of Systematic Reviews

Desvenlafaxine 100 mg: 81/140 (62.0%)

Desvenlafaxine 200 mg: 100/142 (76.0%)

Desvenlafaxine 400 mg: 93/149 (67.0%)

Selective reporting (re-
porting bias)

Low risk

Protocol stated the interim analyses

Other bias

Low risk

Study terminated early, but this was due to interim efficacy analyses not meet-
ing the prespecified criteria.

Anderberg 2000 

Study characteristics

Methods

Design: parallel

Duration: 16 weeks

Assessment: baseline and post-intervention

Country: Sweden

Participants

Pain condition: fibromyalgia

Population: women with fibromyalgia

Minimum pain duration: no

Inclusion criteria

• Diagnosis of fibromyalgia fulfilling the ACR criteria (1990)

Exclusion criteria

• Patients with any severe heart diseases, such as angina pectoris or post-heart infarction, or other se-
vere heart diseases, as well as brain infarction, suicidal thoughts or who were seriously depressed (in
need of immediate psychiatric care)

• Patients taking major or minor tranquillisers, major antidepressants or strong analgesics

Total participants randomised: 40

Age in years (mean, SD): 48.6 (7.5)

Gender: 40/40 were female

Pain duration: 11.9 (7.0) years average duration of fibromyalgia

Interventions

 Citalopram

• 30-40 mg/ day
• Flexibly dosed
• Titrated from 10/20 mg to 30/40 mg in 5 mg doses every 5 days

Placebo

• Inert
• Matched dosing schedule

Outcomes

AE

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Anderberg 2000  (Continued)

Withdrawal

Missing data methods

ITT but no method reported

Cochrane Database of Systematic Reviews

Funding source

The study was supported by grants from H. Lundbeck AB, the Söderström Königska Foundation, the
Swedish Association of Physicians, the Märta and Nicke Nasvell Foundation, the Swedish Health In-
surance System, the Uppsala County Council and ‘Förenade Liv’ Mutual Group Life Insurance Company,
Stockholm, Sweden and the Swedish Medical Research Council (21X-9523)

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information given

Allocation concealment
(selection bias)

Low risk

Randomisation was made at a separate agency, and the investigator had a
coded list. Included patients were given consecutive code numbers.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

No information given regarding appearance of placebo

Unclear risk

Not enough information given

High risk

Unequal attrition, states ITT but no method given

Attrition:

Total: 5/40 (12.5%)

Placebo: 1/19 (5.26%)

Citalopram 30-40 mg: 4/21 (19.1%)

Selective reporting (re-
porting bias)

Low risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Ang 2013 

Study characteristics

Methods

Design: parallel

Duration: 21 weeks

Assessment: baseline and post-intervention (21 weeks)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ang 2013  (Continued)

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 4 out of 10

Inclusion criteria

Cochrane Database of Systematic Reviews

• People aged 18- 65 with a diagnosis of fibromyalgia made by a rheumatologist matching the ACR cri-

teria. On stable doses of current medication for at least 4 weeks

• Have a weekly average pain intensity score as recorded by wristwatch monitor of ≥ 4 out of 10, and

report that fibromyalgia limits ability to perform daily activities.

Exclusion criteria

• Uncontrolled hypertension; history of heart disease, glaucoma, or hepatitis; diagnosis of peripher-
al neuropathy; diagnosed with another major rheumatic conditions (i.e. RA, systemic lupus erythe-
matosus, scleroderma and other connective tissue diseases) BMI of > 34; frequent thoughts of sui-
cide or self-harm; currently pregnant or planning to become pregnant, or breastfeeding; diagnosis of
schizophrenia or bipolar disorder; currently taking fluoxetine, paroxetine, citalopram, sertraline, esc-
italopram, venlafaxine, mirtazapine or duloxetine; currently participating in other pain research; have
been previously enrolled in any study or class that includes CBT or education to help control pain or
stress related to fibromyalgia

Total participants randomised: 58

Age in years (mean, SD): 46.59 (10.39)

Gender: 54/58 were female

Pain duration: average duration since fibromyalgia of 12.07 (10.04) years

Interventions

CBT

• 8  telephone-delivered  therapy  sessions  from  baseline  to  week  9,  with  a  companion  handbook  for

home practice.

• Inert placebo pill to match antidepressant doses

CBT + milnacipran

• Milnacipran 100 mg/day combined with 8 weekly telephone-delivered therapy sessions from baseline

to week 9, with a companion handbook for home practice

• Milnacipran doses titrated over 8 days until participants were taking 50 mg twice a day.

Milnacipran + education

• Milnacipran 100 mg/day combined with 8 weekly telephone general pain education sessions delivered

from baseline to week 9

• Milnacipran doses titrated over 8 days until participants were taking 50 mg twice a day.

Outcomes

Pain intensity

Moderate pain relief

Physical function

Quality of life

Depression

AEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ang 2013  (Continued)

SAEs

Withdrawal

Missing data methods

NR

Cochrane Database of Systematic Reviews

Funding source

National Institute of Arthritis and Musculoskeletal and Skin Diseases (Grant number:
1R21AR056046-01A2). The authors thank Forest Research Institute for providing the active drug and
placebo.

Conflicts of interest

Authors state no conflicts of interest to declare

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Does not report how the participants were randomised - just says "participants
were randomised to one of the three treatment arms".

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

No information given

High risk

The professionals delivering the CBT and education sessions are authors on
the paper, and would have been unblinded to participant selection

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Participants likely to identify which psychological therapy group they were in,
and study authors did not report participants' identification of group assign-
ment

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

No missing data methods reported

Attrition:

Total: 9/58 (15.5%)

CBT: 4/19 (21.1%)

CBT + milnacipran: 3/20 (15.0%)

Education + milnacipran: 2/19 (10.5%)

Selective reporting (re-
porting bias)

High risk

Stated in the protocol that they would measure participants' identification of
group assignment but NR.

Other bias

Low risk

No other sources of bias were identified

Aragona 2005 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Aragona 2005  (Continued)

Assessment: baseline and post-intervention

Country: Italy

Participants

Pain condition: somatoform DSM-IV-TR pain disorder

Population: people with somatoform DSM-IV-TR pain disorder 

Minimum pain intensity: no

Inclusion criteria

• People with DSM-IV-TR pain disorder as assessed by clinicians. Pain had to have no direct, organic ex-
planation, and participants had to have presence of psychological factors that could have influenced
consent/clinical course of pain.

Exclusion criteria

• Pregnancy
• Medical conditions of clinical importance
• Diagnosis of another mental health condition

Total participants randomised: 35

Age in years (mean, SD): NR

Gender: 21/35 were female

Pain duration: NR

Interventions

Citalopram

• Fixed dose of 40 mg/day (2 x 20 mg doses)
• Titrated over 4 days
• SSRI

Reboxetine

• Fixed dose of 8 mg/day (2 x 4 mg doses)
• Titrated over 4 days
• NaRI

Outcomes

Pain intensity

Depression

AEs

SAEs

Withdrawal

Missing data methods

LOCF

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Aragona 2005  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Participants were randomly assigned using random tables

Unclear risk

No information given

Unclear risk

No information given regarding appearance of medications

Unclear risk

No information given regarding appearance of medications

High risk

Used LOCF as imputation method, high attrition

Attrition:

Total: 6/35 (17.1%)

Citalopram 40 mg: 6/17 (35.3%)

Reboxetine 8 mg: 9/18 (50.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Arnold 2002 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: women with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Aged over 18 and meeting the ACR 1990 criteria for fibromyalgia

Exclusion criteria

• Evidence  of  traumatic  injury,  inflammatory  rheumatic  disease,  or  infectious  or  endocrine-related
arthropathy; clinically unstable medical illness; a history of seizure, head trauma, or stroke; a lifetime
history of hypomania, mania, psychosis, or dementia; alcohol or substance dependence during the

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2002  (Continued)

Cochrane Database of Systematic Reviews

past 6 months; a substantial risk of suicide; any current Axis I diagnosis; or a score of  ≥ 10 on the 17-
item Hamilton Depression Rating Scale.

• Received monoamine oxidase inhibitors, tricyclics, lithium, SSRIs, or other antidepressants within 2
weeks before randomisation; received investigational medications within 3 months before randomi-
sation; or previously received fluoxetine for fibromyalgia

Total participants randomised: 60

Age in years (mean, SD): 46 (11)

Gender: 46/46 were female

Pain duration: average duration of fibromyalgia was 11 (9) years 

Interventions

Fluoxetine

• SSRI
• Flexibly dosed depending upon tolerance and improvement: starting dose 20 mg/day, maximum dose

80 mg/day

• Mean dose was 45 mg/day

Placebo

• Inert
• Identical capsules to fluoxetine, with matched titration process

Outcomes

Pain intensity

Quality of life

Depression

Physical function

Withdrawal

Missing data methods

LOCF

Funding source

Pharmaceutical: Eli Lilly

Conflicts of interest

NR, but authors in other papers have declared conflicts of interest regarding involvement with Eli Lilly

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Authors' judgement

Support for judgement

Unclear risk

Not enough information - just says that participants were 'randomly assigned'

Unclear risk

No information given

Low risk

Identical capsules and titration process

Low risk

Self-reported outcomes from blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2002  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

High attrition and used LOCF

Attrition:

Total: 23/60 (38.3%)

Placebo: 12/30 (40.0%)

Fluoxetine 10- 30 mg: 11/30 (36.7%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Arnold 2004 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention (12 weeks)

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia with and without MDD

Minimum pain intensity: ≥ 4 out of 10

Inclusion criteria 

• ≥ 8 years of age and met the ACR criteria for fibromyalgia
• Score ≥ 4 on the pain intensity item of the Fibromyalgia Impact Questionnaire (with 10 indicating very

severe pain) at visits 1 and 2

• Have an educational level and degree of understanding that allowed them to communicate intelligi-

bly.

Exclusion criteria

• Pain from traumatic injury or structural or regional rheumatic disease; RA, inflammatory arthritis, or
autoimmune disease; unstable medical or psychiatric illness; current dysthymia, which is more treat-
ment-resistant  than  major  depression,  or  primary  psychiatric  disorder  other  than  MDD;  substance
abuse in the last year; history of psychosis; pregnancy or breastfeeding; unacceptable contraception
in those of childbearing potential; or involvement in disability reviews that might compromise treat-
ment response

• Use of an investigational drug within 30 days; prior participation in a study of duloxetine; severe aller-
gic reactions to multiple medications; intolerance to 3 psychoactive drugs or 1 SSRI; and failure to re-
spond to 2 adequate regimens of 2 different classes of antidepressants for depression or fibromyalgia

Total participants randomised: 207

Age in years (mean, SD): 

Gender: 184/200 were female

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2004  (Continued)

Pain duration: NR

Interventions

Duloxetine

Cochrane Database of Systematic Reviews

• SNRI
• Fixed dose of 120 mg/day, 2 x 60 mg doses
• Forced titration from 20 mg/day to 120 mg/day over 2  weeks

Placebo

• Inert
• Identical dosing strategy to duloxetine

Outcomes

Pain intensity

Quality of life

Physical function

Mood

PGIC

AEs

Withdrawal

Missing data methods

Mixed-effects model and LOCF

Funding source

Pharmaceutical - Eli Lilly

Conflicts of interest

Drs Crofford and Arnold have received consulting fees or honoraria in the last 2 years from Eli Lilly and
Company (DrCrawford USD 10,000, Dr Arnold USD 10,000). In addition to the authors employed by Eli
Lilly and Company listed above, Dr Goldstein's wife is employed by Eli Lilly and Company

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to treatment groups was determined by a computer-generated
random sequence.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Participants were allocated using an interactive voice response system.

Low risk

Matched appearance and dosing schedule

Low risk

Self-reported outcomes from blinded participants

High risk

High attrition, unequal reasons for dropout, used LOCF

Attrition:

Total: 83/207 (40.1%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2004  (Continued)

Placebo: 37/103 (35.9%)

Duloxetine 120 mg: 46/104 (44.2%)

Selective reporting (re-
porting bias)

Unclear risk

Trial registration was retrospective.

Other bias

Low risk

No other sources of bias were identified.

Cochrane Database of Systematic Reviews

Arnold 2005 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: women with fibromyalgia, with and without MDD

Minimum pain intensity: ≥ 4 out of 10

Inclusion criteria

• Female outpatients aged ≥ 18 who met the criteria for primary fibromyalgia as defined by the ACR
• Had a score of ≥ 4 on the average pain severity item of the Brief Pain Inventory at randomisation

Exclusion criteria

• Pain from traumatic injury or structural or regional rheumatic disease; RA, inflammatory arthritis, or
autoimmune disease; unstable medical or psychiatric illness; current primary psychiatric diagnosis
other than MDD, a primary anxiety disorder within the past year (specific phobias allowed); substance
abuse within the past year; serious suicide risk; pregnancy or breastfeeding.

• Women who, in the opinion of the investigator, were treatment refractory or may have had an involve-
ment in disability reviews that might compromise treatment response; severe allergic reactions to
multiple medications; or prior participation in a study of duloxetine

Total participants randomised: 354

Age in years (mean, SD): 49.6 (10.9)

Gender: 354/354 were female

Pain duration: NR

Interventions

Duloxetine 60 mg

• SNRI
• Fixed dose of 60 mg/day

Duloxetine 120 mg

• SNRI
• Fixed dose of 120 mg/day, titrated from 60 mg/day over 3 days

Placebo

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2005  (Continued)

Outcomes

• Inert

Pain intensity

Quality of life

Physical function

Mood

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

LOCF

Funding source

Pharmaceutical - Eli Lilly

Conflicts of interest

NR, but have declared CoIs in other papers with this sponsor/funder

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

No information regarding randomisation procedures given

Unclear risk

No information regarding allocation concealment given

Unclear risk

No information regarding matched dose schedules or identical appearance of
medications given

Unclear risk

Self-reported outcomes from participants, uncertain about blinding proce-
dures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

High attrition and significantly different reasons for dropout between groups.
Used LOCF

Attrition:

Total: 138/354 (39.0%)

Placebo: 52/121 (43.0%)

Duloxetine 60 mg: 41/117 (35.0%)

Duloxetine 120 mg: 45/115 (39.1%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2005  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Arnold 2010a 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention (8 weeks)

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 VAS

Inclusion criteria

• People aged ≥ 18 meeting the ACR criteria for fibromyalgia (widespread pain for at least 3 months, and

pain in at least 11 of 18 specific tender point sites)

• Score of ≥ 40 on 100 mm ViAS of the Short Form McGill Pain Questionnaire

Exclusion criteria

• Other severe pain conditions; severe hepatic impairment; any inflammatory musculoskeletal disor-
der; rheumatic disease; active infection; untreated endocrine disorder; previous or current significant
psychiatric disorder; severe depression (in the investigator's judgement); serious suicide risk; seizure
disorder; uncontrolled narrow-angle glaucoma; recurrent syncope or evidence of low blood pressure;
symptomatic postural hypotension; significant or unstable medical or psychological conditions; preg-
nancy, use of an unacceptable mode of contraception, or breastfeeding; or involvement in disability
claims, civil litigation, or workman's compensation claims for fibromyalgia

• Exclusions based on concomitant medications or treatments included tender-point injections and
use of fluoxetine or opioids within 30 days before the study; use of thioridazine or inhibitors of cy-
tochrome P450 3A4 within 14 days before the study; use of muscle relaxants, antidepressants, an-
ticonvulsants, oral steroids, mexiletine, dopamine agonists, long-acting benzodiazepines, acupunc-
ture, or TENS within 7 days before the study; and use of diphenhydramine or melatonin within 1 day
before the study.

Total participants randomised: 268

Age in years (mean, range): 50 (20-84)

Gender: 239/268 were female

Pain duration in years (mean, range): 7 (0-46.8)

Interventions

Esreboxetine

• SNRI
• Initial dose 2 mg/day, titrated to individual tolerability by 2 mg/day to a maximum of 8 mg/day

Placebo

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2010a  (Continued)

Outcomes

• Inert
• Matched appearance

Pain intensity

Quality of life

Sleep

Mood

Physical function

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Missing data methods

LOCF

Funding source

Pharmaceutical - Pfizer

Conflicts of interest

Notes

Risk of bias

Bias

Dr Arnold has received grants/research support from Allergan, Boehringer Ingelheim, Cypress Bio-
sciences Inc., Forest Laboratories Inc., Eli Lilly and Company, Pfizer Inc., Sanofi-Aventis, and Wyeth
Pharmaceuticals. She has been a consultant for Allergan, AstraZeneca, Boehringer Ingelheim, Cypress
Biosciences, Forest Laboratories, Eli Lilly and Company, Organon, Pfizer, sanofi-aventis, Sepracor,
Takeda, Theravance, Inc., DCB, Vivus, Inc., and Wyeth. She has served on speakers' bureaus for Forest
Laboratories, Eli Lilly and Company, and Pfizer. Drs Chatamra, Hirsch, and Stoker were employees of
Pfizer at the time of the study. They have indicated that they have no other conflicts of interest with re-
gard to the content of this article.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation to treatment groups was performed according to a computer-gen-
erated randomisation code.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Allocation was managed through a centralised telerandomisation system.

Low risk

Placebo matched appearance and dose

Low risk

Self-reported outcomes from blinded participants

Low risk

Equal attrition (20%), LOCF supplemented by BOCF

Attrition:

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2010a  (Continued)

Cochrane Database of Systematic Reviews

Total: 55/267 (20.5%)

Placebo: 27/133 (20.3%)

Esreboxetine: 27/134 (20.1%)

Selective reporting (re-
porting bias)

Unclear risk

Some changes in what were secondary or primary outcomes, not 100% lining
up with protocol but primary outcome remains the same

Other bias

Low risk

No other sources of bias were identified.

Arnold 2010b 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention (12 weeks)

Country: USA and Canada

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 VAS

Inclusion criteria

• People aged 18-70 who met the ACR 1990 criteria for fibromyalgia
• Patients were required to have a raw score of 4 on the physical function domain of the Fibromyalgia
Impact Questionnaire at screening and a mean VAS pain score of between 40 and 90 on the electronic
patient experience diary 24-hour recall pain report (0-100 VAS) during the 14-day baseline period

Exclusion criteria

• Other rheumatic or medical conditions that displayed symptoms similar to fibromyalgia; previous ex-
posure to milnacipran; treatment with an investigational drug within 30 days of screening; BDI score
> 25 at screening or baseline; current major depressive episode as determined by the MINI; significant
risk of suicide according to the investigator’s judgement or the results of the MINI or the BDI; lifetime
history of psychosis, hypomania, or mania, substance abuse; other severe psychiatric illness as deter-
mined by investigator judgement; history of behaviour that would, in the investigator’s judgement,
prohibit compliance for the duration of the study; active or pending disability claim; worker’s com-
pensation claim, or litigation; pregnancy or breastfeeding; unacceptable contraception method; ac-
tive or unstable medical illness

• Concomitant  treatments  considered  to  be  criteria  for  exclusion  included  digitalis;  centrally  acting
medications for fibromyalgia; TENS; biofeedback; tender and trigger point injections; acupuncture;
and anaesthetic or narcotic patches

Total participants randomised: 1025

Age in years (mean, SD): NR

Gender: 977/1025 were female

Pain duration in years (mean): 10.8 

Interventions

Milnacipran

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2010b  (Continued)

• n = 516
• SNRI
• 100 mg/day, forced titration over 6 weeks

Placebo

• n = 509
• Inert
• Matched appearance and dosing schedule

Outcomes

Pain intensity

Physical function

Mood

Quality of life

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

BOCF

Funding source

Pharmaceutical - Forest Laboratories

Conflicts of interest

Dr Arnold has received consulting fees, speaking fees, and/or honoraria from Cypress Bioscience,
Wyeth, Boehringer Ingelheim, Allergan, Takeda, UCB, Theravance, AstraZeneca, and Sanofi-Aventis
(less than USD 10,000 each) and from Eli Lilly, Pfizer, and Forest Laboratories (> USD 10,000 each) and
has received research support from Eli Lilly, Cypress Bioscience, Wyeth, Boehringer In-gelheim, Aller-
gan, Forest Laboratories, and Pfizer. Drs R. M. Gendreau and J. F. Gendreau own stock or stock options
in Cypress Bioscience. Drs Palmer and Wang own stock or stock options in Forest Laboratories.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation assignment by computer code in blocks of 4

Allocation concealment
(selection bias)

Low risk

Assignment to treatment groups was conducted centrally (i.e. at the study lev-
el) using an interactive voice response system.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Low risk

Identical placebo appearance and matched dosing schedule

Low risk

Self-reported outcomes from blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2010b  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Similar attrition across both arms, BOCF used for imputation

Attrition:

Total: 309/1025 (30.1%)

Placebo: 150/509 (29.5%)

Milnacipran 100 mg: 159/516 (30.8%)

Selective reporting (re-
porting bias)

Low risk

Trial registered prospectively on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified.

Arnold 2010c 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention (12 weeks)

Country: USA and Puerto Rico

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 4 out of 10

Inclusion criteria

• Aged ≥ 18, met the criteria for fibromyalgia as defined by the ACR
• Scored ≥ 4 on the average pain item of the Brief Pain Inventory Short Form at visit 1 and visit 2.

Exclusion criteria

• Current or diagnosed within the past year with any primary psychiatric disorder other than MDD or
GAD defined by the DSM-IV; clinically judged to be at serious risk of suicide; had any unstable med-
ical illness that was likely to require intervention or hospitalisation; pain symptoms unrelated to fi-
bromyalgia that could interfere with interpretation of outcome measures; regional pain syndromes;
multiple surgeries or failed back syndrome; a confirmed current or previous diagnosis of RA, inflam-
matory arthritis, or other autoimmune disease; severe liver disease; pregnant or breastfeeding; or his-
tory of substance abuse within the past year

• Treated with an adequate trial of duloxetine and did not respond or could not tolerate duloxetine;
were judged by the opinion of the investigator to be treatment-refractory in fibromyalgia; or those in
whom treatment response might be compromised by disability compensation issues

Total participants randomised: 530

Age in years (mean, SD): 50.2 (11.1)

Gender: 494/530 were female

Pain duration in years: NR 

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2010c  (Continued)

Interventions

Duloxetine

Cochrane Database of Systematic Reviews

• n = 263
• SNRI
• 3 doses depending on patient tolerability: 60 mg/day, 90 mg/day, or 120 mg/day
• Mean dose 81.7 mg/day

Placebo

• n = 267
• Inert
• Identical appearance

Outcomes

Pain intensity

Mood

Physical function

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

LOCF and MMRM

Funding source

Pharmaceutical - Lilly USA LLC

Conflicts of interest

Dr Mease has received grants/research support from Eli Lilly and Company; Pfizer, Inc; Cypress Bio-
science, Inc; Forest Laboratories, Inc; Allergan; Fralex; and Boehringer Ingelheim. He has been a con-
sultant for Eli Lilly and Company; Pfizer, Inc; Cypress Bioscience, Inc; Forest Laboratories, Inc; Allergan;
Fralex; Boehringer Ingelheim; Pierre Fabre; and Wyeth; and he is on the Speakers Bureau of Pfizer, Inc.
Dr Arnold has received grants/research support from Eli Lilly and Company; Pfizer, Inc; Cypress Bio-
science, Inc; Boehringer Ingelheim; and Forest Laboratories, Inc, and received honoraria as a consul-
tant to Eli Lilly and Company; Pfizer, Inc; Cypress Bioscience, Inc; Boehringer Ingelheim; Forest Labora-
tories, Inc; Allergan; Takeda; UCB Inc.; Theravance; AstraZeneca; Sanofi-Aventis; and Grunenthal. Drs
Mohs, Ahl, Gaynor, and Wohlreich are all employees and stockholders in Eli Lilly andCompany. Dr Wang
is a former employee of Lilly USA, LLC.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Low risk

Computer-generated random sequence

Low risk

Allocation was managed using an Interactive Voice Response System.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2010c  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Good blinding procedures, identical appearing placebo

Low risk

Self-reported outcomes from blinded participants

Low risk

HIgh attrition but equal, ITT with LOCF and BOCF

Attrition:

Total: 167/530 (31.5%)

Placebo: 80/267 (30.0%)

Duloxetine 60-120 mg: 87/263 (33.1%)

Selective reporting (re-
porting bias)

Low risk

Trial registered prospectively and all outcomes reported

Other bias

Low risk

No other sources of bias were identified.

Arnold 2012a 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention (12 weeks)

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 4 out of 10

Inclusion criteria

• People aged ≥ 18 who met the ACR 1990 criteria for primary fibromyalgia
• Patients with MDD or GAD were included

Exclusion criteria

• Prior treatment with duloxetine; prior participation in a duloxetine study; a history of substance abuse
within the past year; a primary psychiatric disorder other than MDD or GAD within the last year; a
history of psychosis or bipolar disorder; clinically judged to be at risk of suicide; pregnant or breast-
feeding; pain symptoms unrelated to fibromyalgia that could interfere with interpretation of outcome
measures; regional pain syndromes; failed back syndrome; chronic localized pain related to any past
surgery, and a confirmed current or previous diagnosis of RA; inflammatory arthritis, or infectious
arthritis; or an autoimmune disease

• Patients  who,  in  the  opinion  of  the  investigator,  were  judged  to  be  treatment-refractory  or  whose
response might be compromised by disability compensation, or had an unstable medical condition
were also excluded

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2012a  (Continued)

Total participants randomised: 308

Age in years (mean): 51

Gender: 95.2% were female

Pain duration in years (mean): 6.5

Interventions

Duloxetine

Cochrane Database of Systematic Reviews

• n = 155
• SNRI
• Fixed dose of 30 mg/day (participants with MDD whose depression worsened during the trial had their

dose increased to 60 mg/day)

Placebo

• n = 153
• Inert
• Matched appearance to duloxetine

Outcomes

Pain intensity

Mood

Quality of life

Moderate pain relief

Substantial pain relief

PGIC

Adverse

SAE

Withdrawal

Missing data methods

LOCF and BOCF

Funding source

Pharmaceutical - Eli Lilly

Conflicts of interest

B.A.P. and S.Z. are full time employees and stockholders at Eli Lilly and Company. L.M.A. has received
grants from and/or is a consultant for Eli Lilly and Company, Pfizer Inc, Cypress Bioscience Inc, Forest
Laboratories, Boehringer Ingelheim, Novartis, Takedo, Grunenthal and Daiichi Sankyo

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)

Authors' judgement

Support for judgement

Low risk

Computer-generated random sequence

Low risk

Aloocation was managed using an interactive voice response system.

Low risk

Double-blind with placebo identical appearance to duloxetine

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2012a  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Attrition and reasons for withdrawal similar across groups. Mix of methods for
missing data including LOCF and BOCF

Attrition:

Total: 77/308 (25.0%)

Placebo: 31/110 (28.2%)

Duloxetine 30 mg: 29/121 (23.9%)

Selective reporting (re-
porting bias)

Low risk

Trial registered prospectively, outcomes match those predefined

Other bias

Low risk

No other sources of bias were identified.

Arnold 2012b 

Study characteristics

Methods

Design: parallel

Duration: 14 weeks

Assessment: baseline and post-intervention

Country: USA and Canada

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 40 out of 100

Inclusion criteria

• People aged ≥ 18 who met the ACR 1990 criteria for primary fibromyalgia
• Score of ≥ 40 mm on 100 mm VAS for pain intensity

Exclusion criteria

• Comorbid physical and mental health conditions excluded

Total participants randomised: 1122

Age in years (mean, range): 50 (19-84)

Gender: 1009/1122 were female

Pain duration in years (mean, range): 7 (0-55) 

Interventions

Esreboxetine 4 mg

• n = 245
• SNRI

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arnold 2012b  (Continued)

Cochrane Database of Systematic Reviews

• Fixed dose

Esreboxetine 8 mg

• n = 254
• SNRI
• Fixed dose

Esreboxetine 10 mg

• n = 255
• SNRI
• Fixed dose

Placebo

• n = 255
• Identical appearance
• Inert

Outcomes

Pain intensity

Physical function

Mood

Quality of life

Moderate pain relief

Substantial pain relife

PGIC

AEs

SAEs

Withdrawal

Missing data methods

LOCF with BOCF as a sensitivity analysis on pain outcomes

Funding source

Pharmaceutical - Pfizer

Conflicts of interest

Dr Arnold has received consulting fees from Eli Lilly, Cypress Bioscience, Forest Laboratories, Take-
da, AstraZeneca, Sanofi-Aventis, Grunenthal, Johnson & Johnson, and Daiichi Sankyo (less than
USD 10,000 each) and from Pfizer (> USD 10,000); she has received research grants from Eli Lilly, Pfiz-
er, Cypress Bioscience, Boehringer Ingelheim, Forest Laboratories, Novartis, and Takeda. Dr Hirsch
owns stock or stock options in AstraZeneca. Dr Sanders owns stock or stock options in Pfizer and As-
traZeneca. Drs Ellis and Hughes own stock or stock options in Pfizer.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Eligible patients were then randomised, according to a computer-generated
pseudorandom code, in a 1:1:1:1 ratio

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arnold 2012b  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

A centralised telerandomisation system was used to manage the allocation of
treatment

Patients received esreboxetine or matching placebo once daily in the form of
round, light grey tablets; all of the tablets were identical in appearance, to pre-
serve blinding.

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

High dropout across arms and significant differences in rates between placebo
and intervention arms

Attrition:

Total: 406/1122 (36.2%)

Placebo: 76/278 (27.3%)

Esreboxetine 4 mg: 103/277 (37.2%)

Esreboxetine 8 mg: 111/284 (39.1%)

Esreboxetine 10 mg: 108/283 (38.2%)

Selective reporting (re-
porting bias)

High risk

Primary outcomes were switched on the trial registry. Protocol states they will
collect and report HADS, SDI, and Sleep Interference but not published

Other bias

Low risk

No other sources of bias were identified.

Ash 1999 

Study characteristics

Methods

Design: parallel

Duration: 10 weeks

Assessment: baseline and post-intervention

Country: UK

Participants

Pain condition: RA

Population: women with RA and depression

Minimum pain intensity: NR

Inclusion criteria:

• Patients with definite or classical RA as diagnosed per the ARA criteria
• Aged between 18 and 70
• Scored a) > 7 on the depression or anxiety subscales of HADS, b) total score of > 11 on HADS scale, or

c) considered to be depressed on clincial assessment

Exclusion criteria

• Experiencing an acute flare in RA symptoms

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ash 1999  (Continued)

Cochrane Database of Systematic Reviews

• Taking oral steroids, antidepressants, or had received a steroid injection in the previous month

Total participants randomised: 48

Age in years (mean, SD): NR

Gender: 48/48 were female

Pain duration in years (mean, SD): NR

Interventions

Dothiepin

• n = 25
• TCA
• Flexible dosing dependent on tolerability and side-effects

Placebo

• n = 23
• Identical appearance
• Inert

Outcomes

Pain intensity

Mood

Physical function

Withdrawal

Missing data methods

ITT but does not state imputation methods

Funding source

Pharmaceutical - Boots

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

States random allocation but no method given

Unclear risk

No information given

Low risk

Double-blind with identical appearing antidepressants and placebo

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Over 40% of participants did not compelte the study due to lack of effect or in-
tolerable side effects.

Attrition:

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ash 1999  (Continued)

Total: 21/48 (43.75%)

Placebo: 10/23 (43.5%)

Dothiepin 75 to 150 mg: 11/25 (44.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Cochrane Database of Systematic Reviews

Atkinson 1998 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Population: men with chronic low back pain

Minimum pain intensity: NR

Inclusion criteria

• Aged between 21 and 65
• Had low back pain (T-6 or below) present for daily basis for at least 6 months

Exclusion criteria

• Comorbid physical or mental health condition

Total participants randomised: 78

Age in years (mean, SD): 47.13 (10.65)

Gender: 0/78 were female

Pain duration in years (mean, SD): 14.81 years

Interventions

Nortriptyline:

• n = 38
• TCA
• Forced titration to maximum tolerated dose between 25 mg and 100 mg

Placebo:

• n = 40
• Identical appearance
• Inert

Outcomes

Pain intensity

Physical function

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Atkinson 1998  (Continued)

Mood

Quality of life

AEs

Withdrawal

Cochrane Database of Systematic Reviews

Missing data methods

ITT, but no methods of imputation given

Funding source

Non-pharmaceutical: United States Department of Veteran's Affairs and the National Institutes of
Health

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomly assigned using a random number table

Allocation concealment
(selection bias)

Low risk

Randomisation performed by research pharmacist not involved in any other
aspects of the trial

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blinded with identical appearing placebo

Low risk

Self-reported outcomes from blinded participants

High risk

26% of participants withdrew. LOCF imputation only.

Attrition:

Total: 21/78 (26.9%)

Placebo: 11/40 (27.5%)

Nortriptyline 25 to 100 mg: 10/38 (26.3%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found.

Other bias

Low risk

No other sources of bias were identified.

Atkinson 1999 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Atkinson 1999  (Continued)

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Cochrane Database of Systematic Reviews

Population: adults with low back pain

Minimum pain intensity: NR

Inclusion criteria

• Aged between 21 and 65
• Low back pain (at T-6 or below) present daily for at least 6 months

Exclusion criteria

• Comorbid physical and mental health conditions

Total participants randomised: 103

Age in years (mean, SD): NR

Gender: 40/103 were female

Pain duration in years (mean, SD): 14.5 (11.1)

Interventions

Maprotiline 50-150 mg

• n = 33
• TeCA
• Fixed doses of 50 mg, 100 mg, or 150 mg depending on tolerability

Paroxetine 10 to 30 mg

• n = 34
• SSRI
• Fixed doses of 10 mg, 20 mg, or 30 mg depending on tolerability

Placebo (diphenhydramine 37.5 mg)

• n = 36
• Identical appearance and matched dosing
• Active placebo - antihistamine

Outcomes

Pain intensity

AEs

Withdrawal

Missing data methods

ITT using LOCF

Funding source

Non-pharmaceutical: funded by the United States Department of Veterans Affairs and the National In-
stitutes of Health

Conflicts of interest

NR

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Atkinson 1999  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using a random number table

Allocation concealment
(selection bias)

Low risk

Randomisation was performed by a research pharmacist not otherwise in-
volved in the trial

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blinded, active placebo, all capsules had identical appearance

Low risk

Self-reported outcomes by blinded participants

High risk

ITT using LOCF. Unequal dropout across arms

Attrition

Total: 29/103 (28.2%)

Maprotiline 50-150 mg: 13/33 (39.4%)

Paroxetine 10-30 mg: 12/34 (35.3%)

Placebo: 4/36 (11.1%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found. Only report data for primary outcome
despite collecting post-intervention data for other outcomes

Other bias

Low risk

No other sources of bias were identified

Atkinson 2007 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Population: adults with low back pain

Minimum pain intensity: NR

Inclusion criteria

• Aged 21-65
• Low back pain (T-6 or below) present on a daily basis for at least 6 months

Exclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Atkinson 2007  (Continued)

• Comorbid physical and mental health conditions

Total participants randomised: 121

Age in years (mean, SD): NR

Gender: NR

Pain duration in years (mean, SD): NR

Interventions

Placebo (benzotropine mesylate 0.5 mg)

• n = 26
• Identical
• Active placebo - anticholinergic
• Fixed dose of 0.5 mg

Desipramine 50 mg

• n = 17
• TCA
• Fixed dose

Desipramine 100 mg

• n = 17
• TCA
• Fixed dose

Desipramine 150 mg

• n = 18
• TCA
• Fixed dose

Fluoxetine 20 mg

• n = 14
• SSRI
• Fixed dose

Fluoxetine 40 mg

• n = 14
• SSRI
• Fixed dose

Fluoxetine 60 mg

• n = 15
• SSRI
• Fixed dose

Outcomes

No useable data provided

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: US Department of Veterans Affairs

Conflicts of interest

NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Atkinson 2007  (Continued)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using a computerised random number genera-
tor

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Randomisation was completed by a research pharmacist not involved in other
aspects of the study

Double-blinded, double-dummy design, no significant difference in partici-
pants guessing allocation

Low risk

Self-reported outcomes by blinded participants

High risk

ITT with LOCF

Attrition:

Total: 38/121 (31.4%)

Attrition by arm NR

Selective reporting (re-
porting bias)

Unclear risk

Only 1 outcome prespecified in protocol. Do not perform their original analysis

Other bias

Low risk

No other sources of bias were identified.

Bansal 2009 

Study characteristics

Methods

Design: cross-over

Duration: 5 weeks

Assessment: baseline and post-intervention

Country: India

Participants

Pain condition: diabetic peripheral neuropathy

Population: adults with diabetic peripheral neuropathy

Minimum pain intensity: ≥ 50 on 0-100 VAS

Inclusion criteria

• Aged 18-75
• Painful diabetic neuropathy for at least 1 month
• Pain rating of 50 on 0-100 VAS

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bansal 2009  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

• Comorbid physical and mental health conditions (aside from diabetes)

Total participants randomised: 51

Age in years (median, range): 54.5 (48-61)

Gender: 25/44 completers were female

Pain duration in months (mean, IQR): 12 (3-24)

Interventions

Pregabalin

• Anticonvulsant
• Flexible dosing
• Mean dose of 218 mg/day

Amitriptyline

• TCA
• Flexible dosing
• Mean dose of 16 mg/day

Outcomes

Pain intensity

PGIC

Withdrawal

Missing data methods

ITT but no method of imputation reported

Funding source

Funding: NR

Conflicts of interest

No conflicts of interest to declare

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using a random number table

Allocation concealment
(selection bias)

Low risk

Blinding and randomisation were carried out by an independent person unre-
lated to the study, while drug administration and patient assessment were car-
ried out by the investigator.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)

Low risk

Double-blinded, identical appearing tablets

Low risk

Self-reported outcomes by blinded participants

Unclear risk

States ITT but no method of imputation reported

Attrition:

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bansal 2009  (Continued)

All outcomes

Cochrane Database of Systematic Reviews

Total: 7/51 (13.7%)

Amitriptyline 10-50 mg: 3/25 (12.0%)

Pregabalin 75-300 mg: 4/26 (15.4%)

Selective reporting (re-
porting bias)

Unclear risk

Trial registration, but registered retrospectively

Other bias

Low risk

No other sources of bias were identified.

Bateman 2013 

Study characteristics

Methods

Design: parallel

Duration: 10 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: people with fibromyalgia who did not respond to duloxetine

Minimum pain intensity: VAS pain score ≥ 40 mm/100 mm

Inclusion criteria

• Diagnosis of fibromyalgia
• Pain intensity of ≥ 40/100
• Dissatisfaction with duloxetine after 6 weeks

Exclusion criteria

• Comorbid physical and mental health conditions

Total participants randomised: 107

Age in years (mean): 48.6

Gender: 92/107 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 21
• Matched dosing schedule
• Inert

Milnacipran 50-200 mg

• n = 86
• SNRI
• Flexible dosing

Outcomes

Pain intensity

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 2013  (Continued)

Quality of life

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical - Forest Laboratories Inc.

Conflicts of interest

LB has received research support and speaker fees from Forest Laboratories, Inc. and Forest Research
Institute, Inc. RHP, JMT, and YL are full-time employees of Forest Research Institute, Inc., a wholly
owned subsidiary of Forest Laboratories, Inc., and hold stock in the parent company. This study was
supported by Forest Laboratories, Inc. The authors thank Allan Spera at Forest Research Institute, Inc.
for his contributions to the study and development of this paper. The authors also thank Mildred Bahn
at Prescott Medical Communications Group (Chicago, IL, USA) for medical writing assistance supported
by Forest Research Institute, Inc.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

No information given

Unclear risk

No information given

Unclear risk

Included small placebo arm to ensure blinding, matched dosing schedule but
no information given regarding appearance

Unclear risk

Self-reported outcomes from participants, but unsure of blinding

High risk

ITT with LOCF and high attrition

Attrition

Total: 45/107 (42.1%)

Placebo: 10/21 (47.6%)

Milnacipran 50-200 mg: 35/86 (40.7%)

Selective reporting (re-
porting bias)

Low risk

Primary measures match those listed prospectively in trial registry

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
 
Cochrane Database of Systematic Reviews

Placebo group spent first week still taking duloxetine while active drug group
had no down taper between taking duloxetine and milnacipran

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 2013  (Continued)

Other bias

High risk

Bird 2000 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Countries: UK, Ireland, Germany, Italy, and Belgium

Participants

Pain condition: RA

Population: adults with RA and depression

Minimum pain intensity: NR

Inclusion criteria

• Aged 18-70
• RA for > 1 year
• Diagnosis of mild, moderate, or severe depression
• Had a total MADRS score of ≥ 16

Exclusion criteria

• Severe comorbid physical conditions

Total participants randomised: 191

Age in years (mean): 54.8

Gender: 150/191 were female

Pain duration in years (mean, SD): NR

Interventions

Paroxetine 20-40 mg

• n = 94
• SSRI
• Flexible dosing based on efficacy

Amitriptyline 75-150 mg

• n = 97
• TCA
• Flexible dosing based on efficacy

Outcomes

Mood

PGIC

AEs

SAEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bird 2000  (Continued)

Withdrawal

Missing data methods

ITT but imputation method not specified

Funding source

Pharmaceutical - educational grant from SmithKline Beecham

Conflicts of interest

NR

Cochrane Database of Systematic Reviews

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

No information given

Unclear risk

No information given

Low risk

Double-blinded - double-dummy dosing schedule

Low risk

Self-reported outcomes from blinded participants

Unclear risk

States ITT but no information regarding imputation method given

Attrition

Total: 37/191 (19.4%)

Paroxetine 20-40 mg: 18/95 (18.9%)

Amitriptyline 75-150 mg: 20/105 (19.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Boyle 2012 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Assessment: baseline and post-intervention

Country: UK

Participants

Pain condition: diabetic peripheral neuropathy

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Boyle 2012  (Continued)

Population: adults with diabetic peripheral neuropathy

Minimum pain intensity: NR

Inclusion criteria

• Adults with a diagnosis of diabetic peripheral neuropathy for > 1 year
• Score > 12 on the Leeds Assessment of Neuropathic Symptoms and Signs Scale

Exclusion criteria

• Severe physical health condition
• Comorbid mental health condition

Total participants randomised: 83

Age in years (mean, SD): 65.1 (8.9)

Gender: 26/83 were female

Pain duration in years (mean, SD): NR

Interventions

Pregabalin 600 mg

• n = 27
• Anticonvulsant
• Forced titration to fixed dose

Amitriptyline 75 mg

• n = 28
• TCA
• Forced titration to fixed dose

Duloxetine 120 mg

• n = 28
• SNRI
• Forced titration to fixed dose

Outcomes

Pain intensity

Sleep

Physical function

Mood

Withdrawal

Missing data methods

ITT but imputation methods not specified

Funding source

Pharmaceutical - Pfizer

Conflicts of interest

Notes

This study was funded by an investigator-led research grant, which was awarded by Pfizer Ltd. J.B. re-
ceived an honorarium to present the research findings internally to a Pfizer consultancy board. D.K.re-
ceived consultancy fees and honoraria from Eli Lilly, Novo Nordisk, Abbott Diabetes Care, and Roche,
companies providing medicine and monitoring equipment used by participants in this study. No other
potential conflicts of interest relevant to this article were reported.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Boyle 2012  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation method not specified

Unclear risk

Procedure for allocation not specified

Unclear risk

Matched dosing, but no information given regarding appearance of tablets

Unclear risk

Self-reported pain outcomes, but not enough information regarding blinding
procedures

Unclear risk

Missing data methods: NR

Attrition

Total: 18/83 (21.7%)

Pregabalin 300 mg: 5/27 (18.5%)

Amitriptyline 75 mg: 4/28 (14.3%)

Duloxetine 120 mg: 0/28 (0.0%)

Selective reporting (re-
porting bias)

Low risk

Pre-registered protocol lists primary outcomes

Other bias

Low risk

No other sources of bias were identified.

Branco 2010 

Study characteristics

Methods

Design: parallel

Duration: 17 weeks

Assessment: baseline and post-intervention

Country: Czech Republic, Denmark, Finland, France, Germany, Italy, Norway, Poland, Portugal, Roma-
nia, Spain, Sweden, UK

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: baseline VAS pain intensity rating between 40 and 90 (0-100 scale)

Inclusion criteria

• Aged 18-70
• Diagnosed with fibromyalgia as per the ACR criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Branco 2010  (Continued)

Cochrane Database of Systematic Reviews

• Raw score ≥ 3 on physical function component of the FIQ
• Baseline VAS pain intensity rating between 40 and 90 (0-100 scale)

Exclusion criteria

• Severe mental health conditions
• Comorbid physical health conditions

Total participants randomised: 884

Age in years (mean): 48.4

Gender: 826 were female

Pain duration in years (mean): 9.5

Interventions

Placebo

• n = 449
• Matched dosing and identical appearance
• Inert

Milnacipran 200 mg

• n = 435
• SNRI
• Forced titration to fixed dose

Outcomes

Pain intensity

Quality of life

Physical function

Mood

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF, and BOCF sensitivity analyses

Funding source

Pharmaceutical - Pierre Fabre Medicament, France

Conflicts of interest

Dr Branco has received grant support as an investigator and consultant for Pierre Fabre Medicament.
Drs Zachrisson and Perrot have served as speakers and consultants for Pierre Fabre Medicament. Dr
Mainguy is an employee and shareholder of Pierre Fabre Medicament. Medical writing assistance pro-
vided by Prescott Medical Communications Group was supported by Pierre Fabre Medicament.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Branco 2010  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedure not specified

Unclear risk

Matched dosing but no information regarding appearance of drugs

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

ITT with LOCF and BOCF as sensitivity analysis. More dropouts in antidepres-
sant arm related to side-effects

Attrition

Total: 206/882 (23.3%)

Placebo: 79/449 (17.6%)

Milnacipran 200 mg: 127/435 (29.2%)

Selective reporting (re-
porting bias)

Unclear risk

Primary outcome matches trial registry, but secondary outcomes not listed

Other bias

Low risk

No other sources of bias were identified.

Braz 2013 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Brazil

Participants

Pain condition: fibromyalgia

Population: women with fibromyalgia

Minimum pain intensity: NR

Inclusion criteria

• Women aged 21-60
• Fibromyalgia diagnosed as per the ACR criteria

Exclusion criteria

• Physical health comorbidity
• Use of TCA in the previous 3 months

Total participants randomised: 52

Age in years (mean): 43.2

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Braz 2013  (Continued)

Gender: 52/52 were female

Pain duration in months (mean): 43.8

Interventions

Placebo

• n = 17
• Identical appearance
• Inert

Amitriptyline 25 mg

• n = 16
• TCA
• Fixed dose with no titration

Panax ginseng 100 mg

• n = 19
• Plant extract
• Fixed dose with no titration

Outcomes

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation procedure not specified

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, drugs identical appearance

Low risk

Self-reported measures completed by blinded participants

High risk

Completer-only analysis, unequal attrition

Attrition

Total: 14/52 (26.9%)

Placebo: 4/17 (23.5%)

Amitriptyline 25 mg: 3/16 (18.8%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Braz 2013  (Continued)

Selective reporting (re-
porting bias)

Panax ginseng 100 mg: 7/19 (36.8%)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Calderon 2011 

Study characteristics

Methods

Design: parallel

Duration: 7 weeks

Assessment: baseline, post-intervention, follow-up (4 weeks after post-intervention)

Country: Brazil

Participants

Pain condition: orofacial pain

Population: women with temporomandibular disorders

Minimum pain intensity: ≥ 40 mm on a 0-100 mm VAS

Inclusion criteria

• Women aged between 17 and 55
• Orofacial pain for > 6 months
• Pain occurring daily or almost daily
• Pain ≥ 40 on a 0-100 mm VAS

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 47

Age in years (mean, range): 35.6 (17-52)

Gender: 47/47 were female

Pain duration in months (mean, range): 72.35 (6-384)

Interventions

Placebo

• n = 13
• Inert

Placebo + CBT

• n = 11
• Inert placebo
• Weekly 90-min CBT sessions for 7 weeks

Amitriptyline 25 mg

• n = 11
• TCA
• Fixed dose with no titration

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Calderon 2011  (Continued)

Amitriptyline 25 mg + CBT

• n = 12
• TCA - antidepressant
• Weekly 90-min CBT sessions for 7 weeks

Outcomes

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Non-pharmaceutical - Ministry of Education in Brazil

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised using the website www.randomization.com

Unclear risk

Allocation procedures not specified

High risk

Due to nature of CBT group participants cannot be blinded. When comparing
the placebo versus amitriptyline group(s) there was no description of whether
pills were matched.

High risk

Self-reported outcomes from unblinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

No clear explanation of reasons for withdrawal and from which group, not
clear on handling missing data or group sizes in outcomes

Attrition

Total: 10/47 (21.3%)

Placebo: 2/13 (15.4%)

CBT: 2/11 (18.2%)

Amitriptyline 25 mg: 2/11 (18.2%)

CBT + amitriptyline 25 mg: 4/12 (33.3%)

Selective reporting (re-
porting bias)

Unclear risk

No trial registration or protocol found

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cannon 1994 

Study characteristics

Methods

Design: parallel

Duration: 3 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: non-cardiac chest pain

Population: adults with non-cardiac chest pain

Minimum pain intensity: NR

Inclusion criteria

• People with chest pain and normal coronary angiograms
• Psychiatric conditions included

Exclusion criteria

• NR

Total participants randomised: 60

Age in years (mean, range): 50 (29-72)

Gender: 40/60 were female

Pain duration in months (mean, range): 53 (3-175)

Interventions

Placebo

• n = 20
• Inert
• Matched dosing schedule and identical capsules

Clonidine 0.2 mg

• n = 20
• Anti-hypertensive
• Fixed dose of 0.2 mg/day
• Forced titration over 1 week

Imipramine 50 mg

• n = 20
• TCA
• Fixed dose of 50 mg/day
• Forced titration over 1 week

Outcomes

Missing data methods

AEs

NR

Funding source

Funding: NR

Conflicts of interest

NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cannon 1994  (Continued)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation procedure not specified

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, matched dosing schedules and identical appearance

Low risk

Self-reported outcomes from blinded participants

Unclear risk

No information given regarding dropout or missing data analyses - could be
that everyone completed the trial but NR

Attrition

NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Cardenas 2002 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: pain resulting from spinal cord injury

Population: adults with persistent pain from spinal cord injury

Minimum pain intensity: average of ≥ 3 out of 10 over the last month

Inclusion criteria

• Aged 18-65
• Spinal cord injury > 6 months ago
• Pain for at least 3 months
• Average pain rating of ≥ 3 out of 10 over the last month

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cardenas 2002  (Continued)

Exclusion criteria

• Comorbid physical and mental health conditions

Total participants randomised: 84

Age in years (mean): 41.5

Gender: 17/84 were female

Pain duration in months (mean): 168.3

Interventions

Placebo (benztropine mesylate 0.5 mg)

• n = 40
• Active placebo - anticholinergic
• Identical appearance
• Fixed dose

Amitriptyline 10-125 mg

• n = 44
• TCA
• Flexible titration based on efficacy and tolerance

Outcomes

Pain intensity

Mood

Physical function

AEs

Withdrawal

Missing data methods

ITT but no imputation method specified

Funding source

Non-pharmaceutical - National Institutes of Health

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified

Allocation concealment
(selection bias)

Low risk

Random assignment to treatment group and provision of medication was
done by the University of Washington Medical Center Pharmacy Investigation-
al Drug Services.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Low risk

Double-blind, active placebo, identical appearance

Low risk

Self-reported outcomes from blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cardenas 2002  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Low levels of dropout, not significantly different across both arms. ITT analysis
but no imputation method specified

Attrition

Total: 11/84 (13.1%)

Benzotropine mesylate 0.5 mg: 3/40 (7.5%)

Amitriptyline 10-125 mg: 8/44 (18.2%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Carette 1986 

Study characteristics

Methods

Design: parallel

Duration: baseline and post-intervention

Assessment: 9 weeks

Country: Canada

Participants

Pain condition: primary fibrositis/fibromyalgia

Population: people with fibromyalgia

Minimum pain intensity: NR

Inclusion criteria

• Widespread pain lasting > 3 months
• Local tenderness at 12 out of 14 specified sites

Exclusion criteria

• History of heart conditions
• Treated with amitriptyline in the previous year

Total participants randomised: 70

Age in years (mean): 41

Gender: 54/70 were female

Pain duration in months (mean): 84

Interventions

Placebo

• n = 36
• Identical appearance
• Inert

Amitriptyline 10-50 mg

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carette 1986  (Continued)

• n = 34
• TCA
• Forced titration to fixed doses dependent upon tolerability

Cochrane Database of Systematic Reviews

Outcomes

Pain intensity

AEs

Withdrawal

Missing data methods

Completer analysis only

Funding source

Non-pharmaceutical - Arthritis Grant

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedure not specified

High risk

Although the study used double-blind procedures, the authors noted that 70%
of the amitriptyline participants experienced side effects that, in some cases,
unblinded participants and research staff.

High risk

Self-reported outcomes from participants who may have been unblinded

High risk

Completer analysis only

Attrition

Total: 11/70 (15.7%)

Placebo: 4/32 (11.1%)

Amitriptyline 10-50 mg: 7/27 (20.6%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Carette 1994 

Study characteristics

Methods

Design: parallel

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carette 1994  (Continued)

Duration: 25 weeks

Assessment: baseline and post-intervention

Country: Canada

Participants

Pain condition: fibromylagia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 4 on a 0-10 VAS

Inclusion criteria

• Adults with a diagnosis of fibromyalgia as per the ACR criteria
• Score of ≥ 4 on at least 1 of two 0-10 VAS, one evaluating pain, one evaluating fibromyalgia symptoms

Exclusion criteria

• History of cardiac conditions
• Previous treatment with amitriptyline or cyclobenzaprine

Interventions

Total participants randomised: 208

Age in years (mean): 44.9

Gender: 199/208 were female

Pain duration in months (mean): 92.6

Placebo

• n = 42
• Inert

Amitriptyline 25-50 mg

• n = 84
• TCA
• Forced titration to fixed doses
• 25 mg/day for 12 weeks, then 50 mg/day for 12 weeks

Cyclobenzaprine 20-30 mg

• n = 82
• Muscle relaxant
• Forced titration to fixed doses
• 20 mg/day for 12 weeks, then 30 mg/day for 12 weeks

Outcomes

Pain intensity

Physical function

Mood

AEs

Withdrawal

Missing data methods

ITT but no imputation methods stated

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carette 1994  (Continued)

Funding source

Partly pharmaceutical - supported by grants from the Canadian Arthritis Society and Merck Frosst
Canada

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised using a random number table

Unclear risk

Allocation procedure not described

Unclear risk

Matched dosing but no information on appearance. Not enough information
about physician blinding as there were some physician-reported measures.

Unclear risk

Mostly self-reported outcomes from participants. Not enough information re-
garding blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Do not clearly report reasons for withdrawal and numbers between groups.
State ITT but no methods specified

Attrition

Total: 52/208 (25.0%)

Placebo: 14/84 (33.3%)

Amitriptyline 50 mg: 14/82 (16.7%)

Cyclobenzaprine 20-30 mg: 24/42 (29.3%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Caruso 1987 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline, week 2, week 4, post-intervention

Country: Italy

Participants

Pain condition: fibromyalgia

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Caruso 1987  (Continued)

Population: adults with fibromyalgia

Minimum pain intensity: NR

Inclusion criteria

• Aged 25-65
• Affected by fibromyalgia

Exclusion criteria: NR

Total participants randomised: 60

Age in years (mean): 46

Gender: 52/60 were female

Pain duration in years (mean): 5.7

Interventions

Placebo

• n = 30
• Identical appearance and matched dosing
• Inert

Dothiepin 75 mg

• n = 30
• TCA
• Fixed dose

Outcomes

AEs

Withdrawal

Missing data methods

NR

Funding source

Funding: NR

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Authors' judgement

Support for judgement

Unclear risk

Randomsiation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind with matched dosing and identical appearance of tablets

Low risk

Self-reported outcomes by blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Caruso 1987  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer analysis only

Attrition

Total: 8/60 (13.3%)

Placebo: 4/30 (13.3%)

Dothiepin 75 mg: 4/30 (13.3%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Chappell 2008 

Study characteristics

Methods

Design: parallel

Duration: 27 weeks

Assessment: baseline and post-intervention

Country: USA, Germany, Spain, Sweden, UK

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: none

Inclusion criteria

• Adults with fibromyalgia diagnosed as per the ACR criteria
• With or without MDD

Exclusion criteria

• Severe physical health comorbidity

Total participants randomised: 330

Age in years (mean, SD): 50.5 (10.7)

Gender: 308/330 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 168
• Inert

Duloxetine

• n = 162
• SNRI

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chappell 2008  (Continued)

Outcomes

• Blind forced titration to fixed doses dependent upon efficacy for pain relief
• Mean dose at end of trial was 113.4 mg/day

Pain intensity

Quality of life

Mood

Physical function

Moderate pain relief

Substantial pain relief

PGIC

AEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharamaceutical - Eli Lilly and Boehringer Ingelheim GmbH

Conflicts of interest

Notes

Risk of bias

Bias

Drs Chappell, Detke, and D'Souza are employees and stockholders of Eli Lilly and Company. Dr Wiltse
is a former employee of Eli Lilly and Company. Dr Spaeth is a consultant to Allergan, Eli Lilly, Jazz, and
Pierre Fabre Medicament, and is on the speaker bureaus of Eli Lilly and Pierre Fabre Medicament. Dr
Bradley is a consultant for Eli Lilly, Pfizer, and Forest; has received grant/research support from the
National Institutes of Health, the Agency for Healthcare Research and Quality, Eli Lilly, Pfizer, and the
American Fibromyalgia Syndrome Association; has received honoraria from Eli Lilly, Pfizer, Forest, and
the Society for Women's Health Research; is a member of the speaker/advisory board for Pfizer; and
has received royalties from UpToDate Rheumatology.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to treatment groups was determined by a computer-generated
random sequence within each study centre, stratiﬁed by MDD status

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedure not described

Low risk

Double-blind, identical appearance tablets

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Significant difference in participants withdrawing due to lack of efficacy (high-
er in placebo). Uses ITT with LOCF

Attrition

Total: 126/330 (38.2%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chappell 2008  (Continued)

Cochrane Database of Systematic Reviews

Placebo: 65/168 (38.7%)

Duloxetine 60-120 mg: 61/162 (37.7%)

Selective reporting (re-
porting bias)

Low risk

Outcomes match those listed in trial registration record

Other bias

Low risk

No other sources of bias were identified.

Chappell 2009a 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks open-label, 52 weeks double-blind

Assessment: baseline and post-intervention

Country: Argentina, Australia, Brazil, Canada, Mexico, Poland, Taiwan, USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Adults with fibromyalgia that met the ACR criteria
• ≥ 4 on 0-10 BPI pain item for 2 consecutive visits

Exclusion criteria

• Physical health comorbidity
• Suicide risk (scoring ≥ 2 on item 9 of the BDI-II)

Total participants randomised in double-blind phase: 307

Age in years (mean, SD): 49 (11.07)

Gender: 335/350 were female (including those in the open-label phase)

Pain duration in years (mean, SD): NR

Interventions

Duloxetine 60 mg

• n = 104
• SNRI
• Titrated to fixed dose of 60 mg over 8-week open-label phase
• Continued on fixed 60 mg dose for 52-week double-blind phase

Duloxetine 120 mg

• n = 203
• SNRI
• Titrated to fixed dose of 60 mg over 8-week open-label phase, then increased to 120 mg fixed dose

for double-blind phase

Outcomes

Pain intensity

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chappell 2009a  (Continued)

Quality of life

Physical function

Sleep

Mood

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical - Eli Lilly and Co and Boehringer Ingelheim

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation procedure not specified

Allocation concealment
(selection bias)

Low risk

Patients were allocated using an interactive voice response system that was
accessed via telephone by each investigator.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

States double-blind but not enough information on medication i.e. appear-
ance or number of tablets

Unclear risk

Self-reported outcomes from participants, but not enough information regard-
ing blinding

High risk

Use ITT with LOCF. Similar but significant attrition rates in both arms

Attrition

Total: 112/307 (36.5%)

Duloxetine 60 mg: 33/104 (31.7%)

Duloxetine 120 mg: 79/203 (38.9%)

Selective reporting (re-
porting bias)

Unclear risk

Protocol not very detailed, report matched domains but did not register mea-
sures and time points, etc

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chappell 2009b 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention

Country: USA, Puerto Rico, Romania

Participants

Pain condition: knee OA

Population: adults aged ≥ 40 with knee OA

Minimum pain intensity: ≥ 4 on 24-h 0-10 VAS

Inclusion criteria

• Adults aged ≥ 40 with knee OA matching ACR criteria
• Pain ≥ 14 days a month for 3 months prior to study entry
• Mean score of ≥ on 24-h average pain score (0-10) on first 2 study visits

Exclusion criteria

• Comorbid physical and mental health conditions
• Previous exposure to duloxetine

Total participants randomised: 231

Age in years (mean): 62.3

Gender: 151/231 were female

Pain duration in years (mean): 9

Interventions

Placebo

• n = 120
• Identical in appearance, smell, and taste
• Matched dosing
• Inert

Duloxetine

• n = 111
• SNRI
• Fixed dose of 60 mg for 6 weeks, then re-randomised to fixed dosage of 60 mg or 120 mg for weeks 7-13

Outcomes

Pain intensity

Sleep

Quality of life

Mood

Physical function

Moderate pain relief

Substantial pain relief

PGIC

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chappell 2009b  (Continued)

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF, and MMRM

Funding source

Pharmaceutical - Eli Lilly

Cochrane Database of Systematic Reviews

Conflicts of interest

NR, but authors are employed by Eli Lilly and declare CoIs in other papers.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised using a computer-generated random sequence

Low risk

Participants were allcoated using an Interactive Voice Response System (IVRS).

Low risk

Double-blinded, matched dosing and identical appearance, smell, and taste of
capsules

Low risk

Self-reported outcomes from blinded participants

Low risk

ITT with LOCF, BOCF, and MMRM

Attrition

Total: 58/231 (25.1%)

Placebo: 24/120 (20.0%)

Duloxetine 60-120 mg: 34/111 (30.6%)

Selective reporting (re-
porting bias)

Low risk

Outcomes and procedures match those listed prospectively in trial registration

Other bias

Low risk

No other sources of bias were identified.

Chappell 2011 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chappell 2011  (Continued)

Country: USA, Canada, Greece, Russia, Sweden

Participants

Pain condition: knee OA

Population: adults aged ≥ 40 with knee OA

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Adults aged ≥ 40 with knee OA matching ACR criteria
• Pain ≥ 14 days a month for 3 months prior to study entry
• Mean score of ≥ on 24-h average pain score (0-10) on first 2 study visits

Exclusion criteria

• Comorbid physical and mental health conditions

Total participants randomised: 256

Age in years (mean): 62.5

Gender: 196/256 were female

Pain duration in years (mean): 7.4

Interventions

Placebo

• n = 128
• Inert
• Matched dosing

Duloxetine

• n = 128
• SNRI
• Fixed dose of 60 mg for 6 weeks, then titrated to fixed dosage of 120 mg for weeks 7-13 dependent

on 30% pain relief

Outcomes

Pain intensity

Physical function

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF, sensitivity analysis of primary outcome with BOCF and modified-BOCF

Funding source

Pharmaceutical - Eli Lilly

Conflicts of interest

This study was sponsored by Eli Lilly and Company, Indianapolis, IN, USA. Drs Chappell, Skljarevski,
Desaiah, Liu-Seifert, and Ms Zhang are employees and stockholders of Eli Lilly and Company. Drs Be-

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chappell 2011  (Continued)

Cochrane Database of Systematic Reviews

lenkov and Brown were participating investigators in the conduct of this study and received funding
from Eli Lilly and Company.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to treatment was determined by a computer-generated random
sequence

Allocation concealment
(selection bias)

Low risk

Participants were allocated using an interactive voice response system to en-
sure blinding.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

States double-blind and matched dosing, but don't mention drug appearance

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Attrition rates may be influenced by group allocation: "Significantly more pa-
tients in the duloxetine group (n = 24, 18.8%) discontinued from the study due
to adverse events (P = 0.002) than patients in the placebo group (n = 7, 5.5%)."
Used LOCF, BOCF, mBOCF, ITT to handle/impute missing data

Attrition

Total:

Placebo: 17/128 (13.3%)

Duloxetine 60-120 mg: 35/128 (27.3%)

Selective reporting (re-
porting bias)

High risk

Data not presented on outcomes that were non-significant

Other bias

Low risk

No other sources of bias were identified.

Clauw 2008 

Study characteristics

Methods

Design: parallel

Duration: 15 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 VAS

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Clauw 2008  (Continued)

Inclusion criteria

Cochrane Database of Systematic Reviews

• Aged 18-70 with a diagnosis of fibromyalgia as per ACR
• ≥ 40 on 0-100 pain intensity VAS
• ≥ 4 on physical function component of FIQ

Exclusion criteria

• Current physical or mental health condition
• Previous exposure to milnacipran

Total participants randomised: 1207

Age in years (mean): 50.2

Gender: 1151/1207 were female

Pain duration in years (mean): 9.7

Interventions

Placebo

• n = 405
• Inert
• Matched dosing with identical appearance

Milnacipran 100 mg

• n = 401
• SNRI
• Fixed dose, titrated over 6 days
• Sham escalation to match 200 mg arm

Milnacipran 200 mg

• n = 401
• SNRI
• Fixed dose, titrated over 6 days

Outcomes

Pain intensity

Moderate pain relief

Physical function

Mood

Quality of life

Sleep

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF and BOCF

Funding source

Pharmaceutical - Forest Research Institute, Inc. and Cypress Bioscience, Inc.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Clauw 2008  (Continued)

Conflicts of interest

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

This research was financially supported by Forest Research Institute, Inc., Jersey City, New Jersey,
and Cypress Bioscience, Inc., San Diego, California. The study drug was manufactured by Pierre Fabre
Medicament, Boulogne, France. Drug supply and data collection were managed by Forest Research In-
stitute.

The study was designed and conducted under the supervision of Drs Gendreau, Palmer, and Clauw. The
manuscript was prepared with the editorial assistance of Prescott Medical Communications Group,
Chicago, Illinois, under the supervision of Dr Clauw.

Dr Clauw has received grant support from Cypress Bioscience, Inc., and serves as a consultant to Cy-
press Bioscience, Forest Laboratories, and Pierre Fabre Medicament, all of which are involved in the de-
velopment of milnacipran for fibromyalgia. He also acts as a consultant to Eli Lilly and Company, Pfiz-
er Inc., Procter & Gamble, and Wyeth Pharmaceuticals. He has owned stock in Cypress Bioscience. Dr
Mease has received research grant support from Allergan, Inc.; Cypress Bioscience; Forest Laboratories;
Fralex Therapeutics Inc.; Jazz Pharmaceuticals; Eli Lilly; Pfizer; and Wyeth. Drs Palmer and Wang are
employees of Forest Research Institute and own stock in Forest Laboratories. Dr Gendreau is an em-
ployee of Cypress Bioscience and owns stock in that company.

Authors' judgement

Support for judgement

Low risk

Randomisation lists for each site were generated by a computer program.

Low risk

Assignments made via an interactive voice response system

Low risk

Double-blind, matched dosing, and identical appearance of tablets

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

High attrition rates, did not adhere to the mentioned plan with handling and
reporting missing data

Attrition

Total:

Placebo: 115/405 (28.4%)

Milnacipran 100 mg: 137/401 (34.2%)

Milnacipran 200 mg: 144/401 (35.9%)

Selective reporting (re-
porting bias)

Unclear risk

Trial registration available but did not specify outcome measures - just out-
comes

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Creed 2003 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Cochrane Database of Systematic Reviews

Assessment: baseline, post-intervention, follow-up 1 year post-intervention

Country: UK

Participants

Pain condition: IBS

Population: adults with IBS

Minimum pain intensity:

Inclusion criteria

• Aged 18-65
• Rome I criteria for IBS
• Severe abdominal pain, defined as > 59 on a VAS

Exclusion criteria

• Psychotic disorder, severe personality disorder, active suicidal ideation
• Consumed > 50 units of alcohol per week

Total participants randomised: 257

Age in years (mean): 43.3

Gender: 205/257 were female

Pain duration in years (mean, SD): NR

Interventions

Psychotherapy

• n = 85
• Psychodynamic interpersonal therapy
• 8 sessions of 3 months

Paroxetine 20 mg/day

• n = 86
• SSRI
• Fixed dose

Usual treatment

• n = 86
• Usual  treatment  -  patients  continued  to  be  seen  either  by  their  gastroenterologist  and/or  general
practitioner, using whatever management was deemed appropriate throughout the 15 months of the
study.

Outcomes

Pain intensity

Physical function

Mood

Withdrawal

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Creed 2003  (Continued)

Missing data methods

ITT, data imputed using SOLAS (data imputation software)

Funding source

Non-pharmaceutical - Medical Research Council and UK North West Regional Health Authority Re-
search and Development Directorate

Conflicts of interest

F Creed has consultancy links with Lilly. He has received payment for sitting on an advisory panel. All
other authors declare that they have no competing interests.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation was performed by a computer-generated series of random
numbers.

Allocation concealment
(selection bias)

Unclear risk

When patients had been assessed and accepted into the trial, they were then
allocated to a treatment group by the trial administrator using the next slot on
the appropriate randomisation list.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Participants and researchers unable to be blinded to due to nature of psy-
chotherapy

High risk

Self-reported outcomes from unblinded participants

Unclear risk

Unequal attrition. State ITT and data imputed by SOLAS - but no explanation
given

Attrition

Total: 69/257 (26.8%)

Psychotherapy: 26/85 (30.6%)

Paroxetine 20 mg: 32/86 (37.2%)

Usual treatment: 11/86 (12.8%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

de Zanette 2014 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

de Zanette 2014  (Continued)

Country: Brazil

Participants

Pain condition: fibromyalgia

Cochrane Database of Systematic Reviews

Population: women with fibromyalgia

Minimum pain intensity: ≥ 50 on 0-100 VAS

Inclusion criteria

• Women with fibromyalgia matching ACR criteria
• Pain intensity of ≥ 50 on 0-100 VAS

Exclusion criteria

• Physical health comorbidities
• BMI > 35

Total participants randomised: 63

Age in years (mean): 48.9

Gender: 63/63 were female

Pain duration in years (mean, SD): NR

Interventions

Melatonin 10 mg

• n = 21
• Hormone
• Identical appearance
• Double-dummy to match combined arm

Amitriptyline 25 mg

• n = 21
• TCA
• Fixed dose, no titration
• Double-dummy to match combined arm

Melatonin 10 mg + amitriptyline 25 mg

• n = 21
• Hormone and TCA antidepressant
• Fixed doses, no titration

Outcomes

Pain intensity

Quality of life

Sleep

AEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical - multiple Brazilian governmental agencies

Conflicts of interest

The authors declare that there are no financial or other relationships that might lead to CoIs involving
any of the following arrangements: financial relationship to the work, employees of a company, consul-

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

de Zanette 2014  (Continued)

Cochrane Database of Systematic Reviews

tants for a company, stockholders of the company, members of a speakers' bureau or any other form of
financial compensation.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods: NR

Low risk

Sealed, sequentially numbered envelopes

Low risk

Double-blind, double-dummy trial, identical appearance of tablets

Low risk

Self-reported outcomes from blinded participants

Unclear risk

States ITT but no method of imputation specified. Low attrition

Attrition

Total: 6/63 (9.5%)

Melatonin 10 mg: 2/21 (9.5%)

Amitriptyline 25 mg: 2/21 (9.5%)

Melatonin + amitriptyline: 2/21 (9.5%)

Selective reporting (re-
porting bias)

Low risk

Outcomes match those listed on trial registration

Other bias

Low risk

No other sources of bias were identified.

Dickens 2000 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: UK

Participants

Pain condition: low back pain

Population: adults with chronic low back pain and depression

Minimum pain intensity: NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dickens 2000  (Continued)

Inclusion criteria

Cochrane Database of Systematic Reviews

• Aged 18-65
• Chronic low back pain for > 6 months
• Significant depressive symptoms as measured with the MADRS scale
• Significant disability in daily living tasks as measured by the ODI

Exclusion criteria

• Any other significant physical or mental health condition

Total participants randomised: 98

Age in years (mean, SD): 45.2 (10.2)

Gender: 53/98 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 48
• Inert
• Identical in appearance to antidepressant

Paroxetine 20 mg

• n = 44
• SSRI
• Fixed dose

Outcomes

Pain intensity

Physical function

Mood

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: SmithKline Beecham

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation of order of treatment allocation was achieved using a comput-
er-generated randomisation list in which treatments were balanced.

Allocation concealment
(selection bias)

Low risk

Sequentially numbered treatment packs containing the medication were held
in and distributed by the hospital pharmacy. The packs were allocated to con-
secutive participants in strict sequential order.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Low risk

Double-blind, appearance of both placebo and antidepressant was identical

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Dickens 2000  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

Low risk

ITT with LOCF, but very low dropout

Attrition

Total: 6/98 (6.1%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Drossman 2003 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA and Canada

Participants

Pain condition: functional bowel disorders

Population: women with moderate to severe functional bowel disorders

Minimum pain intensity: NR

Inclusion criteria

• Women aged 18-70
• Moderate to severe abdominal pain with or without altered bowel habit (functional bowel disorder)

for at least 2 days per week for 6 months

Exclusion criteria

• Serious physical health conditions
• Schizophrenia or bipolar disorder
• Previous use of desipramine

Total participants randomised: 431

Age in years (mean, SD): 38.6 (12.0)

Gender: 431/431 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 71
• Inert
• Matched dosing

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Drossman 2003  (Continued)

Desipramine 150 mg

Cochrane Database of Systematic Reviews

• n = 144
• TCA
• Flexible dosing based on tolerability and efficacy

CBT

• n = 144
• 12 weekly hour-long sessions of CBT

Education

• n = 71
• 12 weekly hour-long pain education sessions involving reviewing symptom diaries and educational

materials from a book on functional bowel disorders

Outcomes

Pain intensity

Quality of life

Withdrawal

Missing data methods

ITT but imputation method not specified

Funding source

Non-pharmaceutical: supported by a research grant from the National Institutes of Health (RO1-
DK49334).

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Randomisation was performed by computer

Unclear risk

Allocation procedures not specified

High risk

Unable to be double-blinded across all study arms due to the nature of CBT

High risk

Self-reported outomes from unblinded participants

Unclear risk

States ITT but method not specified

Attrition

Total: 123/431 (28.5%)

Placebo: 16/72 (22.2%)

Desipramine 150 mg: 49/144 (34.0%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Drossman 2003  (Continued)

Cochrane Database of Systematic Reviews

CBT: 33/144 (22.9%)

Education: 25/71 (35.2%)

Selective reporting (re-
porting bias)

Unclear risk

Protocol registered but no outcome measures listed

Other bias

Low risk

No other sources of bias were identified

Eberhard 1988 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: Sweden

Participants

Pain condition: idiopathic pain syndromes

Population: adults with idiopathic pain syndromes

Minimum pain intensity: NR

Inclusion criteria

• Fulfilled diagnosis of idiopathic pain syndromes according to criteria given by Williams and Spitzer

(1982), comparable to somatoform pain disorder in DSM-III R

Exclusion criteria

• Major depressive disorder and other psychiatric illnesses

Total participants randomised: 70

Age in years (mean, SD): 50.3 (12.5)

Gender: 51/70 were female

Pain duration in years (range): 0.5-28

Interventions

Maprotiline 25-150 mg

• n = 30
• TeCA
• Flexible dosing dependent upon efficacy and tolerability
• Mean dose = 100 mg/day

Clomipramine 25-150 mg

• n = 40
• TCA
• Flexible dosing dependent upon efficacy and tolerability
• Mean dose = 97.2 mg/day

Outcomes

Pain intensity

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Eberhard 1988  (Continued)

Mood

Withdrawal

Missing data methods

None - completer-only analysis

Funding source

Conflicts of interest

NR

NR

Cochrane Database of Systematic Reviews

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

No information regarding sequence generation given

Unclear risk

Allocation procedures not described

Low risk

Double-blind, identical appearing tablets with matched dosing

Low risk

Self-reported outcomes from blinded participants

High risk

Completer analysis only

Attrition

Total: 18/70 (25.7%)

Maprotiline 25-150 mg: 5/30 (16.7%)

Clomipramine 25-150 mg: 13/40 (32.5%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Engel 1998 

Study characteristics

Methods

Design: cross-over

Duration: 15 weeks (6 weeks per cross-over period)

Assessment: baseline and post-intervention

Country: USA

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Engel 1998  (Continued)

Participants

Pain condition: pelvic pain

Cochrane Database of Systematic Reviews

Population: women with chronic pelvic pain

Minimum pain intensity: no

Inclusion criteria

• Aged 18-50
• Pelvic pain persisting for ≥ 3 months

Exclusion criteria

• Laparoscopy within the last 3 months

Total participants randomised: 25

Age in years (mean, SD): 29.0 (7.2)

Gender: 25/25 were female

Pain duration in years (mean, SD): NR

Placebo

• n = 25
• Inert

Sertraline 100 mg

• n = 25
• SSRI
• Fixed dose, 50 mg taken twice daily

Interventions

Outcomes

No useable data were able to be extracted from the study.

Missing data methods

Completer analysis only

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

No information on blinding procedures

Unclear risk

Self-reported outcomes but unsure of blinding procedures

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Engel 1998  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Completer analysis but low dropout

Attrition

Total: 2/25 (8%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Enomoto 2018 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Japan

Participants

Pain condition: peripheral diabetic neuropathy

Population: adults with peripheral diabetic neuropathy

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Aged 20-80
• Diagnosed with peripheral diabetic neuropathy
• ≥ 4 on 0-10 pain intensity VAS

Exclusion criteria

• Poor glycemic control
• Mental health conditions including MDD

Total participants randomised: 303

Age in years (mean, SD): 59.6 (9.03)

Gender: 83/303 were female

Pain duration in years (mean, SD): 4.59 (4.25)

Interventions

Pregabalin 300-600 mg

• n = 151
• Anticonvulsant
• Matched dosing to antidepressant arm
• Forced titration dependent upon efficacy
• Mean dose 348.7 mg/day

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Enomoto 2018  (Continued)

Duloxetine 40-60 mg

• n = 152
• SNRI
• Forced titration dependent upon efficacy
• Mean dose 42.5 mg/day

Outcomes

Pain intensity

Quality of life

Mood

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

MMRM

Funding source

Pharmaceutical: Eli Lilly Japan

Conflicts of interest

HE, SF, MT and AY are employees of Eli Lilly Japan K.K. AN is an employee of Shionogi & Co. Ltd., and
MF, MI and TT are employees and minor stockholders of Shionogi & Co. Ltd. LA is an employee of Eli
Lilly Turkey. SF and LA hold shares in Eli Lilly and Company. HY reports speaking fees from Nippon
Boehringer Ingelheim Co. Ltd., Eli Lilly Japan K.K., Shionogi & Co. Ltd., Sanwa Kagaku Kenkyusyo Co.
Ltd., and Sumitomo Dainippon Pharma Co. Ltd., and consulting fees from Shionogi & Co.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Patients were assigned to duloxetine or pregabalin in a 1:1 ratio via a comput-
er-generated random sequence.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Patients were assigned via a computer-generated random sequence using an
interactive web response system.

Double-blind, study drugs were identical in appearance and followed a
matched dosing schedule

Low risk

Self-reported outcomes from blinded participants

Unclear risk

In the statistical analysis plan in their protocol they mention they will handle
missing data and impute using LOCF and BOCF but this is not mentioned any-
where in the paper. State MMRM

Attrition

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Enomoto 2018  (Continued)

Cochrane Database of Systematic Reviews

Total: 36/303 (11.9%)

Pregabalin 300-600 mg: 21/151 (13.9%)

Duloxetine 40-60 mg: 15/152 (9.9%)

Selective reporting (re-
porting bias)

Low risk

All outcomes prospectively listed on clinicaltrials.gov before trial started

Other bias

Low risk

No other sources of bias were identified

Enteshari-Moghaddam 2019 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline to post-intervention

Country: Iran

Participants

Pain condition: knee OA

Population: adults with moderate-severe knee OA

Minimum pain intensity: ≥ 5 on 0-10 VAS

Inclusion criteria

• Aged 45-75
• ≥ 5 on 0-10 VAS for pain intensity
• ≥ 48 on WOMAC scale
• Radiographic evidence of OA

Exclusion criteria

• Physical health comorbidities

Total participants randomised: 150

Age in years (mean): 54.4

Gender: 110/150 were female

Pain duration in years (mean): 8.44

Interventions

Paracetamol 2000 mg

• n = 50
• Forced titration to fixed dose

Duloxetine 60 mg

• n = 50
• SNRI
• Forced titration to fixed dose

Gabapentin 600 mg

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Enteshari-Moghaddam 2019  (Continued)
• n = 50
• Anticonvulsant
• Forced titration to fixed dose

Outcomes

AEs

Withdrawal

Missing data methods

All participants completed the trial

Funding source

Non-pharmaceutical: Ardabil University of Medical Sciences

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Low risk

Participants were randomised using random number blocks.

Low risk

Participants were allocated to an arm using sealed, opaque envelopes.

Unclear risk

States double-blind but does not report blinding procedures

Unclear risk

Self-reported outcomes by participants, but unsure of blinding procedures

Low risk

All participants completed the trial

Attrition: none

High risk

Do not report quality of life as stated in protocol

Other bias

Low risk

No other sources of bias were found

Forssell 2004 

Study characteristics

Methods

Design: cross-over

Duration: 4 weeks

Assessment: baseline to post-intervention

Country: Finland

Participants

Pain condition: atypical facial pain

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Forssell 2004  (Continued)

Cochrane Database of Systematic Reviews

Population: adults with atypical facial pain

Minimum pain intensity: ≥ 3 on 0-10 scale

Inclusion criteria

• No clear pathology or somatic findings explaining the facial pain
• ≥ 3 on 0-10 pain intensity scale

Exclusion criteria

• Cardiac, hepatic, or renal disease

Total participants randomised: 30

Age in years (median, range): 52 (38-66)

Gender: 12/30 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 30
• Inert
• Matched dosing schedule and identical appearance to antidepressants

Venlafaxine 37.5-70 mg

• n = 30
• SNRI
• Flexible dosing based on tolerability

Outcomes

Pain intensity

Mood

Withdrawal

Missing data methods

Completer analysis only

Funding source

Non-pharmaceutical: funded by Helsinki University Central Hospital Research Fund

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised using computer-generated random numbers.

Low risk

Allocation procedure not specified

Low risk

Double-blind with identical appearance and matched dosing schedules

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Forssell 2004  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

High risk

Completer-only analysis

Attrition

Total: 10/30 (33.3%)

Venlafaxine 37.5-70 mg: 6/30 (20.0%)

Placebo: 4/30 (13.3%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Foster 2010a 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: vulvodynia

Population: women with vulvodynia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Aged 18-50
• 3 continuous months of insertional (entryway) dyspareunia, pain, or both with tampon insertion
• Mean score ≥ 4 out of 10 on NRS of pain intensity

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 133

Age in years (mean): 30.4

Gender: 133/133 were female

Pain duration in years (range): 4.4-6.5

Interventions

Placebo

• n = 33
• Inert
• Placebo tablet and cream to match intervention arms

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Foster 2010a  (Continued)

Cochrane Database of Systematic Reviews

• Matched dosing for antidepressant
• Placebo cream for lidocaine

Lidocaine 5% cream

• n = 33
• Topical local anaesthetic
• Participants also took placebo tablet to match antidepressant arm

Desipramine 150 mg

• n = 33
• TCA
• Fixed dose with forced titration
• Participants also used placebo cream to match lidocaine arm

Desipramine 150 mg and lidocaine 5% cream

• n = 34
• Combined intervention
• Fixed dose of antidepressant with forced titration

Outcomes

Pain intensity

Mood

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharamaceutical: supported by grant RO-1 HD040123-05 from the Eunice Kennedy Shriver Nation-
al Institute of Child Health and Human Development, National Institutes of Health

Conflicts of interest

The study authors did not report any potential CoIs.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using permuted block randomisation scheme
by means of a computer-based random numbers generator.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Drug assignments were determined by the Department of Biostatistics.

Low risk

Double-blind, identical-appearing pills and creams, matched dosing with ac-
tive drug treatment for both tablets and creams

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

ITT with LOCF. 4 x higher number of dropouts in desipramine+lidocaine arm
than placebo

Attrition

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Foster 2010a  (Continued)

Cochrane Database of Systematic Reviews

Total: 21/133 (15.8%)

Placebo: 2/33 (6.1%)

Lidocaine 5%: 5/33 (15.2%)

Desipramine 150 mg: 6/33 (18.2%)

Desipramine 150 mg + lidocaine 5%: 6/34 (17.7%)

Selective reporting (re-
porting bias)

Low risk

All outcomes listed prospectively on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified.

Foster 2010b 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA and Canada

Participants

Pain condition: Interstitial Cystitis/Painful Bladder Syndrome

Population: people with painful bladder pain with no prior treatment experience for IC/PBS.

Minimum pain intensity: ≥ 3 on 0-10 VAS

Inclusion criteria

• ≥ 3 on 0-10 pain intensity VAS
• ≥ 3 on 0-10 symptom score of abnormal urinary frequency VAS
• No prior significant treatment for IC/PBS

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 271

Age in years (median): 38

Gender: 216/271 were female

Pain duration in years (mean): 6.4

Interventions

Placebo

• n = 136
• Inert
• Matched dosing schedule

Amitriptyline 25-75 mg

• n = 135
• TCA

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Foster 2010b  (Continued)

• Flexible dosing based on tolerability

Outcomes

Pain intensity

AEs

Withdrawal

Missing data methods

ITT but do not specify missing data methods

Funding source

Non-pharmaceutical: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), collab-
orator: University of Pennsylvania

Conflicts of interest

Dr Foster reports having no conflicts. Dr Hanno reports Astellas, Pfizer, and Trillium. Dr Nickel reports
receiving consulting fees from Merck, Glaxo-Smith-Kline, Pfizer, Ortho Women's Health, Farr Labs, Wat-
son, Medtronic, NeurAxon, Genyous Biomed and research support from Merck, Glaxo-Smith Kline, Aller-
gan, Watson, Pfizer and American Medical Systems. Dr C. Yang reports Medtronic. Dr Chai reports Pfizer
and Allergan. Dr Kusek reports holding stock in deCode Genetics. No other potential COI relevant to this
manuscript was reported.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

States double-blind but no information given regarding study drug appear-
ance

Unclear risk

Self-reported outcomes from participants but unsure of blinding procedures

Unclear risk

State ITT but no imputation methods specified

Attrition

Total: 40/271 (14.8%)

Placebo: 17/136 (12.5%)

Amitriptyline 25-75 mg: 23/135 (17.0%)

Selective reporting (re-
porting bias)

High risk

Primary outcome reported according to protocol, not all secondary outcomes
reported. Added new outcomes into the outcome measures under methods
but never report the outcome for these.

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Frakes 2011 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline to post-intervention

Country: USA and Puerto Rico

Participants

Pain condition: knee OA

Population: adults over 40 with OA who have not responded to NSAIDs

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria:

• Aged ≥ 40
• Met ACR diagnostic criteria for knee OA
• Knee pain for at least 14 days/month in the 3 months preceding study
• Use of oral NSAIDs for knee pain on most days

Exclusion criteria

• Physical health comorbidities

Total participants randomised: 524

Age in years (mean, SD): 61 (9.2)

Gender: 299/524 were female

Pain duration in years (mean, SD): 9.5 (8.9)

Interventions

Placebo

• n = 260
• Inert

Duloxetine 60-120 mg

• n = 264
• SNRI
• Forced titration to fixed doses
• At week 3 of active treatment, participants who had a mean average pain severity rating of at least 4

during the previous week had a blinded dose escalation to 120 mg/day.

Outcomes

Pain intensity

Moderate pain relief

Substantial pain relief

Physical function

Mood

Sleep

PGIC

AEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Frakes 2011  (Continued)

SAEs

Withdrawal

Missing data methods

ITT, modified ITT, BOCF, LOCF, MMRM

Funding source

Pharmaceutical: Eli Lilly

Cochrane Database of Systematic Reviews

Conflicts of interest

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

"At the time this manuscript was written, E.P.F., R.C.R., and M.M.W. were full-time employees of Eli Lil-
ly and/or one of its subsidiaries and were minor stockholders of Eli Lilly and Company. M.C.H. current-
ly receives research support from the National Institutes of Health; is a consultant for Abbott Labora-
tories, Amgen, Astra-Zeneca Pharmaceutical Co., Bioiberica S.A., Bristol Myers Squibb Company, Covi-
dien, Eli Lilly and Company, EMD Serono, Inc., Genentech/Roche, Iroko Pharmaceuticals, Merck & Co.
Inc., NiCox S.A., Pfizer Inc., Pozen Inc., Rand Corporation, Smith & Nephew, TransPharma Medical Ltd,
and UCB Inc.; is a member or chair of DSMB, National Eye Institute, Novartis Pharma A.G., Savient Phar-
maceuticals Inc., and Stryker Biotech LLC; and is a member of the medical advisory board and owns
stock in Theralogixx, LLC. TDB is a full-time employee of i3 Data Services, a division of InVentiv Health
Company. She was contracted by Eli Lilly for writing services. CMRO peer reviewers may have received
honoraria for their review work. The peer reviewers on this manuscript have disclosed that they have
no relevant financial relationships."

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods were not specified

Unclear risk

Allocation procedures were not specified

Unclear risk

States double-blind but no information on drug appearance and dosing sched-
ules

Unclear risk

Self-reported outcomes from participants but unsure of blinding

Low risk

ITT with LOCF, BOCF, and mBOCF

Attrition

Total: 136/524 (30.0%)

Placebo: 61/260 (23.5%)

Duloxetine 60-120 mg: 75/264 (28.4%)

Selective reporting (re-
porting bias)

Low risk

All outcomes reported match those registered prospectively on clincaltrial-
s.gov

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gao 2010 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: China

Participants

Pain condition: diabetic peripheral neuropathy

Population: adults with diabetic peripheral neuropathy

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• ≥ 4 on 0-10 pain intensity VAS
• Daily pain for ≥ 6 months
• 3 on the clinical portion of the MNSI

Exclusion criteria

• Unstable glycemic control, any other medical condition that could compromise participation
• Risk for suicide

Total participants randomised: 215

Age in years (mean): 59.3

Gender: 14/215 were female

Pain duration in years (mean): 3.2

Interventions

Placebo

• n = 109
• Inert
• Matched to antidepressant

Duloxetine 60 to 120 mg

• n = 106
• SNRI
• Flexible dosing dependent on efficacy and tolerance

Outcomes

Pain intensity

Sleep

Mood

Quality of life

Moderate pain relief

Substantial pain relief

PGIC

AEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gao 2010  (Continued)

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Cochrane Database of Systematic Reviews

Funding source

Pharmaceutical: Eli Lilly and Boehringer Ingelheim Pharmaceuticals

Conflicts of interest

Drs Vladimir Skljarevski, Durisala Desaiah, Zhang Shu-yu, and Zhang Qi are employees and stockhold-
ers of Eli Lilly and Company. All other authors from China were the investigators and received funding
from Eli Lilly and Company for conducting this study.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind with identical placebo and matched dosing schedule

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 36/215 (16.7%)

Placebo: 17/109 (15.6%)

Duloxetine 60-120 mg: 19/106 (17.9%)

Selective reporting (re-
porting bias)

Low risk

All outcomes registered prospectively on clinicaltrials.gov

Other bias

Low risk

No other sources of bias identified

Gao 2015 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gao 2015  (Continued)

Country: China

Participants

Population: adults with diabetic peripheral neuropathy

Cochrane Database of Systematic Reviews

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• ≥ 4 on 0-10 pain intensity VAS
• Daily pain for ≥ 6 months
• 3 on the clinical portion of the MNSI

Exclusion criteria

• Unstable glycemic control, any other medical condition that could compromise participation
• Mental health conditions

Total participants randomised: 405

Age in years (mean, SD): 61.4 (9.5)

Gender: 223/405 were female

Pain duration in years (mean, SD): 3.3 (3.6)

Interventions

Placebo

• n = 202
• Inert
• Matched dosing

Duloxetine 60 mg

• n = 203
• SNRI
• Fixed dose with forced titration

Outcomes

Pain intensity

Physical function

Sleep

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

MMRM, ITT with LOCF

Funding source

Pharmaceutical: Eli Lilly

Conflicts of interest

Drs Gao, Guo, Han, Li, Yang, and Qu have no conflicts of interest. Drs Due~nas, Yue, Wang, Skljarevski,
and Raskin are employees and minor shareholders of Eli Lilly

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gao 2015  (Continued)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

States double-blind but no information regarding study drugs appearance etc

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

High risk

ITT with LOCF

Attrition

Total: 56/405 (13.2%)

Placebo: 26/202 (12.9%)

Duloxetine 60 mg: 30/203 (14.8%)

Selective reporting (re-
porting bias)

Low risk

All outcomes listed prospectively to trial on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified

Gillving 2021 

Study characteristics

Methods

Design: Denmark

Duration: 5 weeks

Assessment: baseline and post-intervention

Country: cross-over

Participants

Pain condition: painful polyneuropathy of any aetiology

Population: people with painful polyneuropathy

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria:

• Polyneuropathy for > 6 months
• Polyneuropathy diagnosis confirmed by clinical signs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gillving 2021  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria:

• Physical health comorbidities
• ≥ 20 on the BDI

Total participants randomised: 51

Age in years (median, range): 59 (20-76)

Gender: 22/51 were female

Pain duration in years (median, range): 40 (10-156)

Interventions

Placebo

• n = 38
• Inert
• Matched appearance to intervention drugs, and matched dosing

Terbutaline 5-15 mg

• n = 41
• b2-agonist
• Flexible dosage dependent on whether participants were metabolisers and ≥ 70 years of age
• Mean dose: 14.4 mg/day

Imipramine 30-150 mg

• n = 44
• TCA
• Flexible dosing dependent on whether participants were metabolisers and ≥ 70 years of age
• Mean dose: 85.1 mg/day

Outcomes

Pain intensity

Quality of life

Sleep

Substantial pain relief

Moderate pain relief

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: grants from Danish Regions (Grant no. 14/217) and the Research Foundation of
Odense University Hospital. S.S. Gylfadottir was funded by a grant from the Novo Nordic Foundation
(Grant no. 14OC0011633).

Conflicts of interest

The study authors have no conflicts of interest to declare

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gillving 2021  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised through a computer-generated randomisation
list.

Allocation concealment
(selection bias)

Low risk

Participants were consecutively allocated to the next available randomisa-
tion number. The study drugs were packed in containers marked with a ran-
domisation number and treatment period by the hospital pharmacy. Sealed,
opaque envelopes containing the treatment sequence for each participant
were present at the study sites for emergency situations.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs and double-dummy design

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 12/51 (23.5%)

Placebo: 3/51 (5.9%)

Terbutaline 5-15 mg: 5/51 (9.8%)

Imipramine 30-150 mg: 4/51 (7.8%)

Selective reporting (re-
porting bias)

Low risk

Trial registered prospectively and outcomes matched those registered

Other bias

Low risk

No other sources of bias were identified

Gilron 2009 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: Canada

Participants

Pain condition: neuropathic pain from diabetic peripheral neuropathy or post-herpetic neuralgia

Population: adults with diabetic polyneuropathy or post-herpetic neuralgia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• diagnoses of either diabetic peripheral neuropathy or post-herpetic neuralgia
• ≥ 4 on 0-10 pain intensity VAS

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gilron 2009  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

• Physical and mental health comorbidities

Total participants randomised: 56

Age in years (median, range): diabetic peripheral: 61 (53-69); post-herpetic: 68 (65-73)

Gender: 21/56 were female

Pain duration in years (median, range): diabetic peripheral: 5.2 (3.4); post-herpetic: 2.8 (4.3)

Interventions

Gabapentin ≤ 3600 mg

• n = 51
• Anticonvulsant
• Flexible dosing dependent on tolerability
• Double-dummy design

Nortriptyline ≤ 100 mg

• n = 51
• TCA
• Flexible dosing dependent on tolerability
• Double-dummy design

Nortriptyline ≤ 100 mg and gabapentin ≤ 3600 mg

• n = 51
• Combined intervention: TCA + anticonvulsant
• Flexible dosing dependent on tolerability
• Double-dummy design

Outcomes

Pain intensity

Sleep

Mood

Physical fucntion

SAEs

Withdrawal

Missing data methods

ITT but no method specified

Funding source

Non-pharmaceutical: Canadian Institutes of Health Research (grant numbers MCT-69422 and
MSH-55041)

Conflicts of interest

IG has received honoraria for consulting or being a member of an advisory board, or both for Pfizer.
RLH has received research grant support from Pfizer. All other authors declare that they have no con-
flicts of interest.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gilron 2009  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using computer randomisation of the 3 se-
quences in blocks of 3.

Allocation concealment
(selection bias)

Low risk

A trial pharmacist prepared a concealed allocation schedule, and the pharma-
cist had no further involvement in the trial. Patients were assigned in turn to
the next consecutive number, and the corresponding series of study drugs was
dispensed.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, double-dummy design

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF, unequal dropout

Attrition

Total: 11/56 (19.6%)

Gabapentin ≤ 3600 mg: 8/56 (14.3%)

Nortriptyline ≤ 100 mg: 1/56 (1.8%)

Gabapentin ≤ 3600 mg + nortriptyline ≤ 100 mg: 2/56 (3.6%)

Selective reporting (re-
porting bias)

Unclear risk

Can't find global pain relief reported in study (was stated in prospective
ISRCTN registration). In the protocol, the Profile of Mood State questionnaire
was listed as a secondary outcome but it is NR.

Other bias

Low risk

No other sources of bias identified

Gilron 2015 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline to post-intervention

Country: Canada

Participants

Pain condition: any chronic neuropathic pain

Population: adults with chronic peripheral neuropathic pain

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Peripheral neuropathy for at least 6 months
• ≥ 4 on 0-10 pain intensity VAS

Exclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gilron 2015  (Continued)

• Physical or mental health comorbidities

Total participants randomised: 52

Age in years (median, range): 66 (49-80)

Gender: 14/52 were female

Pain duration in years (mean, SD): 6.1 (6.4)

Interventions

Morphine ≤ 100 mg

• n = 52
• Analgesic
• Flexible dosing dependent on tolerability
• Mean dose: 65.4 mg/day

Nortriptyline

• n = 52
• TCA
• Flexible dosing dependent on tolerability
• Mean dose: 83.9 mg/day

Nortriptyline and morphine

• n = 52
• Combined intervention: TCA and analgesic
• Flexible dosing dependent on tolerability
• Mean dose: 60.2 mg/day

Outcomes

Pain intensity

Mood

Sleep

Moderate pain relief

Substantial pain relief

Withdrawal

Missing data methods

NR

Part funded by pharmaceutical: "This work was supported by CIHR (Canadian Institutes of Health Re-
search) Grant #MCT-94187 and a CIHR-Pfizer Rx&D Collaborative Research Investigator Program (CIHR
Grant #MSH-55041)."

I. Gilron has received support from Adynxx, TARIS Biomedical, AstraZeneca, Pfizer, and Johnson &
Johnson and has received grants from the Canadian Institutes of Health Research, Physicians' Services
Incorporated Foundation, and Queen's University. R. R. Holden has received research funding from the
Canadian Institutes of Health Research, the Social Sciences and Humanities Research Council of Cana-
da, the American Foundation for Suicide Prevention, and Queen's University. A. C. Jackson has received
grants from the Canadian Institutes of Health Research, Research Manitoba (formerly the Manitoba
Health Research Council), and the University of Manitoba. The remaining authors have no conflicts of
interest to declare.

Funding source

Conflicts of interest

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gilron 2015  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using computer randomisation of the 3 se-
quences in blocks of 3.

Allocation concealment
(selection bias)

Low risk

A trial pharmacist prepared a concealed allocation schedule, and the pharma-
cist had no further involvement in the trial. Patients were assigned in turn to
the next consecutive number, and the corresponding series of study drugs was
dispensed.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, double-dummy design

Low risk

Self-reported outcomes from blinded participants

High risk

Unequal attrition across arms, states ITT but no imputation methods specified

Attrition

Total: 16/52 (30.8%)

Morphine: 9/52 (17.3%)

Nortriptyline ≤ 100 mg: 2/52 (3.9%)

Nortriptyline + morphine: 7/52 (13.5%)

Selective reporting (re-
porting bias)

Low risk

All outcomes prospectively reported on ISRCTN.com

Other bias

Low risk

No other sources of bias were identified

Gilron 2016 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: Canada

Participants

Pain condition: fibromyalgia

Population: people with fibromyalgia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Aged 18-70
• Fibromyalgia that matches the ACR criteria
• ≥ 4 on 0-10 pain intensity VAS

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gilron 2016  (Continued)

Exclusion criteria

• Physical health comorbidity
• Severe mood disorder

Total participants randomised: 41

Age in years (median, range): 56 (20-71)

Gender: 36/41were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 41
• Inert
• Identical appearance and matched dosing schedule
• Double-dummy design

Pregabalin ≤ 450 mg

• n = 41
• Anticonvulsant
• Forced titration to maximum tolerated dose or ceiling dose
• Double-dummy design

Duloxetine ≤ 120 mg

• n = 41
• SNRI
• Forced titration to maximum tolerated dose or ceiling dose
• Double-dummy design

Pregabalin ≤ 450 mg + duloxetine ≤ 120 mg

• n = 41
• Anticonvulsant + SNRI
• Forced titration to maximum tolerated dose or ceiling dose
• Double-dummy design

Outcomes

Pain intensity

Quality of life

Physical function

Mood

Sleep

Withdrawal

Missing data methods

NR

Funding source

Part funded by pharmaceutical: "This work was supported by CIHR (Canadian Institutes ofHealth) Grant
CIHR-MOP-106489 and a CIHR-Pfizer R&D Collaborative Research Investigator Program (CIHR Grant
MSH-55041)."

Conflicts of interest

I. Gilron has received support from Adynxx, Taris Biomedical, Astra Zeneca, Pfizer, and Johnson & John-
son and has received grants from the Canadian Institutes of Health Research, Physicians' Services In-

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gilron 2016  (Continued)

Cochrane Database of Systematic Reviews

corporated Foundation, and Queen's University. L. E. Chaparro received a John J. Bonica Training Fel-
lowship from the International Association for the Study of Pain and also financial support from the
Queen's University Department of Anesthesiology and Perioperative Medicine. R. R. Holden has re-
ceived research funding from the Canadian Institutes of Health Research, the Social Sciences and Hu-
manities Research Council of Canada, the American Foundation for Suicide Prevention, and Queen's
University. R. Milev has received financial support and research grants from CIHR, Ontario Brain Insti-
tute, Ontario Mental Health Foundation, Lundbeck, Lilly, Sunovion, BMS, Otsuka, Pfizer, Paladin, and
Merck. T. Towheed has received financial support from Abbvie and Bristol-Meyers-Squibb and research
funding from the Canadian Institutes of Health Research. D. D. Shore. and S. Walker received no exter-
nal financial support.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using computer randomisation of the 3 se-
quences in blocks of 3.

Allocation concealment
(selection bias)

Low risk

A trial pharmacist prepared a concealed allocation schedule, and the pharma-
cist had no further involvement in the trial. Patients were assigned in turn to
the next consecutive number, and the corresponding series of study drugs was
dispensed.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, matched dosing schedule and double dummy design

Low risk

Self-reported outcomes from blinded participants

Unclear risk

No information on missing data methods

Attrition

Total: 8/41 (19.5%)

Placebo: 1/41 (2.4%)

Pregabalin ≤ 450 mg: 1/41 (2.4%)

Duloxetine ≤ 120 mg: 3/41 (7.32%)

Selective reporting (re-
porting bias)

Low risk

Everything as reported in prospectively registered protocol

Pregabalin ≤ 450 mg + duloxetine ≤ 120 mg: 4/41 (9.76%)

Other bias

High risk

Taper and washout period were combined, only 1 day complete washout.
They state that "primary analysis revealed no significant effects of sequence or
carryover, but effects of period and treatment were significant".

Ginsberg 1996 

Study characteristics

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ginsberg 1996  (Continued)

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline, 4 weeks (halfway point), post-intervention

Country: Belgium

Participants

Pain condition: fibromyalgia

Cochrane Database of Systematic Reviews

Population: people with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Fibromyalgia meeting the ACR 1990 criteria
• History of widespread pain for at least 3 months
• Pain in at least 11 of 18 specific tender points

Exclusion criteria

• Physical health comorbidities

Total participants randomised: 51

Age in years (mean): 46

Gender: 38/51 were female

Pain duration in years (mean): 3.2

Interventions

Placebo

• n = 22 (completers)
• Inert
• Identical appearance and matched dosing schedule

Amitriptyline 25 mg

• n = 24 (completers)
• TCA
• Fixed dose with no titration

Outcomes

Pain intensity

Sleep

AEs

Withdrawal

Missing data methods

ITT but no information regarding imputation methods given

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ginsberg 1996  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

No information given, just says patients were "randomised"

Unclear risk

Allocation procedures not specified

Unclear risk

Double-blind, identical study drugs and matched dosing

Low risk

Self-reported outcomes from blinded participants

Unclear risk

State ITT but no imputation methods reported

Attrition

Total: 6/51 (11.8%)

Placebo: 3/25 (12.0%)

Amitriptyline 25 mg: 3/26 (11.5%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Ginsberg 1998 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Assessment: baseline and post-intervention

Country: Belgium

Participants

Pain condition: fibromyalgia

Population: people with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Aged between 18 and 75
• Fibromyalgia meeting the ACR 1990 criteria
• History of widespread pain for at least 3 months
• Pain in at least 11 of 18 specific tender points

Exclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ginsberg 1998  (Continued)

• Physical health comorbidities

Total participants randomised: 100

Age in years (mean): 39.8

Gender: 85/100 were female

Pain duration in months (mean): 34.7

Interventions

Placebo

• n = 50
• Inert
• Matched dosing

Pirlindole 150 mg

• n = 50
• Reversible MAOI
• Fixed dose

Outcomes

Pain intensity

Mood

AEs

Withdrawal

Missing data methods

Funding source

Conflicts of interest

NR

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

States double-blind, but no information regarding study drugs' appearance

Unclear risk

Self-reported outcomes from participants, but unsure of blinding

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer analysis only. Unclear with number randomised, completer analy-
sis and no clear explanation of when and who withdrew.

Attrition

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ginsberg 1998  (Continued)

Total: 39/100 (39.0%)

Placebo: 22/44 (50.0%)

Pirlindole 150 mg: 17/45 (37.8%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Goldenberg 1986 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Fibromyalgia matching criteria reported by Yunus 1983
• At least 3 months' duration
• ≥ 4 on 0-10 pain intensity VAS

Exclusion criteria

• History of peptic ulcer disease or cardiac arrhythmias

Total participants randomised: 62

Age in years (mean, range): 43.8 (21-69)

Gender: 59/62 were female

Pain duration in years (mean, range): 3.5 (0.25-20)

Interventions

Amitriptyline 50 mg + naproxen 1000 mg

• n = NR
• Combined intervention: TCA + NSAID
• Fixed doses

Placebo + naproxen 1000 mg

• n = NR
• NSAID
• Fixed dose
• Double-dummy design

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goldenberg 1986  (Continued)

Cochrane Database of Systematic Reviews

Amitriptyline 50 mg + placebo

• n = NR
• TCA
• Fixed dose
• Double-dummy design

Placebo + placebo

• n = NR
• Double dummy to match intervention arms

Outcomes

Withdrawal

Missing data methods

Completer analysis

Funding source

Partly pharmaceutical: supported by grants from the Arthritis Foundation, Multipurpose Arthritis Cen-
ter grant no. AM-20613, and a clinical investigator grant from Syntex Co.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

Double-dummy design, but no information on study drug appearance and
dosing

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Low risk

Completer analysis but very low dropout

Attrition

Total: 4/62 (6.5%)

Attrition per arm NR

Selective reporting (re-
porting bias)

High risk

Only present the data for the groups that had significant differences. No proto-
col or trial registration found

Other bias

Low risk

No other sources of bias were identified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goldenberg 1996 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 30 on 0-100 VAS

Inclusion criteria

• Aged 18-60
• Fibromyalgia that matches ACR criteria
• ≥ 30 on 0-100 pain intensity VAS

Exclusion criteria

• Physical health comorbidities
• Depression: ≥ 18 on Hamilton Rating Scale for Depression

Total participants randomised: 31

Age in years (mean, SD): 43.2 (9.1)

Gender: 28/31 were female

Pain duration/fibromyalgia symptoms in months (mean, SD): 72.6 (48.1)

Interventions

Placebo

• Inert
• Double-dummy design = 2 tablets per day

Amitriptyline 25 mg + placebo

• TCA
• Fixed dose
• Double-dummy design

Fluoxetine 20 mg + placebo

• SSRI
• Fixed dose
• Double-dummy design

Amitriptyline 25 mg + fluoxetine 20 mg

• Combined intervention: TCA + SSRI
• Fixed doses
• Double dummy design

Outcomes

Pain intensity

Quality of life

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goldenberg 1996  (Continued)

Sleep

Mood

Withdrawal

Cochrane Database of Systematic Reviews

Missing data methods

Completer analysis only

Funding source

Non-pharmaceutical: Lot Page Fund, Newton-Wellesley Hospital, Newton

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised using a table of random numbers

Low risk

Randomisation and allocation was performed in the hospital pharmacy

Low risk

Identical tablets and double-dummy to match dosing schedules across groups

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer-only analysis, unequal attrition across arms and high overall
dropout

Attrition

Total: 12/31 (38.7%)

Placebo: 1/31 (3.2%)

Amitriptyline 25 mg: 1/31 (3.2%)

Fluoxetine 20 mg: 4/31 (12.9%)

Amitriptyline 25 mg + fluoxetine 20 mg: 5/31 (16.1%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Goldman 2010 

Study characteristics

Methods

Design: parallel

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goldman 2010  (Continued)

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: arm pain

Cochrane Database of Systematic Reviews

Population: people with persistent arm pain from repetitive use

Minimum pain intensity: ≥ 3 on 0-10 VAS

Inclusion criteria

• Adults with persistent arm pain that had lasted for at least 3 weeks
• ≥ 3 on 0-10 pain intensity VAS

Exclusion criteria

• Physical health conditions that may affect arm pain

Total participants randomised: 118

Age in years (mean): 37.5

Gender: 66/118 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 59
• Inert
• Identical appearance to antidepressant arm
• Matched dosing

Amitriptyline 25 mg

• n = 59
• TCA
• Fixed dose
• If participants complained of side effects during the study, the physician could reduce the dose by

half or more

Outcomes

Pain intensity

Sleep

Mood

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: "This study was supported by Grants 1RO1 AT 00402-01 and 1K24 AT 004095 from
the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of
Health, USA"

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Goldman 2010  (Continued)

Conflicts of interest

Notes

Risk of bias

Bias

"No author had or now has any financial interest in any for-profit organisation related to the treatment
of patients with repetitive strain injuries or related disabling conditions. Dr Rose Goldman sometimes
serves as a paid expert witness, independent medical examiner, and/or consultant in workers' com-
pensation and disability cases that might involve musculoskeletal problems and repetitive strain in-
juries."

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using a permuted block randomisation design

Allocation concealment
(selection bias)

Low risk

Participants were allocated using assignments sealed in sequentially num-
bered opaque envelopes

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs and matched dosing

Low risk

Self-reported outcomes from blinded participants

Low risk

ITT with LOCF but low attrition

Attrition

Total: 12/118 (10.2%)

Placebo: 4/59 (6.8%)

Amitriptyline 25 mg: 8/59 (13.6%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Goldstein 2005 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: painful diabetic neuropathy

Population: people with painful diabetic neuropathy

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goldstein 2005  (Continued)

Cochrane Database of Systematic Reviews

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Daily pain due to diabetic polyneuropathy present for at least 6 months
• ≥ 4 on 0-10 pain intensity VAS
• ≥ 3 on MNSI

Exclusion criteria

• Physical health comorbidities
• Mental health comorbidies, including a diagnosis of MDD

Total participants randomised: 457

Age in years (mean, SD): 60.1 (10.9)

Gender: 176/457 were female

Pain duration in years (mean, SD): 3.7 (3.8)

Interventions

Placebo

• n = 115
• Inert

Duloxetine 20 mg

• n = 115
• SNRI
• Fixed dose

Duloxetine 60 mg

• n = 114
• SNRI
• Fixed dose

Duloxetine 120 mg

• n = 113
• SNRI
• Fixed dose

Outcomes

Pain intensity

Physical function

Quality of life

Mood

Substantial pain relief

PGIC

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: Eli Lilly and Company and PRN Consulting

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Goldstein 2005  (Continued)

Conflicts of interest

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors are employees and/or stockholders of Eli Lilly and Company. David J. Goldstein, MD, PhD, is a
consultant for Eli Lilly and Company

Authors' judgement

Support for judgement

Low risk

Participants were randomised using a computer-generated random sequence.

Low risk

Participants were allocated using an Interactive Voice Response System.

Unclear risk

No information given on blinding procedures in regard to medication, al-
though reported as double-blinded

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Unclear risk

ITT with LOCF

Attrition

Total: 113/457 (24.7%)

Placebo: 28/115 (24.4%)

Duloxetine 20 mg: 24/115 (20.9%)

Duloxetine 60 mg: 28/114 (24.6%)

Duloxetine 120 mg: 33/113 (29.2%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

González-Viejo 2005 

Study characteristics

Methods

Design: parallel

Duration: physical therapy 3 weeks; sertraline 24 weeks

Assessment: baseline and post-intervention

Country: Spain

Participants

Pain condition: fibromyalgia

Population: women with fibromyalgia

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

González-Viejo 2005  (Continued)

Cochrane Database of Systematic Reviews

Minimum pain intensity: no

Inclusion criteria

• Fibromyalgia as per the ACR criteria
• Duration ≥ 6 months

Exclusion criteria

• Hypertension and pregnancy
• Use of antidepressants for at least 4 weeks

Total participants randomised: 70

Age in years (mean, SD): 47.5 (4)

Gender: 70/70 were female

Pain duration in years (mean, SD): NR

Interventions

Physical therapy

• n = 34
• 15 sessions over 3 weeks
• Participants received physiotherapy treatment, learning and practicing physiotherapy exercises for
the cervical spine. They also received ultrasonography (1 W/cm2) on painful points in the cervical area.

Sertraline 50 mg

• n = 36
• SSRI
• 24 weeks
• Fixed dose

Outcomes

Pain intensity

Sleep

Withdrawal

Missing data methods

All participants completed the trial

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

High risk

Unable to be double-blind due to the nature of interventions

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

204

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

González-Viejo 2005  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Self-reported outcomes from unblinded participants

Low risk

All participants completed the trial

Attrition

None

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Goodkin 1990 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Population: adults with low back pain

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Minmum of 1 year of back pain or 2 prior episodes low back pain of at least 2 weeks in duration with

a current episode of at least 2 weeks

• ≥ 4 on 0-10 pain intensity VAS

Exclusion criteria

• ≥ 4 additional pain sites
• Physical and mental health comorbidities

Total participants randomised: 42

Age in years (mean, SD): 53.6 (12.9)

Gender: 16/42 were female

Pain duration in years (mean, SD): 20.3 (16.0)

Interventions

Placebo

• n = 20
• Inert
• Identical appearance and taste, and matched dosing schedule

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goodkin 1990  (Continued)

Trazodone ≤ 600 mg

• n = 22
• SARI
• Forced titration to maximum tolerable dose
• Mean dose: 201 mg/day

Outcomes

Pain intensity

Physical function

Mood

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Partly funded by pharmaeutical: "This work was supported by NIH grants MH18764 and MH16744 and
NIMH Mental Health Clinical Research Center grant MH41115, a grant from the Procter and Gamble
Company, a grant from the Stanford University Health Sciences Research and Development Fund, and
a grant from the Western Research and Development Office of the Veterns Administration."

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Low risk

Low risk

Participants were randomised to either trazodone or placebo groups by the
Stanford University pharmacist who never interacted with participants

Double-blind, identical appearance of study drugs and matched dosing sched-
ule

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 13/42 (31.0%)

Placebo: 4/20 (20.0%)

Trazodone ≤ 600 mg: 9/22 (40.9%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gould 2020 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Population: adults with low back pain

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Aged 18-70
• Non-specific low back with a duration of least ≥ 6 months
• ≥ 4 on a 0-10 pain intensity VAS

Exclusion criteria

• Current physical or mental health comorbidities

Total participants randomised: 142

Age in years (mean, SD): 55.8 (11.7)

Gender: 15/142 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo (benzotropine mesylate 0.125 mg)

• n = 33
• Active placebo
• Fixed dose

Desipramine

• n = 38
• TCA
• Flexible dosage dependent upon patient metabolism

Placebo (benzotropine mesylate 0.125 mg) + CBT

• n = 34
• Combined intervention: active placebo pill + CBT
• Fixed dose of 0.125 mg
• 6 CBT appointments over the course of 8 weeks

Desipramine + CBT

• n = 37
• Combined intervention: TCA + CBT
• Flexible dosage dependent upon patient metabolism
• 6 CBT appointments over the course of 8 weeks

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

207

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gould 2020  (Continued)

Outcomes

Pain intensity

Physical function

Moderate pain relief

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: VA Office of Research and Development Collaborator: University of California,
San Diego

Conflicts of interest

The study authors have no conflicts of interest to declare

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

To minimise the risk of bias in treatment assignment, randomisation using
a random number generator (www.randomizer.org) was conducted by a VA
San Diego Healthcare System Clinical Research Pharmacy (author S.D.F.), who
alone held the key

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures not specified

High risk

Double-blinding across all arms not possible due to the nature of CBT

High risk

Self-reported outcomes from unblinded participants

High risk

ITT with LOCF. Attrition unequal across arms

Attrition

Total:

Placebo: 9/33 (27.3%)

Desipramine 20-60 mg: 11/38 (29.0%)

Placebo + CBT: 7/34 (20.6%)

Desipramine 20-60 mg + CBT: 16/37 (43.2%)

Selective reporting (re-
porting bias)

Unclear risk

Mention in published paper that other outcomes were measured and report-
ed in the protocol (which they don't seem to be) and that they were NR in the
publication as it was not in keeping with the study hypothesis/aim

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

208

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gould 2020  (Continued)

Other bias

Low risk

No other sources of bias were identified

Grace 1985 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline, 4 weeks, 8 weeks, and post-intervention

Country: Canada

Participants

Pain condition: RA

Population: adults with RA

Minimum pain intensity: no

Inclusion criteria

• Patients with 'definite' or 'classical' RA, as defined by the ACR criteria

Exclusion criteria: NR

Total participants randomised: 36

Age in years (mean, range): 58 (27-76)

Gender: 29/36 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 18
• Inert
• Identical appearance to antidepressants

Amitriptyline 50-75 mg

• n = 18
• TCA
• Flexible doses dependent upon tolerability

Outcomes

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

209

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Grace 1985  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical tablets with matched dosing

Low risk

Self-reported outcomes by blinded participants

High risk

Completer analysis only

Attrition

Total: 8/36 (22.2%)

Placebo: 4/18 (22.2%)

Amitriptyline 50-75 mg: 4/18 (22.2%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Graff-Radford 2000 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline to post-intervention

Country: USA

Participants

Pain condition: post-herpetic neuralgia

Population: adults with post-herpetic neuralgia

Minimum pain intensity: no

Inclusion criteria

• Post-herpetic neuralgia for at least 6 months

Exclusion criteria: NR

Total participants randomised: 50

Age in years (mean, SD): 72.9 (10.1)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Graff-Radford 2000  (Continued)

Gender: 22/50 were female

Pain duration in months (mean, SD): 33.4 (29.5)

Interventions

Amitriptyline ≤ 200 mg

• n = 11
• TCA
• Flexible dose dependent upon tolerability
• Double-dummy design

Amitriptyline ≤ 200 mg + fluphenazine ≤ 3 mg

• n = 12
• Combined intervention: TCA + antipsychotic
• Flexible doses dependent upon tolerability

Fluphenazine ≤ 3 mg

• n = 13
• Antipsychotic
• Flexible dose dependent upon tolerability

Placebo (glycopyrrolate)

• n = 13
• Active placebo
• Flexible dose dependent upon tolerability
• Double-dummy design

Outcomes

Pain intensity

Mood

Withdrawal

Missing data methods

Completer analysis only

Funding source

Non-pharmaceutical: "This study was supported by a grant from the National Institute of Health/Na-
tional Institute of Dental Research (1RO3DE10086-01)"

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical appearing study drugs, double-dummy design

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Graff-Radford 2000  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

Low risk

Completer analysis but only 1 person withdrew

Attrition

Total: 1/50 (2.0%)

Amitriptyline 12.5-200 mg: 1/12 (8.3%)

Amitriptyline 12.5-200 mg + fluphenazine 1-3 mg: 0/12 (0.0%)

Fluphenazine 1-3 mg: 0/13 (0.0%)

Placebo: 0/13 (0.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Hadianfard 2012 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline, 2 weeks, 4 weeks, post-intervention, follow-up (10 months post-intervention)

Country: Iran

Participants

Pain condition: fibromyalgia

Population: women ≤ 65 with fibromyalgia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Women aged 20-65
• Diagnosed with fibromyalgia as per ACR criteria
• ≥ 4 on 0-10 pain intensity scale

Exclusion criteria

• Significant physical and mental health comorbidities

Total participants randomised: 30

Age in years (mean): 44

Gender: 30/30 were female

Pain duration in months (mean): 81.2

Interventions

Acupuncture

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

212

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hadianfard 2012  (Continued)

• n = 15
• 2 weeks of 3 sessions (weekly) lasting for 30 min in each session

Cochrane Database of Systematic Reviews

Outcomes

Fluoxetine 20 mg

• n = 15
• SSRI
• Fixed dose

Pain intensity

Quality of life

Mood

Physical function

Missing data methods

ITT but methods not specified

Funding source

Non-pharmaceutical: Shiraz University of Medical Sciences research project No. 88-5035

Conflicts of interest

"We declare no conflict of interest. This article is from Shiraz University of Medical Sciences research
project No. 88-5035"

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation was performed using a computer-generated random sequence
of the numbers

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures not specified

High risk

Not blinded. Lead author was the acupuncturist

High risk

Self-reported outcomes from unblinded participants

Unclear risk

States ITT but no imputation methods reported

Attrition

NR

Selective reporting (re-
porting bias)

Unclear risk

Protocol registered retrospectively

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

213

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hameroff 1984 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Cochrane Database of Systematic Reviews

Participants

Pain condition: chronic cervical and/or lumbar spine pain

Population: adults with chronic cervical and/or lumbar spine pain and depression

Minimum pain intensity: no

Inclusion criteria

• Patients with chronic cervical and/or lumbar spine pain and co-existing clinical depression
• Pain for at least 2 months

Exclusion criteria: NR

Total participants randomised: 60

Age in years (mean): 48.7

Gender: 28/60 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 30
• Inert

Doxepin ≤ 300 mg

• n = 30
• TCA
• Flexible dose dependent upon tolerability and effficacy

Outcomes

Withdrawal

Missing data methods

Funding source

Conflicts of interest

NR

NR

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information, just says "patients were randomly assigned to one of two
treatment groups"

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hameroff 1984  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedures not specified

Unclear risk

Says double-blind but no information regarding procedures

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Only report completer analysis. 50% more dropout in placebo arm than inter-
vention

Attrition

Total: 9/60 (15.0%)

Placebo: 6/30 (20.0%)

Doxepin ≤ 300 mg: 3/30 (10.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Hammody 2015 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline, week 4, week 8, post-intervention

Country: Iraq

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Patients with fibromyalgia fulfilling the Wolfe 2010 criteria

Exclusion criteria

• Inflammatory conditions and cardiovascular problems

Total participants randomised: 123

Age in years (mean, SD): NR

Gender: NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

215

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hammody 2015  (Continued)

Pain duration in years (mean, SD): NR

Interventions

Pregabalin 75 mg

• n = 62
• Anticonvulsant
• Fixed dose, no titration

Amitriptyline 25 mg

• n = 61
• TCA
• Fixed dose, no titration

Pain intensity

Quality of life

Outcomes

Missing data methods

Funding source

Conflicts of interest

NR

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

States double-blind, but no information regarding blinding procedures

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

High risk

High attrition, analysis of per-protocol population

Attrition

Total: 45/123 (36.6%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

High risk

Poorly reported - mistakes throughout document, figures not really adding up
and tables wrongly titled

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

216

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hannonen 1998 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Finland

Participants

Pain condition: fibromyalgia

Population: women with fibromyalgia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Women aged 18-65
• Fulfilling ACR criteria for fibromyalgia
• ≥ 4 out of 0-10 for pain, general health, sleep, and fatigue

Exclusion criteria

• Severe physical health problems, major depression, psychosis, obsessive compulsive disorder

Total participants randomised: 130

Age in years (mean): 48.7

Gender: 130/130 were female

Pain duration in years (mean): 8.2

Interventions

Placebo

• n = 45
• Inert
• Double-dummy design

Moclobemide 450-600 mg

• n = 43
• Reversible MAOI
• Flexible dose dependent upon efficacy
• Double-dummy design

Amitriptyline 25-37.5 mg

• n = 42
• TCA
• Flexible dose dependent upon efficacy
• Double-dummy design

Outcomes

Pain intensity

Sleep

Mood

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hannonen 1998  (Continued)

Physical function

AEs

Withdrawal

Cochrane Database of Systematic Reviews

Missing data methods

States ITT but no methods reported

Funding source

Partly supported by pharmaceutical: "The financial support by Roche Oy, Finland, is gratefully ac-
knowledged."

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods NR

Allocation concealment
(selection bias)

Low risk

The randomisation was organised centrally with sequentially numbered en-
velopes consisting of blocks of 6

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blinded, study drugs were identical, double-dummy design

Low risk

Self-reported outcomes by blinded participants

Unclear risk

States ITT but no methods reported

Attrition

Total: 38/130 (29.2%)

Moclobemide 450-600 mg: 13/43 (30.2%)

Amitriptyline 25-37.5 mg: 10/42 (23.8%)

Placebo: 15/45 (33.3%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Heymann 2001 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Heymann 2001  (Continued)

Assessment: baseline and post-intervention

Country: Brazil

Participants

Pain condition: fibromyalgia

Cochrane Database of Systematic Reviews

Population: women with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Women with fibromyalgia meeting the ACR criteria

Exclusion criteria

• Physical health comorbidities
• Use of nortriptyline or amitriptyline at any point

Total participants randomised: 118

Age in years (mean): 50.5

Gender: 118/118 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 40
• Inert
• Identical tablets, matched dosing

Amitriptyline 25 mg

• n = 40
• TCA
• Fixed dose

Nortriptyline 25 mg

• n = 38
• TCA
• Fixed dose

Outcomes

Quality of life

SAEs

Withdrawal

Missing data methods

Completer analysis

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

219

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Heymann 2001  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Participants were randomised using random number tables

Unclear risk

Allocation procedures NR

Low risk

Double-blind, all study drugs were identical in appearance and packaging

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Much higher attrition in the placebo group than intervention groups. No miss-
ing data methods; report only completer analysis

Attrition

Total: 12/118 (10.2%)

Amitriptyline 25 mg: 3/40 (7.5%)

Nortriptyline 25 mg: 2/38 (5.3%)

Placebo: 7/40 (17.5%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Holbech 2015 

Study characteristics

Methods

Design: cross-over

Duration: 5 weeks

Assessment: baseline and post-intervention

Country: Denmark

Participants

Pain condition: polyneuropathy

Population: adults with polyneuropathy

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Aged 20-85
• Polyneuropathy for > 6 months
• Median pain rating of ≥ 4 on 0-10 scale

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

220

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Holbech 2015  (Continued)

Exclusion criteria

• Pain other than polyneuropathy

Total participants randomised: 73

Age in years (mean, range): 59.3 (29-82)

Gender: 28/73 were female

Pain duration in months (mean, range): 63.5 (9 -24)

Interventions

Placebo

• Inert
• Double-dummy design

Pregabalin 300 mg

• Anticonvulsant
• Fixed dose
• Patients > 70 years were given a lower dose (150 mg)
• Double-dummy design

Imipramine 75 mg

• Antidepressant
• Fixed dose
• Patients  > 70 years were given a lower dose (25 mg)
• Double-dummy design

Pregabalin 300 mg + imipramine 75 mg

• Combined anticonvulsant and antidepressant
• Fixed doses
• Patients > 70 years were given lower doses (pregabalin 150 mg and imipramine 25 mg)
• Double-dummy design

Outcomes

Moderate pain relief

Substantial pain relief

AEs

Withdrawal

Missing data methods

ITT with LOCF and per-protocol analysis

Funding source

Conflicts of interest

Notes

Partly funded by pharmaceutical: "This was an investigator-initiated trial supported by Pfizer with a
grant of USD 52080 (grant no: WS368802). The trial was also supported by a grant from Odense Univer-
sity Hospital."

F. W. Bach reports to have been compensated as an Investigator in clinical trials on neuropathic pain
sponsored by Pfizer and Grunenthal. N. B. Finnerup reports personal fees from Pfizer, grants and per-
sonal fees from Grunenthal, personal fees from Astellas, personal fees from Norpharma, grants from
EU/EFPIA;
outside the submitted work. T. S. Jensen reports to be on Advisory Board for Pfizer, Grunenthal, and
Orion. The other authors have no conflicts of interest to declare.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Holbech 2015  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised through a computer-generated randomisation
list.

Allocation concealment
(selection bias)

Low risk

Participants were allocated using sealed, opaque envelopes containing the
treatment sequence. The randomisation plan was generated by a person at
the hospital pharmacy at Odense University Hospital, who was not otherwise
involved in the conduct of the trial.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical appearing study drugs, double-dummy design

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 23/70 (32.9%)

Placebo: 5/73 (6.9%)

Pregabalin 300 mg: 5/73 (6.9%)

Imipramine 75 mg: 4.73 (5.5%)

Pregabalin 300 mg + imipramine 75 mg: 9/73 (13.0%)

Selective reporting (re-
porting bias)

Low risk

All outcomes reported prospectively on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified

Hudson 2021 

Study characteristics

Methods

Design: parallel

Duration: 14 weeks

Assessment: baseline and post-intervention

Country: New Zealand

Participants

Pain condition: knee OA

Population: people with knee OA on a stable analgesic regime

Minimum pain intensity: ≥ 20 out of 50 on WOMAC pain subscale

Inclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hudson 2021  (Continued)

Cochrane Database of Systematic Reviews

• Primary knee OA defined according to ACR classification criteria
• ≥ 20 out of 50 on WOMAC pain subscale
• Stable analgesic regime for 2 months before study entry

Exclusion criteria

• Prior joint replacement on study knee
• Sensitivity to nortriptyline or other TCAs
• Cardiovascular conditions
• Bipolar disorder

Total participants randomised: 205

Age in years (mean): 64.5

Gender: 87/205 were female

Pain duration in years (mean): 7.6

Interventions

Placebo

• n = 103
• Inert
• Identical appearance and matched dosing schedule

Nortriptyline ≤ 100 mg

• n = 102
• TCA
• Flexible dosing dependent upon efficacy and tolerability
• Mean dose: 55.8 mg/day

Outcomes

Pain intensity

Physical function

Mood

AEs

SAE

Withdrawal

Missing data methods

Imputation using multivariate normal multiple imputation

Funding source

Non-pharmaceutical: project grant from the Health Research Council of New Zealand (reference num-
ber: 14/152).

Conflicts of interest

The authors have declared no competing interests

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised with a 1:1 allocation, computer-generated ran-
domisation list with blocks of varying size (1-4) was prepared by the study sta-
tistician (https://cran.r-project. org/web/packages/blockrand/index.html).

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

223

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hudson 2021  (Continued)

Allocation concealment
(selection bias)

Low risk

Cochrane Database of Systematic Reviews

The contracted pharmacist will determine which group of participants, A or B,
will be allocated to receive nortriptyline. The study medication (nortriptyline
or identical placebo) will be packaged in identical containers. Each container
will be pre-labelled (by the study pharmacist contracted to provide the study
medication) with a study identifier according to randomisation schedule.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Double-blind, identically appearing study drugs, matched dosing schedules

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Very low dropout with no data collection at follow- up (4/205). Multiple impu-
tation for missing data

Attrition

Total: 4/205 (2.0%)

Placebo: 1/103 (1.0%)

Nortriptyline 25-100 mg: 3/102 (2.9%)

Selective reporting (re-
porting bias)

Low risk

Published trial protocol: https://trialsjournal.biomedcentral.com/track/
pdf/10.1186/s13063-015-0961-1.pdf. All outcomes reported or reasons for no
further analysis given. Although there was an error collecting data at baseline
for the first 24 participants, this was reported and accounted for in the analy-
sis.

Other bias

Low risk

No other sources of bias were identified.

Hussain 2011 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Iraq

Participants

Pain condition: fibromyalgia

Population: people aged between 18-65 with early diagnosed fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Aged 18-65
• Primary fibromyalgia diagnosed as per ACR criteria

Exclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

224

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hussain 2011  (Continued)

• Other pathologic disorders that would interfere with the study

Total participants randomised: 101

Age in years (mean, SD): 38.8

Gender: 95/101 were female

Pain duration in years (mean, SD): NR

Interventions

Melatonin 5 mg + placebo

• n = 27
• Hormone
• Fixed dose
• Double-dummy design

Fluoxetine 20 mg + placebo

• n = 24
• SSRI
• Fixed dose
• Double-dummy design

Fluoxetine 20 mg + melatonin 3 mg

• n = 27
• Combined intervention: SSRI + hormone
• Fixed doses

Fluoxetine 20 mg + melatonin 5 mg

• n = 23
• Combined intervention: SSRI + hormone
• Fixed doses

Outcomes

Pain intensity

Quality of life

Mood

Physical function

Missing data methods

NR

Funding source

Non-pharmaceutical: the present data were abstracted from PhD theses submitted to the Department
of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad. "The authors gratefully
thank the College of Pharmacy for supporting the project."

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

225

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hussain 2011  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Allocation procedures not specified

Unclear risk

Double-dummy dosing used, but no information given regarding appearance
of capsules. Also no information regarding AEs given.

Unclear risk

Self-reported outcomes from participants, but uncertain of blinding proce-
dures

Unclear risk

No information on withdrawal. No missing data methods reported

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Isomeri 1993 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Finland

Participants

Pain condition: fibromyalgia

Population: people with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Patients fulfilling the diagnostic criteria of Yunus 1983 for primary fibromyalgic syndrome

Exclusion criteria

• Other diseases causing pain

Total participants randomised: 51

Age in years (mean): 43.7

Gender: 39/51 were female

Pain duration in years (mean): 7.9

Interventions

Physiotherapy and amitriptyline 25 mg

• n = 17
• Combined intervention: physiotherapy + TCA

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

226

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Isomeri 1993  (Continued)

Cochrane Database of Systematic Reviews

• Fixed dose of 25 mg
• Conventional physiotherapy consisting of light muscle stretching exercises only

Physical fitness training

• n = 17
• Cardiovascular fitness training

Physical fitness training and amitriptyline 25 mg

• n = 17
• Combined intervention: physical fitness training + TCA
• Physical fitness training of increasing strenuousness and amitriptyline 25 mg in the evenings
• Fixed dose

Outcomes

Withdrawal

Missing data methods

NR

Funding source

Non-pharmaceutical: supported by grants from the Rheumatism Research Foundation

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

High risk

Not able to be double-blinded due to nature of interventions. Doesn't mention
sham dosing or placebo for group not receiving amitriptyline

High risk

Self-reported outcomes from unblinded participants

High risk

Completer-only analysis, no information given about withdrawal reasons

Attrition

Total: 6/51 (11.8%)

Physiotherapy + amitriptyline 25 mg: 1/17 (5.9%)

Physical fitness training: 2/17 (11.8%)

Physical fitness training + amitriptyline 25 mg: 3/17 (17.7%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

227

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Isomeri 1993  (Continued)

Other bias

Low risk

No other sources of bias were identified.

Iwaki 2020 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Japan

Participants

Pain condition: pain in Parkinson's disease

Population: adults with Parkinson's disease experiencing associated pain

Minimum pain intensity: no

Inclusion criteria

• Aged ≥ 20 with diagnosed Parkinson's disease
• Pain associated with Parkinson's disease

Exclusion criteria

• Evidence of clinically significant disease
• Suicidal risk

Total participants randomised: 47

Age in years (mean): 68.0

Gender: 25/47 were female

Pain duration in years (mean): 2.3

Interventions

Placebo

• n = 23
• Inert
• Matched dosing

Duloxetine 40 mg

• n = 23
• SNRI
• Fixed dose

Outcomes

Pain intensity

Mood

SAEs

Withdrawal

Missing data methods

Not specified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

228

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Iwaki 2020  (Continued)

Funding source

Pharmaceutical: funding was provided by Ehime University under a contract with Shionogi & Co. Ltd
(pharmaceutical company).

Conflicts of interest

The authors have no COI to report

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures not specified

Unclear risk

States double-blinded but no information on appearance of study drugs

Unclear risk

Self-reported outcomes from participants, but uncertain of blinding proce-
dures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Much higher attrition in antidepressant arm than placebo. Unsure of imputa-
tion methods used

Attrition

Total: 9/46 (19.6%)

Placebo: 2/23 (8.7%)

Duloxetine 40 mg: 7/23 (30.4%)

Selective reporting (re-
porting bias)

Low risk

Outcomes match those in protocol

Other bias

Low risk

No other sources of bias were identified

Johansson 1979 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Assessment: baseline and post-intervention

Country: Sweden

Participants

Pain condition: chronic pain conditions

Population: people hospitalised at the Department of Neurology, University of Umeå with chronic pain
syndromes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Johansson 1979  (Continued)

Minimum pain intensity: no

Inclusion criteria

Cochrane Database of Systematic Reviews

• Pain syndromes of at least 6 months with a stable course
• All possibilities of active treatment tried

Exclusion criteria: NR

Total participants randomised: 40

Age in years (range): 25-65

Gender: 23/40 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 20
• Inert
• Matched dosing schedule

Zimelidine 200 mg

• n = 20
• SSRI
• Fixed dose with forced titration

Outcomes

Pain intensity

Withdrawal

Missing data methods

Completer analysis

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or pe-
ripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reac-
tion involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes
eosinophilia. Additionally, zimelidine was found to cause an increase in suicidal ideation and/or at-
tempts among depressive patients.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Patients were then according to a randomisation list given tablets of identical
form, color and taste, containing either Zimelidine 25 mg or a placebo accord-
ing to a fixed dose regimen"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, matched dosing and appearance of study drugs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

230

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Johansson 1979  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

HIgh attrition in Zimeldine arm. Reported compeleter analysis only, with no
missing data methods

Attrition

Total: 8/20 (40.0%)

Placebo: 3/11 (27.3%)

Zimeldine 200 mg: 5/9 (55.6%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol found

Other bias

Low risk

No other sources of bias were identified.

Joharchi 2019 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline, 4 weeks, 8 weeks, post-intervention

Country: Iran

Participants

Pain condition: diabetic peripheral neuropathy

Population: type 2 diabetic adults aged ≥ 40 and ≤ 65 with diabetic peripheral neuropathic pain

Minimum pain intensity: ≥ 40 on 0-100 VAS

Inclusion criteria

• Aged 40-65
• Diabetes duration ≥ 5 years
• Diabetic peripheral neuropathy diagnosis
• Diabetic peripheral neuropathy severity ≥ 40 on 100 VAS with a duration of ≥ 12 months

Exclusion criteria

• Severe physical and mental health comorbidities

Total participants randomised: 180

Age in years (mean): 54.48

Gender: 109/180 were female

Pain duration in years (mean): 3.8

Interventions

Duloxetine 30-60 mg

• n = 90

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

231

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Joharchi 2019  (Continued)

Cochrane Database of Systematic Reviews

• SNRI
• Flexible dose dependent upon efficacy and tolerability
• Mean dose: 42.5 mg/day

Pregabalin 150-300 mg

• n = 90
• Anticonvulsant
• Flexible dose dependent upon efficacy and tolerability
• Mean dose: 235.5 mg/day

Outcomes

Pain intensity

AEs

Withdrawal

Missing data methods

Completer analysis

Funding source

Non-pharmaceutical: part of a PhD project - financially supported by “Research Department of theS-
chool of Medicine Shahid Beheshti University of Medical Sciences(SBUMS)” (Grant No 13/587).

Conflicts of interest

The authors declare that they have no COI.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified: Just states "randomly divided into 2
groups"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures not described

Unclear risk

Used "similar" capsules but participants in pregabalin arm took 2 capsules a
day compared to 1 a day for duloxetine

Unclear risk

Self-reported outcomes from blinded participants, unsure of blinding proce-
dures

High risk

Higher attirition in duloxetine group than pregabalin, completer analysis only

Attrition

Total: 36/180 (20.0%)

Duloxetine 30-60 mg: 24/90 (26.7%)

Pregabalin 150-300 mg: 12/90 (13.3%)

Selective reporting (re-
porting bias)

Low risk

Protocol registered prospectively to study with outcome measures

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

232

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jose 2007 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline, 2 weeks, 4 weeks, post-intervention

Country: India

Participants

Pain condition: diabetic peripheral neuropathy

Population: adults with type 2 diabetes and diabetic peripheral neuropathy

Minimum pain intensity: ≥ 50 on 0-100 scale

Inclusion criteria

• Aged 18-75 with painful diabetic neuropathy
• Painful diabetic neuropathy for at least 1 month and having pain of > 50% as assessed by 0-100 scale

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 75

Age in years (median, range): 56 (50-62)

Gender: 30/75 were female

Pain duration in years (median, range): 12 (4-24)

Interventions

Lamotrigine 50-200 mg

• Anticonvulsant
• Flexible dosing dependent upon efficacy and tolerability
• Identical tablets to amitriptyline

Amitriptyline 10-50 mg

• TCA
• Flexible dosing dependent upon efficacy and tolerability
• Identical tablet to lamotrigine

Outcomes

Pain intensity

AEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

NR

Conflicts of interest

None declared

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

233

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jose 2007  (Continued)

Risk of bias

Cochrane Database of Systematic Reviews

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using random number tables by block randomi-
sation

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedure unclear

Low risk

Double-blind, study drugs appeared identical and matched dosing schedules

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Use ITT and LOCF. Unequal attrition across arms - 100% of participants who
completely dropped out did so from the 1st period in one intervention arm.

Attrition

Total: 7/53 (13.2%)

Lamotrigine 50-200 mg: 0/53 (0.0%)

Amitriptyline 10-50 mg: 7/53 (13.2%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Kalso 1996 

Study characteristics

Methods

Design: cross-over

Duration: 4 weeks

Assessment: baseline, 2 weeks, post-intervention

Country: Finland

Participants

Pain condition: cancer-related neuropathic pain

Population: women with chronic neuropathic pain following treatment for breast cancer

Minimum pain intensity: no

Inclusion criteria

• Moderate-severity neuropathic pain following treatment for breast cancer

Exclusion criteria: NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

234

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kalso 1996  (Continued)

Total participants randomised: 20

Age in years (median, range): 56 (39-72)

Gender: 20/20 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• Inert
• Matched dosing to antidepressant

Amitriptyline 100 mg

• TCA
• Forced titration to maximum tolerated dose or 100 mg/day

Outcomes

The article reported no useable data

Missing data methods

Completer-only analysis

Funding source

Non-pharmaceutical: The study was supported by the Academy of Finland (E.K., T.T.), the Paulo Foun-
dation, Finland (E.K.) and the Centre for International Mobility (T.T.).

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedure not specified

Unclear risk

States double-blind and matched dosing but doesn't specify other blinding
procedures

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer-only analysis. Withdrawal information doesn't specify in which pe-
riod the participants withdrew

Attrition

Total: 5/20 (25.0%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

235

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kalso 1996  (Continued)

Other bias

Low risk

No other sources of bias were identified.

Katz 2005 

Study characteristics

Methods

Design: cross-over

Duration: 7 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Population: adults with chronic low back pain

Minimum pain intensity: no

Inclusion criteria

• ≥ 18 years and chronic low back pain for ≥ 3 months

Exclusion criteria

• Any other significant physical or mental health comorbidity

Total participants randomised: 54

Age in years (mean, SD): 50.6 (10.7)

Gender: 26/54 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• Inert
• Matched dosing schedule

Bupropion 300 mg

• NDRI
• Fixed dose with forced titration

Outcomes

Pain intensity

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Partly funded by pharmaceutical: "Supported in part by an investigator-initiated research grant from
GlaxoSmithKline"

Conflicts of interest

Supported in part by an investigator-initiated research grant from GlaxoSmithKline to R.H.D., who has
also received research support, consulting fees, or lecture honoraria in the past year from Abbott Lab-
oratories, Eli Lilly & Co., Endo Pharmaceuticals, EpiCept Corporation, NeurogesX, Novartis Pharmaceu-

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

236

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Katz 2005  (Continued)

Notes

Risk of bias

Bias

ticals, Organon, Ortho-McNeil Pharmaceutical, Pfizer, Purdue Pharma, Ranbaxy Corporation, Reliant
Pharmaceuticals, Renovis, and UCB Pharma.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using a computer-generated list of random
numbers.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures NR

Unclear risk

States double-blind and used same dosing for placebo as intervention but no
information given regarding other blinding procedures

Unclear risk

Self-reported outcomes from participants but uncertain of blinding proce-
dures

High risk

ITT with LOCF

Attrition

Total: 14/54 (25.9%)

Placebo: 5/54 (9.3%)

Bupropion 300 mg: 9/54 (16.7%)

Selective reporting (re-
porting bias)

High risk

Other bias

Unclear risk

"Several other health-related quality-of-life measures of physical and emo-
tional functioning were administered, but these data were not analyzed be-
cause of the absence of signiﬁcant beneﬁcial effects on the pain intensity and
relief outcome measures."

Participants tapering off of bupropion reported having AEs from reducing the
medication, which could have lasted the washout period, but this is not ex-
plored further in the article.

Kaur 2011 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: India

Participants

Pain condition: diabetic peripheral neuropathy

Population: adults with type 2 diabetes and diabetic peripheral neuropathy

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

237

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kaur 2011  (Continued)

Cochrane Database of Systematic Reviews

Minimum pain intensity: ≥ 50 on 0-100 VAS

Inclusion criteria

• Aged 18-75
• diabetic peripheral neuropathy for at least 1 month
• ≥ 50 on 0-100 pain intensity VAS

Exclusion criteria

• Clinically significant physical or mental health comorbidities

Total participants randomised: 65

Age in years (median, IQR): 52.5 (48.2–62)

Gender: 31/65 were female

Pain duration in years (median IQR): 8 (6–36)

Interventions

Amitriptyline 10-50 mg

• TCA
• Flexible titration with fixed doses: started at 10 mg, with optional titration every 2 weeks to 25 mg,

and then 50 mg

Duloxetine 20-60 mg

• SNRI
• Flexible titration with fixed doses: started at 20 mg, with optional titration every 2 weeks to 40 mg,

and then 60 mg

Outcomes

Moderate pain relief

Substantial pain relief

Missing data methods

Unclear regarding methods

Funding source

NR

Conflicts of interest

No potential conflicts of interest relevant to this study were reported

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using computer-generated randomisation of
blocks of 4

Allocation concealment
(selection bias)

Low risk

The drug packets were administered to patients serially according to the pa-
tient’s reporting sequence.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

Says double-blind but no information given regarding procedure e.g. appear-
ance of tablets

Blinding of outcome as-
sessment (detection bias)

Unclear risk

Self-reported outcomes by participants but not enough information given re-
garding blinding

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

238

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kaur 2011  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Unclear reporting of withdrawals and analysis. State ITT analysis but only in-
cluding those 58 who completed the study

Attrition

Total: 7/65 (10.8%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Kayiran 2010 

Study characteristics

Methods

Design: parallel

Duration: 4 or 8 weeks

Assessment: baseline, 2 weeks (mid-intervention), 4 weeks (post-intervention for neurofeedback), 8
weeks (post-intervention for escitalopram), week 16 (follow-up), week 24 (follow-up)

Country: Turkey

Participants

Pain condition: fibromyalgia

Population: women aged 16-49 with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Aged 16-49
• Meet the ACR criteria for fibromyalgia

Exclusion criteria

• Cardiovascular problems

Total participants randomised: 40

Age in years (mean): 32.1

Gender: 40/40 were female

Pain duration in years (mean): 4.8

Interventions

Neurofeedback

• n = 20
• 5 x 30-min sessions per week
• "Patients were seated on a comfortable armchair in front of a computer screen where they can involve
in the selected computer game during treatment sessions. It was explained to participants to be re-
laxed and concentrated on the computer game and try to widen the river which is seen on the monitor
as a game. Whenever the patients could be successful on widening the river then they enhanced SMR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

239

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kayiran 2010  (Continued)

Cochrane Database of Systematic Reviews

activity and decreased theta activity relative to pre-feedback baseline measures. By this way rewards
(points and auditory beeps) were gained and so their scores were increased."

Outcomes

Escitalopram 10 mg

• n = 20
• SSRI
• Fixed dose

Pain

Mood

Withdrawal

Missing data methods

Funding source

Conflicts of interest

NR

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

High risk

Can't be double-blind due to neurofeedback intervention

High risk

Self-reported outcomes but participants weren't blinded

Low risk

Methods NR but low attrition

Attrition

Total: 4/40 (10.0%)

Neurofeedback: 2/20 (10.0%)

Esciptalopram 10 mg: 2/20 (10.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

240

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Keefe 2011 

Study characteristics

Methods

Design: parallel

Cochrane Database of Systematic Reviews

Duration: 34 weeks

Assessment: baseline, 10 weeks, post-intervention

Country: USA

Participants

Pain condition: non-cardiac chest pain

Population: people who had presented to medical care with complaints of non-cardiac chest pain

Minimum pain intensity: no

Inclusion criteria

• Presented for medical care with complaints of chest pain in the previous 6 months
• Aged 18-85
• No clinical explanation for chest pain

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 115

Age in years (mean, SD): 48 (12)

Gender: 77/115 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 28
• Inert
• Sham dosing to match antidepressant arms

Sertraline ≤ 200 mg

• n = 30
• SSRI
• Flexible dose over first 10 weeks dependent on efficacy
• After the initial 10 weeks of treatment, the dose level was stabilised for the remaining 24 weeks of the

study

Coping skills training + placebo

• n = 29
• Placebo
• Sham dosing to match antidepressant arms
• Coping skills training was delivered in 5, 60-min individual sessions held bi-weekly for 10 weeks and

6, 30-min individual follow-up sessions held monthly for 6 months.

Sertraline ≤ 200 mg + coping skills training

• n = 28
• Combined intervention: SSRI + coping skills training
• Sham dosing to match antidepressant arms

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

241

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Keefe 2011  (Continued)

Cochrane Database of Systematic Reviews

• Coping skills training was delivered in 5, 60-min individual sessions held bi-weekly for 10 weeks and

6, 30-min individual follow-up sessions held monthly for 6 months.

Outcomes

Pain intensity

Mood

Physical function

AEs

SAEs

Withdrawal

Missing data methods

ITT but no method specified

Funding source

Non-pharmaceutical: "This study was supported by a grant from NIMH (R01 MH63429)"

Conflicts of interest

The authors on this manuscript report no COI.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised using a randomisation table

Unclear risk

Allocation procedure NR

High risk

Unable to be double-blind across all arms due to the nature of coping skills
training intervention

High risk

Self-reported outcomes from unblinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

More participants withdrew from the coping skills training+sertraline arm than
other arms. Did not report missing data methods

Attrition

Total:

Placebo: 6/28 (21.4%)

Sertraline ≤ 200 mg: 5/30 (16.7%)

Coping skills training: 8/29 (28.0%)

Coping skills training + sertraline ≤ 200 mg: 12/28 (42.9%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

242

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Khoromi 2007 

Study characteristics

Methods

Design: cross-over

Duration: 9 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: chronic lumbar root pain

Population: people with lumbar radiculopathy

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Evidence of lumbar radiculopathy, including pain in one or both buttocks or legs for ≥ 3 months for

at least 5 days a week

• Average leg pain of at least 4/10 for the past month on a NRS of 0–10 where 0 represents no pain and

10 represents the worst possible pain

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 55

Age in years (median, range): 53 (19-65)

Gender: 25/55 were female

Pain duration in years (median, range): 5 (0.3-37)

Interventions

Placebo (benzotropine ≤ 1 mg)

• Active placebo
• Identical to antidepressant
• Dosing the same as intervention arms: ranged from 0.25-1 mg a day

Morphine ≥ 15 and ≤ 90 mg

• Opioid
• Forced titration to maximum tolerated dose
• Mean dose: 62 ± 29 mg/day

Nortriptyline ≥ 25 and ≤ 100 mg

• TCA
• Forced titration to maximum tolerated dose
• Mean dose: 84 ± 24.44 mg/day

Morphine ≥ 15 and ≤ 90 mg + nortriptyline ≥ 25 and ≤ 100 mg

• Combined intervention: opioid + TCA
• Forced titration to maximum tolerated doses
• Mean doses: morphine, 49 ± 27 mg/day plus nortriptyline, 55 mg ± 33.18 mg/day

Outcomes

Pain intensity

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

243

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Khoromi 2007  (Continued)

Mood

Physical function

AEs

Withdrawal

Missing data methods

Completer-only analysis

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: "This study was supported by an intramural grant from the National Institute of
Dental and Craniofacial Research."

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were assigned by random numbers within blocks of four to 1 of 4
treatment sequences speciﬁed by a Latin square.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures NR

Low risk

Double-blind, identical appearing study drugs, sham dosing

Low risk

Self-reported outcomes from blinded participants

High risk

Completer-only analysis. High attrition overall

Attrition

Total: 27/55 (49.1%)

Placebo: 9/55 (16.4%)

Morphine 15-90 mg: 9/55 (16.4%)

Nortriptyline 25-100 mg: 3/55 (5.5%)

Morphine 15-90 mg + nortriptyline 25-100 mg: 6/55 (10.9%)

Selective reporting (re-
porting bias)

Low risk

All outcomes registered prospectively on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified.

Kim 2013 

Study characteristics

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

244

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kim 2013  (Continued)

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Diagnosed with fibromyalgia by their rheumatologist or physician, with confirmation of the diagnosis

by ACR criteria

Exclusion criteria

• Severe physical and mental health comorbidities (except depression)

Interventions

Total participants randomised: 20

Age in years (mean, SD): 47.6 (9.1)

Gender: 18/20 were female

Pain duration in years (mean, SD): NR

Placebo

• Inert

Milnacipran 12.5-200 mg

• SNRI
• Forced titration to maximum tolerated dosage

Outcomes

AEs

SAEs

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: "This study was supported by Forest Laboratories through an Investigator-Initiated
Award."

Conflicts of interest

"Dr Marks has served as a consultant to Forest, Dey, Gilead, and TTK; has received grant/research sup-
port from Bristol-Myers Squibb, Dov, Eli Lilly, Endo, GlaxoSmithKline, Janssen, Johnson & Johnson,
Pfizer, Saegis, Sepracor, and Somaxon; and has served on the speakers or advisory boards of Alkermes,
Bristol-Myers Squibb, Dey, Pfizer, and Sunovion.

Dr Masand has served as a consultant to Forest, Lundsbeck, Merck, Pfizer, and Sunovion; has received
grant/research support from Forest; has received honoraria from or served on the speakers or adviso-
ry boards of Forest, GlaxoSmithKline, Merck, Pfizer, and Sunovion; and is a stock shareholder in Global
Medical Education.

Dr Millet has received grant/research support from Forest.

Dr Keefe has served as a consultant to Abbvie, Akebia, Amgen, Asubio, BiolineRx, Biomarin, Boehringer-
Ingelheim, Eli Lilly, EnVivo, Lundbeck, Merck, Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire,

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

245

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kim 2013  (Continued)

Cochrane Database of Systematic Reviews

Sunovion, Takeda, and Targacept; has received grant/research support from Feinstein Institute for
Medical Research, GlaxoSmithKline, National Institute of Mental Health, PsychoGenics, Research Foun-
dation for Mental Hygiene, and Singapore Medical Research Council; is a stock shareholder in Neu-
roCog Trials; and has received royalties from the Brief Assessment of Cognition in Schizophrenia (BACS)
and MATRICS Battery (BACS Symbol Coding).

Dr Patkar has served as a consultant to Dey, Forest, Gilead, and TTK; has received grant/research sup-
port from Dey, Duke Endowment, Envivo, Forest, Janssen, Lundbeck, National Institutes of Health
(National Institute on Drug Abuse/National Institute on Alcohol Abuse and Alcoholism), Pfizer, Shire,
Sunovion, and Titan; and has served on the speakers or advisory boards of Alkermes, BristolMyers
Squibb, Dey, Pfizer, and Sunovion.

Dr Kim and Mss Rele and Yerramsetty report no conflicts of interest related to the subject of this article.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not described

Unclear risk

Says double-blinded but no specific information given regarding identical
medication

Unclear risk

Self-reported outcomes by participants but not enough information regarding
blinding

Unclear risk

Authors state that the same 20 participants completed both phases of study
(20) but LOCF numbers are 31. Not clear about ITT, imputation or handling of
missing data

Attrition

Not clearly reported, unable to establish total attrition and attrition per arm

Selective reporting (re-
porting bias)

Unclear risk

Protocol lists pain, fatigue and cognition prospectively but doesn't mention
any of the secondary measures. A lot of missing outcomes

Other bias

Unclear risk

Data NR in numerical forms - all secondary outcomes are classified e.g. "tran-
sient change" which has no interpretation

Konno 2016 

Study characteristics

Methods

Design: parallel

Duration: 14 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

246

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Konno 2016  (Continued)

Country: Japan

Participants

Pain condition: low back pain

Cochrane Database of Systematic Reviews

Population: adults aged 20-80 with chronic low back pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Outpatients of age 20 to < 80 years who had low back pain persisting for at least 6 months
• Used NSAIDs for at least 14 days per month for an average of 3 months before the start of the study

and for at least 14 days during the 1-month period before the start of the study

• Pain intensity ≥ 4 on 0-10 scale

Exclusion criteria

• Low back surgery, current invasive treatment for low back pain
• Depression and suicidal risk

Total participants randomised: 458

Age in years (mean): 58.9

Gender: 237/458 were female

Pain duration in years (mean): 10.1

Interventions

Placebo

• n = 226
• Inert
• Identical appearance to duloxetine

Duloxetine 60 mg

• n = 232
• SNRI
• Fixed dose, forced titration

Outcomes

Pain intensity

Sleep

Quality of life

Physical function

Mood

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

MMRM and LOCF, BOCF as sensitivity analysis for pain

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

247

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Konno 2016  (Continued)

Funding source

Pharmaceutical: Shionogi & Co. Ltd., Eli Lilly Japan K.K., and Eli Lilly and Company funds were received
in support of this work.

Conflicts of interest

Relevant financial activities outside the submitted work: consultancy, employment

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using a stochastic minimisation procedure

Allocation concealment
(selection bias)

Low risk

An "investigator in charge of blinding" randomly assigned participants to
a treatment arm based on an assignment table. This assignment table was
sealed and was inaccessible to all parties until after the clinical report was fi-
nalised.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Double-blind, identical study drugs and matched dosing

Low risk

Self-reported outcomes by blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low attrition rates. Mixture of analyses for primary outcome including MMRM,
LOCF and BOCF. Results were the same across all missing data analyses.

Attrition

Total: 49/458 (10.7%)

Placebo: 26/226 (11.5%)

Duloxetine 60 mg: 23/232 (9.9%)

Selective reporting (re-
porting bias)

Low risk

All outcomes were prospectively registered on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified

Lee 2010 

Study characteristics

Methods

Design: cross-over

Duration: 4 weeks

Assessment: baseline and post-intervention

Country: South Korea

Participants

Pain condition: functional chest pain

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

248

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lee 2010  (Continued)

Population: adults aged 20-29 with functional chest pain

Minimum pain intensity: no

Inclusion criteria

• At least 3 episodes per week of unexplained midline chest pain, for a minimum of 3 months

Exclusion criteria

• Serious physical or mental health comorbidities

Total participants randomised: 50

Age in years (mean, SD): 23.5 (1.9)

Gender: 6/50 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• Inert
• Identical capsules
• Matched to active drug arm (1 capsule in the evening)

Venlafaxine 75 mg

• SNRI
• Fixed dose

Outcomes

Pain intensity

Mood

Physical function

AEs

Withdrawal

Missing data methods

Unclear

Funding source

Not financially supported

Conflicts of interest

No potential competing interests

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)

Authors' judgement

Support for judgement

Low risk

Randomisation was achieved using a computer-generated random list

Low risk

Allocation was concealed using a sealed opaque envelope technique

Low risk

Double-blind, study drugs had identical appearance and matched dosage

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

249

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lee 2010  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

Low risk

Completer analysis but low attrition

Attrition

Total: 4/25 (16.0%)

Placebo: 3/25 (12.0%)

Venlafaxine 75 mg: 1/25 (4.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Lee 2016 

Study characteristics

Methods

Design: cross-over

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: RA

Population: adults aged ≥ 24 with RA in ≥ 5 body pain sites

Minimum pain intensity: ≥ 4 on the BPI short form, ≥ 5 on the Regional Pain Scale

Inclusion criteria

• ≥ 4 on the BPI short form, ≥ 5 on the Regional Pain Scale
• Diagnosis of RA

Exclusion criteria

• Serious physical and mental health comorbidities
• Depression included as long as there was no history of suicide or significant risk of suicide attempt

as assessed by the BDI

Total participants randomised: 43

Age in years (mean): 54.0

Gender: 25/43 were female

Pain duration in years (mean, SD): 11.29

Interventions

Placebo:

• Inert

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

250

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lee 2016  (Continued)

Cochrane Database of Systematic Reviews

• Identical in appearance to the milnacipran tablets
• Sham dosing to match milnacipran

Milnacipran 100 mg

• SNRI
• Fixed dose
• If participants couldn't tolerate dose: decreased to highest tolerable dose

Outcomes

Pain intensity

Moderate pain relief

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: "This work was conducted with support from Forest Research Institute, NIH-NIAMS
K23AR057578, NIH-NIAMS K24 AR055989, Harvard Catalyst"

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised via a random number generator, with 4 partici-
pants per block.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, study drugs had identical appearance and matched dosing

Low risk

Self-reported outcomes from blinded participants

High risk

Says they will use ITT and LOCF, but only report results from completers

Attrition

Total: 9/41 (22.0%)

Placebo: 3/41 (7.3%)

Milnacipran 100 mg: 6/41 (14.6%)

Selective reporting (re-
porting bias)

High risk

Outcomes stated in the methods section of the paper are NR. Protocol
changed on clinicaltrials.gov to remove some outcomes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

251

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lee 2016  (Continued)

Other bias

Low risk

No other sources of bias were identified.

Leijon 1989 

Study characteristics

Methods

Design: cross-over

Duration: 4 weeks

Assessment: baseline, week 1, week 2, week 3, post-intervention

Country: Sweden

Participants

Pain condition: central post-stroke pain

Population: adults with central post-stroke pain

Minimum pain intensity: no

Inclusion criteria

• an unequivocal stroke episode
• the patient should seek remedy for constant or intermittent pain, which started after the stroke

Exclusion criteria:

• Pain of nociceptive, peripheral neuropathic or psychogenic origin
• Known contraindication to both amitriptyline and carbamazepine

Total participants randomised: 15

Age in years (mean, range): 66 (53-74)

Gender: 3/15 were female

Pain duration in months (mean, range): 54 (11-154)

Interventions

Placebo

• Inert
• Identical tablets to intervention arms
• Double-dummy technique

Amitriptyline 75 mg

• TCA
• Fixed dose with forced titration

Carbamazepine 800 mg

• Anticonvulsant
• Fixed dose with forced titration

Outcomes

Pain intensity

PGIC

AEs

SAEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

252

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Leijon 1989  (Continued)

Withdrawal

Missing data methods

NR

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: "The study was supported by grants from the County Council of Ostergotland and
the Swedish Association of the Neurologically Disabled"

Conflicts of interest

None reported

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

No information given apart from "randomised"

Low risk

Separate pharmacy team performed randomisation and allocation

Low risk

Double-blind, study drugs had identical appearance and matched dosing. In-
vestigators were also blinded - separate neurologists were consulted for side-
effects.

Low risk

Self-reported outcomes from blinded participants

Low risk

No missing data methods, but only 1 person withdrew

Attrition

Total: 1/15 (6.7%)

Placebo: 0/15 (0.0%)

Amitriptyline 75 mg: 0/15 (0.0%)

Carbamazepine 800 mg: 1/14 (7.1%)

Selective reporting (re-
porting bias)

Low risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Lipone 2020 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lipone 2020  (Continued)

Country: Czech Republic, Hungary, and Poland

Participants

Pain condition: painful diabetic neuropathy

Population: people with painful diabetic neuropathy

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Aged 18-75
• painful diabetic neuropathy manifesting with distally distributed neuropathic pain
• ≥ 4 on 0-10 pain intensity scale

Exclusion criteria

• Other pain conditions, general physical conditions (glaucoma, hisotry of seizures, etc), and significant

mental disorders

Total participants randomised: 142

Age in years (mean): 62.7

Gender: 68/142 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo + gabapentin 2400 mg

• n = 48
• Placebo + anticonvulsant
• Gabapentin open-label, placebo identical to trazodone

Trazodone 30 mg + gabapentin 2400 mg

• n = 43
• Combined intervention: SARI antidepressant + anticonvulsant
• Fixed dose
• Gabapentin in open-label condition

Trazodone 60 mg + gabapentin 2400 mg

• n = 51
• Combined intervention: SARI antidepressant + anticonvulsant
• Fixed dose
• Gabapentin in open-label condition

Outcomes

Pain intensity

Substantial pain relief

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: "This study was sponsored by Angelini Pharma S.p.A. (S. Palomba, Pomezia, Rome,
Italy)."

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

254

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lipone 2020  (Continued)

Conflicts of interest

Notes

Risk of bias

Bias

Giorgio Cruccu received personal fees for advisory boards or consultancy from Angelini, Grunenthal,
and Lilly, and personal fees for educational activity by PTS Global Services. Andrea Truini received hon-
oraria for speaking at symposia or research financial supports from Alpha-Sigma, Angelini Pharma,
Epitech, FB Health, Pfizer, and Grunenthal. Edvard Ehler has no conflicts of interest that are directly rel-
evant to the content of this study; however, his institution received a fee for conducting the clinical tri-
al from Angelini Pharma S.p.A. Marcin Nastaj and Ilona Palka-Kisielowska received principal investiga-
tor fees from Angelini Pharma S.p.A. Fabrizio Calisti, Agnese Cattaneo, Alessandro Comandini, Alessan-
dra Del Vecchio, Giorgio Di Loreto, Paola Lipone, and Ilena Pochiero are full-time employees of Angelini
Pharma S.p.A.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised in a 1:1:1 ratio to the 3 parallel groups, based on
a computer-generated sequence

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures NR

Low risk

"Double-blinding was maintained throughout all treatment periods by using a
TRZ [trazodone] solution matching PLB [placebo] solution and the same dos-
ing regimen for all groups in terms of timing and number of drops."

Low risk

Self-reported outcomes by blinded participants

High risk

ITT with LOCF

Attrition

Total: 38/142 (26.8%)

Gabapentin 2400 mg: 13/48 (27.1%)

Trazodone 30 mg + gabapentin 2400 mg: 10/43 (23.3%)

Trazodone 60 mg + gabapentin 2400 mg: 15/51 (29.4%)

Selective reporting (re-
porting bias)

Unclear risk

Do not report a lot of the secondary outcomes clearly, the baseline or the post-
intervention, these are also NR in the trial registry

Other bias

Low risk

No other sources of bias were identified.

Loldrup 1989 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

255

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Loldrup 1989  (Continued)

Country: Denmark

Cochrane Database of Systematic Reviews

Participants

Pain condition: idiopathic pain syndromes: (a) tension headache, (b) burning mouth syndrome (oral
dysaesthesia), (c) abdominal pain (gastroscopy negative for ulcer), and (d) low back pain

Population: people with idiopathic pain syndromes

Minimum pain intensity: no

Inclusion criteria

• Pain from 1 of the 4 conditions listed above

Exclusion criteria

• Physical health comorbidies
• Excluded severe psychiatric conditions but included depression and anxiety

Total participants randomised: 253

Age in years (median, range): 51.0 (17-80)

Gender: 185/253 were female

Pain duration in years (median, range): 60.0 (6-636)

Interventions

Placebo

• n = 87
• Inert

Clomipramine 75-150 mg

• n = 84
• Fixed dose of either 75 mg or 150 mg dependent upon side effects
• Mean dose: 125 mg/day

Mianserin 30-60 mg

• n = 82
• Fixed dose of either 30 mg or 60 mg dependent upon side effects
• Mean dose: 45 mg/day

Outcomes

Substantial pain

Withdrawal

Missing data methods

Completer analysis only

Funding source

Conflicts of interest

Notes

Non-pharmaceutical: "This study was financially supported by: Danish Medical Research Council, Dan-
ish Medical Research Council-Region-III, Kleins legat, Geerd Jorgensens fond, Lundbeck Fonden, Mimi
and Victor Larsens Fond, Danish Dental Association (FUT-foundation), Bryde Nielsen Fond, P. Carl Pe-
tersens Fond, Ciba Geigy A/S, and Organon."

"Per Bech has occasionally over the past 3 years until August 2008 received funding from and been
speaker or member of advisory boards for pharmaceutical companies with an interest in drug treat-
ment of affective disorders (Astra-Zeneca, Lilly, H. Lundbeck A/S, Lundbeck Foundation, Organon). All
other authors declare that they have no conflicts of interests."

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

256

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Loldrup 1989  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised by use of random numbers

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, identical study drugs and dosing

Low risk

Self-reported outcomes from blinded participants

High risk

Completer analysis only

Attrition

Total: 75/253 (29.6%)

Placebo: 15/87 (17.2%)

Clomipramine 75-100 mg: 28/84 (33.3%)

Mianserin 30-60 mg: 28/82 (34.2%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Luo 2009 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline, week 1, week 2, week 4, post-intervention

Country: China

Participants

Pain condition: persistent somatoform pain disorder

Population: people aged 18-65 with persistent somatoform pain disorder

Minimum pain intensity: no

Inclusion criteria

• Outpatients meeting the ICD-10 diagnostic criteria for persistent somatoform pain disorder with > 6

months' duration

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

257

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Luo 2009  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

• Coexisting depressive symptoms that occurred prior to pain
• Severe and unstable physical illnesses

Total participants randomised: 80

Age in years (mean, SD): 40.96 (12.69)

Gender: 46/80 were female

Pain duration in months (mean, SD): 21.02 (9.02)

Interventions

Placebo

• n = 40
• Inert
• Identical capsules and matched dosing schedule

Fluoxetine 20 mg

• n = 40
• SSRI
• Fixed dose, no titration

Outcomes

Pain intensity

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: "This research was supported by Shanghai Science and Technology Committee."

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedure not described

Low risk

Double-blind, identical study drugs, matched dosing schedule

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

No withdrawal data reported

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

258

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Luo 2009  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Maarrawi 2018 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Lebanon

Participants

Pain condition: chronic neck pain

Population: people with chronic neck pain

Minimum pain intensity: no

Inclusion criteria

• Chronic neck pain for > 15 days/month during at least 3 consecutive months

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 332

Age in years (mean, SD): 44.23 (11.39)

Gender: 190/332 were female

Pain duration in years (mean, SD): 15.4 (4.86)

Interventions

Placebo

• n = 166
• Inert
• Identical appearance and matched dosing

Amitriptyline 5 mg

• n = 166
• TCA
• Fixed dose, no titration

Outcomes

Pain intensity

Missing data methods

Completer-only analysis

Funding source

Non-pharmaceutical: "This study was supported by the Council of Research of the Saint Joseph Univer-
sity of Beirut – Lebanon (FM201)"

Conflicts of interest

No conflicts of interest

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

259

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Maarrawi 2018  (Continued)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised via the block randomisation method, comput-
er-generated via www.randomization.com)

Allocation concealment
(selection bias)

Low risk

Randomisation was centralised by a staff nurse (who had never seen the pa-
tient) not otherwise involved in the study and noted the group of each partic-
ipant next to the number assigned to him. The same staff nurse delivered the
corresponding medication to each patient.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, study drugs were identical with matched dosing schedule

Low risk

Self-reported outcomes from blinded participants

High risk

Completer-only analysis. Withdrawal rate rate was ~17%

Attrition

Total: 58/332 (17.5%)

Placebo: 25/166 (15.1%)

Amitriptyline 5 mg: 33/166 (19.9%)

Selective reporting (re-
porting bias)

Low risk

All outcomes match up with those prospectively registered on clinicaltrial-
s.gov

Other bias

Unclear risk

Unclear reporting in the publication, especially in relation to sample size and
withdrawal

Macfarlane 1986 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Canada

Participants

Pain condition: RA

Population: adults with RA and elevated self-reported depression

Minimum pain intensity: no

Inclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

260

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Macfarlane 1986  (Continued)

Cochrane Database of Systematic Reviews

• ‘Definite’ or ‘classical’ RA as defined by the ARA
• All of the patients had a score exceeding 50 on the ‘self-rating depression scale’ described by Zung

1965

Exclusion criteria: NR

Total participants randomised: 36

Age in years (mean, SD): 59.15

Gender: 27/36 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 18
• Inert
• Identical tablets

Trimipramine 75 mg

• n = 18
• TCA
• Fixed titration schedule to 75 mg, but if participants experienced side effects they could reduce the

dose

Outcomes

Pain intensity

Mood

Withdrawal

Missing data methods

Funding source

Conflicts of interest

NR

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, identical study drugs

Low risk

Self-reported outcomes from blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

261

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Macfarlane 1986  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

No information on handling missing data, report 9 participants withdrew in
the text but 10 in the table

Attrition

Total: 9/36 (25.0%)

Placebo: 4/18 (22.2%)

Trimipramine 25-75 mg: 5/18 (27.8%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Unclear risk

Not a lot of information on methods, short publication so not enough informa-
tion to assess whether a further risk of bias exists

Mahmoud 2021 

Study characteristics

Methods

Design: parallel

Duration: 16 weeks

Assessment: baseline and post-intervention

Country: Egypt

Participants

Pain condition: neck pain

Population: adults with chronic neck pain

Minimum pain intensity: no

Inclusion criteria

• Chronic neck pain for > 15 days per month and lasting at least 3 months

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 80

Age in years (mean): 46.6

Gender: 52/80 were female

Pain duration in years (mean, SD): NR

Interventions

Amitripyline 5 mg

• n = 40
• TCA
• Fixed dose

Amitripyline 10 mg

• n = 40
• TCA

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

262

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mahmoud 2021  (Continued)

Outcomes

• Fixed dose

Pain intensity

Withdrawal

Missing data methods

Completer-only analysis

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: "This work was funded in part by Fayoum University Hospitals (Fayoum, Egypt)
and by the authors’ personal resources."

Conflicts of interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Simple randomisation using a randomisation table created by a computer
software program

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Participants were allocated using sealed opaque envelopes.

Low risk

Double-blind with identical study drugs

Low risk

Self-reported outcomes from blinded participants

High risk

Completer analysis only

Attrition

Total: 10/80 (12.5%)

Amitriptyline 5 mg: 5/40 (12.5%)

Amitriptyline 10 mg: 5/40 (12.5%)

Selective reporting (re-
porting bias)

Unclear risk

Outcomes published match trial registry though retrospectively registered

Other bias

Unclear risk

Confusing reporting of primary outcome. In the text, it says that neck pain (as
measured by the Neck Pain Driving Index) decreased by 71.9% ± 13.4% in the
10 mg group, which was greater than the decrease in the 5 mg group (47.3% ±
17.3%). However in the figure it says that the decreases were 48.3% for 5 mg
and 68.2% for 10 mg.

Majdinasab 2019 

Study characteristics

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

263

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Majdinasab 2019  (Continued)

Methods

Design: parallel

Cochrane Database of Systematic Reviews

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Iran

Participants

Pain condition: painful diabetic peripheral polyneuropathy

Population: adults with painful diabetic peripheral polyneuropathy

Minimum pain intensity: ≥ 40 on 0-100 VAS

Inclusion criteria

• Aged between 18-75
• Painful diabetic peripheral poly-neuropathy from 1 month to 5 years
• ≥ 40 on 0-100 pain intensity VAS

Exclusion criteria

• Severe illness in vital organs
• Using medication to treat pain

Total participants randomised: 104

Age in years (mean): 60.3

Gender: 50/104 were female

Pain duration in years (mean): 3.75

Interventions

Gabapentin 300-900 mg

• n = 52
• Anticonvulsant
• Flexible dose depending on tolerability
• Identical appearance to duloxetine

Duloxetine 30-60 mg

• n = 52
• SNRI
• Flexible dose depending on tolerability

Outcomes

Pain intensity

Sleep

AEs

Withdrawal

Missing data methods

NR

Funding source

Non-pharmaceutical: "This study was funded by Ahvaz Jundishapur University of Medical Sciences
(grant number IR.AJUMS.REC.1395.78)"

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

264

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Majdinasab 2019  (Continued)

Conflicts of interest

Notes

Risk of bias

Bias

Dr Nastaran Majdinasab, Dr Hossein Kaveyani, and Dr Mojgan Azizi have received research grants from
Ahvaz Jundishapur University of Medical Sciences (grant number IR.AJUMS.REC.1395.78). The authors
report no other conflicts of interest in this work.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using the 4 block randomised method
(equalised 4-blocks).

Allocation concealment
(selection bias)

Low risk

"The medications of this study were ﬁrst made similar to each other by a doc-
tor who had no role in the collection and analysis of data and then sufﬁcient
amounts were packed into packets A and B and were given to the researcher."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Used identical drugs and placebos and packets but: "Before the commence-
ment of the study, the side effects of the medications were explained to the
patients " could then allow participants to know what they're experiencing
and which medication it comes from.

Unclear risk

Self-reported outcomes from participants, but unsure of blinding

Unclear risk

Method of missing data not specified

Attrition

Total: 16/104 (15.4%)

Gabapentin 300-900 mg: 11/52 (21.2%)

Duloxetine 30-60 mg: 5/52 (9.6%)

Selective reporting (re-
porting bias)

Unclear risk

Protocol registered retrospectively

Other bias

Unclear risk

Errors in publication between tables

Masand 2009 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: IBS

Population: adults aged 18-75 with IBS

Minimum pain intensity: no

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

265

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Masand 2009  (Continued)

Inclusion criteria

Cochrane Database of Systematic Reviews

• Confirmed diagnosis of IBS by use of Rome II diagnostic criteria for over 1 year

Exclusion criteria

• Physical and mental health comorbidies

Total participants randomised: 72

Age in years (mean): 49.0

Gender: 63/72 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 36
• Inert
• Dosing matched to antidepressant arm

Paroxetine 12.5-50 mg

• n = 36
• SSRI
• Forced titration to maximum tolerated dose

Outcomes

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: This study was supported by a collaborative research grant from GlaxoSmithKline.

Dr Masand is a consultant for Bristol-Myers Squibb Company, Cephalon, Inc., Eli Lilly and Company,
Forest Pharmaceutical Laboratories Inc., GlaxoSmithKline, Janssen Pharmaceutica, Jazz Pharmaceu-
ticals, Organon, Inc., Pfizer Inc., U.S. Pharmaceuticals Group., Targacept Inc., and Wyeth Pharmaceu-
ticals. He is on the speaker's bureau of Astra-Zeneca, Bristol-Myers Squibb Company, Forest Pharma-
ceutical Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., U.S. Pharmaceuticals
Group., and Wyeth Pharmaceuticals. He has received research support from AstraZeneca Pharmaceu-
ticals, Bristol-Myers Squibb Company, Cephalon, Inc.., Eli Lilly and Company, Forest Pharmaceutical
Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceutica, and
Wyeth Pharmaceuticals, and is an employee of i3CME.

Dr Patkar is a consultant for Bristol-Myers Squibb Company, GlaxoSmithKline, and Reckitt Benckiser;
he is on the speaker's bureau of Bristol-Myers Squibb Company, GlaxoSmithKline, and Reckitt
Benckiser, and has received research support from National Institutes of Health, AstraZeneca Phar-
maceuticals, Bristol-Myers Squibb Company, Forest Pharmaceuticals, Inc., GlaxoSmithKline, Janssen
Pharmaceutica, McNeil Consumer and Specialty Inc., Organon, Inc., Jazz Pharmaceuticals, and Pfizer
Inc., U.S. Pharmaceuticals Group.

Dr Pae has received research support from GlaxoSmithKline.

Mr. Krulewicz is an employee of GlaxoSmithKline and owns common stock in the company.

Conflicts of interest

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

266

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Masand 2009  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Randomisation methods not described

Low risk

Participants were allocated using an Interactive Voice Response System

Low risk

Double-blind, matching drug appearance and identical dosing schedules

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 14/72 (19.4%)

Placebo: 8/36 (22.2%)

Paroxetine 12.5-50 mg: 6/36 (16.7%)

Selective reporting (re-
porting bias)

High risk

Trial registry lists quality of life and IBS symptoms as outcomes but these are
NR. Beck Depression Index and Beck Anxiety Index are NR for all participants,
divided into samples with or without history of anxiety and depression.

Other bias

Low risk

No other sources of bias were identified

Matthey 2013 

Study characteristics

Methods

Design: parallel

Duration: 7 weeks

Assessment: baseline and post-intervention

Country: Switzerland

Participants

Pain condition: fibromyalgia

Population: adult women with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 VAS

Inclusion criteria

• Women who met the ACR fibromyalgia criteria
• Pain intensity of ≥ 40 on 0-100 VAS at baseline

Exclusion criteria

• Physical and mental health comorbidities

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

267

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Matthey 2013  (Continued)

Cochrane Database of Systematic Reviews

Interventions

Outcomes

Total participants randomised: 80

Age in years (mean): 49.7

Gender: 80/80 were female

Pain duration in years (mean, SD): NR

Placebo

• n = 39
• Inert

Milnacipran 100-200 mg

• n = 40
• SNRI
• Flexible dosing to 100 mg, 150 mg, or 200 mg per day based on tolerability

Pain intensity

Quality of life

Physical function

Mood

Sleep

Withdrawal

Missing data methods

ITT wit h LOCF

Funding source

Pharmaceutical: This trial was supported by a grant from Pierre Fabre Médicament.

Conflicts of interest

"Each author certifies that he or she, or a member of his or her immediate family, has no commercial
association, (i.e., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.)
that might post a COI in connection with the submitted manuscript."

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

A randomisation list was computer-generated.

Allocation concealment
(selection bias)

Low risk

Allocation of treatments was done by the investigator according to the
chronological order of the occurring visit 2

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

State double-blind but not enough information about study drug appearance
and dosing

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

268

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Matthey 2013  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

ITT with LOCF, high attrition

Attrition

Total: 37/80 (46.3%)

Placebo: 16/40 (40.0%)

Milnacipran 100-200 mg: 21/40 (52.5%)

Selective reporting (re-
porting bias)

Unclear risk

No changes to protocol, but it's registered 2 years after trial start

Other bias

Low risk

No other sources of bias were identified.

Max 1988 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period was 6 weeks

Assessment: baseline and post-cross-over period

Country: USA

Participants

Pain condition: post-herpetic neuralgia

Population: adults with post-herpetic neuralgia

Minimum pain intensity: no

Inclusion criteria

• Daily pain, persisting at least 3 months after a segmental herpes zoster eruption

Exclusion criteria

• Another type of pain as severe
• Depression

Total participants randomised: 58

Age in years (median, range): 72 (25-86)

Gender: 27/58 were female

Pain duration in months (median, range): 19 months (3 months-25 years)

Interventions

Placebo

• Inert - lactose
• "Placebo (PLAC) is given only during the first period, because both amitriptyline (AMI) and lorazepam
(LOR) have prominent side effects. We predicted that patients given placebo following one of those
drugs would immediately recognize this inert treatment. The design permitted a comparison of AMI,
LOR, and PLAC during the first treatment period."

Amitriptyline 12.5-150 mg

• TCA

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

269

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Max 1988  (Continued)

Cochrane Database of Systematic Reviews

• Forced titration to maximum tolerable dose in first 3 weeks, then held at that dose for final 3 weeks

Lorazepam 0.5-6 mg

• Benzodiazepine
• Forced titration to maximum tolerable dose in first 3 weeks, then held at that dose for final 3 weeks

Outcomes

AEs

Missing data methods

Unclear

Funding source

Non-pharmaceutical: from the Neurobiology and Anaesthesiology Branch, National Institute of Den-
tal Research (Drs Max, Gracely, Smoller, and Dubner). and the Nursing Department, Clinical Center (Ma.
Schnfer and Me. Culnane), National Institutes of Health, Bethesda, MD

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

Says double-blind but no information about this was given

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Unclear risk

No information regarding missing data reported. 41 completed both of the
treatment periods for their group, but authors report data on 58

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Max 1992 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period was 6 weeks

Assessment: baseline and post-cross-over period

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

270

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Max 1992  (Continued)

Country: USA

Cochrane Database of Systematic Reviews

Participants

Pain condition: diabetic peripheral neuropathy

Population: type 1 or 2 diabetic adults with diabetic peripheral neuropathy

Minimum pain intensity: no

Inclusion criteria

• Daily pain of at least moderate severity, the quality and location of which were consistent with the

peripheral neuropathy

Exclusion criteria

• Other pain as severe as the diabetic peripheral neuropathy
• Depression
• Cardiovascular conditions

Total participants randomised: 54

Age in years (median, range): 58 (20-84)

Gender: 21/54 were female

Pain duration in years (median, range): 3 (0.5-12)

Interventions

Desipramine 12.5-150 mg

• TCA
• Forced titration to highest tolerated dose
• Mean dose 111 mg/day (SD 39)

Amitriptyline 12.5-150 mg

• TCA
• Forced titration to highest tolerated dose
• Mean dose 105 mg/day (SD 37)

Outcomes

Pain intensity

AEs

Missing data methods

Completer-only analysis

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

271

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Max 1992  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

States double-blind but no information regarding procedures e.g. study drug
appearance

Unclear risk

Self-reported outcomes from participants, but unsure of blinding process

High risk

Completer analysis only

Attrition

Total: 16/54 (29.6%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Unclear risk

Complicated trial design between 2 studies. Of the 54 participants in the de-
sipramine vs amitriptyline study only 29 were randomised into it.

Mease 2009 

Study characteristics

Methods

Design: parallel

Duration: 27 weeks

Assessment: baseline, 15 weeks, post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 50 on 0-100 scale

Inclusion criteria

• Aged 18-70 with fibromyalgia meeting ACR criteria
• Pain intensity of ≥ 50 on 0-100 scale

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 888

Age in years (mean, SD): 49.5

Gender: 849/888 were female

Pain duration in years (mean, SD): 5.6

Interventions

Placebo

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

272

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mease 2009  (Continued)

• n = 223
• Inert
• Identical appearance and matched dosing

Cochrane Database of Systematic Reviews

Milnacripran 100 mg

• n = 224
• SNRI
• Fixed dose

Milnacripran 200 mg

• n = 441
• SNRI
• Fixed dose

Outcomes

Pain intensity

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF, sensitivity analyses with BOCF

Funding source

Pharmaceutical: supported by Forest Laboratories, Inc., New York, New York, and CypressBioscience,
Inc., San Diego, California, USA

Conflicts of interest

Dr Mease has received research grant support from Pfizer Inc, Cypress Bioscience, Inc., Forest Labora-
tories, Inc., Eli Lilly and Company, Allergan, Wyeth Pharmaceuticals, Jazz Pharmaceuticals, and Fralex
Therapeutics.

Dr Clauw has received grant support from Cypress Bioscience, Inc. and serves as a consultant to Cy-
press Bioscience, Inc, Forest Laboratories, Inc., Pierre Fabre Medicament, Pfizer Inc, Eli Lilly and Com-
pany, Wyeth Pharmaceuticals, and Proctor and Gamble.

Dr Mease was an investigator of this study and a consultant; Dr Clauw was a consultant for this study.
As consultants, Drs Mease and Clauw were involved in the study design, analysis of results, and prepa-
ration of the manuscript. Drs Gendreau, Rao, and Kranzler are employees of Cypress Bioscience, Inc.

Drs Chen and Palmer are employees of Forest Laboratories, Inc

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedure not specified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

273

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mease 2009  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Double-blind with study drugs identical and matched dosing

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Very high attrition rate, especially for the high-dose milnacipran. Use a mix of
imputation methods including LOCF, BOCF and completers, but not all of the
data for this are presented in the paper

Attrition

Total: 376/888 (42.3%)

Placebo: 78/223 (35.0%)

Milnacipran 100 mg: 96/224 (42.9%)

Milnacipran 200 mg: 202/441 (45.8%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Miki 2016 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Japan

Participants

Pain condition: fibromyalgia

Population: Japanese adults aged between 20-64 with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 scale

Inclusion criteria

• Japanese adults aged between 20 and 64 years who met the ACR diagnostic criteria for fibromyalgia
• Pain intensity ≥ 40 on 0-100 scale

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 430

Age in years (mean): 45.2

Gender: 347/430 were female

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

274

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Miki 2016  (Continued)

Pain duration in years (mean): 4.4

Interventions

Placebo

• n = 215
• Inert
• Identical appearance to mirtazapine with matched dosing

Mirtazapine 30 mg

• n = 215
• NaSSA
• Fixed dose

Outcomes

Pain intensity

Mood

Quality of life

Physical function

Moderate pain relief

Substantial pain relief

AEs

Severe AEs

Withdrawal

Missing data methods

NR

Funding source

Pharmaceutical: funded by Meiji Seika Pharma Co, Ltd.

Conflicts of interest

The authors have no conflicts of interest to declare. K. Miki, M. Murakami, H. Oka, K. Osada received
honorarium from Meiji Seika Pharma Co, Ltd. K. Onozawa and S. Yoshida are employees of Meiji Seika
Pharma Co, Ltd.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

The randomisation was done by a computer-generated allocation sequence

Allocation concealment
(selection bias)

Low risk

Allocation was delivered by a telephone randomisation service (randomisation
manager) not involved in participant recruitment or treatment to ensure allo-
cation concealment

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes from blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

275

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Miki 2016  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

ITT but methods not specified

Attrition

Total: 48/430 (11.2%)

Placebo: 23/215 (10.7%)

Mirtazapine 30 mg: 25/215 (11.6%)

Selective reporting (re-
porting bias)

Unclear risk

Protocol published prospectively but no outcomes specified apart from
"amount of change from baseline"

Other bias

High risk

Pain intensity change scores reported in the paper do not seem to be correct.
When calculated into SMD, an SMD of over 4 resulted, which is improbable.
Emailed study authors for clarification but no response, and no correction
found.

Morello 1999 

Study characteristics

Methods

Design: cross-over

Duration: cross-over periods were 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: diabetic peripheral neuropathy

Population: type 1 and 2 diabetic veterans with diabetic peripheral neuropathy pain

Minimum pain intensity: no

Inclusion criteria

• Chronic daily pain for > 3months, during which both the quality and location were consistent with

diabetic peripheral neuropathy pain, as diagnosed by a neurologist

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 25

Age in years (mean, SD): 60.4 (10.8)

Gender: 1/25 were female

Pain duration in years (mean, SD): 5.7 (4.2)

Interventions

Gabapentin 900-1800 mg

• Anticonvulsant
• Flexible dosing dependent upon tolerance
• Mean dose after titration: 1565 mg/day

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

276

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morello 1999  (Continued)

Amitriptyline 25-75 mg

• TCA
• Flexible dosing dependent upon tolerance
• Mean dose after titration: 59 mg/day

Outcomes

Pain intensity

AEs

Withdrawal

Missing data methods

Completer analysis only

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedure not specified

Low risk

Double-blind medications, same dosing schedules and appearance

Low risk

Self-reported outcomes by blinded participants

High risk

Completer-only analysis

Attrition

Total: 4/25 (16.0%)

Gabapentin 900-1800 mg: 2/25 (8.0%)

Amitriptyline 25-75 mg: 2/25 (8.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

High risk

Post hoc power analysis and report needing sample of 280 to detect effect,
they have 25 participants randomised

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

277

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Muller 2008 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: South Africa

Cochrane Database of Systematic Reviews

Participants

Pain condition: multisomatoform disorder

Population: people aged 18-65 with somatoform symptoms and medically unexplained symptoms

Minimum pain intensity: no

Inclusion criteria

• Aged 18-65
• Multisomatoform disorder defined as ≥ 3 bothersome medically unexplained symptoms within the

past month, together with a history of ≥ 1 somatoform symptoms for at least 2 years

Exclusion criteria

• Current or past psychotic disorder, any unstable mental illness, suicide risk

Total participants randomised: 51

Age in years (mean, SD): 39.6

Gender: 46/51 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 26
• Inert
• Identical apprearance and matched dosing

Escitalopram 10-20 mg

• SSRI
• Flexible dose according to tolerability

Outcomes

Pain intensity

Mood

Physical function

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: this study was funded by H. Lundbeck A/S

Conflicts of interest

At the time this study was conducted, Professor Stein, Professor Seedat and Dr Muller were funded by
the Medical Research Council of South Africa

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

278

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Muller 2008  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Patients were randomly assigned via computer-generated randomisation lists

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, with study drugs identical and matched dosing schedule

Low risk

Self-reported outcomes by blinded participants

Low risk

ITT and LOCF, but only 1 person withdrew

Attrition

Total: 1/51 (2.0%)

Placebo: 0/26 (0.0%)

Escitalopram 10-20 mg: 1/25 (4.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Murakami 2015 

Study characteristics

Methods

Design: parallel

Duration: 14 weeks

Assessment: baseline and post-intervention

Country: Japan

Participants

Pain condition: fibromyalgia

Population: adults aged 20-75 with fibromyalgia

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Outpatients aged between 20 and 75 years who met the ACR 1990 criteria for fibromyalgia
• Pain intensity of ≥ 4 on 0-10 scale

Exclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

279

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Murakami 2015  (Continued)

Cochrane Database of Systematic Reviews

• Severe or unstable disease, psychiatric disorders other than major depressive disorder within the last

year

Total participants randomised: 393

Age in years (mean, SD): 48.7 (11.9)

Gender: 321/393 were female

Pain duration in years (mean): 5.6

Interventions

Placebo

• n = 197
• Inert
• Identical appearance and matched dosing schedule

Duloxetine 60 mg

• n = 196
• SNRI
• Forced titration to fixed dose

Outcomes

Pain intensity

Mood

Sleep

Quality of life

Physical function

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF, MMRM, and sensitivity analyses using BOCF and WOCF

Funding source

Pharmaceutical: Shionogi & Co. Ltd., Eli Lilly Japan K.K., and Eli Lilly & Company provided funding for
the study

Conflicts of interest

HM and TO are employees of Shionogi & Co. Ltd. LA is an employee of Eli Lilly Japan K.K. MM, KO, and
KN have provided consultancy services and MM and KO received compensation from Shionogi & Co.
Ltd. for their participation in this study. MM, KO, and KN did not receive any compensation for their in-
put into this study. The authors confirm that there are no non-financial competing interests to declare
in relation to this article.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Patients were assigned randomly to receive duloxetine or placebo in a 1:1 ra-
tio, using a web-based patient registration system (ACRONET Corp., Tokyo,
Japan) with a stochastic minimisation procedure.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

280

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Murakami 2015  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, study drugs had identical appearance, packaging, and labelling,
matched dosing schedule

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Although there was attrition, sensitivity analyses of the primary outcomes with
LOCF, BOCF, and WOCF showed no signficiant differences.

Attrition

Total: 78/393 (19.9%)

Placebo: 48/198 (24.4%)

Duloxetine 60 mg: 30/196 (15.3%)

Selective reporting (re-
porting bias)

Low risk

All outcomes listed prospectively on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified.

Nabi 2021 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline, 4 weeks, post-intervention

Country: Iran

Participants

Pain condition: painful diabetic neuropathy

Population: adults with type I or type II diabetes and a diagnosis of diabetic peripheral neuropathic
pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Diabetic peripheral neuropathic pain for at least 6 months diagnosed according to the MNSI scale
• Pain intensity of ≥ 4 on 0-10 scale

Exclusion criteria

• Hepatic, heart, or renal failure; uncontrolled hypertension; psychological disorders; epilepsy; other

neuropathies

Total participants randomised: 72

Age in years (mean, SD): 57.71 (7.43)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

281

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nabi 2021  (Continued)

Gender: 29/72 were female

Pain duration in months (mean, SD): 22.46 (9.52)

Interventions

TENS

Cochrane Database of Systematic Reviews

• n = 30
• TENS
• For 4 weeks, sessions every other day. Then, twice a week for 3 months

Duloxetine - 60 mg

• n = 42
• SNRI
• Fixed dose with forced titration

Outcomes

Pain intensity

AEs

Withdrawal

Missing data methods

Completer analysis only - 12 participants discontinued treatment due to intolerability and were re-
placed with new cases.

Funding source

Study was not financially supported

Conflicts of interest

The study authors reported no conflicts of interest.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using http://www.graphpad.com/quickcalcs/in-
dex.cfm.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedures not specified

High risk

Unable to be blinded due to the nature of TENS

High risk

Self-reported outcomes from unblinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer analysis only. 12 participants dropped out, all in the duloxetine arm
due to side effects. Participants who dropped out were replaced with new par-
ticipants, and their data not analysed.

Attrition

Total: 12/72 (16.7%)

TENS: 0/30 (0.0%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

282

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Nabi 2021  (Continued)

Selective reporting (re-
porting bias)

Duloxetine 60 mg: 12/42 (28.6%)

Low risk

Trial registered prospectively and outcomes match

Other bias

Low risk

No other sources of bias were identified.

Natelson 2015 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults aged 18-68 with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Fibromyalgia meeting the ACR criteria
• > 10 of 18 tender points, points were considered tender if they were reported to be ≥ 2 on a pain in-

tensity VAS from 0-10 reported by patients

Exclusion criteria

• Severe physical and mental health comorbidities

Total participants randomised: 34

Age in years (mean, SD): 46.8

Gender: 33/34 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 17
• Inert
• Identical appearance and matched dosing schedule

Milnacipran 100 mg

• n = 17
• SNRI
• Forced titration to fixed dose

Outcomes

Pain intensity

AEs

SAEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

283

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Natelson 2015  (Continued)

Withdrawal

Missing data methods

Completer-only analysis

Cochrane Database of Systematic Reviews

Funding source

Conflicts of interest

Notes

Risk of bias

Bias

Part funded by pharmaceutical: "This work was supported by a Forest Laboratories Investigator-initiat-
ed grant to B.H.N., and, in part, by National Institutes of Mental Health (NIMH) grant R01 MH100005 to
D.C.S."

"J.D.C. has been a speaker for Pfizer, Forest, Bristol Myers Squibb, Glaxo Smith Kline, Eli Lilly, and
Sunovion. He has received grants from Pfizer Pharmaceuticals, GSK, Corcept, and Neurocrine. There
were no other conflicts of interest in doing this research. This work was supported by a Forest Labora-
tories Investigator-initiated grant to B.H.N., and, in part, by National Institutes of Mental Health (NIMH)
grant R01 MH100005 to D.C.S. The sources of funding had no involvement in any of the aspects of run-
ning this study, analyzing the data, or preparing this manuscript."

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified

Allocation concealment
(selection bias)

Low risk

Mount Sinai Beth Israel Pharmacy dispensed the drug or placebo according to
the randomisation list in sequential order.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, with identical study drugs and matched dosage schedule

Low risk

Self-reported outcomes from blinded participants

High risk

Completer-only analysis

Attrition

Total: 8/34 (23.5%)

Placebo: 4/17 (23.5%)

Milnacipran 100 mg: 4/17 (23.5%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

NCT00066937 

Study characteristics

Methods

Design: parallel

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

284

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00066937  (Continued)

Duration: 8 weeks

Cochrane Database of Systematic Reviews

Assessment: baseline, post-intervention, 3-month follow-up, 6-month follow-up

Country: USA

Participants

Pain condition: temporomandibular joint disorders

Population: adults aged 18-65 with temporomandibular joint disorders

Minimum pain intensity: no

Inclusion criteria

• Age 18-65
• Pain ≤ 3 months duration due to temporomandibular joint disorder

Exclusion criteria

• Severe physical and mental health co-morbidities

Total participants randomised: 140

Age in years (mean, SD): 37.2 (11.5)

Gender: 28/140 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo (benztropine mesylate) + CBT

• n = 38
• Active placebo + CBT
• Flexible titration: benztropine titrated up from 0.125 mg every night at bedtime to a maximum dose

of 0.750 mg every night at bedtime based on treatment response and side effect profile

• 6 in-person, individual sessions of CBT for pain management

Nortriptyline + CBT

• n = 41
• TCA + CBT
• Flexible titration: nortriptyline titrated up from 25 mg every night at bedtime to a maximum dose of

150 mg every night at bedtime based on treatment response and side effect profile

• 6 in-person, individual sessions of CBT for pain management

Placebo (benztropine mesylate) + management

• n = 24
• Active placebo + management
• Flexible titration: benztropine titrated up from 0.125 mg every night at bedtime to a maximum dose

of 0.750 mgevery night at bedtime based on treatment response and side effect profile
• 6 in-person, individual sessions of temporomandibular joint disorder disease management

Nortriptyline + management

• n = 37
• TCA + management
• Flexible titration: nortriptyline titrated up from 25 mg every night at bedtime to a maximum dose of

150 mg every night at bedtime based on treatment response and side effect profile

• 6 in-person, individual sessions of temporomandibular joint disorder disease management

Outcomes

Pain intensity

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

285

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00066937  (Continued)

Mood

AEs

SAEs

Withdrawal

Missing data methods

Completer analysis

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: Johns Hopkins University. Collaborator: National Institute of Dental and Cranio-
facial Research (NIDCR)

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

Although there are matched active placebos/interventions there is not enough
information to determine blinding

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

High risk

Completer-only analysis

Attrition

Total: 24/140 (17.1%)

CBT: 5/38 (13.2%)

Nortriptyline 25-150 mg + CBT: 3/41 (7.3%)

Disease management: 5/24 (20.8%)

Nortriptyline 25-150 mg + disease management: 11/37 (29.7%)

Selective reporting (re-
porting bias)

High risk

Changed primary outcome from physical and psychosocial function to "pain"

Other bias

High risk

Not published, all information and data extracted from trial registration:
https://clinicaltrials.gov/ct2/show/study/NCT00066937

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

286

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT01225068 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Population: adults aged 18-70 with chronic neuropathic low back pain

Minimum pain intensity: ≥ 50 on 0-100 scale

Inclusion criteria

• Aged 18-70
• Low back pain for a minimum of 6 months with radiation to leg or buttocks
• ≥ 50 on 0-100 scale

Exclusion criteria

• Significant other medical disease and major psychiatric disorders excluded

Total participants randomised: 40

Age in years (mean, SD): 47.7 (10.3)

Gender: 21/40 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 20
• Inert
• Identical appearance and matched dosing schedule

Milnacipran 100-200 mg

• n = 20
• SNRI
• Flexible dose: 100-200 mg/day

Outcomes

AEs

SAEs

Withdrawal

Missing data methods

Completer analysis

Funding source

Partly funded by pharmaceutical: sponsor: Northwestern University; Collaborators: Forest Laborato-
ries; Shirley Ryan Ability; Lab Best Practice

Conflicts of interest

NR

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

287

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01225068  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical study drugs with matched dosing schedules

Low risk

Self-reported outcomes from blinded participants

High risk

Completer-only analysis

Attrition

Total: 5/40 (12.5%)

Placebo: 1/20 (5.0%)

Milnacipran 100-200 mg: 4/20 (20.0%)

Selective reporting (re-
porting bias)

High risk

Originally had lots of outcome measures listed: effect size of outcome mea-
sures, VAS pain, BPI, McGill Pain Questionnaire and Physical Activity measure-
ment), but only VAS pain reported

Other bias

High risk

Not published. All info and results extracted from trial registration: https://
clinicaltrials.gov/ct2/show/study/NCT01225068

NCT01510457 

Study characteristics

Methods

Design: parallel

Duration: approximately 8 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: knee OA

Population: adults with knee OA

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Confirmed knee OA
• Chronic pain for ≥ 6 months

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

288

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT01510457  (Continued)

Cochrane Database of Systematic Reviews

• Average pain rating of worse knee is ≥ 4 on a 0-10 scale

Exclusion criteria

• Severe or untreated psychiatric disorder (e.g. depression, anxiety)
• Severe ongoing or unaddressed medical conditions

Total participants randomised: 46

Age in years (mean, SD): 56 (8)

Gender: 23/46 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 17
• Inert
• Identical appearance and matched dosing

Milnacipran 100 mg-200 mg

• n = 29
• SNRI
• Forced titration to fixed doses

Outcomes

Pain intensity

Mood

Physical function

AEs

SAEs

Withdrawal

Missing data methods

Completer analysis only

Funding source

Pharmaceutical: Forest Laboratories

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

Blinded procedures, but 0 placebo participants reported AEs and 34% of mil-
nacipran participants did report AEs, somewhat unblinding

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

289

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01510457  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Self-reported outcomes from participants, unsure of blinding

High risk

Completer-only analysis

Attrition

Total: 8/46 (17.4%)

Placebo: 5/17 (29.4%)

Milnacipran 100-200 mg: 3/29 (10.3%)

Selective reporting (re-
porting bias)

Unclear risk

As we're using all outcomes from trial they report all registered outcomes BUT
they first posted the trial in 2012, the trial started in 2010.

Other bias

High risk

Not published - trial registry report only

Nørregaard 1995 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Denmark

Participants

Pain condition: fibromyalgia

Population: people with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Fulfilled the ACR criteria for fibromyalgia during the last year

Exclusion criteria

• Severe physical and mental health comorbidities

Total participants randomised: 43

Age in years (mean, SD): 49

Gender: NR

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 21
• Inert
• Identical appearance and sham dosing

Citalopram 20-40 mg

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

290

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nørregaard 1995  (Continued)

Cochrane Database of Systematic Reviews

• n = 21
• SSRI
• Forced titration to fixed dose depending on response: started on 20 mg a day for 4 weeks (1 tablet),
and then if participants did not report 2-point improvement then they were upped to 40 mg (2 tablets)

Outcomes

Pain intensity

Mood

Physical function

Sleep

Missing data methods

ITT but methods NR

Funding source

Pharmaceutical: "This work was supported by funding from H. Lundbeck A/S."

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical study drugs with sham dosing

Low risk

Self-reported outcomes from blinded participants

Unclear risk

State ITT but no methods specified

Attrition

Total: 10/43 (23.3%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Otto 2008 

Study characteristics

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

291

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Otto 2008  (Continued)

Methods

Design: cross-over

Duration: 5 weeks

Assessment: baseline and post-intervention

Country: Denmark

Participants

Pain condition: polyneuropathy

Cochrane Database of Systematic Reviews

Population: adults aged 20-80 with chronic polyneuropathy

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Symptoms of polyneuropathy within at least 6 months, diagnosis confirmed by physical examination
• Pain intensity ≥ 4 on 0-10 scale

Exclusion criteria

• Other pain conditions and severe physical comorbidities

Total participants randomised: 48

Age in years (median, range): 62 (37–74)

Gender: 12/48 were female

Pain duration in months (median, range): 48 (8–180)

Interventions

Placebo

• Inert
• Identical appearance and matched dosing

Escitalopram 20 mg

• SSRI
• Fixed dose

Outcomes

Pain intensity

Sleep

Mood

AEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Partly pharmaceutical: Odense University Hospital The work behind this study was supported by unre-
stricted grants from H. Lundbeck A/S and Gruenenthal GmbH and a grant from the Danish Clinical Inter-
vention Research Academy.

Conflicts of interest

This was an investigator-initiated study and neither company was responsible for the creation of the
study protocol, the data analysis, data interpretation, or writing of the manuscript.

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

292

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Otto 2008  (Continued)

Risk of bias

Cochrane Database of Systematic Reviews

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to treatment sequence was random via a computer-generated
randomisation code with a block size of 4.

Allocation concealment
(selection bias)

Low risk

The randomisation plan was generated by a person in the hospital pharma-
cy at Odense University Hospital who was not involved in the conduct of the
trial. The study drugs were packed in boxes marked with randomisation num-
ber and treatment period by the hospital pharmacy. Patients were enrolled by
the investigators and, after the baseline period, numbered consecutively by
the investigators and treated with the study drugs with the corresponding ran-
domisation number. Sealed opaque envelopes with the treatment sequence
for each patient for emergency situations were present at the study sites.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 10/41 (24.4%)

Placebo: 4/41 (9.8%)

Escitalopram 20 mg: 6/41 (14.6%)

Selective reporting (re-
porting bias)

High risk

Some outcomes mentioned prospectively on clinicaltrials.gov NR e.g. different
subtypes of pain and quality of life

Other bias

Low risk

No other sources of bias were identified

Ozerbil 2006 

Study characteristics

Methods

Design: cross-over

Duration: 2 weeks

Assessment: baseline and post-intervention

Country: Turkey

Participants

Pain condition: fibromyalgia

Population: adult women aged 20-60 with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

293

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ozerbil 2006  (Continued)

Cochrane Database of Systematic Reviews

• Aged 20-60
• Fibromyalgia according to ACR classification

Exclusion criteria

• Current or past history of systemic illness, including cardiac, renal, haematologic, or hepatic disease

Total participants randomised: 15

Age in years (mean, SD): NR

Gender: 15/15 were female

Pain duration in years (mean, SD): NR

Interventions

Amitriptyline 25 mg + placebo

• TCA + placebo
• Fixed dose
• Double-dummy design

Fluoxetine 20 mg + placebo

• SSRI + placebo
• Fixed dose
• Double-dummy design

Outcomes

The study provided no useable data

Missing data methods

Funding source

Conflicts of interest

NR

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Participants were randomised using randomisation tables

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, dummy dosing technique and identical tablets

Low risk

Researcher blinding - not enough information

Unclear risk

No information regarding missing data or withdrawal given

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

294

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ozerbil 2006  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Pakfetrat 2019 

Study characteristics

Methods

Design: parallel

Duration: 11 weeks

Assessment: baseline, 3 weeks, 7 weeks, post-intervention

Country: Iran

Participants

Pain condition: burning mouth syndrome

Population: people with burning mouth syndrome

Minimum pain intensity: ≥ 5 on 0-10 VAS

Inclusion criteria

• Daily deep bilateral burning sensation in the mouth for at least 4-6 months, persistent or increased

burning intensity throughout the day

• Pain intensity ≥ 5 on 0-10 VAS

Exclusion criteria

• Severe physical and mental health comorbidities

Total participants randomised: 47

Age in years (mean): 50.9

Gender: 32/47 were female

Pain duration in years (mean, SD): NR

Interventions

Crocin (saffron) 30 mg

• n = 26
• Plant extract
• Fixed dose
• Identical appearance to citalopram

Citalopram 20 mg

• n = 21
• SSRI
• Fixed dose

Outcomes

Pain intensity

Mood

Withdrawal

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

295

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pakfetrat 2019  (Continued)

Missing data methods

No participants withdrew

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: "We are thankful to the Vice Chancellor of Mashhad University of Medical
Sciences for providing financial support for this study".

Conflicts of interest

"The authors declare that they have no conflict of interest in this research."

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation methods not specified

Unclear risk

Mention similar package and pill appearance but citalopram is being taken
once daily and saffron twice daily so it's not completely identical in dosing
schedule.

Unclear risk

Blinding of participants who completed self reported measures is unclear

Low risk

No participants withdrew

Unclear risk

Could not access trial registration

Other bias

Low risk

No other sources of bias were identified

Patkar 2007 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: people aged 18-65 with fibromyalgia and depression

Minimum pain intensity: ≥ 5 on 0-10 scale

Inclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

296

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Patkar 2007  (Continued)

Cochrane Database of Systematic Reviews

• People aged 18-65, who fulfilled ACR diagnostic criteria for fibromyalgia
• VAS for pain score of ≥ 5 out of 10
• BDI score of ≤ 23

Exclusion criteria

• Unstable medical conditions and psychotic disorders, severe depression or anxiety

Total participants randomised: 116

Age in years (mean, SD): 48.5

Gender: 109/116 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 58
• Inert
• Identical in appearance and taste

Paroxetine 12.5-62.5 mg

• n = 58
• SSRI
• Forced titration to maximum tolerated dose
• Mean dose 39.1 (8.6) mg/day

Outcomes

Pain intensity

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: this work was supported by a Collaborative Research Grant from GlaxoSmithKline

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation (1:1) was determined by the Investigational Drug Service
through a computer-generated sequence.

Allocation concealment
(selection bias)

Low risk

The trial staff obtained the randomisation assignment over the phone at
screening. The allocation sequence was concealed from the staff before and
after assignment.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Low risk

Double-blind, study drugs identical

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

297

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Patkar 2007  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

ITT with LOCF. Double the number of people withdrew from intervention arm
than placebo

Attrition

Total: 30/116 (25.9%)

Placebo: 10/58 (17.2%)

Paroxetine 12.5-62.5 mg: 20/58 (34.5%)

Selective reporting (re-
porting bias)

High risk

Differs from protocol, though primary outcome remains the same In the pro-
tocol on clinicaltrials.gov it says that they will report change from baseline in
BDI/BAI, but they do not.

Other bias

Low risk

No other sources of bias were identified.

Petzke 2013 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention

Country: UK, Sweden, and Germany

Participants

Pain condition: fibromyalgia

Population: right-handed women, 18–55 years of age, with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 VAS

Inclusion criteria

• Right-handed women, 18–55 years of age, who met the 1990 ACR diagnostic criteria for fibromyalgia
• ≥ 40 on 0-100 pain intensity VAS

Exclusion criteria

• Severe psychiatric illness and other severe or unstable physical health conditions

Total participants randomised: 92

Age in years (mean, SD): 44.2

Gender: 92/92 were female

Pain duration in years (mean, SD): 11.1

Interventions

Placebo

• n = 46
• Inert

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

298

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Petzke 2013  (Continued)

Cochrane Database of Systematic Reviews

• Identical appearance with matched dosing

Milnacipran 200 mg

• n = 46
• SNRI
• Fixed dose, participants who could not tolerate dose were withdrawn

Outcomes

AEs

SAEs

Withdrawal

Missing data methods

MMRM for pain, NR for other outcomes

Funding source

Pharmaceutical: this study (EudraCT # 2004-004249-16) was financed and performed in collaboration
with the pharmaceutical company Pierre Fabre.

Conflicts of interest

This study (EudraCT # 2004-004249-16) was financed and performed in collaboration with the pharma-
ceutical company Pierre Fabre. There are no other conflicts of interest.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Mix of different methods used for missing data. More participants discontin-
ued in intervention arm due to AEs than placebo arm

Attrition

Total: 22/92 (23.9%)

Placebo: 8/46 (17.4%)

Milnacipran: 13/46 (28.3%)

Selective reporting (re-
porting bias)

High risk

Lots of outcomes reported in the EudraCT registration recorded at baseline
and 12 weeks that are NR in the results on there or published papers.

Other bias

Low risk

No other sources of bias were identified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

299

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pickering 2018 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Assessment: baseline and post-interventions

Country: France

Participants

Pain condition: fibromyalgia

Population: adult women with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Fibromyalgia meeting ACR criteria

Exclusion criteria

• Physical or mental health comorbidities

Total participants randomised: 54

Age in years (mean, SD): 46.7 (10.6)

Gender: 54/54 were female

Pain duration in months (mean): 71.9

Interventions

Placebo

• n = 25
• Inert
• Matched dosing

Milnacipran 100 mg

• n = 29
• SNRI
• Fixed dose

Outcomes

Pain intensity

Moderate pain relief

AEs

SAEs

Withdrawal

Missing data methods

Completer analysis only

Funding source

Non-pharmaceutical: "We thank the Apicil foundation for their financial support"

Conflicts of interest

The study authors report no conflicts of interest in this work.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

300

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pickering 2018  (Continued)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

The randomisation sequence was generated using random blocks.

Allocation concealment
(selection bias)

Low risk

Treatment allocation followed a predefined randomisation plan and was con-
ducted by a person independent from the protocol.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes from blinded participants

High risk

Completer analysis only

Attrition:

Total: 6/54 (11.1%)

Placebo: 1/29 (3.5%)

Milnacipran 100 mg: 5/25 (20.0%)

Selective reporting (re-
porting bias)

Low risk

Study protocol published: https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC4393595/

Other bias

Low risk

No other sources of bias were identified.

All outcomes matched those published

Pilowsky 1990 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Australia

Participants

Pain condition: chronic, intractable 'psychogenic' pain

Population: patients with chronic, intractable ‘psychogenic’ pain

Minimum pain intensity: no

Inclusion criteria

• Complaint of pain for at least 1 month, which is not responding adequately to appropriate treatment

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

301

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pilowsky 1990  (Continued)

Cochrane Database of Systematic Reviews

• Absence of objective evidence for the presence of any significant organic disease sufficient to explain

the presence or severity of the pain experience and degree of disability

• Impairment of functioning by at least 25% taking into account biological, personal, social, occupa-

tional and recreational aspects

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 129

Age in years (mean): 42.26

Gender: 80/129 were female

Pain duration in years (mean, SD): NR

Interventions

Amitriptyline + pyschotherapy

• n = 26
• Combined intervention: TCA + psychotherapy
• Amitriptyline: flexibly dosed up to 150 mg/day
• Psychotherapy: 12 weekly, 45-minute psychotherapy sessions focusing on "facing inner conflicts" that

were theorised to be causing physical pain

Amitriptyline + support

• n = 26
• TCA
• Amitriptyline: flexibly dosed up to 150 mg/day
• Support  to  'match'  psychotherapy:  6  x  2-weekly.  15-minute  sessions  that  focused  on  the  physical

symptoms, effects and side effects of medication

Placebo + psychotherapy

• n = 26
• Inert placebo
• Psychotherapy: 12 weekly, 45-minute psychotherapy sessions focusing on "facing inner conflicts" that

were theorised to be causing physical pain

Placebo + support

• n = 24
• Inert placebo
• Support  to  'match'  psychotherapy:  6  x  2-weekly,  15-minute  sessions  that  focused  on  the  physical

symptoms, effects and side effects of medication

Outcomes

Pain intensity

Withdrawal

Missing data methods

Completer analysis

Funding source

Non-pharmaceutical: "We are indebted to the National Health and Medical Research Council who pro-
vided generous support for the conduct of this study."

Conflicts of interest

NR

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

302

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pilowsky 1990  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised to 1 of 4 treatment groups with the use of a ta-
ble of random numbers.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

Allocation procedure not specified

High risk

No mention of blinding procedures between psychotherapy/support and
amitriptyline/placebo.

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Very different intervention experience for those undergoing psychotherapy
versus simple support. Triallists attempt to control for effects of contact in
therapy by having clincian support, but participants would be aware of their
intervention

Completer analysis only. Original numbers of participants in arms not given,
and withdrawal only given in percentages. No reasons given for withdrawal

Attrition

Total: 28/129 (21.7%)

Amitriptyline ≤ 150 mg + psychotherapy: 6/26 (24%)

Amitriptyline ≤ 150 mg + support: 7/26 (25%)

Psychotherapy: 5/26 (19%)

Support: 7/24 (31%)

Selective reporting (re-
porting bias)

High risk

Some outcome measures mentioned in the methods don't seem to be report-
ed in the results section (e.g. McGill pain questionnaire). No protocol or trial
registration found

Other bias

Low risk

No other sources of bias were identified.

Pirbudak 2003 

Study characteristics

Methods

Design: parallel

Duration: 9 months

Assessment: baseline, 2 weeks, 6 weeks, 3 months, 6 months, post-intervention

Country: Turkey

Participants

Pain condition: low back pain

Population: people aged > 35 years with chronic low back pain

Minimum pain intensity: no

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

303

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pirbudak 2003  (Continued)

Inclusion criteria

Cochrane Database of Systematic Reviews

• Chronic low back pain of at least 3 months' duration not responding to other modalities of conserva-

tive management

Exclusion criteria

• Severe clinical ailments such as cardiac disease and chronic renil failure

Total participants randomised: 92

Age in years (mean, SD): 49.1

Gender: 62/92 were female

Pain duration in months (median, range): 16.5 (6-48)

Interventions

Epidural injection + placebo

• n = 46
• Inert placebo
• Epidural injection consisted of 10 mL of betamethasone dipropionate (10 mg) + betamethasone sodi-
um phosphate (4 mg) + bupivacaine (0.25%). Injections were repeated at the end of the 2nd week if
the improvement was partial and at the end of the 6th week if there was still incomplete recovery
from pain.

• Participants took placebo tablets for 9 months in addition to the injection.

Epidural injection + amitriptyline (10-50 mg)

• n = 46
• TCA
• Amitriptyline flexibly dosed between 10 and 50 mg/day depending upon tolerance
• Epidural injection consisted of 10 mL of betamethasone dipropionate (10 mg) + betamethasone sodi-
um phosphate (4 mg) + bupivacaine (0.25%). Injections were repeated at the end of the 2nd week if
the improvement was partial and at the end of the 6th week if there was still incomplete recovery from
pain. Participants took amitriptyline tablets for 9 months in addition to the injection.

Outcomes

Pain intensity

Physical function

Missing data methods

Unclear

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

304

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pirbudak 2003  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Says double-blinded, but doesn't specify information about the medication

Unclear risk

Self-reported outcomes from participants, but unsure of blinding procedures

Unclear risk

No missing data methods and no withdrawal data reported, seems like all par-
ticipants completed but unclear

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Rani 1996 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Assessment: baseline, week 1, week 2, week 3, post-intervention

Country: India

Participants

Pain condition: chronic pain syndrome

Population: 27 presented with low back pain, 16 with OA, 8 with fibromyalgia, and 8 with RA

Minimum pain intensity: ≥ 60 on 0-100 VAS

Inclusion criteria

• People with chronic pain syndrome
• Pain intensity ≥ 60 on 0-100 VAS
• Poor response to NSAIDs after 1 month

Exclusion criteria

• Severe physical health comorbidities

Total participants randomised: 59

Age in years (mean, SD): 40

Gender: 36/59 were female

Pain duration in months (mean): 25.3

Interventions

Placebo

• n = 18
• Inert
• Identical appearance

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

305

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rani 1996  (Continued)

Amitriptyline 25 mg

• n = 20
• TCA
• Fixed dose

Fluoxetine 20 mg

• n = 21
• SSRI
• Fixed dose

Pain intensity

Withdrawal

Outcomes

Missing data methods

Unclear

Funding source

Pharmaceutical: supported by Natco Pharma Limited, India

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes from blinded participants

Unclear risk

No mention of missing data handling/impute methods, it seems like no partici-
pants dropped out but this is unclear

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Raskin 2005 

Study characteristics

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

306

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Raskin 2005  (Continued)

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: "Worldwide"

Cochrane Database of Systematic Reviews

Participants

Pain condition: diabetic peripheral neuropathic pain

Population: type 1 or 2 diabetic adults with diabetic peripheral neuropathic pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus. The pain had

to begin in the feet and with relatively symmetrical onset

• Present for ≥ 6 months
• Pain intensity ≥ 4 on 0-10 scale

Exclusion criteria

• Serious or unstable illness, medical or psychological condition that might compromise participation

in the study, diagnosis of MDD, dysthymia, GAD

Total participants randomised: 348

Age in years (mean, SD): 58.8 (10.1)

Gender: 186/348 were female

Pain duration in years (mean, SD): 4.3 (4.2)

Interventions

Placebo

• n = 116
• Inert
• Identical appearance and matched dosing

Duloxetine 60 mg

• n = 116
• SNRI
• Fixed dose

Duloxetine 120 mg

• n = 116
• SNRI
• Fixed dose

Outcomes

Pain intensity

Mood

Sleep

Moderate pain relief

Substantial pain relief

PGIC

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

307

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Raskin 2005  (Continued)

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: funded by Eli Lilly

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to treatment groups was determined by a computer-generated
random sequence

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Allocation to treatment groups using an Interactive Voice Response System

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

ITT with LOCF. Significantly more people in the duloxetine 120 mg arm
dropped out due to AE than other arm

Attrition

Total: 52/348 (14.9%)

Placebo: 16/116 (13.8%)

Duloxetine 60 mg: 15/116 (12.9%)

Duloxetine 120 mg: 21/116 (18.1%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Razazian 2014 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

308

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Razazian 2014  (Continued)

Assessment: baseline, 2 days, 7 days, 14 days, 1 week post-intervention

Country: Iran

Participants

Pain condition: diabetic polyneuropathy

Population: adults with diabetic polyneuropathy referred to diabetic clinic

Minimum pain intensity: ≥ 40 on 0-100 scale

Inclusion criteria

• Diagnosis  of  metabolically  stable  type  1  or  2  diabetes  with  diabetic  polyneuropathy  according  to

the Boulton 2005 criteria

• History of neuropathic pain for at least 3 months
• Pain intensity of ≥ 40 on 0-100 scale

Exclusion criteria

• Any other pain condition, severe medical conditions including severe depression and psychotic dis-

orders

Total participants randomised: 257

Age in years (mean, SD): 56.3 (10.4)

Gender: 156/257 were female

Pain duration in months (mean, SD): 23.5 (2.5)

Interventions

Carbamazepine 400 mg

• n = 85
• Anticonvulsant
• Fixed dose

Pregabalin 150 mg

• n = 86
• Anticonvulsant
• Fixed dose

Venlafaxine 150 mg

• n = 86
• SNRI
• Fixed dose

Outcomes

Moderate pain relief

Substantial pain relief

Sleep

Mood

AEs

SAEs

Withdrawal

Missing data methods

NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

309

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Razazian 2014  (Continued)

Funding source

Non-pharmaceutical: Kermanshah Univesity Of Medical Science

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised via a computer-generated randomisation
schedule

Allocation concealment
(selection bias)

Low risk

Investigators and participants were blinded to the treatments by preprinted
medication code labels.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

States double-blind but drugs not identical and dosage schedule differs be-
tween participants: venlafaxine taken as tablet twice daily, pregabalin as cap-
sule once daily and carbamazepine twice daily as tablet

High risk

Self-reported outcomes from participants, but not strict blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

No methods for dealing with missing data specified, think they present com-
pleter analysis.

Attrition

Total: 33/257 (12.8%)

Carbamazepine 400 mg: 7/85 (8.2%)

Pregabalin 150 mg: 9/86 (10.5%)

Venlafaxine 150 mg: 17/86 (19.8%)

Selective reporting (re-
porting bias)

High risk

Protocol not very clear, mention reporting 30th day as outcome time point but
in article it's the 35th day. Did not mention work interference as outcome but
have included it in paper, mention primary outcome will be measured with
"PPI" and VAS but seems that PPI NR in article. Protocol registered on IRCT
while recruiting participants, only 2 outcomes specified.

Other bias

High risk

Significant difference in VAS pain between groups at baseline

RBR-5dsrhv 

Study characteristics

Methods

Design: parallel

Duration: 16 weeks

Assessment: baseline and post-intervention

Country: Brazil

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

310

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

RBR-5dsrhv  (Continued)

Participants

Pain condition: temporomandibular pain

Population: women aged 18-59 with chronic temporomandibular pain

Minimum pain intensity: intensity of muscle pain ≥ 7 on a 0-10 VAS

Inclusion criteria

• Women between 18 and 59 with chronic temporomandibular pain
• Intensity of muscle pain ≥ 7 on a 0-10 VAS

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 96

Age in years (mean): 35.9

Gender: 96/96 were female

Pain duration in years (mean, SD): NR

Interventions

Waitlist

• n = 24
• Participants kept on a waiting list for 4 months and instructed not to receive any other treatment for

temporomandibular pain with telephone calls every 2 weeks

Amitriptyline 10 mg

• n = 24
• TCA
• Fixed dose

Amitriptyline 10 mg + splint

• n = 24
• Combined intervention: TCA + splint
• Amitriptyline = fixed dose
• Use of an occlusal plaque stabiliser without occlusal guide during sleep

Acupuncture

• n = 24
• Weekly acupuncture performed by acupuncturist dental surgeons, totaling 16 sessions, with needling

time of 20 min

Outcomes

Pain intensity

Mood

Quality of life

Sleep

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Non-pharmaceutical: thanks the CAPES scholarship for fund

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

311

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

RBR-5dsrhv  (Continued)

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised by means of random numbers generated by
computer

Allocation concealment
(selection bias)

Low risk

The randomisation of patients in the 4 groups was carried out by means of
opaque and sealed envelopes encoded by 'A', 'B', 'C' or 'D', prepared by a re-
searcher without contact with the other procedures.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

It was not possible to blind the participants and the clinicians due to the na-
ture of the interventions.

High risk

Self-reported outcomes from unblinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer analysis only. Unequal attrition - many more participants withdrew
from the acupuncture group than the other groups.

Attrition

Total: 18/96 (18.75%)

Waitlist: 3/24 (12.5%)

Amitriptyline 10 mg: 3/24 (12.5%)

Amitriptyline 10 mg + splint: 1/24 (4.2%)

Acupuncture: 11/24 (45.8%)

Selective reporting (re-
porting bias)

Unclear risk

Trial was registered on the Brazilian Registry of Clinical Trials after completion.

Other bias

Unclear risk

Extracted from a doctoral thesis translated from Portuguese - can't find pub-
lished papers

Richards 2015 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: pain from spinal cord injury

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

312

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Richards 2015  (Continued)

Population: adults aged 18-64 with spinal cord injury and dysthymia/major depression

Minimum pain intensity: no

Inclusion criteria

• At least 1 month post-spinal cord injury
• Meeting DSM-IV criteria for major depression or dysthymia

Exclusion criteria

• Physical health comorbidities
• History of schizophrenia or bipolar disorder; suicidal risk

Total participants randomised: 123

Age in years (mean, SD): 40 (11)

Gender: 31/123 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 59
• Inert
• Identical appearance and matched dosing

Venlafaxine 37.5 - 225 mg

• n = 64
• SNRI
• Flexible dosing dependent upon efficacy and tolerability

Outcomes

Substantial pain relief

Mood

Withdrawal

Missing data methods

NR

Funding source

Non-pharmaceutical: the contents of this article were developed under a grant from the Department of
Education, National Institute on Disability and Rehabilitation Research (grant no. H133A060107).

Conflicts of interest

Supported by Pfizer in the form of study drug (0600B1-4439). Study authors report no CoIs.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation was computer-generated by the study biostatistician

Allocation concealment
(selection bias)

Low risk

Drug allocation handled by outside pharmacy "The investigational drug ser-
vice at the lead center (University of Washington) trained and coordinated
pharmacists at all sites, provided randomisation logs, and supplied active and
placebo drug encapsulated into blinded study drug A and B."

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

313

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Richards 2015  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

Unclear risk

Missing data methods not specified

Attrition

Total: 29/123 (23.6%)

Placebo: 14/59 (23.7%)

Venlafaxine 37.5-300 mg: 15/64 (23.4%)

Selective reporting (re-
porting bias)

Low risk

Outcomes as listed on the main trial registration (https://clinicaltrials.gov/ct2/
show/study/NCT00592384)

Other bias

Low risk

No other sources of bias were identified.

Rintala 2007 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period was 8 weeks

Assessment: baseline and post-cross-over period

Country: USA

Participants

Pain condition: chronic neuropathic pain following spinal cord injury

Population: adults with a spinal cord injury at least 12 months ago with chronic neuropathic pain

Minimum pain intensity: ≥ 5 on 0-10 scale

Inclusion criteria

• Aged 18-70
• Spinal cord injury occurred at least 12 months before entering the study
• At least 1 chronic (6 months) pain component characteristic of neuropathic pain
• At least 1 neuropathic pain component rated as at least 5 on a 0-10 scale

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 38

Age in years (completers; mean, SD): 42.6 (12.6)

Gender (completers): 2/38 were female

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

314

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rintala 2007  (Continued)

Pain duration in years (completers; mean, SD): 7.3 (7.7)

Interventions

Gabapentin ≤ 3600 mg

• Anticonvulsant
• Forced titration to maximum tolerated dose
• Matched dosing schedule

Amitriptyline ≤ 150 mg

• TCA
• Forced titration to maximum tolerated dose
• Matched dosing schedule

Placebo (diphenhydramine ≤ 75 mg)

• Active placebo - antihistamine
• Forced titration to fixed dose
• Matched dosing schedule

Outcomes

Pain intensity

Moderate pain relief

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Non-pharmaceutical: supported by the Department of Veterans Affairs, Veterans Health Administra-
tion, Rehabilitation Research and Development Service (grant no. B2573R)

Conflicts of interest

"No commercial party having a direct financial interest in the results of the research supporting this ar-
ticle has or will confer a benefit upon the author(s) or upon any organisation with which the author(s)
is/are associated"

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

The order of this assignment within the sets of 6 was based on a table of ran-
dom numbers, and varied from set to set.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedure not specified

Low risk

Matched dosing regime, active comparator used as placebo, and identical cap-
sules for medication

Low risk

Self-reported outcomes from blinded participants

High risk

Completer analysis only. High levels of attrition

Attrition

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

315

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rintala 2007  (Continued)

Cochrane Database of Systematic Reviews

Total: 16/38 (42.1%)

Gabapentin ≤ 3600 mg: 12/38 (31.6%)

Amitriptyline ≤ 150 mg: 10/38 (26.3%)

Placebo: 13/38 (34.2%)

As this is a cross-over study, some participants only withdrew from one period
of the study, not the study as a whole, therefore, the numbers of participants
withdrawing per arm does not match the total numbers of participants with-
drawing.

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Robinson 2004 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: phantom/residual limb pain

Population: amputees with chronic phantom limb/residual limb pain

Minimum pain intensity: ≥ 2 on 0-10 scale

Inclusion criteria

• Aged 18-65
• Amputation > 6 months before enrollment, pain for at least 3 months, and average pain rating in the

last month of at least 2 on a scale of 0-10

Exclusion criteria

• Cardiovascular disease or seizures

Total participants randomised: 39

Age in years (mean, SD): 44.9

Gender: 5/20 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo (benztropine mesylate 0.5 mg)

• n = 19
• Active placebo
• Identical appearance

Amitriptyline

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

316

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Robinson 2004  (Continued)

Cochrane Database of Systematic Reviews

• n = 20
• TCA
• Maximum dose: 125 mg/day. Titration: week 1: 10 mg/day, week 2, 25 mg/d; week 3, 50 mg/d; week
4, 75 mg/d; week 5, 100 mg/d; and week 6, 125 mg/day. Dosages were increased by study nurse each
week until pain relief or tolerance

Outcomes

Pain

Mood

Physical function

Withdrawal

Missing data methods

ITT but no methods specified

Funding source

Conflicts of interest

Notes

Risk of bias

Bias

Non-pharmaceutical: supported by the National Institutes of Health, National Institute of Child Health
and Human Development, National Institute of Neurological Disorders and Stroke (grant no. 1PO1 HD/
NS33988)

"No commercial party having a direct financial interest in the results of the research supporting this ar-
ticle has or will confer a benefit upon the authors(s) or upon any organisation with which the author(s)
is/are associated."

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified

Allocation concealment
(selection bias)

Low risk

Provision of medication was done by the Harborview Medical Center Phar-
macy Investigational Drug Services. Medication was provided to each partici-
pant on a weekly basis by the study nurse or by mail for participants who lived
far from the study center. A 7-day supply of medication was provided to each
participant each week in identical gelatin capsules placed in a plastic holder
(Mediset), so that study personnel and participants were blind to medication
assignment

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study medication

Low risk

Self-reported outcomes from blinded participants

Low risk

No missing data methods reported, but low withdrawal

Attrition

Total: 2/39 (5.1%)

Placebo: 0/19 (0.0%)

Amitriptyline ≤ 125 mg: 2/20 (10.0%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

317

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Robinson 2004  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Outcomes not registered in protocol and protocol registered retrospectively

Other bias

Low risk

No other sources of bias were identified

Rowbotham 2004 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: diabetic peripheral neuropathy

Population: type 1 or 2 diabetic adults with diabetic peripheral neuropathy

Minimum pain intensity: ≥ 40 on 0-10 scale

Inclusion criteria

• Metabolically stable type 1 or 2 diabetes were eligible if they had symptomatic peripheral neuropathy

due only to diabetes and daily pain at moderate intensity for at least 3 months

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 245

Age in years (mean): 59

Gender: 99/245 were female

Pain duration in weeks (mean): 252.6

Interventions

Placebo

• n = 81
• Inert
• Identical appearance, double-dummy design

Venlafaxine 75 mg

• n = 82
• SNRI
• Fixed dose

Venlafaxine 150/225 mg

• n = 82
• SNRI
• Flexible dose: 150 mg/day - 225 mg/day depending on clinical response and tolerance.

Outcomes

Substantial pain relief

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

318

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rowbotham 2004  (Continued)

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Cochrane Database of Systematic Reviews

Funding source

Pharmaceutical: support for this study was provided by Wyeth Research, Collegeville, Pennsylvania.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Blinded bottles and capsules, identical dosing schedules between groups

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 43/245 (17.6%)

Placebo: 12/81 (14.8%)

Venlafaxine 75 mg: 13/82 (15.9%)

Venlafaxine 150-225 mg: 18/82 (22.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Rowbotham 2005 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

319

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rowbotham 2005  (Continued)

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: post-herpetic neuralgia

Population: people aged > 40 with post-herpetic neuralgia

Minimum pain intensity: no

Inclusion criteria

• Over the age of 40 were eligible if they had well-established post-herpetic neuralgia (defined as pain

present > 3 months after healing of the skin rash)

Exclusion criteria

• Any pain condition with greater severity than the post-herpetic neuralgia. Depression included and

measured at baseline by a psychologist

Total participants randomised: 47

Age in years (mean, range): 72 (40-84)

Gender: 27/47 were female

Pain duration in months (mean, range): 42 (3-168)

Interventions

Desipramine 25-150 mg

• n = 15
• TCA
• Flexible dose
• Mean dose taken: 93 mg/day

Amitriptyline 25-150 mg

• n = 17
• TCA
• Flexible dose
• Mean dose taken: 77 mg/day

Fluoxetine 10-60 mg

• n = 15
• SSRI
• Flexible dose
• Mean dose taken: 44 mg/day

Outcomes

Withdrawal

Missing data methods

ITT but no methods

Funding source

Non-pharmaceutical: supported by NIH program project grant NINDS 21445 and NINDS K24 NS02164

Conflicts of interest

NR

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

320

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rowbotham 2005  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

Low risk

Double-blind, double-dummy design

Low risk

Self-reported outcomes by blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Says modified ITT but doesn't mention imputation method. Higher attrition in
the fluoxetine arm than other arms

Attrition

Total: 9/47 (19.2%)

Desipramine 25-150 mg: 2/15 (13.3%)

Amitriptyline 25-150 mg: 2/17 (11.8%)

Fluoxetine 10-60 mg: 5/15 (33.3%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registry found

Other bias

Low risk

No other sources of bias were identified.

Rowbotham 2012 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: USA, Canada, France, Germany, Italy, Mexico, Puerto Rico

Participants

Pain condition: diabetic peripheral neuropathy

Population: diabetic adults with diabetic peripheral neuropathic pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• 18-75 years of age with a diagnosis of diabetes mellitus
• Painful distal symmetric diabetic polyneuropathy for P6 months and a score of ≥ 3 on the physical

assessment portion of the MNSI at the screening visit

• An average score ≥ 4 during the 7 days before the baseline visit on the 24-hour average pain scale

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

321

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rowbotham 2012  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

• Cardiovascular and mental health conditions excluded

Total participants randomised: 280

Age in years (mean, SD): NR

Gender: 128/280 were female

Pain duration in years (mean): 4.68

Interventions

Placebo

• n = 51
• Inert

Duloxetine 60 mg

• n = 57
• SNRI
• Fixed dose

ABT-894 2 mg

• n = 61
• Neuronal nicotinic acetylcholine receptor agonist
• Fixed dose

ABT-894 4 mg

• n = 56
• Neuronal nicotinic acetylcholine receptor agonist
• Fixed dose

ABT-894 8 mg

• n = 55
• Neuronal nicotinic acetylcholine receptor agonist
• Fixed dose

Outcomes

Pain intensity

Physical function

Mood

Quality of life

PGIC

AEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: Abbott Laboratories: AbbVie (prior sponsor, Abbott)

Conflicts of interest

These studies were sponsored by Abbott Laboratories. Dr Rowbotham has served as a consultant to
Abbott, Adynxx, Afferent Pharmaceuticals, Allergan, Arcion, Bristol Meyers Squibb, Cardiome, Flex-
ion, Kyowa Hakko Kirin, Neurotherapeutics Pharma, NuvoResearch, Xenon, Xenoport, and Zalicus. Dr
Stacey has received grant support from NeurogesX and Pfizer, and has served as a consultant to As-

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

322

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rowbotham 2012  (Continued)

Cochrane Database of Systematic Reviews

traZeneca, Boehringer Ingelheim, Endo Pharmaceuti-cals, NeurogesX, and Pfizer. Dr Arslanian has no
conflicts of interest to declare. Dr Zhou is an employee of Abbott. Drs Nothaft, Duan, Best, and Pritchett
are employees of Abbott and hold Abbott stock and stock options.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Patients were randomised 1:1 to each treatment arm using a randomisation
schedule that was generated before study start.

Allocation concealment
(selection bias)

Low risk

Patients were allocated to each treatment arm via an interactive voice re-
sponse system.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Not clear on blinding procedures regarding study drug appearance and dosing

Unclear risk

Self-reported outcomes from participants, but unsure of blinding

Unclear risk

States ITT but no methods reported

Attrition

Total: 43/280 (15.4%)

Placebo: 7/51 (13.7%)

Duloxetine 60 mg: 13/57 (22.8%)

ABT-894 2 mg: 8/61 (13.1%)

ABT-894 4 mg: 8/56 (14.3%)

ABT-894 8 mg: 7/55 (12.7%)

Selective reporting (re-
porting bias)

Low risk

Everything as listed in the protocol

Other bias

Low risk

No other sources of bias were identified.

Russell 2008 

Study characteristics

Methods

Design: parallel

Duration: 28 weeks

Assessment: baseline, 3 months, post-intervention

Country: USA and Puerto Rico

Participants

Pain condition: fibromyalgia

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

323

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Russell 2008  (Continued)

Population: adults with fibromyalgia with or without MDD

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Outpatients at least 18 years of age who met criteria for fibromyalgia as defined by the ACR criteria
• Score ≤ 4 on the average pain severity item of BPI
• Patients with or without current MDD were included

Exclusion criteria

• Physical health comorbidities
• Any current primary psychiatric diagnosis other than MDD

Total participants randomised: 520

Age in years (mean, SD): 51.02 (10.87)

Gender: 492/520 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 144
• Inert
• Matched dosing

Duloxetine 20 mg then 60 mg

• n = 79
• SNRI
• Forced titration to fixed dose

Duloxetine 60 mg

• n = 150
• SNRI
• Forced titration to fixed dose

Duloxetine 120 mg

• n = 147
• SNRI
• Forced titration to fixed dose

Pain intensity

Quality of life

Physical function

Mood

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Outcomes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

324

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Russell 2008  (Continued)

Withdrawal

Missing data methods

ITT with LOCF

Cochrane Database of Systematic Reviews

Funding source

Pharmaceutical: this work was sponsored by Eli Lilly and Company and Boehringer Ingelheim GmbH.

Conflicts of interest

Drs Chappell, Detke, Kajdasz, Walker, and Wohlreich are employees and stockholders of Eli Lilly and
Company. Drs Arnold, Mease, Russell, and Smith were Principal Investigators at sites conducting the tri-
al. Their sites received funds for participating in the research study. Dr Arnold has received grants/re-
search support from Eli Lilly and Company, Pfizer Inc, Cypress Biosciences Inc, Wyeth Pharmaceuticals,
Sanofi-Aventis, Boehringer Ingelheim, Allergan, and Forest; she has been a consultant for Eli Lilly and
Company, Pfizer Inc, Cypress Biosciences Inc, Wyeth Pharmaceuticals, Sanofi-Aventis, Boehringer In-
gelheim, Sepracor, Forest Laboratories Inc, Allergan, Vivus Inc, and Organon; and she is on the Speak-
ers Bureau of Eli Lilly and Company and Pfizer, Inc. Dr Mease has received grants/research support from
Eli Lilly and Company, Pfizer Inc, Cypress Bioscience, Forest, Allergan, Fralex, and Boehringer Ingel-
heim; he has been a consultant for Eli Lilly and Company, Pfizer Inc, Cypress Bioscience, Forest, Aller-
gan, Fralex, Boehringer Ingelheim, Pierre Fabre, and Wyeth; and he is on the Speakers Bureau of Pfizer
Inc. Dr Russell has received grants/research support from the National Institutes of Health, RGK Foun-
dation of Austin Texas, The National Fibromyalgia Association, Autoimmune Technologies, LLC, New
Orleans, Louisiana, LKB World (Southern France), Pfizer Central Research, Eli Lilly and Company, Or-
phan Medical/Jazz, Grutnenthal GmbH, Allergan, and Schwarz; and he is on medical advisory boards of
Pfizer Inc, Eli Lilly and Company, Jazz Pharmaceutical, Gruenthal GmbH, and Allergan. Dr Smith has re-
ceived grants/research support from Abbott, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and
Company, GlaxoSmithKline, Johnson and Johnson, Merck, Ortho-McNeil, Pfizer Inc, Minster, Novartis,
Novo Nordisk, Orexigen, Shionogi, Schwarz, Vernalis, and Wyeth; he has been a consultant or on advi-
sory boards of Allergan, Eli Lilly and Company, was previously on a medical advisory board for Eli Lilly
and Compant, GlaxoSmithKline and Merck.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to treatment groups was determined by a computer-generated
random sequence

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures not specified

Unclear risk

All participants only took 1 dose daily to maintain blinding. No information
about appearance, taste etc. Possibly some participants in the 20/60 arm
would become unblinded with the increase in dose.

Unclear risk

Self-reported outcomes but unsure of blinding

High risk

ITT with LOCF. High attrition

Attrition

Total: 24/520 (46.7%)

Placebo: 72/144 (50.0%)

Duloxetine 20 mg then 60 mg: 35/79 (44.3%)

Duloxetine 60 mg: 68/150 (45.3%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

325

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Russell 2008  (Continued)

Selective reporting (re-
porting bias)

High risk

Cochrane Database of Systematic Reviews

Duloxetine 120 mg: 68/147 (46.3%)

Not completely clear in all outcome measures to be used - only domains - in
the protocol. In the trial registry results submitted by study authors: they show
they've measured the same outcomes with multiple scales (Hamilton Depres-
sion Rating Scale and BDI-II) have also measured further outcomes like BPI in-
terference but do not report these. Have reported significant results in the trial
report.

Other bias

Low risk

No other sources of bias were identified.

Sarzi Puttini 1988 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Assessment: baseline and post-intervention

Country: Italy

Participants

Pain condition: RA

Population: adults with RA and with or without depression

Minimum pain intensity: ≥ 50 on 0-100 scale

Inclusion criteria

• Classical or definite active RA, diagnosed according to the ARA criteria
• Pain intensity ≥ 50 on 0-100 scale

Interventions

Exclusion criteria: NR

Total participants randomised: 60

Age in years (mean, SD): NR

Gender: 52/60 were female

Pain duration in years (mean, SD): NR

Placebo

• n = 30
• Inert

Dothiepin 75 mg

• n = 30
• TCA
• Fixed dose

Outcomes

Study provided no useable data

Missing data methods

Completer analysis

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

326

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sarzi Puttini 1988  (Continued)

Funding source

Conflicts of interest

NR

NR

Cochrane Database of Systematic Reviews

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation methods not specified

Unclear risk

Says matched dosing schedules but not other information given

Unclear risk

Self-reported outcomes from participants but unsure of blinding

High risk

Completer analysis only

Attrition

Total: 10/60 (16.7%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Schukro 2016 

Study characteristics

Methods

Design: cross-over

Duration: 4 weeks

Assessment: baseline and post-intervention

Country: Austria

Participants

Pain condition: chronic low back pain with a neuropathic component

Population: adults with chronic low back pain with a neuropathic component

Minimum pain intensity: ≥ 5 on 0-10 scale

Inclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

327

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schukro 2016  (Continued)

Cochrane Database of Systematic Reviews

• Aged 18-80
• Chronic low back and leg pain (> 6-month duration) and VAS score > 5cm on a 10-cm VAS scale

Exclusion criteria

• Mild depression present for > 12 months (defined as ≥ 10 points in the BDI) and severe coexisting dis-

eases

Total participants randomised: 41

Age in years (mean, SD): 57.9 (13.4)

Gender: 21/41 were female

Pain duration in months (mean, SD): 18 (6–70)

Interventions

Placebo

• Inert
• Identical appearance to duloxetine and matched dosing

Duloxetine ≤ 120 mg

• SNRI
• Fixed dose

Outcomes

Pain intensity

Physical function

Mood

Substantial pain relief

AEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: this study was supported by the Medical Scientific Fund of the Mayor of the City
of Vienna, Vienna, Austria

Conflicts of interest

The study authors declare no competing interests.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation was computer-assisted and stratified according to age and sex.

Allocation concealment
(selection bias)

Low risk

Study drugs and placebo were packaged in blue opaque capsules, which were
manufactured by the hospital pharmacy of the Medical University of Vienna,
and administered according to the assignment code, which was held by an in-
dependent study nurse.

Blinding of participants
and personnel (perfor-
mance bias)

Low risk

Double-blind, identical study drugs with matched dosing

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

328

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Schukro 2016  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF. High attrition

Attrition

Total: 20/41 (48.8%)

Placebo: 6/41 (14.6%)

Duloxetine 120 mg: 6/41 (14.6%)

7 participants dropped out after randomisation but before starting to take
study medication, and 1 participant dropped out between study periods.
Therefore the total withdrawal is 20, while only 12 participants' withdrawal
can be attributed to an arm.

Selective reporting (re-
porting bias)

High risk

Says in protocol registered on clinicaltrials.gov that participant data from the
BDI will be collected at screening, week 4 and week 10, but in the paper it was
only used as a screening tool.

Other bias

Low risk

No other sources of bias were identified.

Scudds 1989 

Study characteristics

Methods

Design: cross-over

Duration: 4 weeks per cross-over period

Assessment: baseline and post-cross-over period

Country: Canada

Participants

Pain condition: fibrositis (fibromyalgia)

Population: adults with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• widespread muscular aching lasting at least 3 months
• a non-restorative sleep pattern
• morning stiffness and fatigue
• localised tenderness at ≥ 12 of 14 specific sites

Exclusion criteria

• Severe physical health comorbidities
• Amitriptyline use in previous year

Total participants randomised: 39

Age in years (completers; mean, SD): 39.9 (10.2)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

329

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Scudds 1989  (Continued)

Gender (completers): 32/39 were female

Pain duration in years (completers; mean, SD): 5.1 (4.6)

Interventions

Placebo

• Inert
• Identical appearance to amitriptyline and matched dosing

Amitriptyline 50 mg

• TCA
• Fixed dose

Outcomes

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Non-pharmaceutical: "Supported in part by The Arthritis Society Studentship S-198 to R.A. Scudds and
NSERC Grant AO 392 10"

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures NR

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

Low risk

Completer analysis but low dropout

Attrition

Total: 3/39 (7.7%)

Placebo: 2/39 (5.13%)

Amitriptyline 50 mg: 1/39 (2.6%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

330

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sencan 2004 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline, post-intervention, follow-up (6 months)

Country: Turkey

Participants

Pain condition: fibromyalgia

Population: women aged 18-50 with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• fibromyalgia patients between ages 18–50, diagnosed by the ACR criteria

Exclusion criteria

• Physical health comorbidities

Total participants randomised: 60

Age in years (mean): 34.5

Gender: 60/60 were female

Pain duration in years (mean): 5.4

Interventions

Aerobic exercise

• n = 20
• Aerobic exercises 3 times a week for 6 weeks, each exercise period lasted for 40 minutes

Paroxetine 20 mg

• n = 20
• SSRI
• Fixed dose

Placebo TENS

• n = 20
• Placebo TENS with electrodes applied on the 2 most painful tender points for 20 minutes, 3 times a

week for 6 weeks

Outcomes

Pain intensity

Mood

Missing data methods

No participants withdrew

Funding source

Conflicts of interest

NR

NR

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

331

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sencan 2004  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

High risk

Participants unable to be blinded due to the nature of interventions

High risk

Self-reported outcomes from unblinded participants

Low risk

No participants withdrew during the trial period

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Shakiba 2018 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline, 4 weeks, post-intervention

Country: Iran

Participants

Pain condition: fibromyalgia

Population: adults aged 18-60 with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 scale

Inclusion criteria

• Aged 18-60 years who were diagnosed with fibromyalgia based on ACR criteria

Exclusion criteria

• Psychiatric disorders other than depressive disorders, serious medical conditions, other pain/inflam-

matory conditions

Total participants randomised: 54

Age in years (mean): 41.98

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

332

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shakiba 2018  (Continued)

Gender: 34/54 were female

Pain duration in years (mean, SD): NR

Interventions

Saffron 15 mg

• n = 27
• Plant extract
• Identical appearance to duloxetine

Duloxetine 30 mg

• n = 27
• SNRI
• Fixed dose

Outcomes

Pain intensity

Mood

Quality of life

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: "This study was supported by Tehran University of Medical Sciences (TUMS)
through a grant to Prof. Shahin Akhondzadeh (Grant number 31842)."

Conflicts of interest

"The authors of this manuscript declare that they have no COI. TUMS had no role in the design, con-
duct, data collection, analysis, data interpretation, manuscript preparation, review, final approval, or
decision to submit this paper for publication."

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomisation to either saffron or the duloxetine arm, was carried out in a 1:1
ratio through computerised random number generation by an independent
person.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Treatment allocation concealment was achieved using sequentially numbered
sealed opaque envelopes.

Saffron capsules were identical to duloxetine in shape, size, texture, odour,
and colour. Medications were distributed by an independent investigational
drug pharmacist.

Low risk

Self-reported outcomes from blinded participants

High risk

State that they use ITT with LOCF, but then the n in tables is completers

Attrition

Total: 8/54 (14.8%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

333

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Shakiba 2018  (Continued)

Cochrane Database of Systematic Reviews

Saffron 15 mg: 4/27 (14.8%)

Duloxetine 30 mg: 4/27 (14.8%)

Selective reporting (re-
porting bias)

Low risk

Outcomes listed prospectively: https://en.irct.ir/trial/940

Other bias

Low risk

No other sources of bias were identified

Sindrup 2003 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period lasted 4 weeks

Assessment: baseline, post-cross-over period

Country: Denmark

Participants

Pain condition: polyneuropathy

Population: adults aged 20-70 with painful polyneuropathy

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Aged 20-70
• Symptoms compatible with polyneuropathy present for > 6 months, polyneuropathy diagnosis con-

firmed by nerve conduction studies
• Pain intensity median ≥ 4 on 0-10 scale

Exclusion criteria

• Other pain conditions and severe terminal illness

Total participants randomised: 40

Age in years (mean, range): 56 (31-69)

Gender: 9/40 were female

Pain duration in months (mean, range): 51 (6-300)

Interventions

Placebo

• Inert
• Identical appearance and matched dosing
• Double-dummy design

Venlafaxine 225 mg

• SNRI
• Fixed dose, forced titration

Imipramine 150 mg

• TCA

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

334

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sindrup 2003  (Continued)

• Fixed dose, forced titration

Outcomes

AEs

Missing data methods

Completer analysis

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: supported by the Danish National Research Council (NASTRA grant no. 42820)
and the local research foundation at Odense University Hospital.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to one of the 6 possible treatment sequences was random via a
computer-generated randomisation code.

Allocation concealment
(selection bias)

Low risk

"The study drugs were packed in boxes marked with patient number and treat-
ment period. After the baseline period, the patients were numbered consecu-
tively and were treated with the study drugs with the corresponding randomi-
sation number. Sealed envelopes with treatment sequence for each patient
were present at the study sites for emergency situations."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-dummy technique, matching study drugs and package appearance

Low risk

Self-reported outcomes by blinded participants

High risk

ITT with LOCF

Attrition

Total: 7/40 (17.5%)

Not clear in which arm withdrawals occurred

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Skljarevski 2009 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

335

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Skljarevski 2009  (Continued)

Country: USA and Argentina

Participants

Pain condition: low back pain

Cochrane Database of Systematic Reviews

Population: adult patients with non-radicular chronic low back pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Clinical diagnosis of chronic low back pain with pain present on most days for ≥ 6 months
• Pain intensity ≥ 4 on 0-10 scale

Exclusion criteria

• Surgery or invasive procedures to treat low back pain
• Major depressive disorder

Total participants randomised: 404

Age in years (mean, SD): 53.9 (14.1)

Gender: 232/404 were female

Pain duration in years (mean, SD): 11.7 (11.4)

Interventions

Placebo

• n = 117
• Inert
• Identical in smell, taste and appearance to duloxetine
• Matched dosing across all arms

Duloxetine 20 mg

• n = 59
• SNRI
• Fixed dose

Duloxetine 60 mg

• n = 116
• SNRI
• Fixed dose

Duloxetine 120 mg

• n = 112
• SNRI
• Fixed dose

Outcomes

Pain intensity

Sleep

Physical function

Quality of life

Mood

PGIC

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

336

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Skljarevski 2009  (Continued)

Moderate pain relief

Substantial pain relief

AEs

SAEs

Withdrawal

Cochrane Database of Systematic Reviews

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: study design, funding and drugs were supplied by Eli Lilly and Company.

Conflicts of interest

Authors V. Skljarevski, M. Ossanna, H. Liu-Seifert, Q. Zhang, A. Chappell, S. Iyengar and M. Detke are or
were at the time of submission employees of Eli Lilly and Company and may be minor shareholders.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Patients were randomly assigned by a computer-generated random sequence.

Low risk

Participants were allocated using an Interactive Voice Response System.

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes by blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

High attrition with significantly more missing in higher dose arm due to AEs.
Use ITT and LOCF

Attrition

Total: 137/404 (33.9%)

Placebo: 35/117 (29.9%)

Duloxetine 20 mg: 16/59 (27.1%)

Duloxetine 60 mg: 36/116 (31.0%)

Duloxetine 120 mg: 50/112 (44.6%)

Selective reporting (re-
porting bias)

Low risk

Primary outcomes specified prospectively on clincialtrials.gov along with data
not presented in paper

Other bias

Unclear risk

Some baseline differences in important variables: pain history but not imbal-
anced in a way which favours treatment

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

337

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Skljarevski 2010a 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention

Country: Brazil, France, Germany, Mexico, and Netherlands

Participants

Pain condition: low back pain

Population: adults with chronic low back pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Chronic low back pain as the primary painful condition; pain must have been present in lower back
(T-6 or below) for most days for the past 6 months or longer with a weekly mean of 24-hour average
pain score of ≥ 4 out of 10 at baseline

Exclusion criteria

• Any other pain condition, current depression, psychiatric conditions

Total participants randomised: 236

Age in years (mean): 51.5

Gender: 144/236 were female

Pain duration in years (mean): 9.2

Interventions

Placebo

• n = 121
• Inert
• Sham matched dosing using same criteria as duloxetine arm

Duloxetine 60-120 mg

• n = 115
• SNRI
• Participants who did not meet reponse criteria (30% pain relief) had their doses uptitrated blindly.

Outcomes

Pain intensity

Mood

Physical function

Quality of life

Sleep

PGIC

Moderate pain relief

Substantial pain relief

AEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

338

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Skljarevski 2010a  (Continued)

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: Eli Lilly and Company

Cochrane Database of Systematic Reviews

Conflicts of interest

Notes

Risk of bias

Bias

Drs Skljarevski, Desaiah, Liu-Seifert, Zhang, Chappell, and Iyengar are employees and stockholders of
Eli Lilly and Company. Dr Detke was a full-time employee and a major stock holder of Eli Lilly andCom-
pany until March 2009 and is currently a full-time employee and a major stock holder of Medavante
Corporation. Dr Atkinson serves on Lilly Pain Advisory Board. Dr Backonja serves on Lilly Pain Advisory
Board and in addition performed clinical trials and received research funding from Allergan, Astellas,
Johnson and Johnson, Lilly,Merck, NeurogesX, and Pfizer
Corporate/Industry and Foundation funds were received in support of this work. One or more of the au-
thor(s) has/have received or will receive benefits for personal or professional use from a commercial
party related directly or indirectly to the subject of this manuscript: e.g., honoraria, gifts, consultancies,
royalties, stocks, stock options, decision-making position.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified

Allocation concealment
(selection bias)

Unclear risk

Allocation procedures not specified; only mention voice centralised system for
allocating participants to higher dose, not when randomising and allocating
all sample

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

States double blind, matched dosing but no information on study drug ap-
pearance

Unclear risk

Self-reported outcomes from participants, but uncertain of blinding proce-
dures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

ITT with LOCF. Some data are not the same in the protocol and the paper:
more AEs reported on clinicaltrials.gov than in the paper. Participants did have
significant differences as to why they have missing data: duloxetine group had
significantly more withdrawals due to AEs.

Attrition

Total: 54/236 (22.9%)

Placebo: 23/121 (19.0%)

Duloxetine 60-120 mg: 31/115 (27.0%)

Selective reporting (re-
porting bias)

Low risk

All outcomes match those registered on clinicaltrials.gov

Other bias

Low risk

No other sources of bias identified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

339

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Skljarevski 2010b 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Germany, Netherlands, Poland, Russia, Spain and USA

Participants

Pain condition: low back pain

Population: adults with chronic low back pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Outpatients with chronic low back pain as their primary painful condition present on most days for at

least 6 months and a rating of ≥ 4 on BPI pain intensity item

Exclusion criteria

• Low back surgery in previous year
• Major depressive disorder and other psychiatric disorders excluded

Interventions

Total participants randomised: 401

Age in years (mean): 54.1

Gender: 246/401 were female

Pain duration in years (mean): 8.3

Placebo

• n = 203
• Inert

Duloxetine 60 mg

• n = 198
• SNRI
• Fixed dose

Outcomes

Pain intensity

Sleep

Mood

Physical function

Quality of life

Moderate pain relief

Substantial pain relief

PGIC

AEs

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

340

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Skljarevski 2010b  (Continued)

SAEs

Withdrawal

Cochrane Database of Systematic Reviews

Missing data methods

ITT with LOCF, BOCF for sensitivity analyses of primary outcome

Funding source

Pharmaceutical: Eli Lilly and Company

Conflicts of interest

Drs Skljarevski and Desaiah, Ms Zhang, and Ms Alaka are employees of Eli Lilly and Company and hold
company stocks. Drs Palacios, Miazgowski, and Patrick were study investigators and received funding
from
Eli Lilly and Company, Indianapolis, Indiana. These external authors had access to the data relevant to
this
manuscript.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

States double-blind but no information on study drug appearance or matched
dosing

Unclear risk

Self-reprorted outcomes from participants, but uncertain of blinding proce-
dures

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Used ITT with LOCF but for primary outcome used BOCF and mBOCF for sensi-
tivity analysis. Results using all methods of imputation were significant.

Attrition

Total: 98/401 (24.4%)

Placebo: 47/203 (23.2%)

Duloxetine 60 mg: 51/198 (25.8%)

Selective reporting (re-
porting bias)

Low risk

Published outcomes match protocol

Other bias

Unclear risk

In the trial registry they've registered 2 research sites in Brazil but have just not
mentioned it anywhere after, no reason for excluding those centres stated

Smith 2013 

Study characteristics

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

341

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Smith 2013  (Continued)

Methods

Design: cross-over

Duration: cross-over periods were 5 weeks

Assessment: baseline and post-cross-over period

Country: USA

Cochrane Database of Systematic Reviews

Participants

Pain condition: neuropathic pain caused by chemotherapy

Population: adults aged ≥ 25 with cancer and neuropathic pain after completing chemotherapy

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• At least grade 1 sensory pain based on the National Cancer Institute Common Terminology Criteria for

AEs version 3.0 grading scale, for at least 3 months after completing chemotherapy

• Average pain intensity ≥ 4 on 0-10 scale
• Any cancer diagnosis

Exclusion criteria

• Severe depression, suicidal ideation, bipolar disease, alcohol abuse, a major eating disorder
• Markedly abnormal renal or liver function tests

Total participants randomised: 231

Age in years (mean, SD): 59 (10.5)

Gender: 138/231 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 116
• Inert
• Sham dosing to match duloxetine arm

Duloxetine 60 mg

• n = 115
• SNRI
• Forced titration to fixed doses

Outcomes

Pain intensity

Moderate pain relief

Substantial pain relief

Quality of life

SAEs

Withdrawal

Missing data methods

Completer analysis

Funding source

Non-pharmaceutical: This study was supported by grant CA31946 from the NCI Division of Cancer Pre-
vention, the Alliance Statistics and Data Center, and the Alliance Chairman

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

342

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Smith 2013  (Continued)

Conflicts of interest

Notes

Risk of bias

Bias

"Disclosures: all authors have completed and submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Dr Smith reported receiving support from CALGB/Alliance for travel to meetings.
Dr Paskett reported institutional support from CALGB/Alliance for travel to meetings. Dr Ahles report-
ed receiving support from CALBG/Alliance for travel to meetings. Dr Fadul reported pending institution-
al grants from Genentech. Dr Gilman reported institutional and direct grants pending from the NCI [Na-
tional Cancer Institute]. No other financial disclosures were made."

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

"Randomisation, provided by the CALGB/Alliance Statistical Center, was strati-
fied by neurotoxic drug class (taxanes vs platinums) and by pain risk (high risk
vs no risk). A computer-generated kit number was used to order the blinded
study drug from a distribution center."

"A computer-generated kit number was used to order the blinded study drug
from a distribution center. Drug labels were applied to the capsule bottles at
the distribution center before being mailed to study sites; thus, all patients
and personnel were blinded to the treatment assignment."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes by blinded participants

High risk

Mention ITT and imputation, but only report completer analysis

Attrition

Total: 33/230 (14.3%)

Placebo: 12/111 (10.8%)

Duloxetine 60 mg: 21/109 (19.3%)

Selective reporting (re-
porting bias)

Low risk

Outcomes match those on prospective trial registration on clinicaltrials.gov

Other bias

Low risk

No other sources of bias were identified.

Sofat 2017 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

343

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sofat 2017  (Continued)

Country: UK

Participants

Pain condition: hand OA

Cochrane Database of Systematic Reviews

Population: adults aged 40–75 with hand OA

Minimum pain intensity: ≥ 5 on 0-10 scale

Inclusion criteria

• Aged 40-75
• Fulfilling the ACR criteria for the diagnosis of hand OA
• Receiving usual care for hand OA including paracetamol (acetaminophen) and/or NSAIDs

Exclusion criteria

• History of depression and current uncontrolled depression/anxiety as scored by HADS excluded

Total participants randomised: 65

Age in years (mean, SD): NR

Gender: 52/65 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 22
• Inert
• Identical appearance and matched dosing to intervention arms

Pregabalin 300 mg

• n = 22
• Anticonvulsant
• Fixed dose, forced titration

Duloxetine 60 mg

• n = 21
• SNRI
• Fixed dose, forced titration

Outcomes

Pain intensity

Physical function

Mood

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: "This work was supported by The Rosetrees’ Trust, grant number M11-F1, by the
UK National Institute of Health (NIHR) Clinical Research Network and an NIHR Clinical Academic Fel-
lowship to MR"

Conflicts of interest

Disclosure: the authors report no conflicts of interest in this work.

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

344

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sofat 2017  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods not specified

Allocation concealment
(selection bias)

Low risk

The random allocation sequence, with a block size of nine, was generated by
the manufacturer and implemented through sequentially numbered contain-
ers.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 13/65 (20.0%)

Placebo: 3/22 (13.6%)

Pregabalin 300 mg: 5/22 (22.7%)

Duloxetine 60 mg: 5/21 (23.8%)

Selective reporting (re-
porting bias)

High risk

2 protocols found registed, which have different primary outcomes. The proto-
col was submitted 2.5 years after recruitment started.

Other bias

Unclear risk

Small baseline difference in groups "prior analgesic use", there was slightly
less paracetamol (acetaminophen) use at baseline before enrollment in the
duloxetine group than in the pregabalin and placebo groups, but for other
NSAIDs and opiates, analgesic use was similar in all 3 groups.

Spinhoven 2010 

Study characteristics

Methods

Design: parallel

Duration: 16 weeks

Assessment: baseline, mid-intervention, post-intervention

Country: Netherlands

Participants

Pain condition: non-cardiac chest pain

Population: adult cardiology outpatients with a diagnosis of non-cardiac chest pain

Minimum pain intensity: no

Inclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

345

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Spinhoven 2010  (Continued)

Cochrane Database of Systematic Reviews

• Aged between 18 and 75
• Non-cardiac chest pain as main presenting complaint; non-cardiac chest pain occurring at least once

a week, or at least once per month if accompanied by severe psychological distress

Exclusion criteria

• Physical and mental health comorbidities (except panic disorder)

Total participants randomised: 69

Age in years (mean): 55.9

Gender: 32/69 were female

Pain duration in years (mean): 5.4

Interventions

Placebo

• n = 23
• Inert
• Matched dosing

Paroxetine 10-40 mg

• n = 23
• SSRI
• Forced titration to maximum tolerated dose

CBT

• n = 23
• Psychological therapy
• CBT was based on a tested treatment protocol and consisted of a minimum of 6 to a maximum of 12
sessions of 45–60 minutes. The number of sessions depended on the severity of symptoms and speed
of recovery.

Outcomes

Pain intensity

Mood

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Partly funded by pharmaceutical: supported by a grant of the Dutch Heart Foundation (grant nr.
1998B209) and an unconditional educational grant of Glaxo Smith Kline.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using random permuted blocks with a length of
6.

Allocation concealment
(selection bias)

Unclear risk

States allocation by pharmacists not involved in trial, but procedure not speci-
fied

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

346

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Spinhoven 2010  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Blinding across arms not possible due to nature of CBT intervention

High risk

Self-reported outcomes from unblinded participants

High risk

ITT with LOCF and unequal attrition

Attrition

Total: 11/69 (15.9%)

Placebo: 4/23 (17.4%)

Paroxetine 10-40 mg: 7/23 (30.4%)

CBT: 0/23 (0.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

High risk

Selection bias: 379 (80%) of patients approached refused participation due to
potential of being put on paroxetine

Srinivasan 2021 

Study characteristics

Methods

Design: cross-over

Duration: cross-over periods lasted 6 weeks

Assessment: baseline and post-cross-over period

Country: India

Participants

Pain condition: painful diabetic neuropathy

Population: adults aged 18-75 with type 2 diabetes and painful diabetic neuropathy

Minimum pain intensity: ≥ 50 on 0-100 scale

Inclusion criteria

• Diabetic neuropathic pain present for at least 1 month
• Mean pain intensity of > 50% by patient assessment by VAS

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 67

Age in years (mean, SD): 49 (4)

Gender: 32/67 were female

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

347

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Srinivasan 2021  (Continued)

Pain duration in years (mean, SD): 28 (6)

Interventions

Naltrexone 4-8 mg

• Opioid receptor antagonist
• Identical appearance to amitriptyline
• Flexible dosing between 2 mg and 4 mg
• Mean dose: 3.84 mg/day

Amitriptyline 10-50 mg

• TCA
• Flexible dosing between 25 mg and 50 mg
• Mean dose: 24.02 mg/day

Outcomes

PGIC

AEs

Withdrawal

Missing data methods

ITT with multiple imputation

Funding source

Non-pharmaceutical: postgraduate Institute of Medical Education and Research

Conflicts of interest

The authors have no COI pertaining to this study. The authors are thankful to M/s. Sun Pharmaceutical
Industries Limited, Mumbai (India), and M/s. Wockhardt Pharmaceuticals, Mumbai (India), for providing
the pure naltrexone active pharmaceutical ingredient and amitriptyline tablets, respectively, for this
study.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

The randomisation codes were generated by a random block randomisation
method using the “random allocation software.”

Allocation concealment
(selection bias)

Low risk

"The blinding and allocation concealment was maintained by labeling the
container with the serial numbers provided for each randomisation code by
a person not related to the trial. The drugs were dispensed by an investiga-
tor who was neither involved in screening nor involved in evaluating the end
points of the study."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Double-blind, identical appearance and dosing

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Multiple imputation techniques (multivariate imputation by chained equa-
tions) was used to deal with the missing values for ITT. Low dropouts, balanced
across arms

Attrition

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

348

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Srinivasan 2021  (Continued)

Total: 7/67 (10.5%)

Naltrexone 2-4 mg: 2/67 (3.0%)

Amitriptyline 25-50 mg: 5/67 (7.5%)

Selective reporting (re-
porting bias)

Unclear risk

Trial registered retrospectively

Other bias

Low risk

No other sources of bias were identified.

Cochrane Database of Systematic Reviews

Staud 2015 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia

Minimum pain intensity: ≥ 4 on 0-10 VAS

Inclusion criteria

• Fulfill the 1990 ACR criteria for fibromyalgia including widespread pain

Exclusion criteria

• Significant comorbidities: MDD, anxiety disorders and other chronic illnesses

Total participants randomised: 61

Age in years (mean, SD): NR

Gender: 56/61 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 30
• Inert
• Identical appearance and matched dosing

Milnacipran 100 mg

• n = 31
• SNRI
• Fixed dose

Outcomes

Pain intensity

Mood

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

349

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Staud 2015  (Continued)

Withdrawal

Missing data methods

ITT with LOCF

Cochrane Database of Systematic Reviews

Funding source

Pharmaceutical: This study was supported by an investigator-initiated grant from Forest Laboratories.
All study drugs were provided by Forest Laboratories.

Conflicts of interest

Funded by an investigator-initiated grant from Forest Laboratories. All study drugs were provided by
Forest Laboratories. The sponsors of this trial had no role in planning and implementing the study,
and in the analysis of the data. They were not involved in the writing of this report. None of the authors
have any financial or other relationships that might lead to a COI.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using Research Randomizer (http://www.ran-
domizer.org/)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedure not specified

Low risk

Double-blind, identical study drugs with matched dosing

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Similar attrition in both arms, report that they will use LOCF for missing data
but then state that as "missing data did not result in different conclusions, we
report only the results of uncorrected analyses", so completer analysis.

Attrition

Total: 26/62 (41.9%)

Placebo: 5/23 (21.7%)

Milnacipran 100 mg: 6/23 (26.1%)

15 participants (8 milnacipran, 7 placebo) withdrew post-randomisation prior
to receiving study medication, so were not included in the arm-specific totals
above. No reasons were given for the withdrawals of these 15 participants.

Selective reporting (re-
porting bias)

High risk

Protocol only lists mechanical and heat hyperalgesia and clinical pain as out-
comes. Doesn't specify how these will be collected or the other measures used
in the study.

Other bias

High risk

Create a second baseline essentially: a lot of participants withdrew after ran-
domisation and so the authors ignore that in final analysis and only include
those who came back for a second study visit.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

350

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Suttiruksa 2016 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline, 5 weeks, 9 weeks, post-intervention

Country: Thailand

Participants

Pain condition: fibromyalgia

Population: Thai adults with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 VAS

Inclusion criteria

• Patients of Thai ethnicity who were ≥ 18 years with a diagnosis of fibromyalgia as defined by the ACR

criteria

• Moderate pain: ≥ 40 on 0-100 VAS

Exclusion criteria

• Substance abuse and comorbid inflammatory rheumatic diseases

Total participants randomised: 40

Age in years (mean): 44.7

Gender: 40/40 were female

Pain duration in years (mean): 3.5

Interventions

Placebo

• n = 13
• Inert
• Identical appearance and matched dosing

Mirtazapine 15 mg

• n = 13
• NaSSA
• Fixed dose, forced titration

Mirtazapine 30 mg

• n = 14
• NaSSA
• Fixed dose, forced titration

Outcomes

Pain intensity

Mood

Physical function

SAEs

Withdrawal

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

351

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Suttiruksa 2016  (Continued)

Missing data methods

ITT but no methods specified

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: This work was supported by the Office of theHigher Education Commission, Thai-
land through a grant in the program “Strategic Scholarships for Frontier Research Network for the PhD
Program, Thai Doctoral degree”.

Conflicts of interest

The authors declare that there is no COI in this research.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

The patients were allocated using a block size of 3 in a ratio of 1:1:1 with par-
allel assignment to 1 of 3 groups, using a pharmacy-controlled randomisation
process with a random number table.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Sequentially numbered identical containers that were administered serially

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes by blinded participants

Unclear risk

ITT but no methods specified

Attrition

Total: 8/40 (20.0%)

Placebo: 3/13 (23.1%)

Mirtazapine 15 mg: 2/13 (15.4%)

Mirtazapine 30 mg: 3/14 (21.4%)

Selective reporting (re-
porting bias)

Unclear risk

Trial protocol registered online is for multiple studies (https://clinicaltrial-
s.gov/ct2/show/NCT00919295)

Other bias

Low risk

No other sources of bias were identified

Talley 2008 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

352

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Talley 2008  (Continued)

Country: Australia

Participants

Pain condition: IBS

Cochrane Database of Systematic Reviews

Population: people with IBS

Minimum pain intensity: ≥ 3 on 0-10 scale

Inclusion criteria

• Diagnosis of IBS following specialist consultation
• Pain intensity of ≥ 3 on 0-10 scale

Exclusion criteria

• Major uncontrolled physical or mental health conditions

Total participants randomised: 51

Age in years (mean, SD): NR

Gender: NR

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 16
• Inert
• Identical appearance
• Double-dummy design

Imipramine 50 mg

• n = 18
• TCA
• Fixed dose, forced titration

Citalopram 40 mg

• n = 17
• SSRI
• Fixed dose, forced titration

Outcomes

Pain intensity

Mood

Physical function

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Non-pharmaceutical: this work was supported by the National Health and Medical Research Council of
Australia (Dr Talley, PI).

Conflicts of interest

NR

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

353

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Talley 2008  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Patients were randomised to one of the 3 treatment arms using a comput-
er-generated random list.

Allocation concealment
(selection bias)

Low risk

Concealed allocation was assured by a central drug distribution from the hos-
pital pharmacy.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Double-blind, identical study drugs, double-dummy design

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

ITT with LOCF. Very unequal attrition between arms, high attrition for
imipramine

Attrition

Total: 17/51 (33.3%)

Placebo: 3/16 (18.8%)

Imipramine 50 mg: 9/18 (50.0%)

Citalopram 40 mg: 5/17 (29.4%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Tammiala-Salonen 1999 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Finland

Participants

Pain condition: burning mouth syndrome

Population: women with burning mouth syndrome

Minimum pain intensity: ≥ 30 on 0-100 VAS

Inclusion criteria

• Daily, or almost daily, oral burning pain that had lasted ≥ 6 months
• Moderate pain intensity: ≥ 30 on 0-100 VAS

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

354

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tammiala-Salonen 1999  (Continued)

Exclusion criteria: NR

Total participants randomised: 37

Age in years (mean, range): 58.6 (39-71)

Gender: 37/37 were female

Pain duration in years (mean, range): 2.8, (6 months-20 years)

Interventions

Placebo

• n = 19
• Inert
• Identical appearance to trazodone and matched dosing

Trazodone 200 mg

• n = 18
• SARI
• Fixed dose, forced titration

Outcomes

Withdrawal

Missing data methods

Completer analysis

Funding source

Non-pharmaceutical: the study was supported by the Finnish Dental Society.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer analysis only. Unequal attrition - more participants withdrew due
to AEs in the intervention arm than the placebo arm

Attrition

Total: 9/37 (24.3%)

Placebo: 2/19 (10.5%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

355

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tammiala-Salonen 1999  (Continued)

Trazodone 200 mg: 7/18 (38.9%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Tanum 1996 

Study characteristics

Methods

Design: parallel

Duration: 7 weeks

Assessment: baseline, 3 weeks, post-intervention, follow-up (4 weeks after taper)

Country: Norway

Participants

Pain condition: functional gastrointestinal disorder

Population: adults aged 18-70 functional gastrointestinal disorder

Minimum pain intensity: no

Inclusion criteria:

• Aged between 18 and 70 years of age and have a diagnosis of functional gastrointestinal disorder es-

tablished by a gastroenterologist

• Continuous or chronic intermittent gastrointestinal pain and distress, located in the upper and/or
lower gastrointestinal tract, had to be present during at least the past 12 months. The symptoms had
to be present more days in a week than not, and if there were symptom-free intervals, they could not
exceed 5 days in a row.

Exclusion criteria

• Severe physical comorbidity; depression, mood and affective disorders

Total participants randomised: 49

Age in years (mean): 37.3

Gender: 32/49 were female

Pain duration in years (mean, SD): 8.3 (9.2)

Interventions

Placebo

• n = 22
• Inert
• Identical appearance and matched dosing

Mianserin

• n = 25
• TeCA
• Fixed dose, forced titration

Outcomes

Pain intensity

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

356

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tanum 1996  (Continued)

Substantial pain relief

Withdrawal

Missing data methods

ITT with LOCF

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: the study was on request supported by an educational grant from NV Organon,
Oss, The Netherlands

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

Low risk

ITT with LOCF, but low attrition

Attrition

Total: 2/49 (4.1%)

Placebo: 0/22 (0.0%)

Mianserin 120 mg: 2/27 (7.4%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Tasmuth 2002 

Study characteristics

Methods

Design: cross-over

Duration: cross-over periods were 4 weeks

Assessment: baseline and post-cross-over period

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

357

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tasmuth 2002  (Continued)

Country: Finland

Participants

Pain condition: neuropathic pain following breast cancer treatment

Cochrane Database of Systematic Reviews

Population: women with neuropathic pain following treatment of breast cancer

Minimum pain intensity: moderate severity (no numerical scale)

Inclusion criteria

• Neuropathic pain after treatment for breast cancer. The pain had to be in the anterior chest wall and/

or axilla and/or median upper arm in an area with sensory disturbances.

• The pain had to be at least moderate in severity.

Exclusion criteria

• Free of relapses or metastases of the breast cancer and free from clinically overt cardiac, renal or he-

patic disease

Total participants randomised: 15

Age in years (mean, range): 55 (37-72)

Gender: 15/15 were female

Pain duration in months (mean, range): 20 (18-26)

Interventions

Placebo

• Inert
• Matched dosing

Venlafaxine ≤ 75 mg

• SNRI
• Flexible titration to highest possible dose: dose was increased by 18.75 mg every week to the highest

tolerable dose or ceiling (75 mg)

Outcomes

The study provided no useable data

Missing data methods

NR

Funding source

Non-pharmacetucal: financial support was received from the Helsinki University Central Hospital Re-
search Funds.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Hospital pharmacy performed the randomisation using computer-generated
numbers

Allocation concealment
(selection bias)

Unclear risk

States that hospital pharmacy performed randomisation but not how this was
allocated

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

358

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tasmuth 2002  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

States double-blind, matched dosing, but no information regarding appear-
ance of study drugs

Unclear risk

Self-reported outcomes by blinded participants, but unsure of blinding meth-
ods

Unclear risk

Low attrition, but not explained fully (i.e. during which period dropout hap-
pened)

Attrition

Total: 2/15 (13.3%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Tesfaye 2013 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline to post-intervention

Country: Australia, Canada, Croatia, France, Germany, Greece, Italy, South Korea, Mexico, Netherlands,
Poland, Spain, Sweden, Switzerland, Turkey, UK

Participants

Pain condition: diabetic neuropathy

Population: adults with diabetes type 1 or 2 and diabetic neuropathy

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus, beginning in

the feet in a relatively symmetrical fashion

• Daily pain should have been present for at least 3 months and the diagnosis had to be confirmed by

a score of ≥ 3 on the MNSI at screening
• 24-hour average pain severity of ≥ 4 on BPI

Exclusion criteria

• Any suicidal risk as judged by the investigator or as defined by a score of ≤ 2 on item 9 of the BDI II

Total participants randomised: 811

Age in years (mean): 61.7

Gender: 356/804 were female

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

359

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tesfaye 2013  (Continued)

Pain duration in years (mean, SD): NR

Interventions

Duloxetine 60 mg

• n = 401
• SNRI
• Fixed dose, forced titration

Pregabalin 300 mg

• n = 403
• Anticonvulsant
• Fixed dose, forced titration
• Identical capsules to duloxetine

Outcomes

Pain intensity

Physical function

Mood

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Conflicts of interest

Pharmaceutical: The sponsor, Eli Lilly & Company (Indianapolis, IN, USA), was involved in study design,
in the collection, analysis, and interpretation of data, in the writing of the manuscript, and in the deci-
sion to submit the paper for publication.

The sponsor, Eli Lilly & Company (Indianapolis, IN, USA), was involved in study design, in the collection,
analysis, and interpretation of data, in the writing of the manuscript, and in the decision to submit the
paper for publication.
Stefan Wilhelm, Alexander Schacht, and Vladimir Skljarevski own stock in and are Lilly employees. Al-
berto Lledo, former Lilly employee, owns Lilly stocks. Solomon Tesfaye, Thomas T√∂lle, Didier Bouhas-
sira, Giorgio Cruccu, and Rainer Freynhagen have received economic compensation for participation in
the Lilly EU Pain Advisory Board.

Solomon Tesfaye declares having received honoraria for invited lectures from Eli Lilly & Company and
Pfizer Inc. Thomas Tolle reports consultancy and invited lectures for Grunenthal, Mundipharma, Biogen
Idec, Hexal, Pfizer Inc., Janssen-Cilag, Astellas, Pharmaleads, Boehringer-Ingelheim, Eli Lilly & Compa-
ny, and Esteve. Didier Bouhassira has served on the Speakers‚Äô Bureau for Eli Lilly & Company, Pfiz-
er Inc., and Astellas, and has worked as a consultant to Eli Lilly & Company, Pfizer Inc., Sanofi-Aventis,
SanofiPasteur-MSD, Astra Zeneca, and Astellas and has received research support from Pfizer Inc. Gior-
gio Cruccu has received fees for advisory boards and for lectures by Astellas, Eli Lilly & Company, and
Pfizer Inc.

Rainer Freynhagen has received consultancy and speaker fees in the past 12 months from Astellas, Epi-
onics, Grunenthal, Forrest Research, HRA, Eli Lilly & Company, and Pfizer.

All authors have made substantial contribution to conception and design of the COMBO-DN study, or
analysis or interpretation of the data or revising the manuscript critically for important intellectual con-
tent. Alberto Lledo was responsible for generating the primary hypothesis of the study and reviewed

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

360

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tesfaye 2013  (Continued)

Cochrane Database of Systematic Reviews

the manuscript critically. Solomon Tesfaye, Thomas Tolle, Didier Bouhassira, Giorgio Gruccu, and Rain-
er Freynhagen were involved in the early conception of the study, the selection of the primary and sec-
ondary objectives and the final review of the manuscript. Alexander Schacht was responsible for build-
ing the final statistical plan. Stefan Wilhelm and Alexander Schacht were responsible for data collection
and extraction and completion of the final study report. Solomon Tesfaye and Stefan Wilhelm wrote
the primary version of the manuscript and Vladimir Skljarevski reviewed the manuscript critically with
regard to interpretation of the data.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"At the start of the initial therapy period, patients were randomised in a 1:1:1:1
ratio to 4 parallel groups stratiﬁed by site, based on a computer-generated se-
quence"

Allocation concealment
(selection bias)

Low risk

Participants were allocated using a centralised interactive voice response sys-
tem.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 138/811 (17.1%)

Pregabalin 300 mg: 70/403 (17.4%)

Duloxetine 60 mg: 68/401 (17.0%)

Selective reporting (re-
porting bias)

Low risk

Outcomes match trial registration

Other bias

Low risk

No other sources of bias identified

Trugman 2014 

Study characteristics

Methods

Design: parallel

Duration: 7 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

361

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Trugman 2014  (Continued)

Population: adults with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

Cochrane Database of Systematic Reviews

• Aged 18-70 years of age, who met the 1990 ACR criteria for fibromyalgia

Exclusion criteria

• Excluded major conditions, those with history of hypertension were included. Excluded active or un-

stable mental illness

Total participants randomised: 321

Age in years (mean): 49.2

Gender: 264/321 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 110
• Inert
• "matched"

Milnacipran

• n = 210
• SNRI
• Fixed dose, forced titration

AEs

SAEs

Withdrawal

Outcomes

Missing data methods

Unclear

Funding source

Pharmaceutical: The study was sponsored by Forest Laboratories Inc. in collaboration with Cypress
Bioscience Inc. (acquired by Royalty Pharma).

Conflicts of interest

J.M.T., R.H.P. and Y.M. are all full-time employees with Forest Research Institute Inc., a wholly owned
subsidiary of Forest Laboratories Inc. CMRO peer reviewers may have received honoraria for their re-
view work. The peer reviewers on this manuscript have disclosed that they have no relevant financial
relationships.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

362

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Trugman 2014  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Unclear blinding of study drugs, says "matched" but no other information

Unclear risk

Self-reported outcomes from participants, uncertain of blinding procedures

Unclear risk

Unclear missing data methods

Attrition

Total: 75/321 (23.4%)

Placebo: 25/111 (22.5%)

Milnacipran 200 mg: 50/210 (23.8%)

Selective reporting (re-
porting bias)

Low risk

Primary outcomes match those registered prospectively on clinicaltrials.gov

Other bias

High risk

Outcomes extracted from published paper, but these are very different to
what's registered in the trial registry results

Tétreault 2016 

Study characteristics

Methods

Design: parallel

Duration: 16 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: knee OA

Population: adults aged 45-80 with knee OA

Minimum pain intensity: ≥ 5 on 0-10 scale

Inclusion criteria

• Diagnosed by a clinician for knee OA, fulfilled ACR criteria, and had knee pain for at least 1 year
• Knee pain intensity of at least 4/10

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 40

Age in years (mean, SD): 58.7 (7.6)

Gender: 21/40 were female

Pain duration in years (mean, SD): 10.54 (9.1)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

363

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tétreault 2016  (Continued)

Interventions

Placebo

Cochrane Database of Systematic Reviews

• n = 21
• Inert
• Identical appearance to duloxetine, matched dosing

Duloxetine 60 mg

• n = 19
• SNRI
• Fixed dose, forced titration

Outcomes

Pain intensity

Physical function

Mood

AEs

SAEs

Missing data methods

Completer-only analysis

Funding source

Partly pharmaceutical: Eli Lilly Pharmaceuticals (IIT number: F1J-US-XO61). This research was also par-
tially supported by grants from National Institute of Neurological Disorders and Stroke, ninds.nih.gov
(NS035115), and National Center for Complementary and Integrative Health, nccih.nih.gov (AT007987)
of the US National Institutes of Health. PT was supported by postdoctoral fellowships from the Canadi-
an Institutes of Health Research (CIHR), cihr-irsc.gc.ca.

Conflicts of interest

No financial or other relationships that might lead to a COI

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

High risk

Completer analysis only

Attrition

Total: 21/60 (35.0%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

364

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tétreault 2016  (Continued)

Selective reporting (re-
porting bias)

Attrition per arm NR

Low risk

Outcomes match those in the protocol

Other bias

Low risk

No other sources of bias identified

Uchio 2018 

Study characteristics

Methods

Design: parallel

Duration: 14 weeks

Assessment: baseline and post-intervention

Country: Japan

Participants

Pain condition: knee OA

Population: adults aged 40-80 with chronic knee pain due to OA

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Outpatients aged 40 to < 80 years were eligible if they had experienced pain for ≥ 14 days/month during

the 3-month period before Visit 1
• BPI-Severity average pain score of ≥ 4
• Patients needed to satisfy the ACR criteria for idiopathic knee OA

Exclusion criteria

• Physical and mental health comorbidities

Total participants randomised: 354

Age in years (mean): 65.9

Gender: 274/354 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 176
• Inert
• Identical appearance to duloxetine

Duloxetine 60 mg

• n = 177
• SNRI
• Fixed dose, forced titration

Outcomes

Pain intensity

Sleep

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

365

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Uchio 2018  (Continued)

Cochrane Database of Systematic Reviews

Quality of life

Mood

Physical function

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF and BOCF

Funding source

Pharmaceutical: Eli Lilly and Company and Shionogi

Conflicts of interest

TT is an employee of and owns stock in Shionogi Co. Ltd. HE, SF, NS, and HT are employees of Eli Lilly
Japan K.K. SF and HE own stock in Eli Lilly and Company. YU has been a member of a Board of Directors
and Speakers' Bureau and had a consulting role with Eli Lilly Japan K.K.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Randomised participants an Interactive Web Response System and stochastic
minimisation method

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Participants were allocated using an Interactive Web Response System

Low risk

Double-blind, identical capsules for study drugs, matched doses

Low risk

Self-reported outcomes by blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low attrition. Missing data were imputed using the LOCF, BOCF, or the mod-
ified BOCF. These findings were consistent for all missing data imputation
methods.

Attrition

Total: 31/354 (8.8%)

Placebo: 14/176 (8.0%)

Duloxetine 60 mg: 17/178 (10.0%)

Selective reporting (re-
porting bias)

Low risk

Some results for outcomes (BDI, Patient Global Assessment of Illness) reported
on clinicaltrials.gov but not in the paper

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

366

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Uchio 2018  (Continued)

Other bias

Low risk

No other sources of bias were identified.

Urquhart 2018 

Study characteristics

Methods

Design: parallel

Duration: 24 weeks

Assessment: baseline, 3 months, post-intervention

Country: Australia

Participants

Pain condition: low back pain

Population: people aged 18-75 with chronic non-specific low back pain

Minimum pain intensity: no

Inclusion criteria

• Aged 18–75 years with chronic, nonspecific low back pain lasted > 3 months

Exclusion criteria

• Current physical or mental health comorbidities
• Previously diagnosed depression

Total participants randomised: 146

Age in years (mean, SD): 54.8 (13.7)

Gender: 53/146 were female

Pain duration in years (mean): 14.3

Interventions

Placebo (benzotropine mesylate 1 mg)

• n = 74
• Active placebo
• Identical appearance, matched dosing

Amitriptyline 25 mg

• n = 72
• TCA
• Fixed dose, no titration

Outcomes

Pain intensity

Physical function

Mood

Quality of life

AEs

Withdrawal

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

367

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Urquhart 2018  (Continued)

Missing data methods

ITT using multiple imputation with chained equations

Funding source

Non-pharmaceutical: "This work was supported by theNational Health and Medical Research Coun-
cil(NHMRC, Australia, ID 1024401). Drs Urquhart, Wluka, and Wang are recipients of NHMRC Career De-
velopment Fellowships (Clinical Level 1 No.1011975; Clinical Level 2 No. 1063574; Clinical Level1 No.
1065464, respectively)"

Conflicts of interest

None reported

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Randomisation was based on computer-generated random numbers pre-
pared by a statistician who had no involvement in trial conduct."

Allocation concealment
(selection bias)

Low risk

"The use of a central allocation that involved pharmacy-controlled randomisa-
tion ensured that the allocation could not be accessed by research personnel."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Double-blind, active placebo, identical appearance, matched dosing

Low risk

Self-reported outcomes by blinded participants

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Uses multiple imputation by chained equations, presents comparisons with no
multiple imputation

Attrition

Total: 28/146 (19.2%)

Placebo: 15/74 (20.3%)

Amitriptyline 25 mg: 13/72 (18.1%)

Selective reporting (re-
porting bias)

Low risk

Matches protocol. Explains why Descriptor Differential Scale is NR (partici-
pants had difficulty filling it in)

Other bias

Low risk

No other sources of bias

Vahedi 2005 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline, post-intervention, follow-up (4 weeks post-intervention)

Country: Iran

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

368

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vahedi 2005  (Continued)

Participants

Pain condition: IBS

Cochrane Database of Systematic Reviews

Population: people with pain and constipation-predominant IBS

Minimum pain intensity: no

Inclusion criteria

• People with pain and constipation-predominant IBS as defined by the Rome II criteria were included

Exclusion criteria

• Physical and severe mental health comorbidities

Total participants randomised: 44

Age in years (mean, SD): 34.9 (10.0)

Gender: 27/44 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 22
• Inert
• Identical appearance to fluoxetine, matched dosing

Fluoxetine 20 mg

• n = 22
• SSRI
• Fixed dose

Outcomes

Withdrawal

Missing data methods

No participants withdrew

Funding source

Non-pharmaceutical: This study was supported by a grant from the Digestive Disease Research Center
of Tehran University of Medical Sciences.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Patients were randomly assigned according to a computer-generated ran-
domisation table

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

Allocation procedures NR

Low risk

Double-blind, identical study drugs, matched dosing

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

369

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Vahedi 2005  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Self-reported outcomes by blinded participants

Low risk

No participants withdrew

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Van Ophoven 2004 

Study characteristics

Methods

Design: parallel

Duration: 16 weeks

Assessment: baseline and post-intervention

Country: Germany

Participants

Pain condition: interstitial cystitis

Population: adults with interstitial cystitis

Minimum pain intensity:

Inclusion criteria

• People meeting the symptom criteria of the National Institute of Diabetes, Digestive and Kidney Dis-

eases for interstitial cystitis

Exclusion criteria

• Previous or current intake of amitriptyline

Total participants randomised: 50

Age in years (mean, SD): NR

Gender: 44/50 were female

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 25
• Inert
• Identical appearance and matched dosing

Amitriptyline ≤ 100 mg

• n = 25
• TCA
• Flexible dose and self-titration until satisfactory relief of symptoms, doses of 25 mg, 50 mg, 75 mg,

or 100 mg

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

370

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Van Ophoven 2004  (Continued)

• Mean dose = 52 mg/day

Outcomes

Pain intensity

AEs

SAEs

Withdrawal

Missing data methods

Funding source

Conflicts of interest

NR

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

Unclear risk

Identical study medication, amitriptyline arm could self-titrate, no information
given about whether this was matched for placebo arm

Unclear risk

Self-reported outcomes from participants, uncertain of blinding procedures

Low risk

Completer-only analysis, but ≤ 5% dropout

Attrition

Total: 2/50 (4.0%)

Placebo: 1/25 (4.0%)

Amitriptyline ≤ 100 mg: 1/25 (4.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified.

Ventafridda 1987 

Study characteristics

Methods

Design: parallel

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

371

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ventafridda 1987  (Continued)

Duration: 15 days

Assessment: baseline and post-intervention

Country: Italy

Cochrane Database of Systematic Reviews

Participants

Pain condition: chronic pain syndromes from deafferentation and with oncological pain with deaf-
ferentation component

Population: adults aged 34-79 with cancer pain and other painful syndromes with deafferentation com-
ponent

Minimum pain intensity: no

Inclusion criteria

• Chronic pain from: phantom limb, cancer, post-herpetic neuralgia, traumatic nerve lesion, post-radi-

ation nerve lesion

• Pain lasting at least 6 months

Exclusion criteria

• Glaucoma, myasthenia, hypertrophic prostate, serious cardiopathia and stomach ulcer

Total participants randomised: 45

Age in years (range) 34-79

Gender: NR

Pain duration in years (mean, SD): NR

Interventions

Amitriptyline 75 mg

• n = 22
• TCA
• Fixed dose, forced titration over 3 days

Trazodone 225 mg

• n = 23
• SARI
• Fixed dose, forced titration over 3 days
• Identical appearance to amitriptyline

Outcomes

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Randomisation methods NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

372

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ventafridda 1987  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedures NR

Low risk

Double-blind, identical appearance of study drugs

Low risk

Self-reported outcomes from blinded participants

High risk

Completer analysis with ~30% dropout

Attrition

Total: 14/45 (31.1%)

Amitriptyline 75 mg: 4/22 (18.2%)

Trazodone 225 mg: 10/23 (43.5%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Unclear risk

Unclear - data other than withdrawal not presented in any useable way, no ta-
bles only figures

Vitton 2004 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: adults aged 18-70 with fibromyalgia

Minimum pain intensity: ≥ 10 on a 20-point logarithmic pain scale (Gracely scale)

Inclusion criteria

• Aged between 18 and 70 years, met the ACR 1990 research criteria for fibromyalgia
• Pain intensity of ≥ 10 on a 20-point logarithmic pain scale (Gracely scale)

Exclusion criteria

• Severe psychiatric illness (apart from depression) and a history of severe physical health problems

Total participants randomised: 125

Age in years (mean, SD): 47.0 (11.1)

Gender: 122/125 were female

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

373

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Vitton 2004  (Continued)

Pain duration in years (mean, SD): 4.1 (4.2) years

Interventions

Placebo

• n = 28
• Inert
• Identical appearance, matched dosing
• Double-dummy design

Milnacipran ≤ 200 mg (one dose)

• n = 46
• SNRI
• Flexible titration to maximum tolerated dose
• Taken in 1 dose

Milnacipran ≤ 200 mg (2 doses)

• n = 51
• SNRI
• Flexible titration to maximum tolerated dose
• Taken in 2 doses (1 dose each, morning and evening)

Outcomes

Pain intensity

Sleep

Moderate pain relief

Substantial pain relief

PGIC

SAEs

Withdrawal

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: supported by Cypress Biosciences, San Diego, California

Conflicts of interest

Drs M.Gendreau, J. Gendreau, and J. Kranzler are employees of Cypress Biosciences. Drs Clauw, Grace-
ly, and Williams are paid consultants for and shareholders in Cypress Biosciences. Drs Mease and Thorn
are consultants for Cypress Biosciences.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)

Authors' judgement

Support for judgement

Low risk

Participants were randomised using a randomisation table.

Low risk

Participants were allocated using an automated telephone response system.

Low risk

Double-blind, identical study drugs, matched dosing, double-dummy design

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

374

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Vitton 2004  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Self-reported outcomes from blinded participants

High risk

ITT with LOCF

Attrition

Total: 35/125 (28.0%)

Placebo: 7/28 (25.0%)

Milnacipran 200 mg: 14/46 (30.4%)

Milnacipran 400 mg: 14/51 (27.5%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Unclear risk

Imbalance in prevalence of depression at baseline but no further information
on whether controlled for or which group had more/less

Vollmer 2014 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline and post-intervention

Country: Belgium, Canada, Poland and the USA

Participants

Pain condition: central neuropathic pain due to multiple sclerosis

Population: adults with multiple sclerosis experiencing chronic neuropathic pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Central neuropathic pain due to multiple sclerosis
• ≥ 4 on the daily 24-hour average pain score
• Diagnosis of multiple sclerosis at least 1 year prior to study
• Daily pain for ≥ 3 months

Exclusion criteria

• Majority of psychiatric disorders (except depression and anxiety) and other pain conditions

Total participants randomised: 239

Age in years (mean): 51.8

Gender: 179/239 were female

Pain duration in years (mean): 6.9

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

375

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vollmer 2014  (Continued)

Interventions

Placebo

Cochrane Database of Systematic Reviews

Outcomes

• n = 121
• Inert
• Matched dose

Duloxetine 60 mg

• n = 118
• SNRI
• Fixed dose, titrated over 7 days

Pain intensity

Quality of life

Mood

Sleep

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF and BOCF as sensitivity analysis

Funding source

Pharmaceutical: Eli Lilly and Company

Conflicts of interest

Dr Robinson was a full-time employee and shareholder of Eli Lilly and Company at the time this study
was conducted. Dr Robinson is a current employee of AbbVie. Author TLV is a consultant and/or adviso-
ry board member with Lilly and has received grants from and is involved in research supported by Lilly.
Authors RCR and SKM are current employees and/or stockholders of Lilly.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

Unclear risk

Double-blind, matched doses, but no information regarding study drugs ap-
pearance etc

Blinding of outcome as-
sessment (detection bias)

Unclear risk

Self-reported outcomes from participants, unclear regarding blinding proce-
dures

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

376

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vollmer 2014  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Cochrane Database of Systematic Reviews

ITT with LOCF, BOCF for sensitivity analysis of primary outcome - no significant
differences. Low attriton

Attrition

Total: 30/239 (12.6%)

Placebo: 12/121 (9.9%)

Duloxetine 60 mg: 18/118 (15.3%)

Selective reporting (re-
porting bias)

Low risk

All outcomes pre-specified on clinicaltrials.gov prospectively.

Other bias

Low risk

No other sources of bias identified

Vranken 2011 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Netherlands

Participants

Pain condition: neuropathic pain caused by spinal cord injury or stroke

Population: people with severe neuropathic pain caused by spinal cord injury or stroke

Minimum pain intensity: ≥ 6 on 0-10 scale

Inclusion criteria

• Severe neuropathic pain caused by lesion or dysfunction in the central nervous system
• Pain persisting for ≥ 6 months
• Pain intensity of ≥ 6 on 0-10 scale

Exclusion criteria

• Known history of significant hepatic, renal, or psychiatric disorder; using antidepressants for treat-

ment of depression

Total participants randomised: 48

Age in years (mean, SD): NR

Gender: NR

Pain duration in years (mean, SD): NR

Interventions

Placebo

• n = 24
• Inert
• Identical appearance to duloxetine

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

377

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Vranken 2011  (Continued)

Cochrane Database of Systematic Reviews

• Sham dosing matching duloxetine arm procedure

Duloxetine 60-120 mg

• n = 24
• SNRI
• Flexible dosing of 1-2 capsules of 60 mg a day. Patients started with 1 capsule per day and were titrated
at a 1-week interval; if relief was insufficient (> 1.8 on a VAS) then participants were given 2 capsules
to take.

Outcomes

Pain intensity

Quality of life

Physical function

Mood

PGIC

Withdrawal

Missing data methods

State ITT but no methods

Funding source

Non-pharmaceutical: "Academic Medical Center": assuming the author's institution: Medical Center
Alkmaar

Conflicts of interest

There are no conflicts of interest.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Participants were randomised using computerised random sampling (clorand-
m.exe)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

At baseline each coded medication bottle was supplied by the hospital phar-
macist to the blinded treating physician.

Double-blind, identical study drugs, sham dosing of placebo to match inter-
vention arm

Low risk

Self-reported outcomes from blinded participants

Low risk

Low attrition. State ITT but do not report methods

Attrition

Total: 4/48 (8.3%)

Placebo: 1/24 (4.2%)

Duloxetine 60-120 mg: 3/24 (12.5%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

378

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Vranken 2011  (Continued)

Selective reporting (re-
porting bias)

Low risk

Matches what's registered in protocol: https://www.trialregister.nl/trial/1125

Other bias

Low risk

No other sources of bias were identified.

Vrethem 1997 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period lasted 4 weeks

Assessment: baseline, mid-intervention (8-14 days), post-cross-over period

Country: Sweden

Participants

Pain condition: polyneuropathy (diabetic and non-diabetic)

Population: adults with painful polyneuropathy. 19 had diabetic polyneuropathy, 18 had non-diabetic
polyneuropathy

Minimum pain intensity: no

Inclusion criteria

• Daily moderate or severe polyneuropathic pain for at least 6 months

Exclusion criteria

• Patients with other neurologic diseases were excluded.

Total participants randomised: 37

Age in years (range): 35-83

Gender: 19/37 were female

Pain duration in years (range): 6-168

Interventions

Placebo

• Inert
• Identical appearance
• Double-dummy design

Amitriptyline 75 mg

• TCA
• Fixed dose, forced titration

Maprotiline 75 mg

• TeCA
• Fixed dose, forced titration

Outcomes

Pain intensity

Missing data methods

NR

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

379

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Vrethem 1997  (Continued)

Funding source

Non-pharmaceutical: This work was supported by grants from The Medical Research Council, project
no. 9058, The Swedish Association of Neurologically Disabled, The County Council of Ostergotland, and
The University Hospital of Linkoping

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

This study reported results separately for participants with and without neuropathic pain caused by
diabetes. Therefore, in the NMA we separated the study into 2 to include the 2 sets of results for both
populations.

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

Low risk

Double-blind, identical study drugs, double-dummy design

Low risk

Self-reported outcomes from blinded participants

Unclear risk

No clear information regarding withdrawal, no information regarding missing
data methods

Attrition

Total: 4/37 (10.8%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Wang 2017 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention

Country: China

Participants

Pain condition: knee or hip OA

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

380

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wang 2017  (Continued)

Cochrane Database of Systematic Reviews

Population: adults aged ≥ 40 with knee or hip OA

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Outpatients of at least 40 years who meet clinical and radiographic criteria for the diagnosis of OA of

the knee or hip

Exclusion criteria

• Physical health comorbidities
• All psychiatric conditions including current MDD excluded

Total participants randomised: 407

Age in years (mean): 60.5

Gender: 311/407 were female

Pain duration in years (mean): 7.99

Interventions

Placebo

• n = 202
• Inert
• Identical and matched dosing

Duloxetine 60 mg

• n = 205
• SNRI
• Fixed dose, forced titration

Outcomes

Pain intensity

Physical function

Mood

Sleep

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

MRMM, ITT with LOCF

Funding source

Pharmaceutical: Eli Lilly and Company

Conflicts of interest

Drs Guochun Wang, LiQi Bi, Xiangpei Li, Zhijun Li, Dongbao Zhao, Jinwei Chen, and Dongyi He had no
conflicts of interest to report.

Drs Hector Due nas, Li Yue, Chia-Ning Wang, and Vladimir Skljarevski, are employees and minor share-
holders of Eli Lilly and Company.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

381

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wang 2017  (Continued)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Assignment to treatment groups was determined by a computer-generated
random sequence using an interactive web-response system (IWRS)."

Allocation concealment
(selection bias)

Low risk

"The IWRS was used to assign investigational product packages to each pa-
tient throughout this study."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs, matched dosing

Low risk

Self-reported outcomes from blinded participants

Low risk

Low levels of attrition. Used ITT with both MMRM and LOCF

Attrition

Total: 65/407 (16.0%)

Placebo: 26/202 (12.9%)

Duloxetine 60 mg: 39/205 (19.0%)

Selective reporting (re-
porting bias)

Low risk

All outcomes match those registered prospectively on clinicaltrials.gov.

Other bias

Low risk

No other sources of bias were identified.

Ward 1986 

Study characteristics

Methods

Design: parallel

Duration: 4 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: low back pain

Population: adults with chronic low back pain and diagnosed with depressive mood (major affective
disorder, unipolar depression, dysthymic disorder)

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Hamilton Depression Rating Scale scores of ≥ 18 and were diagnosed as having major affective disor-

der, unipolar depression or dysthymic disorder

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

382

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ward 1986  (Continued)

Cochrane Database of Systematic Reviews

• Stable, chronic low back pain lasting ≥ 6 months, for ≥ 40% of waking hours, with an average severity

of ≥ 4 on a scale of 0 (no pain) to 10 (worst pain imaginable)

Exclusion criteria

• Candidate for back surgery

Total participants randomised: NR

Age in years (mean): 40.2

Gender: 17/35 were female

Pain duration in years (mean, SD): NR

Interventions

Doxepin

• TCA
• Flexible dosing: started at 50 mg/day
• Mean dose: 188 mg/day

Desipramine

• TCA
• Flexible dosing: started at 50 mg/day
• Mean dose: 173 mg/day

Outcomes

Study reports no useable data

Missing data methods

Completer analysis

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

Unclear risk

No information given regarding blinding procedures

Unclear risk

Self-reported outcomes by participants but unsure of blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Completer analysis only. Do not report number of participants randomised,
reasons for dropouts, from which arms, etc.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

383

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ward 1986  (Continued)

Cochrane Database of Systematic Reviews

Selective reporting (re-
porting bias)

High risk

No protocol or trial registration found. Didn't plan to combine data from both
arms until they found no significant differences between arms.

Other bias

Unclear risk

Combined data from both arms in the paper

Ware 2010 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period lasted 2 weeks

Assessment: baseline and post-cross-over period

Country: Canada

Participants

Pain condition: fibromyalgia

Population: adults with fibromyalgia and self-reported chronic insomnia

Minimum pain intensity: no

Inclusion criteria

• People with a diagnosis of fibromyalgia who had self-reported chronic insomnia

Exclusion criteria

• Severe physical comorbidities and psychotic disorders

Total participants randomised: 32

Age in years (mean, SD): 49.5 (11.2)

Gender: 26/32 were female

Pain duration in years (mean, SD): NR

Interventions

Nabilone 0.5-1.0 mg

• Synthetic cannabinoid
• Flexible titration: started at 0.5 mg/day for the first week, physician assessed and if patient could ben-

efit from higher dose the dose was doubled for the second week to 1 mg/day.

Amitriptyline 10-20 mg

• TCA
• Flexible titration: started at 10 mg/day for the first week, physician assessed and if patient could ben-

efit from higher dose the dose was doubled for the second week to 20 mg/day.

Outcomes

SAEs

Missing data methods

Unclear

Funding source

Pharmaceutical: supported by an unrestricted grant from Valeant (Canada) Inc.

Conflicts of interest

MAW and MAF have received honoraria from Valeant Canada for CME activities. YS and LJ have no con-
flicts to declare.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

384

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ware 2010  (Continued)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"The randomisation schedule was prepared (ralloc procedure, Stata version
8.0, Houston, TX) using randomly assigned block sizes ranging from 2 to 8."

Allocation concealment
(selection bias)

Low risk

"The schedule was kept by the study pharmacist away from the investigators.
Study subjects were consecutively assigned to treatment order by the study
nurse based on the randomisation schedule. A coded script was given to the
subject with instructions on the use of the allocated treatment. The subject
then collected the medication from the study pharmacy and began taking the
medication the same night."

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Identical opaque capsules for both nabilone and amitriptyline

Low risk

Self-reported outcomes by blinded participants

Unclear risk

Unclear - no missing data methods reported

Attrition

Total: 3/32 (9.4%)

Attrition per arm NR

Selective reporting (re-
porting bias)

Low risk

All outcomes are prespecified in protocol on clinicaltrials.gov

Other bias

Low risk

No other sources of bias identified

Watson 1992 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period lasted 5 weeks

Assessment: baseline and post-cross-over period

Country: Canada

Participants

Pain condition: post-herpetic neuralgia

Population: adults with post-herpetic neuralgia

Minimum pain intensity: pain of at least moderate severity (disagreeable, unpleasant, uncomfortable)
for at least one half of the day; no numerical values

Inclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

385

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Watson 1992  (Continued)

Cochrane Database of Systematic Reviews

• Pos-therpetic neuralgia of > 3 months' duration
• Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of

the day

Exclusion criteria

• cardiac disease, seizure disorder, severe depression with voiced suicidal intent requiring urgent man-
agement, presence of another significant pain problem, previous brain damage due to head injury,
stroke or other causes, alcoholism

Total participants randomised: 35

Age in years (median, range): 71 (55-85)

Gender: 17/35were female

Pain duration in months (median, range): 14 months (4 months-7 years)

Interventions

Amitriptyline

• TCA
• Flexible titration schedule: start with 12.5 mg/day if > 65 years old or 25 mg/day if < 65
• Median dose at week 5: 100 mg/day (range: 37.5-150 mg)
• Double-dummy design due to different colour/shape of amitriptyline and maprotiline

Maprotiline

• TCA
• Flexible titration schedule: start with 12.5 mg/day if > 65 years old or 25 mg/day if < 65
• Median dose at week 5 was 100 mg/day (range: 50-150 mg)
• Double-dummy design due to different colour/shape of amitriptyline and maprotiline

Outcomes

Withdrawal

Missing data methods

Unclear

Funding source

Non-pharmaceutical: The study was funded by Physicians’ Services Incorporated (PSI) Grant PSI: 88-17.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods NR

Unclear risk

Allocation procedures NR

Low risk

Double-blind, double-dummy design

Low risk

Self-reported outcomes by blinded participants

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

386

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Watson 1992  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Completer analysis but very low dropout

Attrition

Total: 3/35 (8.6%)

Amitriptyline 37.5-150 mg: 2/35 (5.7%)

Maprotiline 50-150 mg: 1/35 (2.9%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found. Lots of measures mentioned in the
methods have no data given in results, just a sentence description

Other bias

Low risk

No other sources of bias were identified

Watson 1998 

Study characteristics

Methods

Design: cross-over

Duration: each cross-over period lasted 5 weeks

Assessment: baseline and post-cross-over period

Country: Canada

Participants

Pain condition: post-herpetic neuralgia

Population: adults with post-herpetic neuralgia

Minimum pain intensity: pain of at least moderate severity (disagreeable, unpleasant, uncomfortable)
for at least one half of the day; no numerical values

Inclusion criteria

• Post-herpetic neuralgia of > 3 months' duration
• Pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of

the day

Exclusion criteria

• Cardiac disease, seizure disorder, severe depression with voiced suicidal intent requiring urgent man-
agement, presence of another significant pain problem, previous brain damage due to head injury,
stroke or other causes, alcoholism

Total participants randomised: 33

Age in years (mean, SD): NR

Gender: NR

Pain duration in months (median): 13 months

Interventions

Nortriptyline

• TCA
• Flexible dose: 10-160 mg

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

387

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Watson 1998  (Continued)

Cochrane Database of Systematic Reviews

• Flexible titration: started on 10 mg/day if > 65 years old or 20 mg/day if < 65 years old. Depending on
efficacy and tolerability, the dose was increased by 10 mg/day every 3-5 days for the first 3 weeks.

• Identical blue capsules

Amitriptyline

• TCA
• Flexible dose: 10-160 mg
• Flexible titration: started on 10 mg/day if > 65 years old or 20 mg/day if < 65 years old. Depending on
efficacy and tolerability, the dose was increased by 10 mg/day every 3-5 days for the first 3 weeks.

• Identical blue capsules

Outcomes

AEs

Withdrawal

Missing data methods

Unclear

Funding source

Conflicts of interest

NR

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Individuals were randomised by telephone at another site by computer.

Low risk

The sequence was concealed in sequential, numbered, sealed envelopes.

Low risk

Double-blind, identical study drugs

Low risk

Self-reported outcomes by blinded participants

Low risk

Missing data methods unclear, but only 1 participant withdrew

Attrition

Total: 2/33 (6.1%)

Amitriptyline 10-160 mg: 1/33 (3.0%)

Nortriptyline 10-150 mg: 1/33 (3.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

388

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wernicke 2006 

Study characteristics

Methods

Design: parallel

Cochrane Database of Systematic Reviews

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: USA

Participants

Pain condition: diabetic peripheral neuropathic pain

Population: type 1 and 2 diabetic adults with diabetic peripheral neuropathic pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• diabetic peripheral neuropathic pain caused by type 1 or type 2 diabetes mellitus. The pain had to

begin in the feet and with relatively symmetrical onset.

• Daily pain must have been present for at least 6 months, and the diagnosis was to be confirmed by a

score of at least 3 on the MNSI

• Pain intensity of ≥ 4 on BPI pain severity item

Exclusion criteria

• Physical health comorbidities
• Any DSM-IV diagnosis of MDD, dysthymia, GAD, alcohol or eating disorders

Interventions

Total participants randomised: 334

Age in years (mean, SD): 60.7 (10.6)

Gender: 130/334 were female

Pain duration in years (mean, SD): 3.8 (4.4)

Placebo

• n = 108
• Inert

Duloxetine 60 mg

• n = 114
• SNRI
• Fixed dose, no titration

Duloxetine 120 mg

• n = 112
• SNRI
• Fixed dose, forced titration over 3 days

Outcomes

Pain intensity

Mood

Quality of life

Physical function

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

389

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wernicke 2006  (Continued)

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Cochrane Database of Systematic Reviews

Missing data methods

ITT with LOCF

Funding source

Pharmaceutical: research for this study was funded by Eli Lilly and Company

Conflicts of interest

"Authors (J.F.W., D.N.D., A.W., S.I., J.R.) are employees and stockholders of Eli Lilly and Company. P.T.
and Y.L.P. are former employees of Eli Lilly and Company. J.F.W., Y.L.P., P.T., and J.R. hold equity in Eli Lil-
ly and Company in excess of USD 10,000."

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment to a treatment group was determined by a computer-generated
random sequence.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Participants were allocated using an interactive voice response system (IVRS).

Unclear risk

No information on blinding procedures for study drugs, appearance, dosing
etc

Unclear risk

Self-reported outcomes from participants, uncertain of blinding procedures

High risk

ITT with LOCF

Attrition

Total: 86/334 (25.8%)

Placebo: 23/108 (21.3%)

Duloxetine 60 mg: 29/114 (25.4%)

Duloxetine 120 mg: 34/112 (30.4%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias were identified

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

390

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wolfe 1994 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Assessment: baseline, 3 weeks, post-intervention

Country: USA

Participants

Pain condition: fibromyalgia

Population: women aged 21-70 with fibromyalgia

Minimum pain intensity: ≥ 1 on a 0-3 VAS

Inclusion criteria

• Patients with fibromyalgia who had at least 7 of 14 tender points, widespread pain according to the
definition of the 1990 ACR criteria for the classification of fibromyalgia, and a pain score ≥ 1 on a 0-3 VAS

Interventions

Exclusion criteria: NR

Total participants randomised: 42

Age in years (mean): 50.5

Gender: 42/42 were female

Pain duration in years (mean, SD): 12.8

Placebo

• n = 21
• Inert

Fluoxetine 20 mg

• n = 21
• SSRI
• Fixed dose

Outcomes

Pain intensity

Sleep

Physical function

Mood

Withdrawal

Missing data methods

Completer-only analysis (but ITT with LOCF for depression?)

Funding source

Pharmaceutical: supported by a grant from Lilly Research Laboratories, Inc, Indianapolis, lN, USA

Conflicts of interest

NR

Notes

Risk of bias

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

391

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wolfe 1994  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Assignment was made by the use of a computer-generated random number
table.

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Allocation procedures not specified

Unclear risk

No blinding procedures reported

Unclear risk

Self-reported outcomes from participants, uncertain of blinding procedures

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Seem to only report completer analysis for each time point (with possible ITT
and LOCF for depression?). Imbalanced withdrawal between groups (double in
placebo compared to fluoxetine).

Attrition

Total: 18/42 (42/9%)

Placebo: 12/21 (57.1%)

Fluoxetine 20 mg: 6/21 (28.6%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Yasuda 2011 

Study characteristics

Methods

Design: parallel

Duration: 12 weeks

Assessment: baseline and post-intervention

Country: Japan

Participants

Pain condition: diabetic neuropathic pain

Population: adults aged 20-80 with diabetic neuropathic pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Sustained pain for ≥ 6 months as a result of distal symmetric polyneuropathy caused by type 1 or type

2 diabetes mellitus

• Pain intensity of ≥ 4 on 0-10 scale

Exclusion criteria

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

392

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Yasuda 2011  (Continued)

Cochrane Database of Systematic Reviews

• Physical health comorbidities that could interact with neuropathic pain
• Psychiatric diseases, such as mania, bipolar disorder, depression, anxiety disorders and eating disor-
ders, or patients with history of these diseases that needed any pharmacotherapy during the past year

Total participants randomised: 339

Age in years (mean, SD): 60.8 (10.0)

Gender: 82/339 were female

Pain duration in years (mean, SD): 4.3 (4.1)

Interventions

Placebo

• n = 167
• Inert
• Matched dosing

Duloxetine 40 mg

• n = 86
• SNRI
• Fixed dose, forced titration over 2 weeks

Duloxetine 60 mg

• n = 86
• SNRI
• Fixed dose, forced titration over 2 weeks

Outcomes

Pain intensity

Mood

Sleep

Moderate pain relief

Substantial pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

MMRM, LOCF

Funding source

Pharmaceutical: This study is financially supported by Shionogi & Co.Ltd., Eli Lilly Japan K.K., and Eli
Lilly and Company.

Conflicts of interest

The study authors have no COI to declare.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

393

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Yasuda 2011  (Continued)

Random sequence genera-
tion (selection bias)

Low risk

Cochrane Database of Systematic Reviews

"Before randomisation, an assigning table was prepared using Create Key
Code 3.3. Patients were randomly assigned to duloxetine 40 or 60 mg or place-
bo groups in a 1:1:2 ratio by stochastic minimisation allocation taking into ac-
count the following 4 factors: (i) weekly mean of 24-h average pain score at
baseline < or ‡6; (ii) duration of diabetic neuropathy < or ‡2 years; (iii) type 1 or
type 2 diabetes mellitus; and (iv) each study center."

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation procedure not specified

Unclear risk

Says double-blind but procedures not specified. No information on drug or
packaging concealment

Unclear risk

Self-reported outcomes from participants but unsure of blinding procedures

Low risk

LOCF, MMRM. Low attrition

Attrition

Total: 44/339 (13.0%)

Placebo: 17/167 (10.2%)

Duloxetine 40 mg: 13/86 (15.1%)

Duloxetine 60 mg: 14/86 (16.3%)

Selective reporting (re-
porting bias)

Unclear risk

Did not include depression outcome in publication, other than that, everything
lines up with protocol

Other bias

Low risk

No other sources of bias were identified.

Yeephu 2013 

Study characteristics

Methods

Design: parallel

Duration: 13 weeks

Assessment: baseline and post-intervention

Country: Thailand

Participants

Pain condition: fibromyalgia

Population: Thai adults with fibromyalgia

Minimum pain intensity: ≥ 40 on 0-100 scale

Inclusion criteria

• Adult outpatients, aged ≥ 18 years, descended from Thai parents, met fibromyalgia criteria as defined

by the ACR criteria

• Pain intensity of ≥ 40 on 0-100 scale

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

394

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Yeephu 2013  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

• Physical health comorbidities
• Severe or unstable physical or psychiatric conditions were excluded

Total participants randomised: 40

Age in years (mean, SD): 44.66 (10.77)

Gender: 40/40 were female

Pain duration in years (mean, SD): 3.44 (2.71)

Interventions

Placebo

• n = 13
• Inert
• Identical appearance to mirtazapine

Mirtazapine 15 mg

• n = 13
• NaSSA
• Fixed dose, forced titration

Mirtazapine 30 mg

• n = 14
• NaSSA
• Fixed dose, forced titration

Outcomes

Moderate pain relief

PGIC

AEs

SAEs

Withdrawal

Missing data methods

ITT with LOCF, BOCF

Funding source

Non-pharmaceutical: This study was supported by a scholarship from the Commission on Higher Edu-
cation Staff Development Project for the Joint PhD Program in Biopharmaceutical Sciences, Thailand.

Conflicts of interest

Study authors reported no conflicts of interest.

Notes

Risk of bias

Bias

Same study as Suttiruksa 2016 - however different outcomes were reported in the two papers.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

The patients were allocated using a block size of 3 in a ratio of 1:1:1 with par-
allel assignment to 1 of 3 groups using a pharmacy-controlled randomisation
process.

Allocation concealment
(selection bias)

Low risk

Participants were allocated with sequentially numbered identical containers.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

395

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Yeephu 2013  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Double-blind, identical study drugs

Low risk

Self-reported outcomes from blinded participants

Unclear risk

State that they use LOCF and BOCF measures, but don't present the numbers
of participants in each of these analyses. Low attrition rates across all arms.

Attrition

Total: 8/40 (20.0%)

Placebo: 3/13 (23.1%)

Mirtazapine 15 mg: 2/13 (15.4%)

Mirtazapine 30 mg: 3/14 (21.4%)

Selective reporting (re-
porting bias)

Low risk

All outcomes in protocol reported either in this article or Suttiruksa 2016

Other bias

Low risk

No other sources of bias were identified

Yucel 2005 

Study characteristics

Methods

Design: parallel

Duration: 8 weeks

Assessment: baseline and post-intervention

Country: Turkey

Participants

Pain condition: neuropathic pain of any cause

Population: people aged between 20 and 70 with neuropathic pain

Minimum pain intensity: ≥ 4 on 0-10 scale

Inclusion criteria

• Aged between 20 and 70 years, having symptoms compatible with neuropathic pain present for a pe-

riod > 6 months

• Pain intensity of ≥ 4 on 0-10 scale

Exclusion criteria

• Pain other than neuropathic pain, pain presumably of mixed origin, exclude majority psychiatric ill-

ness

Total participants randomised: 60

Age in years (mean): 50.2

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

396

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Yucel 2005  (Continued)

Interventions

Outcomes

Gender: 33/60 were female

Pain duration in years (mean, SD): NR

Placebo

• n = 20
• Inert

Venlafaxine 75 mg

• n = 20
• SNRI
• Fixed dose

Venlafaxine 150 mg

• n = 20
• SNRI
• Fixed dose

AEs

SAEs

Withdrawal

Missing data methods

Completer-only analysis

Funding source

Pharmaceutical: This study was supported by a grant from Wyeth Ilaclari A.S., Istanbul, Turkey.

Conflicts of interest

NR

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

Says double-blinded but no information regarding blinding procedures given

Unclear risk

Self-reported outcomes from participants but unsure of blinding procedures

Low risk

Only report completer analysis, but very low attrition

Attrition

Total: 5/60 (8.3%)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

397

 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Yucel 2005  (Continued)

Placebo: 1/20 (5.0%)

Venlafaxine 75 mg: 1/20 (5.0%)

Venlafaxine 150 mg: 3/20 (15.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

Low risk

No other sources of bias identified

Zabihiyeganeh 2021 

Study characteristics

Methods

Design: parallel

Duration:10 weeks

Assessment: baseline and post-intervention

Country: Iran

Participants

Pain condition: fibromyalgia

Population: women aged 18-65 with fibromyalgia

Minimum pain intensity: no

Inclusion criteria

• Women aged 18-65 with a definitive diagnosis of fibromyalgia

Exclusion criteria

• Presence of co-morbid conditions affecting the serum cytokine levels, including RA, OA, metabolic

disorders, infection, etc.

• Severe psychiatric disorders; severe depression or anxiety (BDI score 30-63)

Total participants randomised: 128

Age in years (mean): 42.5

Gender: 128/128 were female

Pain duration in years (mean): 3.9

Interventions

CBT

• n = 64
• Psychological therapy
• Traditional face-to-face CBT was implemented based on the Beck and Ellis method, which was organ-
ised by Free 2007. The CBT was offered in twice-weekly sessions over 10 weeks. Each session lasted 2 h.

Duloxetine 60 mg

• n = 64
• SNRI
• Fixed dose, forced titration

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

398

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Zabihiyeganeh 2021  (Continued)

Outcomes

Pain intensity

Quality of life

AEs

Withdrawal

Missing data methods

ITT with LOCF

Cochrane Database of Systematic Reviews

Funding source

Non-pharmaceutical: This study was funded by Iran University of Medical Sciences under the Grant
code of 32415.

Conflicts of interest

The study authors declare that they have no confict of interest.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Unclear - state that was perfomed via a random number list, but also that par-
ticipants were allocated depending upon order of referral: "the frst 64 random
numbers were assigned to the CBT group, and the following 64 random num-
bers were assigned to the duloxetine group"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Allocation methods unclear (see random sequence generation)

High risk

Unable to be blinded due to nature of CBT intervention

High risk

Self-reported outcomes from unblinded participants

High risk

ITT with LOCF

Attrition

Total: 23/128 (18.0%)

CBT: 12/64 (18.8%)

Duloxetine 60 mg: 11/64 (17.2%)

Selective reporting (re-
porting bias)

Unclear risk

Prospectively registered protocol (https://en.irct.ir/trial/24406). Primary out-
comes match but secondary outcomes (FIQ, Widespread Pain Index) not regis-
tered, no plan of analysis

Other bias

High risk

In the protocol they state a third group, a control group with no treatment, but
this isn't mentioned anywhere in the paper.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

399

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Zitman 1990 

Study characteristics

Methods

Design: parallel

Duration: 6 weeks

Cochrane Database of Systematic Reviews

Assessment: baseline, 2 weeks, post-intervention, follow-up (6 weeks post-intervention)

Country: Netherlands

Participants

Pain condition: chronic pain of various origins

Population: adults aged 30-60 with chronic pain of various origins

Minimum pain intensity: no

Inclusion criteria

• Aged 30-60
• Any chronic pain for > 6 months

Exclusion criteria

• No serious mental disease requiring other medication and/or higher doses of antidepressants
• No organic disease in which antidepressants are contraindicated

Total participants randomised: 49

Age in years (mean, SD): 45.2 (1.3)

Gender: 20/49 were female

Pain duration in years (mean, SD): 5.1 (3.4)

Interventions

Placebo (riboflavin 15 mg)

• n = 24
• Active placebo: vitamin B2
• Fixed dose

Amitriptyline 75 mg + placebo (riboflavin 15 mg)

• n = 25
• Combined: TCA + vitamin B
• Tablets containing amitriptyline + riboflavin
• Fixed doses

Outcomes

Pain intensity

Mood

Withdrawal

Missing data methods

Completer analysis

Funding source

Conflicts of interest

NR

NR

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

400

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Zitman 1990  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Randomisation methods not specified

Unclear risk

Allocation procedures not specified

Unclear risk

Says double-blind but no information given regarding appearance of tablets
etc. Also the 12-week follow-up was open-label and participants could choose
what they wanted.

Unclear risk

Self-reported outcomes, but unsure of blinding conditions

High risk

No missing data methods given, completer analysis only

Attrition

Total: 10/49 (20.4%)

Placebo: 4/24 (16.7%)

Amitriptyline 75 mg: 6/25 (24.0%)

Selective reporting (re-
porting bias)

Unclear risk

No protocol or trial registration found

Other bias

High risk

A lot of imbalances at baseline.

Authors class vitamin B as a placebo, but this could have a beneficial effect on
mood.

ACR:  American  College  of  Rheumatology;  AE:  adverse  events;  ARA:  American  Rheumatism  Association;  BAI:  Beck  Anxiety  Inventory;
BDI:  Beck  Depression  Inventory;  BMI:  body  mass  index;  BOCF:  baseline  observation  carried  forward;  BPI:  Brief  Pain  Inventory;  CBT:
cognitive behavioural therapy; CoI: conflict of interest; DMS-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSM-
IV-TR:Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; ECG: electrocardiogram; FIC: functional impairment
checklist;  FIQ:  Fibromyalgia  Impact  Questionnaire;  FM:  fibromyalgia;  GAD:  generalised  anxiety  disorder;  HADS:  Hospital  Anxiety  and
Depression  Scale;  IBS:  irritable  bowel  syndrome;  ICD-10:International  Classification  of  Diseases  10th  Revision;  IQR:  interqurtile  range;
ITT: intention-to-treat; LOCF: last observation carried forward; MADRS: Montgomery–Åsberg Depression Rating Scale; MAOI: monoamine
oxidase  inhibitors;  mBOCF:  mean  baseline  observation  carried  forward;  MDD:  major  depressive  disorder;  MINI:  Mini  International
Neuropsychiatric  Interview;  MMRM:  mixed  models  for  repeated  measures;  MNSI:  Michigan  Neuropathy  Screening  Instrument;  NaRI:
noradrenaline  reuptake  inhibitors;  NaSSA:  noradrenergic  and  specific  serotonergic  antidepressant;  NR:  not  reported;  NRS:  numerical
rating  scale;  NSAID:  non-steroidal  anti-inflammatory  drug;  OA:  osteoarthritis;  ODI:  Oswestry  Disability  Index;  PGIC:  Patient  Global
Impression of Change; RA: rheumatoid arthritis; SAE: serious adverse events; SARI: serotonin antagonist and reuptake inhibitors; SD:
standard deviation; SDI: Sleep Disorders Inventory; SNRI: serotonin-noradrenalin reuptake inhibitors; SSRI: selective serotonin reuptake
inhibitors;  TCA:  tricyclic  antidepressants;  TeCA:  tetracyclic  antidepressants;  TENS:  transcutaneous  electrical  nerve  stimulation;  VAS:
visual analogue scale; WOCF: worst observation carried forward; WOMAC: Western Ontario and McMaster Universities Osteoarthritis pain
scale

Characteristics of excluded studies [ordered by study ID]

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

401

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Amelin 1991

Amr 2010

Arnold 2014

Avan 2018

Beaumont 1980

Braak 2011

Carette 1995

Reason for exclusion

One combined arm, no comparator

Prevention not treatment

All participants currently taking antidepressants

Not chronic pain

Study invalidated - paper describes an attempt at a trial of clomipramine and a matching placebo
which failed

Condition does not meet chronic pain criteria

Cross-over trial - no washout period

ChiCTR-TRC-12001968

Pain inclusion criteria not met

ChiCTR-TRC-12001969

Pain inclusion criteria not met

ChiCTR2000030195

Pain treatment/prevention post-surgery

Chitsaz 2009

Pain inclusion criteria not met

CTRI/2015/05/005791

Pain inclusion criteria not met

Daghaghzadeh 2015

Pain inclusion criteria not met

Dinat 2015

Not chronic pain

Ehrnrooth 2001

Not chronic pain

EUCTR2005-005555-17-NL

Study terminated due to insufficient clinical response

EUCTR2006-003656-38-GB

Study was prematurely ended, but no reason given

EUCTR2006-005506-32-DK

Trial registration says prematurely ended, but no reason given

EUCTR2009-013061-26-FI

Study prematurely ended due to poor recruitment

EUCTR2016-003146-89-GB

No antidepressant-only arm

EUCTR2017-003307-21-NL

Pain inclusion criteria not met

EUCTR2018-000133-12-GB

No antidepressant-only arm

EUCTR2019-003437-42-DK

Study terminated but reason not given

Farshchian 2018

Not chronic pain

Frank 1988

Washout period not > 5 half-lifes of antidepressant

Gardela 1991

Not chronic pain

Gelijkens 2014

Not chronic pain

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

402

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Ghadir 2011

Pain inclusion criteria not met

Goldenberg 2010

Participants re-randomised partway through study

Gomez-Perez 1985

No antidepressant-only arm, just a combined arm

Greenbaum 1987

Pain inclusion criteria not met

Henry 2018

Not chronic pain

IRCT201506171647N4

Pain inclusion criteria not met

IRCT20170829035966N1

Pain inclusion criteria not met

IRCT20191210045685N1

Treatment/prevention of pain post-surgery

ISRCTN16086699

Pain inclusion criteria not met

ISRCTN63671932

Pain inclusion criteria not met

Kaosombatwattana 2015

Pain inclusion criteria not met

Kautio 2008

Not chronic pain

Khalilian 2021

Pain inclusion criteria not met

Khosrawi 2018

Not chronic pain

Kieburtz 1998

Not chronic pain

Kishore-Kumar 1990

Washout period not > 5 half-lifes of antidepressant

Kreiter 2021

Pain inclusion criteria not met

Kroenke 2006

Pain inclusion criteria not met

Kuiken 2003

Pain inclusion criteria not met

Kvinesdal 1984

Cross-over study - no washout period

Ladabaum 2010

Pain inclusion criteria not met

Lara Muñoz 1986

Effect of amitriptyline on the pain relief provided by other analgesics, not the effect of amitripty-
line itself

Li 2019

Pain inclusion criteria not met

Matsuoka 2019a

Not chronic pain

Max 1987

Max 1991

Cross-over study - no washout period

Cross-over study - no washout period

McQuay 1992

Cross-over study - no washout period

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

403

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Mishra 2012

NCT00006157

NCT00189059

NCT00191919

NCT00283842

NCT00592384

NCT00610909

NCT00619983

NCT00625833

NCT00696787

NCT00754793

NCT00945945

NCT01116531

NCT01173055

NCT01268709

NCT01288937

NCT01359514

NCT01359826

NCT01377038

NCT01451606

NCT01471379

NCT01579279

NCT01869907

NCT01910259

NCT02650544

NCT02970591

Reason for exclusion

Not chronic pain

Pain inclusion criteria not met

Study terminated but reason not given

Somatic symptoms of depression, not chronic pain condition

Study terminated for business reasons

Pain inclusion criteria not met

Pain inclusion criteria not met

Study terminated due to poor recruitment

Study terminated due to insufficient clinical response

Study terminated by sponsor

Study terminated due to poor recruitment

Study invalidated - study drugs were mislabelled, participants who were supposed to receive
placebo actually received duloxetine and vice versa.

Study withdrawn

Experimental pain

Pain inclusion criteria not met

Study terminated due to poor recruitment

Pain prevention rather than treatment

Principle Investigator left institution and unable to locate any study documents

Study withdrawn due to funding issues

Study terminated due to poor recruitment

Terminated due to recruitment difficulties

Study terminated but no reason given

Pain inclusion criteria not met

Pain inclusion criteria not met

Pain inclusion criteria not met

No specific antidepressant, just "optimised management", which could include an antidepressant
option

NCT03364075

Study terminated due to recruitment issues

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

404

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

NCT03522207

NCT04747314

Nickel 2005

Panerai 1990

Parker 2003

Reason for exclusion

Study terminated due to short-staffing

Antidepressant arm is not one single antidepressant, it's a mixture

No antidepressant only arm, just a combined arm

Cross-over study - no washout period

No antidepressant-only arm

Parkman 2013

Pain inclusion criteria not met

Pilowsky 1982

Cross-over study - no washout period

Pilowsky 1995

All participants received antidepressant

Poulsen 1987

Unable to determine trial length

Raja 2002

Participants could take different antidepressants/comparators, no comparisons per drug

Rajagopalan 1998

Pain inclusion criteria not met

Saxe 2009

Results from discontinuation phase of trial

Seddighnia 2020

Pain inclusion criteria not met

Selvarajah 2018

No antidepressant-only arm

Semenchuk 2001

No washout period

Strauss 2019

Not chronic pain

Tadyon Najafabadi 2019

Pain inclusion criteria not met

Tondlova 2002

Not chronic pain

van Houdenhove 1992

Washout period not > 5 half-lifes of natidepressant

Varia 2000

Vork 2018

Wang 2014

Not chronic pain

Pain inclusion criteria not met

Pain inclusion criteria not met

Characteristics of studies awaiting classification [ordered by study ID]

ACTRN12620000656932 

Methods

Double-blind, parallel-arm, placebo-controlled RCT

Participants

Unclear from trial registration whether this is acute or chronic pain

Inpatients and outpatients with diagnoses of cancer and neuropathic pain (probable or definite
neuropathic pain by IASP criteria)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

405

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12620000656932  (Continued)

Cochrane Database of Systematic Reviews

Pain related to cancer with a worst pain score of ≥ 4 on BPI item 3 (worst pain intensity) score in the
past 24 h
Neuropathic Pain on LANSS ≥ 12

Taking stable regular analgesics within 72 hours before commencing on the study.

Target: 160

Interventions

Duloxetine 30/day orally for 7 days, then increase to 60 mg/day for 7 days, then downward titrate
to 30 mg/day for 7 days

Pregabalin 50/day orally for 3 days, 150 mg/day for 4 days, then 300 mg/day for 7 days, then down-
ward titration to 150 mg/day for 4 days, and 50 mg/day for 3 days

Outcomes

Notes

Brown 2015 

Methods

Pain intensity

Anxiety

Depression

Daily opioid use

Double-blind, placebo-controlled, parallel, 2-arm RCT

Participants

Patients with multiple sclerosis

Interventions

Outcomes

n = 38

Duloxetine

Placebo

Pain

PGIC

Depression

Quality of life

Sleep

Notes

Unable to ascertain pain duration, unsure if chronic

Chandra 2006 

Methods

Double-blind, parallel, head-to-head, 2-arm RCT

9 weeks

Participants

Adult PHN patients

8 weeks of postherpetic neuralgia pain after healing of rash

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

406

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chandra 2006  (Continued)

Cochrane Database of Systematic Reviews

Pain intensity of at least 40 mm on a 100 mm VAS at screening and at randomisation

Average pain score of at least 4 on the Likert scale during the baseline week

Interventions

Outcomes

n = 70

Gabapentin

Nortriptyline

Flexibly dosed to maximum tolerated dose

Pain intensity

Sleep

Notes

Unable to ascertain pain duration - not sure if chronic

Cánovas Martínez 2009 

Methods

Parallel RCT

3 months

Participants

60 patients with severe neuropathic pain (VAS > 6)

Interventions

Outcomes

Duloxetine

Placebo

Pain intensity

Symptom relief

Notes

Unable to ascertain blinding

Di 2019 

Methods

Parallel, 2-arm RCT

Participants

Patients with severe cancer pain and depression

n = 46

Interventions

Oxycontin + amitriptyline

Outcomes

Oxycontin

Cancer pain

Depression

Notes

Unable to ascertain blinding

Unable to ascertain pain duration - unclear if chronic

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

407

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hammack 2002 

Methods

Participants

Double-blind, placebo-controlled, cross-over, RCT

Patients who had received CDDP (cisplatin) chemotherapy, and have had painful paresthaesiae for
at least 1 month attributed to CDDP neuropathy.

n = 51

Interventions

Nortriptyline 100 mg

Outcomes

Placebo

Pain

Sleep

Quality of life

AEs

Notes

Unable to ascertain pain duration - inclusion criteria only says at least 1 month

Jia 2006 

Methods

Double-blind, placebo-controlled, double-dummy, parallel, 2-arm RCT

2 weeks

Participants

Patients with painful peripheral diabetic neuropathy

n = 132

Interventions

Carbamazepine 0.2 mg

Outcomes

Venlafaxine 50 mg

Pain intensity

Quality of life

Mood

Sleep

AEs

Notes

Unable to establish pain duration, unsure if chronic

Keskinbora 2006 

Methods

Double-blind, comparative, parallel, 2-arm RCT

4 weeks

Participants

Patients with neuropathic pain

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

408

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Keskinbora 2006  (Continued)

Interventions

Outcomes

n = 46

Gabapentin

Amitriptyline

Pain sensations

Satisfaction

Cochrane Database of Systematic Reviews

Notes

States chronic pain, but no duration reported in article, so unable to confirm chronic

Riesner 2008 

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

8 weeks

Participants

People with knee and hip OA

Interventions

Fluvoxamine 50-150 mg

Outcomes

Placebo

Pain

WOMAC total score

PGIC

AEs

Notes

Unable to ascertain pain duration, unsure if chronic

Salehifar 2020 

Methods

Participants

Double-blind, comparative, parallel, 2-arm RCT

6 weeks

Patients with breast cancer who had a ≥ grade 1 neuropathy and who had score ≥ 4 neuropathic
pain severity based on the VAS

Interventions

Pregabalin 150 mg

Duloxetine 60 mg

Outcomes

Pain

Sensory neuropathy grade

Notes

Unable to ascertain pain duration - unclear if chronic

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

409

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shabbir 2011 

Methods

Participants

Parallel, 3-arm RCT

Patients with peripheral diabetic neuropathy for at least 6 months duration, an average pain score
≥ 4 (on an 11-point, Likert-like NRS; 0 = “no pain” to 10 = “worst possible pain”) over a 7-day base-
line period

Interventions

Amitriptyline

Pregabalin

Placebo

Flexibly dosed depending upon tolerance

Outcomes

Pain intensity

50% pain relief

Notes

Unable to ascertain blinding

Shlay 1998 

Methods

Comparative RCT

Participants

Patients with HIV- associated, symptomatic, lower-extremity peripheral neuropathy

n = 250

Interventions

Acupuncture

Outcomes

Notes

Amitriptyline 75 mg

Placebo

Pain intensity

Unable to establish pain duration, unsure if chronic

Taghizadeh 2020 

Methods

Comparative, 2-arm RCT

12 weeks

Participants

Women with mastalgia

Interventions

Outcomes

Notes

n = 62

Fluoxetine

Tamoxifen

Pain intensity

Unable to ascertain blinding, and duration of pain

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

410

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Xu 2006 

Methods

Comparative, 2-arm RCT

4 weeks

Participants

Patients with primary fibromyalgia syndrome

n = 46

Interventions

Amitriptyline 25 mg ~ 50 mg

Paroxetine 10 mg ~ 20 mg

Outcomes

Pain intensity

AEs

Notes

Unable to ascertain blinding

Zakerkish 2017 

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

6 weeks

Participants

Patients with diabetic peripheral neuropathy

n = 134

Interventions

Duloxetine 30-60 mg

Outcomes

Placebo

Pain intensity

50% pain relief

AEs

Notes

Unable to establish pain duration, unclear if chronic

AE:  adverse  event;  BPI:  Brief  Pain  Inventory;  IASP:  International  Association  for  the  Study  of  Pain;  LANSS:  Leeds  Assessment  of
Neuropathic  Symptoms  and  Signs;  NRS:  numeric  rating  scale;  OA:  osteoarthritis;  PGIC:  Patient  Global  Impression  of  Change;  RCT:
randomised controlled trial; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis pain scale

Characteristics of ongoing studies [ordered by study ID]

ACTRN12619000878178 

Study name

Methods

Participants

A randomised controlled trial of venlafaxine to treat patients with knee osteoarthritis pain

Double-blind, parallel-arm, placebo-controlled, 2-arm RCT

• Age 40-80 years
• Knee pain for ≥ 14 days of each month for > 3 months
• Significant knee pain on most days (defined as a VAS > 40 mm) on 100 mm VAS pain

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

411

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ACTRN12619000878178  (Continued)

• Meet ACR clinical criteria for knee OA confirmed by a rheumatologist

Interventions

Venlafaxine; 75 mg daily for 4 weeks and then increase to 150 mg daily for next 8 weeks

Outcomes

Placebo

Pain intensity

Physical function

Quality of life

painDETECT score

Anxiety

Pain catastrophising

Pain disability

Depression

Responders (using OMERACT-OARSI criteria)

Starting date

20 June 2019

Contact information

Dr Feng Pan

Menzies Institute for Medical Research
17 Liverpool Street
Hobart
Tasmania 7000
Australia

Feng.Pan@utas.edu.au

Notes

ACTRN12619001082190 

Study name

Methods

Participants

Venlafaxine compared to duloxetine for the treatment of osteoarthritis pain: A double-blind, ran-
domised, non-inferiority trial

Double-blind, parallel arm, antidepressant head-to-head, 2-arm RCT

Men and women at least 40 years old who have radiographic evidence of knee OA and meet the
ACR clinical criteria for the diagnosis of knee OA
A history of knee pain for > 14 days of each month for ≥ 3 months
A BPI average pain rating of at least 4/10 at the time of initial screening

Target: 146

Interventions

Venlafaxine 75 mg for 1 week, then 150 mg for 7 weeks

Duloxetine 30 mg for 1 week, then 60 mg for 7 weeks

Outcomes

Pain intensity

Anxiety

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

412

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12619001082190  (Continued)

Cochrane Database of Systematic Reviews

Depression

Physical function

Quality of life

PGIC

Moderate pain relief (30% reduction)

Substantial pain relief (50% reduction)

Starting date

6 August 2019

Contact information

Dr David Rice

Waitemata Pain Services, Level 10, North Shore Hospital, 124 Shakespeare Road, Takapuna, Auck-
land 0622, New Zealand

david.rice@aut.ac.nz

Notes

Ammitzboll 2021 

Study name

A mechanism based proof of concept study of the effects of duloxetine in the treatment of patients
with osteoarthritic knee pain

Methods

Double-blind, crossover, placebo-controlled, 2-arm trial

Participants

Men and women between 40 and 75 years of age

Patients with knee OA based on disease diagnostic criteria

Self-reported pain intensities ≥ 5 cm on a 0-10 cm VAS when asked to assess the worst pain within
the last 24 hours

Knee pain for at least 14 days per month for the last 3 months before study entry

Interventions

Patients will be randomised to 1 of 2 treatment sequences:

• Sequence 1: 20 mg duloxetine every day for 1 week, 40 mg duloxetine every day for 1 week, 60 mg
duloxetine every day for 10 weeks, 40 mg duloxetine every day for 1 week, 20 mg duloxetine every
day for 1 week, followed by 14 weeks of corresponding placebo

• Sequence 2: 14 weeks of placebo followed by 20 mg duloxetine every day for 1 week, 40 mg du-
loxetine every day for 1 week, 60 mg duloxetine every day for 10 weeks, 40 mg duloxetine every
day for 1 week and 20 mg duloxetine every day for 1 week

The 2 treatment periods of 14 weeks each are separated by a washout period of 2 weeks and in-
clude a 2-week titration period.

Outcomes

Pressure Pain Threshold

Starting date

13 January 2020

Contact information

Kristian Kjær Petersen, Aalborg University

Notes

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

413

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ChiCTR1900027038 

Study name

Synergistic analgesia of duloxetine in phantom limb pain of amputees from bone tumors: a ran-
domized controlled trial

Methods

Unclear on blinding or chronic pain from trial registration

Placebo-controlled, 2-arm, RCT

Participants

Bone tumour patients, phantom limb pain after amputation

Aged 18-65

Target: 120

Interventions

Duloxetine 60 mg

Placebo

Outcomes

Pain intensity

Starting date

29 October 2019

Contact information

Shuang Jiang

44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning, China 110042

jiangshuang@cancerhosp-ln-cmu.com

Notes

CTRI/2018/10/015944 

Study name

A comparative evaluation of duloxetine and gabapentin in painful diabetic neuropathy: a ran-
domised control trial

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

12 weeks

Participants

• Patients of either sex with type 2 diabetes mellitus, aged 18 -75 years, who were on stable glu-
cose-lowering medications during the preceding month and who had painful diabetic neuropa-
thy for at least1 month

• Had a pain score of > 50%, as assessed by VAS

Target: 86

Interventions

Duloxetine 60 mg daily

Gabapentin 300 mg daily

Outcomes

Pain intensity

Diabetic neuropathy symptom score

Starting date

22 October 2018

Contact information

Dr Sameer Khasbage

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

414

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

CTRI/2018/10/015944  (Continued)

Cochrane Database of Systematic Reviews

Department of Pharmacology Basni 2 AIIMS Jodhpur Rajasthan 342005 Jodhpur, Rajasthan, India

samkhasbage@gmail.com

Notes

CTRI/2018/10/015983 

Study name

Effectiveness of vitamin D as a supplement with conventional therapy in the treatment of diabetic
peripheral neuropathy - a randomized controlled clinical trial

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

3 months

Participants

• Patients with diabetic peripheral neuropathy
• Both male and female patients > 18 years
• Patients who are willing to give written informed consent

Target: 80

Interventions

Amitriptyline 25 mg

Vitamin D

Outcomes

Vitamin D levels

Pain intensity

Quality of life

Starting date

10 October 2018

Contact information

Dr Melvin George

Notes

CTRI/2021/02/031068 

Study name

Department of Pharmacology SRM Medical College Hospital and Research Centre SRM Institute of
Science and Technology (SRMIST) Kattankulathur 603203 Kancheepuram, Tamil Nadu, India

melvingeorge2003@gmail.com

A randamized double-blind comparative study evaluating the efficacy of a combination of prega-
balin and duloxetine versus pregabalin alone and the modulation of mRNA expression of PPARG
and Akt genes in patients of painful diabetic peripheral neuropathy

Methods

Unclear blinding from trial registration

2-arm, combination vs antidepressant-only RCT

12 weeks

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

415

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

CTRI/2021/02/031068  (Continued)

Participants

Interventions

Outcomes

• Male or female patients ≥ 18 years of age with pain due to diabetic peripheral neuropathy caused
by type -I or II diabetes mellitus for at least 3 months with confirmed diagnosis on MNSI with score
≤ 3 at the time of screening

• Patients must have average pain severity of ≥ 4/10 on NRS
• BPI-Modified short form ≥ 4
• Patients should have stable glycaemic control with HbA1C < 12%

Target: 60

Combination of tablet pregabalin 75 mg and tablet duloxetine 30 mg pregabalin 75 mg twice a day
orally

Sleep

Pain

Physical function

Modulation of mRNA expression of PPARG and Akt gene

Starting date

08 February 2021

Contact information

Dr Ashok Kumar

Department of Anaesthesia and Critical Care, second floor University College of Medical Sciences
and GTB Hospital, Dilshad Garden, Delhi 110095 East, Delhi, India

profashoksaxena2@gmail.com

Notes

CTRI/2021/03/031875 

Study name

Efficacy of duloxetine in patients with central post-stroke pain: a randomised double blind placebo
controlled study

Methods

Double-blind, placebo-controlled, parallel, 2-arm, RCT

4 weeks

Participants

• Positive  history  of  haemorrhagic  or  ischaemic  stroke  with  lesion  in  the  unilateral  brain  region

proved by computed tomography or magnetic resonance imaging of the brain

• Presence of spontaneous or stimulated pain in the affected side, which could be smaller or the
same in size as the sensory impairment area, fulfilling the mandatory criteria proposed by Klit
2009

• Patients with moderate to severe pain (NRS score of ≥ 4) are included

Target: 82

Interventions

Duloxetine: 30 mg in the night every day and followed up at 2 weeks if no response, i.e. decrease in
NRS score < 2 then the dose is doubled and again followed up after 2 weeks

Placebo: the similar appearing placebo tablets are given at night every day and followed up at 2
weeks, if no response, i.e. decrease in NRS score < 2 the dose is doubled and again followed up af-
ter 2 weeks

Outcomes

Pain intensity

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

416

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

CTRI/2021/03/031875  (Continued)

Disability

PGIC

Starting date

10 March 2021

Contact information

Dr Rameshwar Nath Chaurasiya

Cochrane Database of Systematic Reviews

Notes

EUCTR2019-000243-27-DK 

Study name

Methods

Participants

Department of Neurology, Institue of Medical Sciences, Banaras Hindu University, 221005 Varanasi,
Uttar Pradesh, India

goforrameshwar@gmail.com

The effect of bupropion in peripheral neuropathic pain. A randomized, double-blind, placebo-con-
trolled study

Double-blind, placebo-controlled, parallel, 2-arm RCT

• Age > 18 years
• Peripheral neuropathic pain for > 3 months
• Pain score at least 4 and not higher than 9 on NRS 0-10 points

Target: 90

Interventions

Bupropion 150 mg

Outcomes

Placebo

Pain intensity

Pain modulation

PGIC

Neuropathic pain symptoms

Suicide ideation

Starting date

28 January 2019

Contact information

Neuromuscular Clinic

J.B.Winsløws Vej 4 5000 Odense Denmark

soeren.sindrup@rsyd.dk

Notes

EUCTR2019-000324-17-GB 

Study name

Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (the
ATLANTIS study): a double-blind placebo-controlled trial - the ATLANTIS study

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

417

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

EUCTR2019-000324-17-GB  (Continued)

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

Participants

Unclear about pain chronicity from trial registration

• A diagnosis of IBS (of any subtype of stool pattern (diarrhoea, constipation, mixed) in their primary

care record, and fulfilling the Rome IV criteria

• Ongoing symptoms, defined as an IBS severity scoring system (IBS-SSS) score of = 75 at screening

Target: 518

Interventions

Amitriptyline 10 mg

Placebo

Outcomes

IBS symptoms

Anxiety

Depression

Quality of life

Health care use

Ability to work

Starting date

07 November 2019

Contact information

Dr Heather Cook

CTRU, University of Leeds LS2 9JT Leeds United Kingdom

Atlantis@leeds.ac.uk

Notes

EUCTR2019-001202-14-NL 

Study name

Methods

CiPA Trial: effect of citalopram on chest pain in patients with achalasia

Double-blind, placebo-controlled, parallel, 2-arm RCT

6 weeks

Participants

Diagnosed with achalasia type 1 or 2, confirmed by high-resolution manometry

Recurrent chest pain

• Midline chest pain or discomfort that is not of burning quality
• At least 3 episodes per week of unexplained chest pain, for a minimum of 3 months

Interventions

Target: 68

Citalopram

Placebo

Outcomes

Pain intensity and frequency

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

418

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

EUCTR2019-001202-14-NL  (Continued)

Quality of life

Anxiety

Depression

AEs

Starting date

18 April 2019

Contact information

Research Team

Meibergdreef 9 1105 AZ Amsterdam Netherlands

j.m.schuitenmaker@amc.uva.nl

Notes

EUCTR2021-002288-24-NL 

Study name

Methods

Participants

Interventions

Effect of citalopram on chest pain in patients with functional chest pain - Ci-FCP

Double-blind, placebo-controlled, parallel, 2-arm RCT

12 weeks

• Minimum age: 18 years
• Functional chest pain according to Rome IV criteria
• Ruled out cardiac origin of chest pain
• Symptoms of chest pain for at least 6 months
• Frequency of symptoms at least once a week

Target: 52

Citalopram

Placebo

Outcomes

Reduction in chest pain

Chest pain severity and frequency

Quality of life

Depression

Anxiety

AEs

Starting date

27 July 2021

Contact information

Research Team

Meibergdreef 9 1105 AZ Amsterdam Netherlands

t.kuipers1@amsterdamumc.nl

Notes

Potentially linked to Euctr 2019?

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

419

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

IRCT20110413006186N13 

Study name

Methods

Participants

Interventions

A comparison of the effectiveness of transcutaneous electrical nerve stimulation and duloxetine on
diabetic peripheral neuropathic pain

Parallel, 2-arm RCT

Patients with type I or II diabetes mellitus, with diabetic neuropathic pain
Resistant to usual drug treatments, at least for 6 months
Minimum Pain Rating ≥ 4 based on NRS

Target: 60

TENS

Duloxetine 60 mg

Outcomes

Pain intensity

Starting date

22 June 2019

Contact information

Dr Bahram Naderi Nabi

Poursina Hospital 4193713189 Rasht Iran (Islamic Republic of)

naderi_bahram@yahoo.com

Notes

IRCT20200205046381N1 

Study name

Comparing the analgesic effect of fluoxetine and vitamin E with vitamin E only in mastalgia due to
fibrocystic breast disease

Methods

Double-blind, double-dummy, parallel, 2-arm RCT

8 weeks

Participants

• Unclear pain duration from trial registry
• Women 20-50 years old with fibrocystic breast disease-induced mastalgia
• Women with mastalgia criterion ≥ 4 on the VAS scale
• Women whose pain lasts > 5 days per month

Target: 70

Interventions

Vitamin E + fluoxetine: 600 units of vitamin E daily and 10 mg of fluoxetine

Vitamin E: 600 units of vitamin E and placebo daily

Outcomes

Pain intensity

Starting date

20 March 2020

Contact information

Sheida Shabanian

Hajar Hospital of Shahrekord University of Medical Sciences, Parastar street, Shahrekord, Iran
818718791 Shahrekord Iran (Islamic Republic of)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

420

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

IRCT20200205046381N1  (Continued)

shabanian@skums.ac.ir

Notes

Cochrane Database of Systematic Reviews

IRCT20200620047852N1 

Study name

Methods

Participants

Comparing the analgesic effect of agomelatin versus placebo in combination with pregabalin in pa-
tients with chronic low back pain: a randomized, double-blinded study

Double-blind, double-dummy, parallel, 2-arm RCT

• Patients with chronic low back pain without an indication for surgery
• Chronic low back pain = low back pain for at least 3 months (almost every day)
• Patients aged between 18-60

Interventions

Pregabalin 75mg twice daily + agomelatine 25 mg

Pregabalin 75 mg twice daily + placebo

Outcomes

Pain

Anxiety

Depression

Quality of life

Disability

Starting date

06 July 2020

Contact information

Shayan Amiri

No 24, First West Street, 24 Metres Boulvard, Saadat Abad, Tehran, Iran, 1998667133 Tehran, Iran
(Islamic Republic of)

Amiri.shayan23@gmail.com

Notes

NCT00981149 

Study name

Duloxetine for treatment of painful temporomandibular joint disorder

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

Participants

6 weeks

n = 24

Unclear whether chronic pain from trial registration

• Patients with chronic temporomandibular joint disorder pain of 2 weeks' duration
• Pain score of ≥ 4 on the baseline VAS (0-10)
• Aged 18-65

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

421

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00981149  (Continued)

Interventions

Duloxetine 30 mg

Placebo

Outcomes

Pain intensity

Starting date

May 2009

Cochrane Database of Systematic Reviews

Contact information

Notes

NCT03249558 

Study name

Effect of combined morphine and duloxetine on chronic pain

Methods

Double-blind, combination + double-dummy, parallel, 3-arm RCT

Participants

10 weeks

• 18-70 years old
• Chronic neck or back pain for at least 3 months
• VAS ≥ 5

Target: 135

Interventions

Morphine 60 mg + duloxetine 60 mg

Outcomes

Morphine 60 mg + placebo

Duloxetine 60 mg + placebo

Opioid dose

Pain intensity

Starting date

01 February 2018

Contact information

Karina de Sousa

kdesousa1@mgh.harvard.edu

Notes

NCT03324035 

Study name

Treatment of neuropathic pain in leprosy: a randomized double blind controlled study

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

Participants

• Presence of spontaneous pain of medium intensity in the last 24 hours with a minimum value of

4 in 10 on a numerical scale, with a maximum of 10 points (summed pain questionnaire)

• Duration of pain of at least 6 months

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

422

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT03324035  (Continued)

Cochrane Database of Systematic Reviews

• Presence of neuropathic pain "pure" or of clearly dominant character (no other pain, or pain as-

sociated unimportant)

• Pain due to leprosy confirmed by clinical examination and/or appropriate electrophysiological

examination

n = 102

Interventions

Amitriptyline, flexible doses varying from 25-75 mg

Placebo, flexible doses from 1-3 capsules

Outcomes

30% pain relief

Pain intensity

Neuropathic pain symptoms

Quality of life

AEs

Starting date

01 March 2017

Contact information

Daniel Ciampi Araujo de Andrade, MD, PhD, Principal Investigator, Pain Center coordinator, Depart-
ment of Neurology, University of Sao Paulo, São Paulo, Brazil, University of Sao Paulo

Notes

NCT04704453 

Study name

Phase II randomized controlled study aiming to evaluate the interest of Qutenza in patients with
head and neck cancer in remission and with sequelae neuropathic pain

Methods

Double-blind, parallel, 2-arm RCT

9 months

Participants

Unclear pain duration from trial registration

• Head and neck cancer in remission: absence of clinical or radiological signs of progression at least

3 months after specific treatments

• Pain of the cervico-facial sphere persisting for > 3 months after surgical and/or radiotherapy treat-

ment

• Peripheral neuropathic character of pain objectified to a score ≥ 4/10 on the DN (Douleur Neu-

ropathique) 4 questionnaire

• Pain whose average intensity over the last 24 hours is assessed on the numerical scale as ≥ 2/10

Target: 130

Interventions

Capsaïcin patch (Qutenza) 8%

Amitriptyline flexibly dosed 25-75 mg

Outcomes

Pain intensity

Neuropathic pain symptoms

Quality of life

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

423

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT04704453  (Continued)

AEs

Starting date

28 April 2021

Contact information

Antoine Boden

05 31 15 57 91

boden.antoine@iuct-oncopole.fr

Cochrane Database of Systematic Reviews

Notes

NCT04727502 

Study name

Comparison of duloxetine versus pregabalin in post-mastectomy pain syndrome: a randomized
controlled trial

Methods

Double-blind, comparative, parallel, 2-arm RCT

12 weeks

Participants

Patients with 3 months of chronic neuropathic pain after breast surgery

Target: 70

Interventions

Duloxetine 30 mg

Pregabalin 150 mg

Outcomes

Pain intensity

Starting date

20 December 2020

Contact information

Mohamed Abdel Wadod, MD

+201006645981

m_wadod@yahoo.com

Notes

PACTR202001764151121 

Study name

Methods

Participants

Efficacy of clomipramine for chronic lumbar radicular pain: a randomized clinical trial

Double-blind, placebo-controlled, parallel, 2-arm RCT

• Male and female participants
• Aged 20-80 years
• Chronic lumbar radicular pain whatever the aetiology, defined as pain lumbosacral radicular ra-

diating into the leg below the knee, which had been present for > 3 months

• VAS pain= 6/10
• Pain which was not improved by NSAIDs, analgesics and physical treatment

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

424

 
 
 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

PACTR202001764151121  (Continued)

Target: 62

Interventions

Clomipramine

Placebo

Outcomes

Pain intensity

Neuropathic pain symptoms

Walking

Disability

Anxiety

Depression

27 May 2019

Starting date

Contact information

Redouane Abouqal

Faculty of Medicine and Pharmacy, Impasse Souissi, Rabat, Morocco

Redouane.abouqal@yahoo.fr

Notes

RBR-6pqx4n 

Study name

Efficacy of duloxetine in chronic temporomandibular disorder: a randomized clinical trial

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

12 weeks

Participants

Temporomandibular disorder

Presence of pain for at least 3 months

Interventions

Duloxetine 60 mg

Outcomes

Placebo

Pain intensity

Sleep

Psychosocial profile

Mechanical somatosensory profile

Starting date

01 October 2018

Contact information

Dyna Mara Araújo Oliveira Ferreira

Al. Octávio Pinheiro Brisola, 9-75 17012-901 Bauru Brazil

dyna.mara@hotmail.com

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

425

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

RBR-6pqx4n  (Continued)

Notes

Reckziegel 2017 

Study name

Imaging pain relief in osteoarthritis (IPRO): protocol of a double-blind randomised controlled
mechanistic study assessing pain relief and prediction of duloxetine treatment outcome

Methods

Double-blind, placebo-controlled, parallel, 2-arm RCT

Participants

Chronic knee pain with radiographically defined OA changes (Kellgren Lawrence ≥ grade 2)

Aged ≥ 35

n = 77

Interventions

Duloxetine 60 mg

Placebo

Outcomes

Experimental pain

Functional magnetic resonance imaging

Starting date

December 2014

Contact information

University of Nottingham - School of Medicine - Radiological Sciences

Nottingham, Nottinghamshire, United Kingdom, NG7 2UH

Notes

TCTR20190303001 

Study name

Methods

Participants

A comparison of analgesic efficacy between amitriptyline and mianserin in chronic low back pain
patients: a randomized double-blind controlled trial

Double-blind, placebo-controlled, parallel, 2-arm RCT

• 18 - 65 years old
• Chronic low back pain for > 3 months with NRS > 4

Target: 60

Interventions

Amitriptyline 10-50 mg

Outcomes

Mianserin 10-50 mg

Pain intensity

Quality of life

Starting date

01 November 2018

Contact information

Suratsawadee Wangnamthip

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

426

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

TCTR20190303001  (Continued)

Bangkok Noi 10700 Bangkok Thailand

suratsawadee.wang@gmail.com

Cochrane Database of Systematic Reviews

Notes

TCTR20210311009 

Study name

Methods

Participants

Comparison effectiveness of nortriptyline and placebo in the treatment of chronic osteoarthritis
knee

Uncertain of blinding from trial registry

• OA knee as ACR criteria with Kellgren-Lawrence II, III
• 3 months of clinical pain
• WOMAC pain score > 20 points

Target: 200

Interventions

Nortriptyline 25 mg

Placebo

Outcomes

WOMAC total score

Pain intensity

Starting date

29 May 2019

Contact information

Krittamuk Ompornnuwat

681 Samsen road, Vajira hospital, 20300 10300 Dusit Thailand

krittamuk@nmu.ac.th

Notes

Wluka 2021 

Study name

Knee osteoarthritis pain study (KOPS)

Methods

Double-blind, parallel arm, placebo controlled 2-arm RCT

12 weeks

Participants

Adults aged 40-75 with knee OA as defined by the ACR clinical and radiographic criteria

Pain intensity of ≥ 30 on 0-100 pain scale

Interventions

Amitriptyline 25 mg

Placebo

Outcomes

Pain intensity

WOMAC total score

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

427

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wluka 2021  (Continued)

Moderate pain relief (30% reduction)

Substantial pain relief (50% reduction)

Starting date

07 July 2015

Contact information

Mrs Aruna Kartik

Cochrane Database of Systematic Reviews

Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Com-
mercial Road, Melbourne, VIC 3004, Australia

jointstudy@monash.edu

Notes

ACR: American College of Rheumatology; AE: adverse event; BPI: Brief Pain Inventory; IBS: irritable bowel syndrome; MNSI: Michigan
Neuropathy Screening Instrument; NRS: numeric rating scale; NSAID: non-steroidal anti-inflammatory drug; OA: osteoarthritis; OMERACT-
OARSI: Outcome Measures in Rheumatology-Osteoarthritis Research Society International; PGIC: Patient Global Impression of Change;
RCT: randomised controlled trial; s; TENS: transcutaneous electrical nerve stimulation; VAS: visual analogue scale;

A D D I T I O N A L   T A B L E S

Table 1.   Antidepressant dose categorisation 

Antidepressant

Total daily dosage

Amitriptyline

Bupropion

Citalopram

Clomipramine

Desipramine

Desvenlafaxine

Dothiepin (dosulepin)

Doxepin

Duloxetine

Escitalopram

Esreboxetine

Fluoxetine

Imipramine

Nortriptyline

Low

< 25 mg

n/aa

< 20 mg

< 30 mg

< 100 mg

n/ab

< 75 mg

< 75 mg

< 60 mg

< 10 mg

n/ac

< 20 mg

< 75 mg

< 75 mg

Standard

25-75 mg

150-300 mg

20 mg

30-150 mg

100-200 mg

50 mg

75-150 mg

75-150 mg

60 mg

10 mg

4-8 mg

20-40 mg

75-150 mg

75-100 mg

High

> 75 mg

> 300 mg

40 mg

> 150 mg

> 200 mg

> 50 mg

> 150 mg

> 150 mg

> 60 mg

20 mg

> 8 mg

> 40 mg

> 150 mg

> 100 mg

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

428

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 1.   Antidepressant dose categorisation  (Continued)

Cochrane Database of Systematic Reviews

Maprotiline

Mianserin

Milnacipran

Mirtazapine

Moclobemide

Paroxetine

Pirlindole

Reboxetine

Sertraline

Trazodone

Trimipramine

Venlafaxine

Zimelidine

150 mg

< 30 mg

< 100 mg

< 30 mg

150 mg

< 20 mg

300 mg

30-40 mg

100 mg

30 mg

300 mg

20 mg

< 225 mg

225-300 mg

< 8 mg

n/ad

< 150 mg

< 75 mg

< 75 mg

< 300 mg

8 mg

50 mg

150-300 mg

75-150 mg

75-150 mg

300 mg

> 300 mg

> 40 mg

> 100 mg

> 30 mg

600 mg

50 mg

> 300 mg

> 8 mg

> 50 mg

> 300 mg

> 150 mg

> 150 mg

> 300 mg

aLowest dose form is 150 mg.
bDesvenlafaxine is not available in UK, lowest dose form is 50 mg.
cEsreboxetine is not available in UK, and no doses lower than 4 mg have been used in trials.
d50 mg is both the initial and standard dose, no recommendations of lower doses in the British National Formulary.

Table 2.   Substantial pain - overview of interventions in the NMA 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Desvenlafaxine high dose

Duloxetine low dose

Duloxetine standard dose

Duloxetine high dose

Esreboxetine standard dose

Esreboxetine high dose

Milnacipran standard dose

Milnacipran high dose

Mirtazapine standard dose

2

6

15

14

1

1

2

1

1

655

593

2429

1837

553

280

644

239

211

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

429

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Substantial pain - overview of interventions in the NMA  (Continued)

Antidepressants with < 200 participants (excluded from summaries)

Amitriptyline dose unable to be categorised

Clomipramine standard dose

Desvenlafaxine standard dose

Esreboxetine dose unable to be categorised

Imipramine standard dose

Mianserin high dose

Imipramine + pregabalin standard dose

Venlafaxine standard dose

Venlafaxine high dose

Venlafaxine dose unable to be categorised

Non-antidepressant interventions (excluded from summaries)

Carbamazepine

Pregabalin

Terbutaline

RCT: randomised controlled trial

1

1

2

1

2

2

1

1

1

1

1

4

1

Participant numbers reflect the total number of participants receiving the antidepressant.

58

62

194

133

113

89

69

86

82

64

85

678

39

Table 3.   Top-ranked antidepressants for substantial pain relief 

Antidepressant

Odds ratio

(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Duloxetine standard dose

1.91

(1.69 to 2.17)

Duloxetine high dose

1.91

(1.66 to 2.21)

Milnacipran high dose

1.64

(1.04 to 2.58)

Esreboxetine standard dose

1.72

(1.13 to 2.62)

8.3

8.5

10.9

11.0

5

5

4

4

12

12

19

19

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

430

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 3.   Top-ranked antidepressants for substantial pain relief  (Continued)

Milnacipran standard dose

1.65

(1.28 to 2.13)

Mirtazapine standard dose

1.30

(0.79 to 2.15)

Duloxetine low dose

1.71

(1.36 to 2.20)

Esreboxetine high dose

1.29

(0.79 to 2.11)

Desvenlafaxine high dose

1.19

(0.83 to 1.70)

CI: confidence interval

11.8

15.4

15.7

15.7

16.8

6

6

11

7

11

18

21

20

22

21

Table 4.   Overview of interventions in pain intensity change-score analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Duloxetine low dose

Duloxetine standard dose

Duloxetine high dose

Milnacipran standard dose

Milnacipran high dose

Antidepressants with < 200 participants (excluded from summaries)

Amitriptyline high dose

Amitriptyline low dose

Amitriptyline standard dose

Amitriptyline dose unable to be categorised

Citalopram standard dose

Desipramine standard dose

Desipramine standard dose + lidocaine

Desvenlafaxine standard dose

6

18

14

4

2

1

1

2

1

2

2

1

1

560

2727

1925

943

823

38

70

130

24

38

59

30

49

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

431

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 4.   Overview of interventions in pain intensity change-score analysis  (Continued)

Desvenlafaxine high dose

Esreboxetine dose unable to be categorised

Fluoxetine dose unable to be categorised

Imipramine low dose

Milnacipran dose unable to be categorised

Nortriptyline dose unable to be categorised

Paroxetine low dose

Paroxetine dose unable to be categorised

Non-antidepressant interventions (excluded from summaries)

ABT-894

Cognitive behavioural therapy

Gabapentin

Lidocaine

Pregabalin

Psychotherapy

Usual treatment

1

1

1

1

2

1

1

1

1

1

1

1

2

1

1

RCT: randomised controlled trial

Participant numbers reflect the total number of participants receiving the antidepressant.

175

133

25

18

176

38

74

58

170

15

19

27

550

74

79

Table 5.   Top-ranked antidepressants for pain intensity change scores 

Standardised mean difference 
(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Duloxetine high dose

-0.37

(-0.45 to -0.28)

Duloxetine standard dose

-0.31

(-0.39 to -0.24)

Milnacipran high dose

-0.22

(-0.40 to -0.05)

Milnacipran standard dose

-0.22

9.3

11.1

14.0

14.2

8

10

12

12

13

15

19

20

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

432

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 5.   Top-ranked antidepressants for pain intensity change scores  (Continued)

(-0.39 to -0.06)

Duloxetine low dose

-0.11

17.0

12

21

(-0.25 to 0.03)

CI: confidence interval

Table 6.   Overview of interventions in mood change-score analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Duloxetine

Milnacipran

Mirtazapine

Antidepressants with < 200 participants (excluded from summaries)

Citalopram

Desipramine

Desipramine + lidocaine

Esreboxetine

Fluoxetine

Imipramine

Milnacripran + cognitive behavioural therapy

Nortriptyline

Paroxetine

Non-antidepressant interventions (excluded from summaries)

ABT-894

Cognitive behavioural therapy

Pregabalin

Psychotherapy

Usual treatment

RCT: randomised controlled trial

26

5

1

2

1

1

1

1

1

1

1

1

1

1

2

1

1

4837

1753

204

38

27

32

126

25

18

17

38

59

166

15

548

58

63

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

433

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 7.    Top-ranked antidepressants for mood change-score analysis 

Standardised mean difference
(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Mirtazapine

−0.5

(−0.78 to −0.22)

Duloxetine

−0.16

(−0.22 to −0.1)

Milnacipran

−0.13

(−0.26 to 0.01)

CI: confidence interval

3.7

8.0

8.9

2

5

5

7

11

13

Table 8.   Overview of interventions in adverse event treatment-dose analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Amitriptyline standard dose

Desvenlafaxine high dose

Duloxetine high dose

Duloxetine low dose

Duloxetine standard dose

Esreboxetine standard dose

Milnacipran high dose

Milnacipran standard dose

Mirtazapine standard dose

Antidepressants with < 200 participants (excluded from summaries)

Amitriptyline low dose

Amitriptyline standard dose + melatonin

Amitriptyline high dose

Amitriptyline dose unable to be categorised

Desipramine low dose

10

2

15

6

20

1

7

8

1

1

1

2

5

1

518

685

2088

594

2834

556

1573

1256

229

67

21

150

175

38

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

434

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 8.   Overview of interventions in adverse event treatment-dose analysis  (Continued)

Desipramine low dose + cognitive behavioural therapy

Desipramine standard dose

Desvenlafaxine standard dose

Dothiepin standard dose

Escitalopram high dose

Esreboxetine high dose

Esreboxetine dose unable to be categorised

Imipramine low dose

Imipramine standard dose

Imipramine standard dose + pregabalin

Imipramine high dose

Maprotiline low dose

Milnacipran standard dose + cognitive behavioural therapy

Milnacipran dose unable to be categorised

Mirtazapine low dose

Moclobemide high dose

Nortriptyline low dose

Nortriptyline low dose + morphine

Nortriptyline standard dose

Nortriptyline dose unable to be categorised

Nortriptyline dose unable to be categorised + cognitive behavioural therapy

Nortriptyline dose unable to be categorised + disease management

Paroxetine unable to be categorised

Pirlindole low dose

Sertraline high dose

Sertraline high dose + coping skills training

Trazadone low dose + gabapentin

Venlafaxine low dose

1

1

2

1

1

1

1

2

2

1

1

1

1

2

1

1

1

1

1

2

1

1

3

1

1

1

1

3

37

54

199

30

41

107

134

85

121

69

40

33

20

105

13

43

99

28

28

61

41

37

186

45

30

28

94

123

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

435

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 8.   Overview of interventions in adverse event treatment-dose analysis  (Continued)

Venlafaxine standard dose

Venlafaxine high dose

Non-antidepressant interventions (excluded from summaries)

ABT-894

Acetaminophen (paracetamol)

Carbamazepine

Clonidine

Cognitive behavioural therapy

Coping skills training

Cyclobenzaprine

Disease management

Gabapentin

Lamotrigine

Lorazepam

Melatonin

Morphine

Naltrexone

TENS

Terbutaline

2

2

1

1

2

1

4

1

1

1

4

1

1

1

1

1

1

1

106

122

172

50

99

20

155

29

42

24

175

46

41

21

28

67

30

51

RCT: randomised controlled trial; TENS: transcutaneous electrical nerve stimulation

Participant numbers reflect the total number of participants receiving the antidepressant.

Table 9.   Top-ranked antidepressants for adverse events analysis 

Odds ratio
(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Desvenlafaxine high dose

1.67

(0.92 to 2.41)

Mirtazapine standard dose

1.70

(0.48 to 2.91)

30.4

31.1

16

11

48

52

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

436

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 9.   Top-ranked antidepressants for adverse events analysis  (Continued)

Duloxetine standard dose

1.88

(1.58 to 2.17)

Milnacipran standard dose

1.92

(1.37 to 2.46)

Duloxetine high dose

1.93

(1.64 to 2.23)

Duloxetine low dose

2.03

(1.45 to 2.62)

Milnacipran high dose

2.44

(1.89 to 2.98)

Amitriptyline standard dose

2.66

(2.14 to 3.19)

Esreboxetine standard dose

2.92

(1.90 to 3.93)

CI: confidence interval

32.7

33.2

33.5

35.0

38.9

41.0

41.5

24

20

24

21

25

28

21

42

45

43

47

50

51

56

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

437

 
 
 
Table 10.   Moderate pain summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence for moderate pain relief in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: mirtazapine, duloxetine, milnacipran. all doses were combined for each antidepressant.

Comparator (reference): placebo

Outcome: moderate pain relief (defined as 30% reduction in pain intensity from baseline to post-intervention; measured on a range of scales including 0-10 VAS, 0-100 VAS,
and hort-form McGill Pain Questionnaire

Direction: Higher is better (i.e. more people reporting moderate pain relief)

Total studies: 40

Relative effect

Anticipated absolute effect (event rate)*

Total participants: 14,208

(OR and 95%
CI)

With placebo

With interven-
tion

Difference

Certainty of
the evidence
(CINeMA)

1.92

70/224

112/238

(1.45 to 2.39)

313 per 1000

466 per 1000

154 more per
1000

Lowe

Ranking**

(2.5% to
97.5% credi-
ble interval)

7

(3 to 13)

Interpretation of
findings

Equivalent NNTB
is 6.5

1.79

1324/3271

2469/4562

(1.67 to 1.91)

405 per 1000

549 per 1000

144 more per
1000

Moderatea

7

(4 to 11)

Equivalent NNTB
is 6.9

1.7

347/1128

825/1928

(1.48 to 1.92)

308 per 1000

430 per 1000

123 more per
1000

Moderatea

8

(4 to 12)

Equivalent NNTB
is 8.1

1.65

107/409

356/965

(1.32 to 1.98)

262 per 1000

369 per 1000

107 more per
1000

Lowa,e

9

(4 to 13)

Equivalent NNTB
is 9.3

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
3
8

Mirtazapine

RCTs: 2

Participants: 462

Duloxetine

RCTs: 24

Participants: 7833

Milnacipran

RCTs: 7

Participants: 3056

Esreboxetine

RCTs: 2

Participants: 1374

Network meta-analysis-summary of findings table definitions

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 10.   Moderate pain summary of findings  (Continued)

* Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the
control group.

** Mean rank and credible intervals are presented.

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; NNTB: number needed to treat for an additional beneficial outcome; OR: odds ratio; RCT: ran-
domised controlled trial; VAS: visual analogue scale

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
3
9

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 11.   Overview of all interventions in the moderate pain relief analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Duloxetine

Esreboxetine

Milnacipran

Mirtazapine

Antidepressants with < 200 participants (excluded from summaries)

Amitriptyline

Desipramine

Desipramine + cognitive behavioural therapy

Imipramine

Imipramine + pregabalin

Venlafaxine

Non-antidepressant interventions (excluded from summaries)

Carbamazepine

Cognitive behavioural therapy

Gabapentin

Pregabalin

Terbutaline

24

2

7

2

2

1

1

2

1

1

2

2

1

4

1

RCT: randomised controlled trial

Participant numbers reflect the total number of participants receiving the antidepressant.

4562

965

1928

238

80

37

37

113

69

86

85

53

22

680

39

Table 12.   Top-ranked antidepressants moderate pain relief 

Odds ratio
(95% CI)

Mirtazapine

1.92

(1.45 to 2.39)

Duloxetine

1.79

Mean rank

Credible intervals

2.5%

97.5%

6.9

7.4

3

4

13

11

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

440

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 12.   Top-ranked antidepressants moderate pain relief  (Continued)

(1.67 to 1.91)

Milnacipran

1.7

(1.48 to 1.92)

Esreboxetine

1.65

(1.32 to 1.98)

CI: confidence interval

8.2

8.7

4

4

12

13

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

441

 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
4
2

Table 13.   Physical function summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence of antidepressants on physical function in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: duloxetine standard dose (60 mg) and high dose (> 60 mg); milnacipran standard dose (100 mg) and high dose (> 100 mg); mirtazapine standard dose (30
mg)

Comparator (reference): placebo

Outcome: change in physical function (lower scores are better) from a range of measures, including Fibromyalgia Impact Questionnaire and the SF-36

Direction: lower is better (i.e. a greater improvement in physical function and disability)

Total studies: 32

Total participants: 11,760

Duloxetine standard dose

RCTs: 15

Participants: 3887

Duloxetine high dose

RCTs: 13

Participants: 3503

Milnacipran standard dose

RCTs: 3

Participants: 1840

Milnacipran high dose

RCTs: 2

Participants: 1670

Mirtazapine standard dose

Relative ef-
fect

Anticipated absolute effect (event rate)

With placebo With inter-

Difference

vention

Certainty of
the evidence
(CINeMA)

Ranking*

(2.5% to
97.5% credi-
ble interval)

Interpretation of
findings**

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

SMD −0.24

High

6

Small effect

(−0.32 to −0.18)

(3 to 8)

SMD −0.23

Moderatea

6

Small effect

(−0.30 to −0.16)

(2 to 9)

SMD −0.18

Moderatea

7

Small effect

(−0.30 to −0.07)

(4 to 11)

SMD −0.1

Very lowa,c

9

(−0.22 to 0.07)

(6 to 13)

Not significant-
ly different from
placebo

SMD 0.62

Very lowe

16

Moderate to large
effect

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 13.   Physical function summary of findings  (Continued)

RCTs: 1

Participants: 204

Network meta-analysis-summary of findings table definitions

** Mean rank and credible intervals are presented.

(0.11 to 0.69)

(15 to 16)

**SMD interpretation based on clinical judgement and in line with Cohen 1988 and the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2022) as
small (0.2), moderate (0.5) and large (0.8).

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; RCT: randomised controlled trial; SMD: standardised mean difference; VAS: visual analogue scale

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
4
3

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 14.   Overview of all interventions in the physical function analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Duloxetine high dose

Duloxetine standard dose

Milnacipran high dose

Milnacipran standard dose

Mirtazapine standard dose

Antidepressants with < 200 participants (excluded from summaries)

Citalopram standard dose

Duloxetine low dose

Esreboxetine dose unable to be categorised

Fluoxetine

Imipramine

Milnacipran standard + cognitive behavioural therapy

Nortriptyline dose unable to be categorised

Paroxetine low dose

Non-antidepressant interventions (excluded from summaries)

ABT-894

Cognitive behavioural therapy

Pregabalin

Psychotherapy

Usual treatment

RCT: randomised controlled trial

13

14

2

3

1

2

2

1

1

1

1

1

1

1

1

1

1

1

Participant numbers reflect the total number of participants receiving the antidepressant.

1831

2157

823

930

204

38

150

126

25

18

17

38

59

166

15

401

58

63

Table 15.   Top-ranked antidepressants for physical function change-score analysis 

Standardised mean difference
(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

444

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 15.   Top-ranked antidepressants for physical function change-score analysis  (Continued)

Duloxetine standard

−0.24

(−0.32 to −0.18)

Duloxetine high

−0.23

(−0.30 to −0.16)

Milnacipran standard

−0.18

(−0.30 to −0.07)

Milnacipran high

−0.10

(−0.22 to 0.07)

5.5

6.0

7.3

9.5

3

2

4

6

Mirtazapine standard

0.62

15.9

15

(0.11 to 0.69)

CI: confidence interval

8

9

11

13

16

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

445

 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
4
6

Table 16.   Sleep summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence of antidepressants on sleep in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: duloxetine standard dose (60 mg) and high dose (> 60 mg); milnacipran standard dose (100 mg) and high dose (> 100 mg)

Comparator (reference): placebo

Outcome: change in sleep as measured on various scales, primarily Brief Pain Inventory Sleep Item

Direction: lower is better (i.e. greater improvement in sleep compared to baseline)

Total studies: 18

Total participants: 6301

Relative ef-
fect

Anticipated absolute effect (event rate)

With placebo With inter-

Difference

vention

Certainty of
the evidence
(CINeMA)

Ranking*

(2.5% to
97.5% credi-
ble interval)

Interpretation of
findings**

Duloxetine standard

RCTs: 11

Participants: 2615

Duloxetine high

RCTs: 6

Participants: 1494

Milnacipran standard

RCTs: 1

Participants: 799

Milnacipran high

RCTs: 1

Participants: 797

-

-

-

-

-

-

-

-

-

-

-

-

SMD −0.21

Moderatea,d

3

Small effect

(−0.30 to −0.12)

(1 to 6)

SMD −0.14

Very lowa,c,d

4

Small effect

(−0.27 to −0.01)

(2 to 7)

SMD −0.06

Very lowa,c,d,e

6

(−0.30 to 0.17)

(2 to 9)

Not significantly dif-
ferent from placebo

SMD −0.03

Very lowa,c,d,e

7

(−0.29 to 0.20)

(2 to 9)

Not significantly dif-
ferent from placebo

Network meta-analysis-summary of findings table definitions

* Mean rank and credible intervals are presented.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 16.   Sleep summary of findings  (Continued)

**SMD interpretation based on clinical judgement and in line with Cohen 1988 and the  Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2022) as
small (0.2), moderate (0.5) and large (0.8).

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; RCT: randomised controlled trial; SMD: standardised mean difference

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
4
7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 17.   Overview of all interventions in the sleep analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Duloxetine standard dose

Duloxetine high dose

Milnacipran standard dose

Milnacipran high dose

Antidepressants with < 200 participants (excluded from summaries)

Citalopram standard dose

Duloxetine low dose

Esreboxetine unable to be categorised

Milnacipran unable to be categorised

RCT: randomised controlled trial

11

6

1

1

1

1

1

1

Participant numbers reflect the total number of participants receiving the antidepressant.

1640

891

398

396

21

141

126

97

Table 18.   Top-ranked antidepressants for sleep change-score analysis 

Standardised mean difference
(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Duloxetine standard

−0.21

(−0.30 to −0.12)

Duloxetine high

−0.14

(−0.27 to −0.01)

Milnacipran standard

−0.06

(−0.30 to 0.17)

Milnacipran high

−0.03

(−0.29 to 0.20)

CI: confidence interval

3.0

4.4

6.0

6.6

1

2

2

2

6

7

9

9

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

448

 
 
 
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
4
9

Table 19.   Quality of life summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence of antidepressants on quality of life in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: duloxetine, esreboxetine. All doses were combined for each antidepressant.

Comparator (reference): placebo

Outcome: quality of life (post-intervention scores) as reported on various scales including the EQ5D and the Fibromyalgia Impact Questionnaire

Direction: higher is better (i.e. a greater improvement in quality of life compared to baseline)

Total studies: 19

Total participants: 3103

Relative ef-
fect

Anticipated absolute effect (event rate)

With placebo With inter-

Difference

vention

Certainty of
the evidence
(CINeMA)

Ranking*

(2.5% to 97.5%
credible inter-
val)

Interpretation of find-
ings**

Esreboxetine

RCTs: 1

Participants: 998

Duloxetine

RCTs: 6

Participants: 867

-

-

-

-

-

-

SMD −0.30

Very lowe

8

(−1.24 to 0.64)

(1 to 21)

Not significantly different
from placebo

SMD 0.02

Lowa,e

12

(−0.56 to 0.58)

(4 to 20)

Not significantly different
from placebo

Network meta-analysis-summary of findings table definitions

* Mean rank and credible intervals are presented

**SMD interpretation based on clinical judgement and in line with Cohen 1988 and the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2022) as
small (0.2), moderate (0.5) and large (0.8).

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; RCT: randomised controlled trial; SMD: standardised mean difference

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 19.   Quality of life summary of findings  (Continued)

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
5
0

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 20.   Overview of all interventions in the quality-of-life post-intervention analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Duloxetine

Esreboxetine

Antidepressants with < 200 participants (excluded from summaries)

Amitriptyline

Amitriptyline + fluoxetine

Amitriptyline + melatonin

Amitriptyline + splint

Desipramine

Duloxetine + pregabalin

Fluoxetine

Fluoxetine + melatonin

Imipramine

Milnacipran

Nortriptyline

Non-antidepressant interventions (excluded from summaries)

ABT-894

Acupuncture

Cognitive behavioural therapy

Education

Melatonin

Pregabalin

Saffron

Terbutaline

Waitlist

6

1

1

1

1

1

1

1

1

1

1

1

1

1

1

306

736

181

19

21

23

135

39

61

50

42

53

36

169

28

199

66

48

63

23

40

21

RCT: randomised controlled trial

Participant numbers reflect the total number of participants receiving the antidepressant.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

451

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 21.   Top-ranked antidepressants for quality-of-life analysis 

Standardised mean difference 
(95% CI)

Mean rank

Credible intervals

Esreboxetine

−0.30

(−1.24 to 0.64)

Duloxetine

0.02

(−0.56 to 0.58)

CI: confidence interval

2.5%

97.5%

8.2

12.1

1

4

21

20

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

452

 
 
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
5
3

Table 22.   Patient Global Impression of Change much/very much improved summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence of antidepressants on Patient Global Impression of Change in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: desvenlafaxine high dose (> 50 mg); duloxetine standard dose (60 mg) and high dose (> 60 mg); esreboxetine standard dose (4-8 mg) and high dose (> 8 mg);
milnacipran standard dose (100 mg) and high dose (> 100 mg)

Comparator (reference): Placebo

Outcome: Patient Global Impression of Change (PGIC) – people reporting much or very much improved (i.e. 1 or 2 on the 7-point PGIC scale)

Direction: higher is better (i.e. more people reporting much or very much improved from baseline)

Total studies: 12

Total participants: 6995

Relative ef-
fect

(OR and 95%
CI)

Anticipated absolute effect (event rate)*

With placebo With interven-

Difference

tion

Certainty of
the evidence
(CINeMA)

Ranking**

(2.5% to
97.5% credi-
ble interval)

Interpretation of
findings

Duloxetine standard dose

2.29

215 per 1000

382 per 1000

RCTs: 3

Participants: 974

(1.98 to 2.60)

106/493

184/481

Duloxetine high dose

2.03

250 per 1000

404 per 1000

RCTs: 2

Participants: 567

(1.62 to 2.44)

70/280

113/287

170 more per
1000

Moderatea

2

(1 to 6)

Equivalent to NNTB
of 5.9

154 more per
1000

Very lowa,e

4

Equivalent to NNTB
of 6.5

Equivalent to NNTB
of 6.4

(1 to 7)

4

(1 to 7)

Milnacipran high dose

1.99

282 per 1000

439 per 1000

RCTs: 3

Participants: 2057

(1.77 to 2.21)

280/992

480/1065

157 more per
1000

Lowa

Milnacipran standard dose

1.95

303 per 1000

459 per 1000

RCTs: 3

Participants: 2098

(1.73 to 2.17)

320/1055

462/1043

156 more per
1000

Moderatea

4

(1 to 7)

Equivalent to NNTB
of 6.4

Esreboxetine standard dose

1.79

291 per 1000

423 per 1000

133 more per
1000

Very lowa,e

5

Equivalent to NNTB
of 7.5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 22.   Patient Global Impression of Change much/very much improved summary of findings  (Continued)

RCTs: 1

Participants: 811

(1.44 to 2.14)

80/275

226/536

(1 to 7)

Esreboxetine high dose

1.63

291 per 1000

401 per 1000

RCTs: 1

Participants: 550

(1.24 to 2.02)

80/275

110/275

Desvenlafaxine high dose

1.01

429 per 1000

431 per 1000

RCTs: 1

Participants: 528

(0.58 to 1.44)

54/126

173/402

Network meta-analysis-summary of findings table definitions

110 more per
1000

Very lowa,e

6

(2 to 8)

Equivalent to NNTB
of 9.1

2 more per
1000

Very lowa,b,e

8

(6 to 9)

Not significantly dif-
ferent from placebo

* Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the
control group.

** Mean rank and credible intervals are presented.

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; NNTB: number needed to treat for an additional beneficial outcome; OR: odds ratio; PGIC: Patient
Global Impression of Change; RCT: randomised controlled trial; VAS: visual analogue scale

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
5
4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 23.   Overview of all interventions in the Patient Global Impression of Change much/very much improved
analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Desvenlafaxine high dose

Duloxetine high dose

Duloxetine standard dose

Esreboxetine high dose

Esreboxetine standard dose

Milnacipran high dose

Milnacipran standard dose

Antidepressants with < 200 participants (excluded from summaries)

Desvenlafaxine standard dose

Milnacipran dose unable to be categorised

RCT: randomised controlled trial

1

2

3

1

1

3

3

1

1

402

287

481

275

536

1065

1043

131

79

Participant numbers reflect the total number of participants receiving the antidepressant.

Table 24.   Top-ranked antidepressants for Patient Global Impression of Change much/very much improved analysis 

Odds ratio
(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Duloxetine standard dose

2.29

(1.98 to 2.60)

Duloxetine high dose

2.03

(1.62 to 2.44)

Milnacipran high dose

1.99

(1.77 to 2.21)

Milnacipran standard dose

1.95

(1.73 to 2.17)

Esreboxetine standard dose

1.79

(1.44 to 2.14)

2.3

3.5

3.6

3.9

4.7

1

1

1

1

1

6

7

7

7

7

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

455

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 24.   Top-ranked antidepressants for Patient Global Impression of Change much/very much improved
analysis  (Continued)

Esreboxetine high dose

1.63

5.6

2

8

Desvenlafaxine high dose

1.01

8.2

6

9

(1.24 to 2.02)

CI: confidence interval

(0.58 to 1.44)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

456

 
 
 
Table 25.   Patient Global Impression of Change continuous summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence of antidepressants on Patient Global Impression of Change in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg)

Comparator (reference): placebo

Outcome: Patient Global Impression of Change (PGIC) measured continuously on the PGIC 1-7 scale

Direction: lower is better (1 on the scale represents ‘very much improved’, 7 represents ‘very much worse’)

Total studies: 24

Total participants: 8415

Duloxetine standard dose

RCTs: 14

Participants: 3847

Duloxetine high dose

RCTs: 14

Participants: 3520

Duloxetine low dose

RCTs: 5

Participants: 1097

Relative ef-
fect

Anticipated absolute effect (event rate)

With placebo With inter-

Difference

vention

Certainty of
the evidence
(CINeMA)

Ranking*

(2.5% to 97.5%
credible inter-
val)

Interpretation of
findings

-

-

-

-

-

-

-

-

-

SMD −0.36

Moderated

3

(−0.44 to −0.29)

(1 to 4)

Small to moder-
ate effect

SMD −0.33

Moderated

3

(−0.40 to −0.26)

(2 to 5)

Small to moder-
ate effect

SMD −0.23

Moderatea,d

5

Small effect

(−0.35 to −0.11)

(3 to 6)

NMA-SoF table definitions

*Mean rank and credible intervals are presented.

**SMD interpretation based on clinical judgement and in line with Cohen 1988 and the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2022) as
small (0.2), moderate (0.5) and large (0.8).

CI: confidence interval; CINeMA: Confidence in Network Meta-Analysis; RCT: randomised controlled trial; SMD: standardised mean difference

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
5
7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 25.   Patient Global Impression of Change continuous summary of findings  (Continued)

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

CINeMA grades of confidence in the evidence

High: further research is unlikely to change our confidence in the estimate of effect.

Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low: we are very uncertain about the estimate.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
5
8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 26.   Overview of all interventions in the Patient Global Impression of Change continuous analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Duloxetine low dose

Duloxetine standard dose

Duloxetine high dose

Antidepressants with < 200 participants (excluded from summaries)

Desvenlafaxine high dose

Desvenlafaxine standard dose

Non-antidepressant interventions (excluded from summaries)

ABT-394

Pregabalin

RCT: randomised controlled trial

5

14

14

1

1

1

2

Participant numbers reflect the total number of participants receiving the antidepressant.

554

2183

1838

184

54

172

552

Table 27.   Top-ranked antidepressants for Patient Global Impression of Change continuous analysis 

Standardised mean difference
(95% CI)

Mean rank

Credible intervals

2.5%

97.5%

Duloxetine standard

−0.36

(−0.44 to −0.29)

Duloxetine high

−0.33

(−0.40 to −0.26)

Duloxetine low

−0.23

(−0.35 to −0.11)

CI: confidence interval

2.7

3.4

5.0

1

2

3

4

5

6

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

459

 
 
 
 
 
 
 
Table 28.   Serious adverse events summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence for serious adverse events with antidepressants in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: desvenlafaxine high dose (> 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); esreboxetine standard dose (4-8 mg)
and high dose (> 8 mg); milnacipran standard dose (100 mg), high dose (> 100 mg), and dose unable to be categorised; mirtazapine standard dose (30 mg)

Comparator (reference): placebo

Outcome: serious adverse events (events that are life-threatening or resulting in: hospitalisation, persistent or significant disability, or death) as reported per study

Direction: lower is better (i.e. fewer people having serious adverse events)

Total studies: 71

Total participants: 19304

Relative ef-
fect

(OR and 95%
CI)

Anticipated absolute effect (event rate)*

With placebo With inter-

Difference

vention

Certainty of
the evidence
(GRADE)

Ranking**

Interpretation of findings

(2.5% to
97.5% credi-
ble interval)

Desvenlafaxine high dose

0.51

12/221

20/691

RCTs: 2

Participants: 912

(-0.27 to 1.29)

54 per 1000

28 per 1000

26 fewer per
1000

Very lowa,b,c

11

(4 to 24)

Not significantly different
from placebo

Milnacipran dose unable to be
categorised

0.66

3/69

5/203

(-0.95 to 2.27)

43 per 1000

29 per 1000

14 fewer per
1000

Very lowa,b,c

15

(2 to 36)

Not significantly different
from placebo

RCTs: 3

Participants: 272

Duloxetine low dose

0.89

11/462

9/473

RCTs: 4

Participants: 935

(-0.05 to 1.83)

24 per 1000

21 per 1000

3 fewer per
1000

Very lowa,b,c

19

(6 to 32)

Not significantly different
from placebo

Duloxetine high dose

0.92

33/1601

40/1803

RCTs: 12

(0.43 to 1.41)

21 per 1000

19 per 1000

2 fewer per
1000

Very lowa,b,c

19

(9 to 29)

Not significantly different
from placebo

Participants: 3404

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
6
0

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 28.   Serious adverse events summary of findings  (Continued)

Milnacipran standard dose

0.94

22/1234

21/1240

RCTs: 7

(0.31 to 1.57)

18 per 1000

17 per 1000

Participants: 2474

Mirtazapine standard dose

0.99

3/241

3/243

RCTs: 3

Participants: 484

(-0.83 to 2.81)

12 per 1000

12 per 1000

1 fewer per
1000

Very lowa,b,c

19

(9 to 31)

Not significantly different
from placebo

0 fewer per
1000

Very lowb,c

10

(3 to 38)

Not significantly different
from placebo

Milnacipran high dose

1.08

28/1257

35/1569

RCTs: 7

(0.55 to 1.61)

22 per 1000

24 per 1000

2 more per
1000

Very lowa,b,c

22

(11 to 32)

Not significantly different
from placebo

Participants: 2826

Duloxetine standard dose

1.16

34/1082

52/2507

RCTs: 15

(0.71 to 1.61)

16 per 1000

19 per 1000

3 more per
1000

Very lowa,b,c

23

(13 to 32)

Not significantly different
from placebo

Participants: 4589

Esreboxetine standard dose

2.25

1/277

3/556

RCTs: 1

Participants: 833

(-0.69 to 5.19)

4 per 1000

8 per 1000

Esreboxetine high dose

2.75

1/277

2/281

RCTs: 1

Participants: 558

(-0.35 to 5.85)

4 per 1000

10 per 1000

Network meta-analysis-summary of findings table definitions

4 more per
1000

Very lowa,b,c,e

27

(4 to 41)

Not significantly different
from placebo

6 more per
1000

Very lowa,b,c,e

28

(4 to 41)

Not significantly different
from placebo

* Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the
control group.

** Mean rank and credible intervals are presented.

CI: confidence interval; OR: odds ratio; RCT: randomised controlled trial

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
6
1

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 28.   Serious adverse events summary of findings  (Continued)

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
6
2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 29.   Overview of all interventions in the serious adverse events analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Desvenlafaxine high dose

Duloxetine high dose

Duloxetine low dose

Duloxetine standard dose

Esreboxetine high dose

Esreboxetine standard dose

Milnacipran high dose

Milnacipran standard dose

Milnacipran dose unable to be categorised

Mirtazapine standard dose

Antidepressants with < 200 participants (excluded from summaries)

Amitriptyline high dose

Amitriptyline low dose

Amitriptyline standard dose

Amitriptyline dose unable to be categorised

Bupropion standard dose

Citalopram standard dose

Desipramine low dose

Desipramine + cognitive behavioural therapy

Desvenlafaxine standard dose

Esreboxetine dose unable to be categorised

Imipramine low dose

Imipramine standard dose

Milnacipran standard + cognitive behavioural therapy

Mirtazapine low dose

Nortriptyline low dose

2

12

4

15

1

1

7

7

3

3

1

1

3

1

1

2

1

1

2

1

1

1

1

1

2

691

1803

473

2507

281

556

1569

1240

203

243

96

32

114

25

54

34

38

37

199

134

18

51

17

26

137

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

463

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 29.   Overview of all interventions in the serious adverse events analysis  (Continued)

Nortriptyline unable to be categorised

Nortriptyline unable to be categorised + cognitive behavioural therapy

Nortriptyline unable to be categorised + disease management

Paroxetine low dose

Paroxetine dose unable to be categorised

Reboxetine standard dose

Sertraline high dose

Trazadone + gabapentin

Venlafaxine high dose

Venlafaxine low dose

Venlafaxine standard dose

Non-antidepressant interventions (excluded from summaries)

Carbamazepine

Cognitive behavioural therapy

Coping skills training

Disease management

Gabapentin

Nabilone

Pregabalin

Terbutaline

1

1

1

2

2

1

1

1

1

1

1

2

3

1

1

2

1

3

1

56

41

37

62

152

18

30

94

82

82

86

99

72

29

24

56

32

643

51

RCT: randomised controlled trial

Participant numbers reflect the total number of participants receiving the antidepressant.

Table 30.   Top-ranked antidepressants for serious adverse events analysis 

Odds ratio
(95% CI)

Mean rank

Credible intervals

Desvenlafaxine high dose

0.51

11.4

(−0.27 to 1.29)

2.5%

4

97.5%

24

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

464

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 30.   Top-ranked antidepressants for serious adverse events analysis  (Continued)

Milnacipran dose unable to be cate-
gorised

0.66

(−0.95 to 2.27)

Duloxetine low dose

0.89

(−0.05 to 1.83)

Duloxetine high dose

0.92

(0.43 to 1.41)

Milnacipran standard dose

0.94

(0.31 to 1.57)

Mirtazapine standard dose

0.99

(−0.83 to 2.81)

Milnacipran high dose

1.08

(0.55 to 1.61)

Duloxetine standard dose

1.16

(0.71 to 1.61)

Esreboxetine standard dose

2.25

(−0.69 to 5.19)

Esreboxetine high dose

2.75

(−0.35 to 5.85)

CI: confidence interval

15.5

18.5

18.8

19.3

10.0

21.6

22.8

26.7

28.3

2

6

9

9

3

11

13

4

4

36

32

29

31

38

32

32

41

41

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

465

 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
6
6

Table 31.   Withdrawal summary of findings 

Estimates of effects, credible intervals, and certainty of the evidence for withdrawal from studies in people with chronic pain

Bayesian network meta-analysis summary of findings table

Patient or population: people with chronic pain

Interventions: amitriptyline, desipramine, desvenlafaxine, duloxetine, esreboxetine, milnacipran, mirtazapine, nortriptyline, paroxetine, venlafaxine. All doses were com-
bined for each antidepressant.

Comparator (reference): placebo

Outcome: withdrawal from the study (for any reason)

Direction: lower is better (i.e. fewer people withdrawing from studies)

Total studies: 152

Total participants: 28120

Relative ef-
fect

(OR and 95%
CI)

Anticipated absolute effect (event rate)*

With placebo With inter-

Difference

vention

Certainty of
the evidence
(GRADE)

Ranking**

(2.5% to
97.5% credi-
ble interval)

Interpretation of
findings

Nortriptyline

RCTs: 7

Participants: 612

Mirtazapine

RCTs: 3

Participants: 510

Amitriptyline

RCTs: 34

Participants: 2126

Duloxetine

RCTs: 45

Participants: 10140

0.54

101 per 1000

57 per 1000

44 fewer per 1000

Very lowa,b

13

(0.09 to 1.17)

(111 fewer to 15 more)

(5 to 26)

0.99

120 per 1000

119 per 1000

1 fewer per 1000

Very lowb,c

28

(0.34 to 1.64)

(76 fewer to 63 more)

(11 to 52)

1.12

138 per 1000

152 per 1000

14 more per 1000

Very lowa,b,c

31

(0.85 to 1.39)

(18 fewer to 44 more)

(20 to 43)

1.20

207 per 1000

239 per 1000

32 more per 1000

Lowa,b

33

(1.06 to 1.34)

(10 more to 52 more)

(24 to 43)

Desvenlafaxine

1.25

450 per 1000

506 per 1000

56 more per 1000

Very lowa,b,c

35

Not significantly dif-
ferent from placebo

Not significantly dif-
ferent from placebo

Not significantly dif-
ferent from placebo

Equivalent to NNTH
of 31

Not significantly dif-
ferent from placebo

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
6
7

Table 31.   Withdrawal summary of findings  (Continued)

RCTs: 2

(0.82 to 1.68)

(48 fewer to 129 more)

(19 to 53)

Participants: 1105

Milnacipran

RCTs: 17

Participants: 5088

Venlafaxine

RCTs: 6

Participants: 624

Esreboxetine

RCTs: 2

Participants: 1389

Desipramine

RCTs: 4

Participants: 368

Paroxetine

RCTs: 9

Participants: 568

1.34

254 per 1000

314 per 1000

59 more per 1000

Very lowa,b

38

(1.12 to 1.56)

(22 more to 93 more)

(27 to 49)

140

158 per 1000

208 per 1000

50 more per 1000

Very lowa,b,c

40

(0.91 to 1.89)

(12 fewer to 104 more)

(21 to 59)

1.42

251 per 1000

322 per 1000

71 more per 1000

Very lowa,b,c

41

(1.01 to 1.83)

(2 more to 129 more)

(23 to 56)

1.57

196 per 1000

276 per 1000

81 more per 1000

Very lowa,b,c

44

(1.02 to 2.12)

(3 more to 145 more)

(24 to 61)

1.68

173 per 1000

260 per 1000

87 more per 1000

Very lowa,b

46

(1.23 to 2.12)

(32 more to 134 more)

(28 to 60)

Equivalent to NNTH
of 17

Not significantly dif-
ferent from placebo

Equivalent to NNTH
of 31

Equivalent to NNTH
of 14

Equivalent to NNTH
of 11

Network meta-analysis-summary of findings table definitions

* Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risk of the intervention group with the risk of the
control group.

** Mean and credible intervals are presented. Rank statistics is defined as the probabilities that a treatment out of n treatments in a network meta-analysis is the best, the
second, the third and so on until the least effective treatment.

CI: confidence interval; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; RCT: randomised controlled trial

The number of participants for each antidepressant reflects the total number of participants taking the antidepressant or placebo from the studies in the network meta-
analysis.

GRADE Working Group grades of evidence

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 31.   Withdrawal summary of findings  (Continued)

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

aDowngraded due to within-study bias.
bDowngraded due to imprecision in the estimate.
cDowngraded due to heterogeneity in the estimate.
dDowngraded due to incoherence in the network.
eDowngraded due to a small number of trials and participants; we cannot draw reliable conclusions.

C
o
p
y
r
i
g
h
t

©
2
0
2
3
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
f
o
r
p
a
i
n
m
a
n
a
g
e
m
e
n
t

i

n
a
d
u
l
t
s
w

i
t
h
c
h
r
o
n
i
c
p
a
i
n
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4
6
8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 32.   Overview of all interventions in the withdrawal analysis 

Treatment

RCTs

Participants

Antidepressants with ≥ 200 participants

Amitriptyline

Desipramine

Desvenlafaxine

Duloxetine

Esreboxetine

Imipramine

Milnacipran

Mirtazapine

Nortriptyline

Paroxetine

Venlafaxine

Antidepressants with < 200 participants (excluded from summaries)

Amitriptyline + fluoxetine

Amitriptyline + fluphenazine

Amitriptyline + naproxen

Amitriptyline + psychotherapy

Amitriptyline + splint

Amitriptyline + support

Bupropion

Citalopram

Clomipramine

Cognitive behavioural therapy and milnacipran

Cognitive behavioural therapy and amitriptyline

Coping skills training + sertraline

Desipramine + cognitive behavioural therapy

Desipramine + lidocaine

34

4

2

45

2

5

17

3

7

9

6

1

1

1

1

1

1

1

4

2

1

1

1

1

1

1326

230

885

6082

978

240

3090

269

374

389

409

31

12

19

26

24

26

54

76

124

20

12

28

37

34

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

469

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 32.   Overview of all interventions in the withdrawal analysis  (Continued)

Dothiepin

Doxepin

Escitalopram

Fluoxetine

Fluphenazine

Gabapentin + nortriptyline

Maprotiline

Melatonin + amitriptyline

Mianserin

Moclobemide

Morphine + nortriptyline

Nortriptyline + cognitive behavioural therapy

Nortriptyline + disease management

Nortriptyline + morphine

Pirlindole

Pregabalin + duloxetine

Pregabalin + imipramine

Reboxetine

Sertraline

Trazodone

Trazodone + gabapentin

Trimipramine

Zimeldine

Non-antidepressant interventions (excluded from summaries)

ABT-894

Acetaminophen (paracetamol)

Acupuncture

Aerobic exercise

2

1

3

6

1

1

3

1

2

1

1

1

1

1

1

1

1

1

2

3

2

1

1

1

1

1

1

55

30

86

140

13

56

98

21

109

43

55

41

37

52

45

41

73

18

66

63

94

18

17

172

50

24

20

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

470

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 32.   Overview of all interventions in the withdrawal analysis  (Continued)

Carbamazepine

Cognitive behavioural therapy

Coping skills training

Cyclobenzaprine

Disease management

Education

Gabapentin

Lamotrigine

Lidocaine

Melatonin

Morphine

Naltrexone

Naproxen

Neurofeedback

Panax ginseng

Physical therapy

Pregabalin

Psychotherapy

Saffron/crocin

Support

TENS

Terbutaline

Usual treatment

Waitlist

2

7

1

1

1

1

6

1

1

1

2

1

1

1

1

1

9

2

2

1

1

1

1

1

99

333

29

42

24

71

269

53

33

21

107

67

19

20

19

34

919

116

53

24

50

51

70

24

RCT: randomised controlled trial; TENS: transcutaneous electrical nerve stimulation

Participant numbers reflect the total number of participants receiving the antidepressant.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

471

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 33.   Top-ranked antidepressants for withdrawal analysis 

Antidepressant

Odds ratio
(95% CI)

Nortriptyline

0.54

(0.09 to 1.17)

Mirtazapine

0.99

(0.34 to 1.64)

Amitriptyline

1.12

(0.85 to 1.39)

Duloxetine

1.20

(1.06 to 1.34)

Desvenlafaxine

1.25

(0.82 to 1.68)

Milnacipran

1.34

(1.12 to 1.56)

Venlafaxine

1.40

(0.91 to 1.89)

Esreboxetine

1.42

(1.01 to 1.83)

Desipramine

1.57

(1.02 to 2.12)

Paroxetine

1.68

(1.23 to 2.12)

CI: confidence interval

Mean rank

Credible intervals

2.5%

97.5%

13.3

27.8

30.9

33.4

35.3

38.4

39.9

40.6

43.8

46.3

5

11

20

24

19

27

21

23

24

28

26

52

43

43

53

49

59

56

61

60

Table 34.    Top-ranked antidepressant classes for withdrawal analysis. 

Class

Antidepressant

Participants

Mean rank

Credible intervals

NaSSA

Mirtazapine

TCA

Amitriptyline

Clomipramine

2.5%

97.5%

242

2593

3.61

4.33

1

2

10

7

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

472

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 34.    Top-ranked antidepressant classes for withdrawal analysis.  (Continued)

Desipramine

Dothiepin

Doxepin

Imipramine

Nortriptyline

SNRI

Duloxetine

7804

6.24

Esreboxetine

Milnacipran

Venlafaxine

TeCA

Maprotiline

Mianserin

SSRI

Citalopram

Escitalopram

Fluoxetine

Paroxetine

Sertraline

Zimeldine

207

713

6.96

7.7

4

2

4

9

11

10

NaSSA: noradrenergic and specific serotonergic antidepressant;SNRI: serotonin-noradrenalin reuptake inhibitors; SSRI: selective
serotonin reuptake inhibitors; TCA: tricyclic antidepressants; TeCA: tetracyclic antidepressants

A P P E N D I C E S

Appendix 1. Search strategies

MEDLINE

1. pain/ or exp abdominal pain/ or exp arthralgia/ or exp back pain/ or breakthrough pain/ or cancer pain/ or exp chest pain/ or chronic
pain/  or  earache/  or  eye  pain/  or  facial  pain/  or  flank  pain/  or  glossalgia/  or  exp  headache/  or  mastodynia/  or  metatarsalgia/  or  exp
musculoskeletal pain/ or exp neck pain/ or neuralgia/ or exp nociceptive pain/ or pain, intractable/ or exp pain, postoperative/ or pain,
referred/ or exp pelvic pain/ or renal colic/
2. pain.tw.
3. (headache* or migraine* or fibromyalgia* or neuralgia*).tw.
4. Fibromyalgia/
5. 1 or 2 or 3 or 4
6. exp ANTIDEPRESSIVE AGENTS/
7. exp MONOAMINE OXIDASE INHIBITORS/
8. exp NEUROTRANSMITTER UPTAKE INHIBITORS/
9. ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) and (uptake or reuptake or re uptake)).tw.
10. (noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or
heterocyclic or pharmacotherap* or psychotropic).tw.
11. (antidpress* or anti-depress*).tw.
12. (MAOI* or RIMA).tw.
13. monoamine oxidase inhibit*.tw.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

473

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

14.  (Agomelatine  or  Amoxapine  or  Amineptine  or  Amitriptylin*  or  Amitriptylinoxide  or  Atomoxetine  or  Befloxatone  or  Benactyzine  or
Brofaromin*).tw.
15.  (Bupropion  or  Amfebutamone  or  Butriptylin*  or  Caroxazone  or  Cianopramin*  or  Cilobamin*  or  Cimoxatone  or  Citalopram  or
Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine).tw.
16. (Clorgyline or Clovoxamin* or "CX157" or Tyrima or Tririma or Demexiptilin* or Deprenyl or Desipramin* or Pertofrane or Desvenlafaxine
or  Dibenzepin  or  Diclofensin*  or  Dimetacrin*  or  Dosulepin  or  Dothiepin  or  Doxepin  or  Duloxetine  or  Desvenlafaxine  or  "DVS-233"  or
Escitalopram or Etoperidone or Femoxetin* or Fluotracen or Fluoxetine or Fluvoxamin*).tw.
17. (Hyperforin or Hypericum or St John* or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran
or  Lofepramin*  or  "Lu  AA21004"  or  Vortioxetine  or  "Lu  AA24530"  or  Tedatioxetine  or  "LY2216684"  or  Edivoxetine  or  Maprotilin*  or
Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mirtazapin* or Moclobemide).tw.
18. (Nefazodone or Nialamide or Nitroxazepine or Nomifensin* or Norfenfluramin* or Nortriptylin* or Noxiptilin* or Opipramol or Paroxetine
or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or
Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin* or Toloxatone or
Tranylcypromin* or Trazodone or Trimipramin* or Tryptophan* or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone).tw.
19. or/6-18
20. randomized controlled trial.pt.
21. controlled clinical trial.pt.
22. randomized.ab.
23. placebo.ab.
24. drug therapy.fs.
25. randomly.ab.
26. trial.ab.
27. or/20-26
28. exp animals/ not humans.sh.
29. 27 not 28
30. 5 and 19 and 29
31. limit 30 to "all adult (19 plus years)"

Cochrane Central Register of Controlled Trials (CENTRAL)

#1 MeSH descriptor: [Antidepressive Agents] explode all trees

#2 MeSH descriptor: [Monoamine Oxidase Inhibitors] explode all trees

#3 MeSH descriptor: [Neurotransmitter Uptake Inhibitors] explode all trees

#4 (((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) and (uptake or reuptake or re uptake))):ti,ab,kw
(Word variations have been searched)

#5 ((noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or
heterocyclic or pharmacotherap* or psychotropic)):ti,ab,kw (Word variations have been searched)

#6 (antidpress* or anti-depress*):ti,ab,kw (Word variations have been searched)

#7 (MAOI* or RIMA):ti,ab,kw (Word variations have been searched)

#8 (monoamine oxidase inhibit*):ti,ab,kw (Word variations have been searched)

#9  ((Agomelatine  or  Amoxapine  or  Amineptine  or  Amitriptylin*  or  Amitriptylinoxide  or  Atomoxetine  or  Befloxatone  or  Benactyzine  or
Brofaromin*)):ti,ab,kw (Word variations have been searched)

#10  ((Bupropion  or  Amfebutamone  or  Butriptylin*  or  Caroxazone  or  Cianopramin*  or  Cilobamin*  or  Cimoxatone  or  Citalopram  or
Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine)):ti,ab,kw (Word variations have been searched)

#11  ((Clorgyline  or  Clovoxamin*  or  "CX157"  or  Tyrima  or  Tririma  or  Demexiptilin*  or  Deprenyl  or  Desipramin*  or  Pertofrane  or
Desvenlafaxine  or  Dibenzepin  or  Diclofensin*  or  Dimetacrin*  or  Dosulepin  or  Dothiepin  or  Doxepin  or  Duloxetine  or  Desvenlafaxine  or
"DVS-233" or Escitalopram or Etoperidone or Femoxetin* or Fluotracen or Fluoxetine or Fluvoxamin*)):ti,ab,kw (Word variations have been
searched)

#12 ((Hyperforin or Hypericum or St John* or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran
or  Lofepramin*  or  "Lu  AA21004"  or  Vortioxetine  or  "Lu  AA24530"  or  Tedatioxetine  or  "LY2216684"  or  Edivoxetine  or  Maprotilin*  or
Medifoxamin*  or  Melitracen  or  Metapramin*  or  Mianserin  or  Milnacipran  or  Minaprin*  or  Mirtazapin*  or  Moclobemide)):ti,ab,kw  (Word
variations have been searched)

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

474

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

#13  ((Nefazodone  or  Nialamide  or  Nitroxazepine  or  Nomifensin*  or  Norfenfluramin*  or  Nortriptylin*  or  Noxiptilin*  or  Opipramol  or
Paroxetine  or  Phenelzine  or  Pheniprazine  or  Pipofezine  or  Pirlindole  or  Pivagabine  or  Pizotyline  or  Propizepine  or  Protriptylin*  or
Quinupramine  or  Reboxetine  or  Rolipram  or  Scopolamine  or  Selegiline  or  Sertraline  or  Setiptiline  or  Teciptiline  or  Thozalinone  or
Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramin* or Tryptophan* or Venlafaxine or Viloxazine or Vilazodone or
Viqualine or Zalospirone)):ti,ab,kw (Word variations have been searched)

#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13

#15 ((headache* or migraine* or fibromyalgia* or neuralgia*)):ti,ab,kw (Word variations have been searched)

#16 (pain):ti,ab,kw (Word variations have been searched)

#17 MeSH descriptor: [Fibromyalgia] this term only

#18 MeSH descriptor: [Abdominal Pain] explode all trees

#19 MeSH descriptor: [Arthralgia] explode all trees

#20 MeSH descriptor: [Back Pain] explode all trees

#21 MeSH descriptor: [Back Pain] this term only

#22 MeSH descriptor: [Cancer Pain] this term only

#23 MeSH descriptor: [Chest Pain] explode all trees

#24 MeSH descriptor: [Chronic Pain] this term only

#25 MeSH descriptor: [Earache] this term only

#26 MeSH descriptor: [Eye Pain] this term only

#27 MeSH descriptor: [Facial Pain] this term only

#28 MeSH descriptor: [Flank Pain] this term only

#29 MeSH descriptor: [Glossalgia] this term only

#30 MeSH descriptor: [Headache] explode all trees

#31 MeSH descriptor: [Mastodynia] this term only

#32 MeSH descriptor: [Metatarsalgia] this term only

#33 MeSH descriptor: [Musculoskeletal Pain] explode all trees

#34 MeSH descriptor: [undefined] explode all trees

#35 MeSH descriptor: [Neuralgia] this term only

#36 MeSH descriptor: [Nociceptive Pain] explode all trees

#37 MeSH descriptor: [Pain, Intractable] this term only

#38 MeSH descriptor: [Pain, Postoperative] explode all trees

#39 MeSH descriptor: [Pain, Referred] this term only

#40 MeSH descriptor: [Pelvic Pain] explode all trees

#41 MeSH descriptor: [Renal Colic] this term only

#42 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34
or #35 or #36 or #37 or #38 or #39 or #40 or #41

#43 #14 and #42

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

475

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Embase

Cochrane Database of Systematic Reviews

1. *pain/ or exp abdominal pain/ or exp arthralgia/ or exp back pain/ or *breakthrough pain/ or *cancer pain/ or exp chest pain/ or *chronic
pain/ or *earache/ or *eye pain/ or *facial pain/ or *flank pain/ or *glossalgia/ or exp headache/ or *mastodynia/ or *metatarsalgia/ or exp
musculoskeletal pain/ or exp neck pain/ or *neuralgia/ or exp nociceptive pain/ or *pain, intractable/ or exp pain, postoperative/ or pain,
referred/ or exp pelvic pain/ or *renal colic/

2. pain.tw.

3. (headache* or migraine* or fibromyalgia* or neuralgia*).tw.

4. Fibromyalgia/

5. 1 or 2 or 3 or 4

6. exp ANTIDEPRESSIVE AGENTS/

7. exp MONOAMINE OXIDASE INHIBITORS/

8. exp NEUROTRANSMITTER UPTAKE INHIBITORS/

9. ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) and (uptake or reuptake or re uptake)).tw.

10. (noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or
heterocyclic or pharmacotherap* or psychotropic).tw.

11. (antidpress* or anti-depress*).tw.

12. (MAOI* or RIMA).tw.

13. monoamine oxidase inhibit*.tw.

14.  (Agomelatine  or  Amoxapine  or  Amineptine  or  Amitriptylin*  or  Amitriptylinoxide  or  Atomoxetine  or  Befloxatone  or  Benactyzine  or
Brofaromin*).tw.

15.  (Bupropion  or  Amfebutamone  or  Butriptylin*  or  Caroxazone  or  Cianopramin*  or  Cilobamin*  or  Cimoxatone  or  Citalopram  or
Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine).tw.

16. (Clorgyline or Clovoxamin* or "CX157" or Tyrima or Tririma or Demexiptilin* or Deprenyl or Desipramin* or Pertofrane or Desvenlafaxine
or  Dibenzepin  or  Diclofensin*  or  Dimetacrin*  or  Dosulepin  or  Dothiepin  or  Doxepin  or  Duloxetine  or  Desvenlafaxine  or  "DVS-233"  or
Escitalopram or Etoperidone or Femoxetin* or Fluotracen or Fluoxetine or Fluvoxamin*).tw.

17. (Hyperforin or Hypericum or St John* or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran
or  Lofepramin*  or  "Lu  AA21004"  or  Vortioxetine  or  "Lu  AA24530"  or  Tedatioxetine  or  "LY2216684"  or  Edivoxetine  or  Maprotilin*  or
Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mirtazapin* or Moclobemide).tw.

18. (Nefazodone or Nialamide or Nitroxazepine or Nomifensin* or Norfenfluramin* or Nortriptylin* or Noxiptilin* or Opipramol or Paroxetine
or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or
Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin* or Toloxatone or
Tranylcypromin* or Trazodone or Trimipramin* or Tryptophan* or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone).tw.

19. or/6-18

20. random$.tw.

21. factorial$.tw.

22. crossover$.tw.

23. cross over$.tw.

24. cross-over$.tw.

25. placebo$.tw.

26. (doubl$ adj blind$).tw.

27. (singl$ adj blind$).tw.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

476

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

28. assign$.tw.

29. allocat$.tw.

30. volunteer$.tw.

31. Crossover Procedure/

32. double-blind procedure.tw.

33. Randomized Controlled Trial/

34. Single Blind Procedure/

35. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34

36. (animal/ or nonhuman/) not human/

37. 35 not 36

38. 5 and 19 and 37

39. limit 38 to (adult <18 to 64 years> or aged <65+ years>)

AMED

1. *pain/ or exp abdominal pain/ or exp arthralgia/ or exp back pain/ or *breakthrough pain/ or *cancer pain/ or exp chest pain/ or *chronic
pain/ or *earache/ or *eye pain/ or *facial pain/ or *flank pain/ or *glossalgia/ or exp headache/ or *mastodynia/ or *metatarsalgia/ or exp
musculoskeletal pain/ or exp neck pain/ or *neuralgia/ or exp nociceptive pain/ or *pain, intractable/ or exp pain, postoperative/ or pain,
referred/ or exp pelvic pain/ or *renal colic/

2. pain.tw.

3. (headache* or migraine* or fibromyalgia* or neuralgia*).tw.

4. Fibromyalgia/

5. 1 or 2 or 3 or 4

6. exp ANTIDEPRESSIVE AGENTS/

7. exp MONOAMINE OXIDASE INHIBITORS/

8. exp NEUROTRANSMITTER UPTAKE INHIBITORS/

9. ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) and (uptake or reuptake or re uptake)).tw.

10. (noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or
heterocyclic or pharmacotherap* or psychotropic).tw.

11. (antidpress* or anti-depress*).tw.

12. (MAOI* or RIMA).tw.

13. monoamine oxidase inhibit*.tw.

14.  (Agomelatine  or  Amoxapine  or  Amineptine  or  Amitriptylin*  or  Amitriptylinoxide  or  Atomoxetine  or  Befloxatone  or  Benactyzine  or
Brofaromin*).tw.

15.  (Bupropion  or  Amfebutamone  or  Butriptylin*  or  Caroxazone  or  Cianopramin*  or  Cilobamin*  or  Cimoxatone  or  Citalopram  or
Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine).tw.

16. (Clorgyline or Clovoxamin* or "CX157" or Tyrima or Tririma or Demexiptilin* or Deprenyl or Desipramin* or Pertofrane or Desvenlafaxine
or  Dibenzepin  or  Diclofensin*  or  Dimetacrin*  or  Dosulepin  or  Dothiepin  or  Doxepin  or  Duloxetine  or  Desvenlafaxine  or  "DVS-233"  or
Escitalopram or Etoperidone or Femoxetin* or Fluotracen or Fluoxetine or Fluvoxamin*).tw.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

477

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

17. (Hyperforin or Hypericum or St John* or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran
or  Lofepramin*  or  "Lu  AA21004"  or  Vortioxetine  or  "Lu  AA24530"  or  Tedatioxetine  or  "LY2216684"  or  Edivoxetine  or  Maprotilin*  or
Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mirtazapin* or Moclobemide).tw.

18. (Nefazodone or Nialamide or Nitroxazepine or Nomifensin* or Norfenfluramin* or Nortriptylin* or Noxiptilin* or Opipramol or Paroxetine
or Phenelzine or Pheniprazine or Pipofezine or Pirlindole or Pivagabine or Pizotyline or Propizepine or Protriptylin* or Quinupramine or
Reboxetine or Rolipram or Scopolamine or Selegiline or Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin* or Toloxatone or
Tranylcypromin* or Trazodone or Trimipramin* or Tryptophan* or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone).tw.

19. or/6-18

20. (random* or factorial* or placebo* or assign* or allocat* or crossover).tw.

21. (cross adj over*).tw.

22. (trial* and (control* or comparative)).tw.

23. ((blind* or mask*) and (single or double or triple or treble)).tw.

24. (treatment adj arm*).tw.

25. (control* adj group*).tw.

26. (phase adj (III or three)).tw.

27. (versus or vs).tw.

28. rct.tw.

29. RANDOM ALLOCATION/

30. DOUBLE BLIND METHOD/

31. placebos/

32. randomized controlled trials/

33. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32

34. 5 and 19 and 33

35. exp adult/

36. 34 and 35

PsycINFO

S29 S20 AND S28

S28 S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27

S27 (singl* OR doubl* OR trebl* OR tripl*) N3 (blind* OR mask*)

S26 clinical N3 trial* OR research N3 design OR evaluat* N3 stud* OR prospectiv* N3 stud*

S25 placebo* OR random* OR "comparative stud*"

S24 DE "Followup Studies"

S23 DE "Placebo"

S22 DE "Treatment Outcomes" OR DE "Psychotherapeutic Outcomes" OR DE "Side Effects (Treatment)" OR DE "Treatment Compliance"
OR DE "Treatment Duration" OR DE "Treatment Refusal" OR DE "Treatment Termination" OR DE "Treatment Withholding"

S21 DE "Treatment Effectiveness Evaluation"

S20 S15 AND S19

S19 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S16 OR S17 OR S18

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

478

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

S18  DE  "Neurotransmitter  Uptake  Inhibitors"  OR  DE  "Atomoxetine"  OR  DE  "Serotonin  Norepinephrine  Reuptake  Inhibitors"  OR  DE
"Serotonin Reuptake Inhibitors"

S17  DE  "Monoamine  Oxidase  Inhibitors"  OR  DE  "Iproniazid"  OR  DE  "Isocarboxazid"  OR  DE  "Moclobemide"  OR  DE  "Nialamide"  OR  DE
"Pargyline" OR DE "Phenelzine" OR DE "Pheniprazine" OR DE "Tranylcypromine"

S16 DE "Antidepressant Drugs" OR DE "Bupropion" OR DE "Citalopram" OR DE "Fluoxetine" OR DE "Fluvoxamine" OR DE "Iproniazid" OR DE
"Isocarboxazid" OR DE "Lithium Carbonate" OR DE "Methylphenidate" OR DE "Mianserin" OR DE "Moclobemide" OR DE "Molindone" OR DE
"Nefazodone" OR DE "Nialamide" OR DE "Nomifensine" OR DE "Paroxetine" OR DE "Phenelzine" OR DE "Pheniprazine" OR DE "Pipradrol"
OR DE "Serotonin Norepinephrine Reuptake Inhibitors" OR DE "Sertraline" OR DE "Sulpiride" OR DE "Tranylcypromine" OR DE "Trazodone"
OR DE "Tricyclic Antidepressant Drugs" OR DE "Venlafaxine" OR DE "Zimeldine"

S15 S12 OR S13 OR S14

S14 DE "Fibromyalgia"

S13 pain OR ( headache* or migraine* or fibromyalgia* or neuralgia* )

S12 DE "Pain" OR DE "Aphagia" OR DE "Back Pain" OR DE "Chronic Pain" OR DE "Headache" OR DE "Myofascial Pain" OR DE "Neuralgia"
OR DE "Neuropathic Pain" OR DE "Somatoform Pain Disorder"

S11 PAIN

S10  (Nefazodone  or  Nialamide  or  Nitroxazepine  or  Nomifensin*  or  Norfenfluramin*  or  Nortriptylin*  or  Noxiptilin*  or  Opipramol  or
Paroxetine  or  Phenelzine  or  Pheniprazine  or  Pipofezine  or  Pirlindole  or  Pivagabine  or  Pizotyline  or  Propizepine  or  Protriptylin*  or
Quinupramine  or  Reboxetine  or  Rolipram  or  Scopolamine  or  Selegiline  or  Sertraline  or  Setiptiline  or  Teciptiline  or  Thozalinone  or
Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramin* or Tryptophan* or Venlafaxine or Viloxazine or Vilazodone or
Viqualine or Zalospirone)

S9 (Hyperforin or Hypericum or St John* or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran
or  Lofepramin*  or  "Lu  AA21004"  or  Vortioxetine  or  "Lu  AA24530"  or  Tedatioxetine  or  "LY2216684"  or  Edivoxetine  or  Maprotilin*  or
Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mirtazapin* or Moclobemide)

S8 (Clorgyline or Clovoxamin* or "CX157" or Tyrima or Tririma or Demexiptilin* or Deprenyl or Desipramin* or Pertofrane or Desvenlafaxine
or  Dibenzepin  or  Diclofensin*  or  Dimetacrin*  or  Dosulepin  or  Dothiepin  or  Doxepin  or  Duloxetine  or  Desvenlafaxine  or  "DVS-233"  or
Escitalopram or Etoperidone or Femoxetin* or Fluotracen or Fluoxetine or Fluvoxamin*)

S7  (Bupropion  or  Amfebutamone  or  Butriptylin*  or  Caroxazone  or  Cianopramin*  or  Cilobamin*  or  Cimoxatone  or  Citalopram  or
Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine)

S6  (Agomelatine  or  Amoxapine  or  Amineptine  or  Amitriptylin*  or  Amitriptylinoxide  or  Atomoxetine  or  Befloxatone  or  Benactyzine  or
Brofaromin*)

S5 monoamine oxidase inhibit*

S4 MAOI* or RIMA

S3 antidpress* or anti-depress*

S2 (noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or
heterocyclic or pharmacotherap* or psychotropic)

S1 ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) and (uptake or reuptake or re uptake))

CINAHL

S31 S4 AND S18 AND S30

S30 S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29

S29 TX allocat* random*

S28 (MH "Quantitative Studies")

S27 (MH "Placebos")

S26 TX placebo*

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

479

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

S25 TX random* allocat*

S24 (MH "Random Assignment")

S23 TX randomi* control* trial*

Cochrane Database of Systematic Reviews

S22 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) )
or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )

S21 TX clinic* n1 trial*

S20 PT Clinical trial

S19 (MH "Clinical Trials+")

S18 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17

S17  (Nefazodone  or  Nialamide  or  Nitroxazepine  or  Nomifensin*  or  Norfenfluramin*  or  Nortriptylin*  or  Noxiptilin*  or  Opipramol  or
Paroxetine  or  Phenelzine  or  Pheniprazine  or  Pipofezine  or  Pirlindole  or  Pivagabine  or  Pizotyline  or  Propizepine  or  Protriptylin*  or
Quinupramine  or  Reboxetine  or  Rolipram  or  Scopolamine  or  Selegiline  or  Sertraline  or  Setiptiline  or  Teciptiline  or  Thozalinone  or
Tianeptin* or Toloxatone or Tranylcypromin* or Trazodone or Trimipramin* or Tryptophan* or Venlafaxine or Viloxazine or Vilazodone or
Viqualine or Zalospirone)

S16 (Hyperforin or Hypericum or St John* or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran
or  Lofepramin*  or  "Lu  AA21004"  or  Vortioxetine  or  "Lu  AA24530"  or  Tedatioxetine  or  "LY2216684"  or  Edivoxetine  or  Maprotilin*  or
Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mirtazapin* or Moclobemide)

S15 (Clorgyline or Clovoxamin* or "CX157" or Tyrima or Tririma or Demexiptilin* or Deprenyl or Desipramin* or Pertofrane or Desvenlafaxine
or  Dibenzepin  or  Diclofensin*  or  Dimetacrin*  or  Dosulepin  or  Dothiepin  or  Doxepin  or  Duloxetine  or  Desvenlafaxine  or  "DVS-233"  or
Escitalopram or Etoperidone or Femoxetin* or Fluotracen or Fluoxetine or Fluvoxamin*)

S14  (Bupropion  or  Amfebutamone  or  Butriptylin*  or  Caroxazone  or  Cianopramin*  or  Cilobamin*  or  Cimoxatone  or  Citalopram  or
Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine)

S13  (Agomelatine  or  Amoxapine  or  Amineptine  or  Amitriptylin*  or  Amitriptylinoxide  or  Atomoxetine  or  Befloxatone  or  Benactyzine  or
Brofaromin*)

S12 monoamine oxidase inhibit*

S11 MAOI* or RIMA

S10 antidpress* or anti-depress*

S9 (noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or
heterocyclic or pharmacotherap* or psychotropic)

S8 ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) and (uptake or reuptake or re uptake))

S7 (MH "Neurotransmitter Uptake Inhibitors+")

S6 (MH "Monoamine Oxidase Inhibitors+")

S5 (MH "Antidepressive Agents+")

S4 S1 OR S2 OR S3

S3 (MH "Fibromyalgia")

S2 pain OR ( headache* or migraine* or fibromyalgia* or neuralgia* )

S1 (MH "Pain+")

LILACS

headache$ or migraine$ or fibromyalgia$ or neuralgia$ or pain [Words] and (Nefazodone or Nialamide or Nitroxazepine or Nomifensin$
or Norfenfluramin$ or Nortriptylin$ or Noxiptilin$ or Opipramol or Paroxetine or Phenelzine or Pheniprazine or Pipofezine or Pirlindole
or Pivagabine or Pizotyline or Propizepine or Protriptylin$ or Quinupramine or Reboxetine or Rolipram or Scopolamine or Selegiline or

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

480

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sertraline or Setiptiline or Teciptiline or Thozalinone or Tianeptin$ or Toloxatone or Tranylcypromin$ or Trazodone or Trimipramin$ or
Tryptophan$ or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone) or (Hyperforin or Hypericum or St John$ or Imipramin
$ or Iprindole or Iproniazid$ or Ipsapirone or Isocarboxazid$ or Levomilnacipran or Lofepramin$ or "Lu AA21004" or Vortioxetine or "Lu
AA24530" or Tedatioxetine or "LY2216684" or Edivoxetine or Maprotilin$ or Medifoxamin$ or Melitracen or Metapramin$ or Mianserin or
Milnacipran or Minaprin$ or Mirtazapin$ or Moclobemide) or (Clorgyline or Clovoxamin$ or "CX157" or Tyrima or Tririma or Demexiptilin
$ or Deprenyl or Desipramin$ or Pertofrane or Desvenlafaxine or Dibenzepin or Diclofensin$ or Dimetacrin$ or Dosulepin or Dothiepin
or Doxepin or Duloxetine or Desvenlafaxine or "DVS-233" or Escitalopram or Etoperidone or Femoxetin$ or Fluotracen or Fluoxetine or
Fluvoxamin$) or (Bupropion or Amfebutamone or Butriptylin$ or Caroxazone or Cianopramin$ or Cilobamin$ or Cimoxatone or Citalopram
or Chlorimipramin$ or Clomipramin$ or Chlomipramin$ or Clomipramine) or (Agomelatine or Amoxapine or Amineptine or Amitriptylin$
or Amitriptylinoxide or Atomoxetine or Befloxatone or Benactyzine or Brofaromin$) or ((serotonin or norepinephrine or noradrenaline or
neurotransmitter$ or dopamin$) and (uptake or reuptake or re uptake)) or (noradrenerg$ or antiadrenergic or anti adrenergic or SSRI$ or
SNRI$ or NARI$ or SARI$ or NDRI$ or TCA$ or tricyclic$ or tetracyclic$ or heterocyclic or pharmacotherap$ or psychotropic) or (antidpress
$  or  anti-depress$  or  MAOI$  or  RIMA  or  monoamine  oxidase  inhibit$)  [Words]  and  randomised  OR  randomized  OR  randomisation  OR
randomization OR trial OR placebo OR blind OR "phase 3" OR "phase III" [Words]

Appendix 2. Network meta-analysis reporting decisions

Overview

This appendix details the decisions made in the reporting of the network meta-analyses (NMAs) in the results section of the review. For
each network we took into account heterogeneity, inconsistency, and network geometry.

Substantial pain relief (50% reduction)

Networks – which model is the best fit?

Our primary analysis was a Bayesian network meta-analysis including treatment. This analysis had high heterogeneity (Tau = 0.26) and
inconsistency  in  both  unrelated  mean  effects  and  node-splitting  models.  We  also  explored  networks  that  separated  treatments  into
different doses, conditions and risk of bias categories and aggregated treatment by class. These networks resulted in models that had
similar heterogeneity and variable indications for inconsistency but the model that included antidepressant dose reduced the estimate
of heterogeneity by half (Tau = 0.11) and there was no indication of inconsistency. Therefore, the results are based on the treatment-dose
model.

Pain intensity

Change scores and post-intervention

Studies in the review reported pain intensity results in two ways: change scores and post-intervention scores. Fifty studies with 14,926
participants reported change scores, 74 studies with 7703 participants reported post-intervention scores. As these two types of scores
cannot be combined directly, we selected model-data combinations on the basis of parsimony, minimisation of inconsistency (identified
via unrelated mean-effect models (UME) and node-splitting models), residual deviance and heterogeneity (measured as Tau) to minimise
the risk of over-fitting.

Networks – which model is the best fit?

For both change-score and post-intervention analyses, we generated networks and models based on treatment and treatment dose.

Change

The treatment analysis had low heterogeneity (Tau = 0.17) and low inconsistency in the UME model, however node-splitting models could
not be run due to inappropriate network geometry. Models including dose had lower heterogeneity (Tau = 0.10) and no indications for
inconsistency in both UME and node-splitting models.

Post-intervention scores

The treatment analysis had high heterogeneity (Tau = 2.06) compared to change-score analysis and inconsistency in the UME model, that
suggest it is not possible to fit a robust model to the data. Models including dose continued to have higher heterogeneity than the change-
score analysis (Tau = 0.46), and high residual deviance across multiple studies suggesting that a robust model is unlikely to fit the data. UME
models continued to show inconsistency between direct and indirect evidence, although node-splitting models showed no inconsistency
within studies.

Mood

Change scores and post-intervention

Studies in the review reported pain intensity results in two ways: change scores and post-intervention scores. Thirty-eight studies with
12,985 participants reported change scores, 46 studies with 3885 participants reported post-intervention scores. As these two types of
scores cannot be combined, we reported the most appropriate and robust model for the data.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

481

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Networks – which model is the best fit?

Cochrane Database of Systematic Reviews

For both change-score and post-intervention analyses, the primary analysis was a Bayesian NMA including treatment.

Change

The treatment analysis had low heterogeneity (Tau = 0.09), with no inconsistency in the UME model. We were unable to run node-splitting
models due to the network geometry as the majority of the network is formed from two-arm placebo-controlled studies. As the treatment-
only analysis had low heterogeneity and no inconsistency, no further analyses were undertaken.

Post-intervention

This  analysis  had  moderate  heterogeneity  (Tau  =  0.69),  with  high  residual  deviance  across  multiple  studies.  UME  models  showed
inconsistency between direct and indirect evidence, although node-splitting models showed no inconsistency within studies. We were
unable to run any further analyses including any covariates due to small sample sizes, network geometry and the risk of over-fitting.

Adverse events

Networks – which model is the best fit?

Our primary analysis was a Bayesian NMA including treatment. This analysis had high heterogeneity (Tau = 0.49), with the UME model
indicating high inconsistency and divergent transitions within the network. We were unable to run node-splitting models due to network
geometry. Models including dose continued to have high heterogeneity (Tau = 0.59), and the UME model showed high inconsistency, similar
to the treatment-only model. There continued to be divergent transitions within the network and low effective sample sizes, however the
node-splitting models were able to run and showed no evidence of inconsistency. Due to the network geometry and inappropriateness of
running extra models, no further analyses including other covariates were run. The results are based on the treatment-dose model, due to
similar levels of heterogeneity and inconsistency, and the ability to run node-splitting models.

Moderate pain relief

Networks – which model is the best fit?

Our  primary  analysis  was  a  Bayesian  NMA  including  treatment.  This  analysis  had  low  heterogeneity  (Tau  =  0.13)  and  no  evidence  of
inconsistency in both UME and node-splitting models. Therefore, the results are based on a model including treatment only. Divergent
transitions suggested unstable models when analysing treatment-dose networks.

Physical function

Change scores and post-intervention

Studies in the review reported physical function results in two ways: change scores and post-intervention scores. Thirty-two studies with
11,760 participants reported change scores, while 30 studies with 3645 participants reported post-intervention scores. As these two types
of scores cannot be combined, we reported the most appropriate and robust model for the data.

Networks – which model is the best fit?

For both change score and post-intervention score analyses, the primary analysis was a Bayesian NMA including treatment.

Change scores

Our  primary  analysis  was  a  Bayesian  NMA  including  treatment.  This  analysis  had  low  heterogeneity  (Tau  =  0.05),  and  there  was  little
evidence of inconsistency in the UME model or node-splitting models. Using a model including dose resulted in lower heterogeneity (Tau
= 0.04) and no major indications for inconsistency from both unrelated mean effect and node-splitting models.

Post-intervention scores

Our  primary  analysis  was  a  Bayesian  NMA  including  treatment.  This  analysis  had  moderate  heterogeneity,  higher  than  that  of  the
change score analysis (Tau = 0.69) with no inconsistency in both UME and node-splitting models. Models including dose increased the
heterogeneity (Tau = 0.82) but continued to show no evidence of inconsistency.

Sleep

Change scores and post-intervention

Studies  in  the  review  reported  sleep  results  in  two  ways:  change  scores  and  post-intervention  scores.  Eighteen  studies  with  6301
participants reported change scores, while 18 studies with 1921 participants reported post-intervention scores. As these two types of scores
cannot be combined, we reported the most appropriate and robust model for the data.

Networks – which model is the best fit?

For both change-score and post-intervention score analyses, the primary analysis was a Bayesian NMA including treatment.

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

482

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Change scores

Cochrane Database of Systematic Reviews

Our primary analysis was a Bayesian NMA including treatment. This analysis had low heterogeneity (Tau = 0.06), but due to the star-shaped
network geometry we were unable to explore inconsistency using node-splitting models in the treatment-only network. Models including
dose also had low heterogeneity (Tau = 0.11) and no indications for inconsistency in UME but node-splitting models indicated inconsistency,
although these parameter estimates may be unreliable due to divergent transitions.

Post-intervention scores

The primary analysis was a Bayesian NMA including treatment. This analysis had low heterogeneity (Tau = 0.12) and no inconsistency
in  both  UME  and  node-splitting  models,  although  there  were  three  divergent  transitions.  Models  including  dose  had  slightly  higher
heterogeneity (Tau = 0.16), but the network was disconnected requiring four studies to be removed, and there were 12 divergent transitions.

Model used

Comparing the post-intervention and change-score analyses shows that the change-score treatment network is more robust and reliable
than the post-intervention network as models without divergent transitions were generated. Therefore, the results are based on a model
of change scores including both treatment and dose. Results for the treatment-only model are available in the supplemental files (link
provided in Appendix 3).

Quality of life

Change scores and post-intervention

Studies in the review reported pain intensity results in two ways: change scores and post-intervention scores. Twenty-seven studies with
9693 participants reported change scores, 19 studies with 3103 participants reported post-intervention scores. As these two types of scores
cannot be combined, we reported the most appropriate and robust model for the data.

Networks – which model is the best fit?

For both change-score and post-intervention analyses, the primary analysis was a Bayesian NMA including treatment.

Change scores

The treatment-only analysis had high heterogeneity (Tau = 0.87), with no evidence of inconsistency in UME and node-splitting models.
Models including dose continued to have higher heterogeneity (0.76), with some evidence of inconsistency in the node-splitting models
for milnacipran.

Post-intervention scores

The treatment-only analysis had moderate heterogeneity (Tau = 0.55) and no evidence of inconsistency in both UME and node-splitting
models, although some residual deviance was present on multiple studies. Models including dose had higher heterogeneity (Tau = 0.67)
with similar levels of residual deviance.

Model used

Comparing  the  post-intervention  and  change-score  analyses  shows  that  the  post-intervention  score  treatment  network  has  lower
heterogeneity than the change-score treatment-dose network. Therefore, the results are based on a model of post-intervention scores
including treatment. The results of the change-score analyses are available in the supplemental files (link provided in Appendix 3).

Patient Global Impression of Change (PGIC)

PGIC much/very much improved

Networks – which model is the best fit?

Our  primary  analysis  was  a  Bayesian  NMA  including  treatment.  This  analysis  had  low  heterogeneity  (Tau  =  0.12)  and  no  evidence
inconsistency in both UME and node-splitting models. However, there were several divergent transitions. Models including dose reduced
the heterogeneity (Tau = 0.08) and continued to show no indications for inconsistency. There was only one divergent transition in this
model. Therefore, the results are based on a model including treatment and dose. The results of the treatment-only model are included
in the appendices.

PGIC continuous

Networks – which model is the best fit?

Our  primary  analysis  was  a  Bayesian  NMA  including  treatment.  This  analysis  had  low  heterogeneity  (Tau  =  0.05)  but  some  evidence
of inconsistency in both UME and node-splitting models. Models including dose continued to have low heterogeneity (Tau = 0.05) and
evidence of inconsistency. As the models were very similar, we decide to use the treatment-dose model for clinical utility. The results for
the treatment-only model are available in the supplemental files (link provided in Appendix 3).

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

483

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Serious adverse events

Networks – which model is the best fit?

Cochrane Database of Systematic Reviews

Our primary analysis was a Bayesian NMA including treatment. This analysis had low heterogeneity (Tau = 0.13) and no inconsistency in
both UME and node-splitting models. Including dose into the model did not alter the level of heterogeneity (Tau = 0.16), and continued to
have no inconsistency in the UME and node-splitting models. Both treatment-only and treatment-dose models had multiple studies with
high residual deviance and imprecision. As both models were very similar, we decided to use the treatment-dose model due to clinical
utility. The results for treatment only are available in the supplemental files (link provided in Appendix 3).

Withdrawal

Networks – which model is the best fit?

Our primary analysis was a Bayesian NMA including treatment. This analysis had high residual deviance and relatively high heterogeneity
(Tau = 0.23). We were unable to examine the model using node-splitting models due to the network geometry, as a large proportion of the
model was formed of single study connections only. We decided to use this treatment model for the analysis despite the relatively high
heterogeneity, as including dose or condition would increase network complexity and dilute already weakly informative edges.

Appendix 3. Statistical analyses

Where  additional  analyses  and  the  supplemental  files  are  referred  to  in  the  text,  these  are  available  on  the  Open  Science  Framework
(https://osf.io/ka5hr). For additional statistical queries please contact Gavin Stewart (gavin.stewart@newcastle.ac.uk).

H I S T O R Y

Protocol first published: Issue 4, 2021

C O N T R I B U T I O N S   O F   A U T H O R S

TP, PC, CE, MS, GS, and SW conceived, designed, and gained funding for the review. HB co-ordinated the review. HB and CF were responsible
for screening and selection of studies from the search results, data extraction, and risk of bias assessments. HB cleaned the data for analysis.
PC, MS, and SW were responsible for decisions requiring clinical knowledge. GS undertook data analysis through network meta analyses,
with support from DP. HB and GS assessed the certainty of the evidence using CINeMA. HB drafted the manuscript. All authors contributed
to the interpretation of findings, and writing and editing of the manuscript. TP will be responsible for the update of this review.

D E C L A R A T I O N S   O F   I N T E R E S T

Hollie Birkinshaw: none known

Claire Friedrich: none known

Peter Cole is a Consultant in anaesthesia and pain medicine and manages people with chronic pain.

Christopher Eccleston: none known

Andrew Moore: none known

David Phillippo: none known

Marc Serfaty is a Consultant Psychiatrist and manages people with mental health conditions.

Gavin Stewart: none known

Simon White: none known

Tamar Pincus had one consultancy advisory meeting with Reckitt Benckiser Group PLC in February 2020. Reckitt Benckiser Group PLC are a
multinational company that produce consumer goods, including pharmacological products such as analgesics. Tamar Pincus was asked to
deliver an advisory talk to the company about psychological factors that might compromise randomised controlled trials. The University
of Southampton was paid for her time. This talk did not cover the use of antidepressants.

S O U R C E S   O F   S U P P O R T

Internal sources

• No sources of support provided

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

484

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

External sources

• NIHR Health Technology Assessment programme, UK

Cochrane Database of Systematic Reviews

This review is funded by the NIHR Health Technology Assessment programme through a grant awarded to Professor Tamar Pincus
(Award ID: NIHR128782).

• National Institute for Health Research (NIHR), UK

Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS)

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

There are a number of differences between the protocol and the review (Birkinshaw 2021).

• Updating of the background section

◦ We removed the International Association for the Study of Pain (IASP) pain categories from the background, as there is currently
discourse about the clinical usefulness of primary pain, and we subsequently did not categorise pain types into these. If we were
to have used the IASP categories, then a number of distinct pain conditions (e.g. fibromyalgia, low back pain) would have been
combined, whereas there is evidence for these types of conditions being kept separate to evaluate the effects.

◦ We reference National Institute for Health and Care Excellence (NICE) guidelines to the background which were not published at time

of protocol publication.

◦ We have updated the literature in the How the intervention might work section for clarity, and to reflect current understanding and

theories.

• Methods

◦ We reported continuous pain intensity as an outcome, which was not included in the published version of the protocol. This was

originally in the protocol, and was removed accidentally during the protocol editing process.

◦ We separated adverse events and serious adverse events outcomes as they are defined differently, and we assessed them using

separate NMAs. Therefore, we moved serious adverse events to a secondary outcome.

◦ We rated studies that imputed missing data using the 'last observation carried forward' method as high risk of bias, unless attrition

was very low. This rule was not explained in the protocol.

◦ We stated that we would present the primary outcomes on a 0 to 100 scale. As outcomes were reported on a wide variety of scales,
this was not possible. Instead, we have reported the 'number needed to treat for an additional beneficial outcome' and 'number
needed to treat for an additional harmful outcome' in the summary of findings tables.

◦ We planned to use threshold analysis to analyse how much evidence needed to be added for our conclusions to change. We did not
undertake threshold analysis in the review as we judged the majority of evidence to be low or very low certainty; and therefore it is
already likely that new evidence will affect the conclusions.

◦ We have added in the criteria for antidepressant doses, being categorised as 'low', 'standard', or 'high', and clarified how we included
dose in the analysis in the 'data synthesis' section (moved from the subgroup analysis section). This was done as networks would
not converge when using dose as a continuous measure.

◦ We omitted the 'Other bias' domain from the protocol accidentally - we did assess for this in our risk of bias assessments, and so

have included this in the methods under the risk of bias section.

◦ We reordered parts of the methods section regarding sensitivity analyses for clarification: we moved assessment of consistency
to data synthesis and added further information regarding the sensitivity analyses to the sensitivity analysis section. We did this
because the assessment of consistency was part of our main analysis methods, not as a standalone sensitivity analysis.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Antidepressive Agents  [therapeutic use];  *Chronic Pain  [drug therapy];  Duloxetine Hydrochloride;  Milnacipran;  Network Meta-Analysis;
  Pain Management;  Randomized Controlled Trials as Topic

MeSH check words

Adult; Humans

Antidepressants for pain management in adults with chronic pain: a network meta-analysis (Review)
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

485
